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Preface
The Advancing the Science of Cancer in Latinos national conference was a call to 
action for addressing cancer health disparities observed among Hispanic/Latino 
communities. It emerged from the need for Latino disparities researchers to seek 
solutions through multidisciplinary collaborations and to keep pace with the sub-
stantial advancement in cancer prevention, screening, diagnosis, treatment, and sur-
vivorship. Held in San Antonio from February 21 to February 23, 2018, the 
conference was co-hosted by the Mays Cancer Center and the Institute for Health 
Promotion Research at the UT Health San Antonio and sponsored by the National 
Institute on Minority Health and Health Disparities. The conference uniquely 
reviewed the state of the science and set an agenda for future initiatives to specifi-
cally address cancer health disparities and improve outcomes in Latino communi-
ties. While most conferences on cancer health disparities focus on policy and public 
health issues, this conference incorporated perspectives from basic scientists, clini-
cians, and population health experts in conjunction with policy and public health to 
emphasize the need for timely translation of research. To this end, the conference 
assembled an international, multidisciplinary group of speakers and attendees who 
explored wide-ranging issues including Latino-focused basic research, clinical best 
practices, effective community interventions, and policy implications. Much of the 
research presented was on the cutting edge of science.
Much of the Latino cancer research happening today occurs in silos by research-
ers who often only attend specialty meetings narrowly focused on their specific 
discipline, creating a missed opportunity for discussing broader, systemic issues 
across sectors. The value of Advancing the Science of Cancer in Latinos conference 
is that it united researchers, scientists, physicians, healthcare professionals, patient 
advocates, and students from across the nation and beyond in an open dialogue, 
under one roof, to discuss the broader field of study in Latino cancer and foster col-
laborations that would not have occurred otherwise.
These conference proceedings give readers an overview of what is known about 
cancer disparities in Latinos, what is not known, and suggestions for a way forward. 
With the ongoing rise in the US Latino population and cancer burden, we believe 
these pages hold many key insights into actionable targets for basic science research, 
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suggestions for clinical best practices and community interventions, as well as other 
novel strategies and advocacy opportunities to reduce these disparities.
We hope that you, the reader, will explore all of the vital research delivered, dis-
cussed, and disseminated at Advancing the Science of Cancer in Latinos in order to 
gain a fresh, comprehensive perspective on Latino cancer health disparities. We 
anticipate this will inspire critical thinking and strategizing about how you can 
apply some of this research and practice into your own work at your program, insti-
tution, business, and nonprofit. We are optimistic that our scientific conference and 
the information in these proceedings will provide a much-needed spark that will 
lead to many more conferences, more collaboration, more research, and more suc-
cess in reducing and eliminating cancer health disparities and improving the health 
and lives of the US Latino population.
 
 Amelie G. Ramirez 
San Antonio, TX, USA
  
Edward J. Trapido
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While the overall rate of cancer deaths in the USA has declined by 27% during the 
past 25 years, socioeconomic gaps are widening and cancer remains the leading 
cause of morbidity and premature death among vulnerable populations such as 
Latinos [1–4]. Latino cancer rates are expected to rise 142% in the next 20 years [5]. 
This health crisis is especially alarming given that Latinos, already the nation’s larg-
est minority group, are expected to compose at least 30% of the nation’s population 
by 2050 [6].
Latinos as a group have a unique demographic profile that departs from the US 
public health pattern. For example, even though life expectancy is going down in the 
United States, the US Latino population has the longest life expectancy for both 
women (84.3 years) and men (79.3) compared to non-Latino white women (81) and 
men (76.3) and black women (78.1) and men (71.9). This Latino survival advantage 
increases with age, and the probability that a person will survive from birth to age 
85 is 52.1% in Latinos and 41.9% in non-Hispanic whites [7].
Cancer is the leading cause of death among Latinos; however, the lifetime prob-
ability of developing cancer is lower for Latino men (36%) and women (35%) than 
for non-Latino white men (40%) and women (39%) [2]. Even though Latinos are 
less likely to receive a cancer diagnosis, cancer incidence varies by cancer site. As 
a group, Latinos have a lower incidence than non-Latino whites for some common 
cancers such as breast, colorectal, lung, and prostate. However, there are some less 
common cancers that disproportionately affect Latinos, including gall bladder and 
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infection-related cancers of the liver, intrahepatic bile duct, stomach, and uterine 
cervix [8]. Latino men and women are twice as likely to develop and die from liver 
cancer than non-Latino whites; Latino women are over twice as likely to develop 
stomach cancer as non-Latino white women; and Latino women are 1.6 times as 
likely to develop cervical cancer and 1.3 times as likely to die from it [9, 10].
In addition to increased incidence for some cancers, US Latinos experience other 
cancer disparities. For one, cancer is often diagnosed at a later stage in Latinos 
when the disease is more difficult to treat, perhaps the result of economic and cul-
tural barriers to cancer care and lower use of prevention screening. Second, accu-
rately characterizing Latino cancer risk is challenging because Latinos are 
underrepresented in cancer registries, research, and clinical trials. Thus, these data 
do not reflect the proportion of Latinos in the US population. Compounding the 
problem is the fact that these data commonly consider Latinos as a single group 
when, in fact, Latinos are heterogeneous and may differ by genetic admixture, coun-
try of origin, nativity, degree of acculturation, and socioeconomic status—all fac-
tors that have been implicated in cancer risk.
Advancing the Science of Cancer in Latinos was a timely and critical call to 
action for addressing these cancer health disparities in Latinos. The conference 
brought together researchers, scientists, physicians, healthcare professionals, patient 
advocates, and students from across the nation, engaging them in open dialog that 
moved beyond known cancer disparities to summarize research advancements, 
identify gaps, and develop actionable goals to translate basic research into clinical 
best practices, effective community interventions, and professional training pro-
grams to eliminate cancer disparities in Latinos. Held in San Antonio on February 
21–23, 2018, the conference was co-hosted by the Institute for Health Promotion 
Research (IHPR) at UT Health San Antonio and the Mays Cancer Center, and was 
sponsored by the National Institute on Minority Health and Health Disparities.
The idea for the conference emerged years ago from collaborations among mem-
bers of Redes en Acción: The National Latino Cancer Research Network (Redes), 
which formed almost two decades ago, to address persistent cancer disparities 
among the Latino population in the United States. Created by the IHPR and funded 
by the National Cancer Institute’s (NCI) Center to Reduce Cancer Health Disparities 
(formerly the Special Populations Networks Initiative), Redes is still ongoing and 
connects professionals whose shared purpose is fighting cancer among Latinos 
through community-based education, research, and training. At the time the confer-
ence was discussed, there were a number of new developments in seemingly uncon-
nected areas of science that, if brought together, could be woven into a better 
understanding of cancer in Latinos and where the science ought to go next. Making 
this synthesis happen would require a venue for collaboration among professionals 
from diverse disciplines and perspectives. Advancing the Science of Cancer in 
Latinos provided such a setting for disparities researchers to discuss the latest 
research findings, identify knowledge gaps, and stimulate ideas for new research in 
cancer health disparities among Latinos.
Session topics that support the overall conference theme were set by the Scientific 
Planning Committee members, who had expertise in cancer health disparities 
A. G. Ramirez and E. J. Trapido
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research. The intent was to focus on topics related to the entire cancer continuum, 
specifically, advancements and improvements in risk assessment, primary preven-
tion, screening, detection, diagnosis, treatment, and survivorship. The papers that 
follow are organized into parts that reflect topics of the conference symposia, paper 
sessions, and poster sessions.
 Part II: Genetics, Environment, Lifestyle, and Cancer
In a keynote address, Dr. Eliseo Pérez-Stable, Director of the National Institute on 
Minority Health and Health Disparities, presented an overview of the science of 
cancer in Latinos. He pointed out that most US cancer databases report on Hispanics/
Latinos as a single group; however, it is now widely accepted that this ethnic group 
is, in fact, a heterogeneous mix of subgroups that may differ in country of origin, 
acculturation, nativity (US- or foreign-born), and other factors. Latino ancestry is 
the result of 500 years of admixture in Latin America among indigenous popula-
tions; European colonizers who came from Spain and other parts of Europe; and 
Africans who arrived during the slave trade, most of whom went to the Caribbean 
and Brazil. The proportion of admixture in modern US Latinos is influenced by the 
country of origin and is one important source of variability that exists within this 
group. In addition to genetic ancestry, country of origin, and nativity, Latinos may 
vary also by degree of acculturation, socioeconomic status, and US region in which 
they reside; all of these factors have been implicated in cancer risk and outcome.
In Part II of this volume, Pinheiro, Callahan, and Kobetz make a compelling 
argument for disaggregating Latino data into subgroups by country of origin and 
nativity in order to accurately characterize the cancer experience in Latinos. 
Aggregation of Latinos into one group masks nuances in the data and obscures dif-
ferences among subgroups. They describe some of the methodological challenges in 
determining accurate incidence, survival, and mortality for Hispanic subgroups and 
offer ways to overcome these obstacles.
Gonzalez-Pons and Cruz-Correa report on their studies of colorectal cancer dis-
parities among Puerto Rican and US mainland Hispanics. They propose that dis-
parities between these subgroups may result from a combination of environmental 
and genetic factors including level of European ancestry, genetic predisposition, 
diet, and gut microbiome composition.
 Part III: Cancer Risk, Prevention, and Screening
Incidence rates for cancer vary by cancer site and subgroup. Cancer incidence 
among Latinos as a group is lower than non-Hispanic whites, but cancer is still the 
leading cause of death among Hispanics. Breast cancer is the most common cancer 
diagnosed in Hispanic women and prostate cancer the most common cancer 
1 Advancing the Science of Cancer in Latinos
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 diagnosed among Hispanic men; in both cases the disease is more likely to be diag-
nosed at a later stage than in non-Hispanic whites. Hispanics/Latinos as a group 
have lower incidence rates than non-Hispanic whites for some common cancers 
such as breast, colorectal, lung, and prostate; however, they have higher rates of 
some rarer cancers such as gall bladder and infection-related cancers of the liver, 
intrahepatic bile duct, stomach, and uterine cervix [3]. Strategies for cancer preven-
tion focus on improved screening and altering modifiable risk factors such as smok-
ing, obesity, alcohol use, unhealthy diet, and physical inactivity; infection-related 
cancers may be prevented through vaccination, behavioral change, and treatment 
for infection. Promoting cancer screening and modifying health-related behaviors 
among US Hispanics requires the development of culturally sensitive interventions 
to overcome health disparities and barriers.
In Part III, Fejerman, Serrano-Gomez, and Tamayol summarize what is known 
about breast cancer risk, characteristics, and survival in women of Latin American 
origin. In their review, they point out that the risk of developing breast cancer varies 
among and within Latino subgroups based upon country of origin, nativity, and 
genetic ancestry. The authors also describe some challenges of acquiring the right 
data to predict, prevent, and treat breast cancer in women of Latin American origin, 
such as underrepresentation in large-scale genomic studies and underfunding of 
population-level registries in Latin America.
Stern reviews current knowledge on prostate cancer (PCa) in Latinos and points 
out that while PCa incidence among Latino men is lower than non-Latino whites or 
blacks, there are also reported incidence disparities among Latino subpopulations. 
Other reported disparities include the fact that Latinos have lower rates of PSA 
cancer screening and a higher proportion of cases diagnosed with advanced stages 
than non-Latino white men. Additionally, there are differences in clinical character-
istics and survival pattern among foreign- and US-born Latinos, Latinos with differ-
ent socioeconomic status, and Latino subpopulations defined by the country of 
origin. Why these disparities exist are unknown, but could result from the interplay 
between differences in genetic ancestry, environmental exposures, and attitudes 
toward screening and care. Stern highlights important gaps in knowledge that 
deserve further study such as research on PCa determinants and outcomes among 
Latinos that takes into account Latino heterogeneity.
Tucker and Flanagan describe what is known about diet as a modifiable risk fac-
tor for cancer, specifically obesity; excess alcohol; low intakes of fruits, vegetables, 
fiber and calcium; and high intakes of processed meat and red meat. In addition to 
studying associations between single dietary factors and cancer risk, newer research 
focuses on dietary quality and dietary pattern, that comprises all components of the 
diet. The authors point out that dietary quality differs across Latino subgroups and 
that most Latino groups, particularly Puerto Ricans, fall short of the ideal preventa-
tive diet. Latinos are underrepresented in studies of nutritional risk factors and can-
cer, and the authors recommend that ethnic and cultural background be considered 
when researching dietary habits, in order to reduce bias and establish reasonable 
portion sizes.
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 Part IV: The Biology of Cancer Health Disparities
Using new molecular technologies such as next-generation sequencing, large 
genomics databases (e.g., The Cancer Genome Atlas), and microarray analysis, 
researchers are taking new approaches to study how cancer biology, among other 
factors, contributes to disparities in cancer incidence and outcome. In Part IV of this 
volume, the first two papers discuss the biology of disparities in gastric cancer and 
the second two the biology of disparities in breast cancer among Hispanics/Latinos.
 Gastric Cancer
Gastric cancer (GC) in the United States disproportionately affects Latinos, and the 
incidence varies among Latino subgroups based upon country of origin. Because 
early stage tumors produce no symptoms, gastric cancer is often diagnosed as stage 
IV disease, and the 5-year survival rate is only 29% among Hispanic men and 24% 
among Hispanic women in the United States [3]. Infection with the bacterium, 
Heliobacter pylori, is a risk factor for non-cardia intestinal type gastric cancer, and 
geographic variation in H. pylori prevalence is partly responsible for higher gastric 
cancer incidences and mortality in Latin America than in the United States. Infection 
with H. pylori induces a cascade of predictable (and treatable) pre-malignant, pro- 
inflammatory stages that occur before the onset of dysplasia and gastric cancer. 
Garai, Li, and Zabaleta describe their efforts to find biomarkers of these inflamma-
tory stages and their progression/regression through time. Using samples from 
African American and Caucasian individuals with gastritis, they identified single- 
nucleotide polymorphisms (SNPs) and haplotypes in cytokine genes associated 
with ethnicity. In a cohort of Hispanic/Latino individuals, they identified CD44 as a 
marker of disease progression and DMBT1 as a marker of disease aggressiveness.
Carvajal-Carmona provides an overview of GC epidemiology and describes 
Latino GC disparities including research gaps in etiology and translational research. 
In a discussion of genomic and genetic research disparities, he points out that 
Latinos are underrepresented in all gastric tumor whole exome or whole genome 
sequencing studies; for example, only 1% of GC patients included in The Cancer 
Genome Atlas (TCGA) are Latinos, a population with the highest GC burden. The 
TCGA study divides GC into molecular subtypes that have been associated with 
prognosis or response to therapy. To establish the prevalence of GC molecular sub-
types in Latinos, the author’s research group conducted a pilot study of targeted 
sequencing in tumors from Latino patients, and their results differed from the TCGA 
study. They also found that the mutation frequency of known gastric cancer driver 
genes in Latinos differed from the frequency reported in the TCGA. These results 
suggest that the molecular profiles of GCs in Latinos are unique, pointing to the 
need for more comprehensive tumor genomic studies.
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 Breast Cancer
Even though Hispanic woman have lower incidence and mortality from breast can-
cer than non-Hispanic white women, breast cancer outcome disparities do exist and 
are greatest among young Hispanic women (<40 years) who are more likely to have 
aggressive disease and present in advanced stage. Colon-Otero speculates that this 
early onset disparity is likely a result of genetic factors, environmental factors, and 
altered estrogen metabolism resulting from childhood obesity. Recent data support 
his working hypothesis that increased stress and poor dietary habits associated with 
low socioeconomic status lead to childhood obesity in Hispanics. Obesity results in 
increased production of serum IL-6 and other adipokines, promoting aromatase 
transcription and increased serum estrogen and genotoxic estrogen metabolites. He 
recommends that new studies are needed to clarify the biological factors that pro-
mote outcome disparities among Latinas with breast cancer.
The advent of gene-expression profiling with microarray technology has allowed 
the classification of breast cancer into intrinsic molecular subtypes such as luminal 
A and luminal B, which are estrogen receptor positive (ER+), and HER2-enriched 
and basal-like, which are estrogen receptor negative (ER−). These subtypes are 
prognostic, and their relative prevalence varies among and within subgroups. 
Serrano-Gomez and Zabaleta review what is known about molecular profiles of 
breast cancer in different subgroups and point to the growing evidence that differ-
ences in gene expression profiles may be a consequence of ancestry. In their own 
studies, the authors determined the frequency of intrinsic subtypes of breast cancer 
in Colombia, and they found that the Luminal B subtype was the most prevalent and 
that African ancestry was associated with more aggressive cancer. Using next- 
generation sequencing, they identified 67 genes that were differentially expressed 
between luminal A and luminal B subtypes, six of which were common between 
patients with high European/low Indigenous American ancestries. Their results sug-
gest that ethnicity influences modulation of these genes in breast cancer and may be 
used to study breast cancer susceptibility in minority groups.
 Part V: Advances in Cancer Therapy and Clinical Trials
Biomarker testing, which is now often the standard of care for patients diagnosed 
with cancer, can be used by physicians to assess cancer risk, diagnose a particular 
cancer, select treatment, and/or assess treatment response. In a keynote address, 
Edith Perez, Professor of Medicine at the Mayo Clinic, discussed basic concepts 
and issues of biomarker-based precision medicine in clinical trials and oncology 
practice. In a summary paper presented in Part V of this volume, she describes gen-
eral features of well-designed biomarker-driven clinical trials and offers specific 
suggestions for designing clinical trials to support FDA approval. Perez predicts 
that in the near future, tumor sequencing will become standard clinical practice; 
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liquid biopsies will become available to sample circulating tumor DNA (ctDNA); 
tumor classification will become molecular-based and tumor-agnostic biomarker 
strategies may be used to manage patients; and clinical trials in oncology will use 
sequencing at both enrollment and follow-up. Additionally, she describes some 
basic concepts and challenges in the use of cancer immunotherapy (CIT) biomark-
ers, which are revolutionizing oncology. A new Program for Accelerated Cancer 
Therapies (PACT) was cited as an example of a multidisciplinary collaboration with 
NIH, NCI, and biopharma that aims to support development of standardized bio-
markers for immunoprofiling and exploratory biomarkers of high relevance to 
patient care. Finally, Perez explains why bringing biomarker-based trials to patients 
is challenging and predicts that large collaboratives such as PACT will move preci-
sion medicine and oncology forward by linking clinical retrospective and prospec-
tive cancer genomic and proteomic data with longitudinal clinical outcomes.
A recurring theme throughout the conference was that Hispanics are greatly 
underrepresented in the large cancer and genomic databases and that by placing all 
Latinos into one category, these datasets do not capture the variation in cancer deter-
minants and outcomes that exist among Latino subgroups. Part of the solution is to 
improve Latino recruitment into cancer clinical trials, which is historically low. 
Ruben Mesa, Director for the Mays Cancer Center in San Antonio, points out that 
cancer clinical trials must reflect the population being studied in order to capture 
differences among ethnic groups and to make inferences that are generalizable. 
How to improve Latino accrual into clinical trials is so important and problematic 
that it has become an active area of research. In his presentation, Mesa discusses the 
challenges of enrolling patients into clinical trials and the additional barriers that 
must be overcome to recruit a representative number of Latinos. He describes 
research and model programs from the Massey Cancer Center at Virginia 
Commonwealth University and the Mays Cancer Center at UT Health San Antonio 
that are designed to enhance Hispanic accrual and address underrepresentation in 
clinical trials. Recommended next steps to improve accrual into clinical trials are to 
educate physicians to better promote enrollment, build awareness among Hispanics 
about the role of clinical trials in improving cancer care, enhance care navigation for 
treatment planning including matching the right patient with the right study, develop 
language- and culture-appropriate educational materials, and share lessons learned 
among centers and investigators.
 Part VI: Cancer in the Era of Precision Medicine
Biomarker testing and genetic profiling of tumors are revolutionizing cancer care, 
leading to more refined risk assessment, diagnosis, and targeted treatment. In Part 
VI, two papers address cancer care disparities and the application of precision medi-
cine in Hispanic populations. Zabaleta et  al. make the case for including more 
Hispanics in precision medicine research. Because most genomic and transcrip-
tomic studies are based on tumors from Americans of northern European ancestry, 
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precision medicine based on these data may actually worsen health disparities. In 
the case of breast cancer, another problem is that most epidemiological studies not 
only consider Hispanics/Latinas as a single group, but they also treat breast cancer 
as a single disease. Even though Hispanics have a lower incidence of breast cancer 
than non-Latino whites, they have a higher mortality risk, which may result from 
differences in the prevalence of breast cancer subtypes or molecular differences 
within subtypes. Results from their own research on breast cancer in Colombian 
women and the work of others have led the authors to suspect that luminal subtype 
tumors in Hispanics may be biologically different from other ethnic groups and that 
these differences may result from non-genetic or ancestry-linked factors. Thus, the 
interpretation of gene expression tests and treatment choices may have to take this 
into consideration.
Lorna Rodriguez-Rodriguez, from the Rutgers Cancer Institute of New Jersey, 
describes her team’s study of precision medicine and cancer care disparities within 
the Latino population in New Jersey. They performed a small, longitudinal study of 
patients with rare or refractory tumors who underwent genomic profiling and com-
pared outcomes between Latino and non-Latino white patients. Even though Latino 
patients had more advanced disease at the time of diagnosis, those who received 
targeted therapy survived an average of 10 months longer than their white counter-
parts; Latino patients who did not receive targeted therapy survived an average of 4 
months longer. Further, they found no disparity between Latino ancestry patients 
and non-Latino white patients in the implementation of precision medicine in their 
clinical care. Their final conclusions will be based on a larger sample from their 
ongoing analysis.
 Part VII: Cancer Outcomes and Survivorship in Latinos
Ethnicity, socioeconomic status, and culture can profoundly impact cancer outcome 
and survivorship in Latinos. Culturally and linguistically appropriate interventions 
are needed for Latino cancer survivors to reduce disparities and address the long- 
term physical and psychological effects of cancer treatment on quality of life. In 
Part VII, there are two examples of such interventions—Nuevo Amanacer and 
Nueva Vida.
Cancer centers are often not equipped to meet the needs of Spanish-speaking 
Latinos with cancer, who have limited access to survivorship care that is linguisti-
cally and culturally appropriate. Nápoles provides a vision for improving the quality 
of life among Latina survivors of breast cancer by engaging Latino communities in 
design and implementation of behavioral interventions that can be delivered in com-
munity settings and are linked to cancer care systems. She reviews the randomized 
controlled trial to test Nuevo Amanacer—a peer-delivered stress management inter-
vention to improve the psychosocial health of Spanish-speaking Latina survivors of 
breast cancer. Using community-based participatory research methods, her research 
group created the program by integrating an evidence-based intervention, a 
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 community best-practices program, and their formative research. Participants in the 
trial were urban Latinas with breast cancer, and their results showed that this inter-
vention improved several quality of life domains, decreased breast cancer concerns, 
depression, and bodily symptoms. They are now translating and testing the program 
in rural, low income areas where there are greater disparities in cancer support. 
Nápoles describes their conceptual framework to guide research on behavioral 
interventions for Latino cancer survivors and opportunities for future research.
Patient-centered outcomes research (PCOR) involves patients and other stake-
holders in study design, implementation, and evaluation. Graves presents an exam-
ple of PCOR using “research democracy”—a process in which individuals involved 
in research (e.g., team members, participants, and advisors) have a vote and a voice 
in research decisions and procedures. She describes their Nueva Vida intervention 
study designed to improve quality of life outcomes among Latina breast cancer 
survivors and their caregivers. To evaluate the intervention, her research group con-
ducted a randomized controlled trial using research democracy, and their initial 
results suggest that this can be an advantageous approach that improves PCOR and 
benefits both patients and their caregivers.
 Part VIII: Engaging Latinos in Cancer Research
One of the challenges in eliminating cancer disparities and achieving health equity 
among Latinos is that successful interventions must elicit behavioral change, which 
requires messaging in a culturally nuanced manner that resonates with the targeted 
Latino subgroup. Model interventions with the shared goal of changing health- 
related behaviors are presented in Part VIII, and they range from community-based 
participatory research (CBPR), peer modeling, social reinforcement, and integrat-
ing the effects of culture operating at various levels of influence.
Community-level interventions that engage Latinas from the beginning of 
research through data dissemination can potentially help reduce cancer disparities 
and save lives. In her paper, Baezconde-Garbanati examines key elements for 
engaging Latinas in cervical cancer research and discusses the importance of CBPR 
principles in facilitating knowledge transfer from researchers to the community. 
Also discussed is how citizen scientists/patient advocates and promotores de salud 
can enhance community participation and engagement in patient-centered research. 
She provides specific examples of how their research group has engaged Latinas in 
cervical cancer research through two campaigns—Tamale Lesson and Es Tiempo. 
The widely disseminated Tamale Lesson is a culturally tailored narrative in film 
format that provides information on the human papillomavirus as a cause of cervical 
cancer, prevention with vaccination, and detection with Pap test screening. Es 
Tiempo uses the annual blooming of the Jacaranda tree as a visual reminder to take 
steps to prevent cervical cancer. It includes an outdoor media campaign, clinical 
intervention, and community educational workshops delivered by promotoras de 
salud. These two initiatives demonstrate ways to create a research environment 
1 Advancing the Science of Cancer in Latinos
12
 conducive to engagement, and the cultural strategies used in these cervical cancer 
interventions are generalizable to other diseases.
Text messaging can promote smoking cessation by providing peer modeling and 
eliciting social reinforcement for behavioral change. Chalela et al. present results 
from Quitxt, a tobacco cessation program using bilingual text-messaging promoted 
by social media. The target population was young adult Latinos aged 18–29  in 
South Texas, a marginalized population with low access to smoking cessation ser-
vices. Text messages included links to web pages with additional content and 
YouTube videos that peer modeled reasons and skills to quit smoking. They found 
that 21% of participants reported abstinence at the 7-month follow-up.
Lechuga and Melo present gaps in cervical cancer prevention research and inter-
vention development. These gaps point to a need for interventions that simultane-
ously target cultural factors operating at multiple levels of influence and that broaden 
focus on outcomes beyond cancer screening to include improvement in sexual and 
reproductive health. Additionally, few interventions uniquely target Latinas, and 
few are informed by theories explaining how culture may affect screening and treat-
ment. The authors present results of two research studies to bolster the case for a 
more nuanced conceptualization of the potential effect of culture, which may oper-
ate at various levels of influence. They found from these studies that a larger propor-
tion of mothers who had vaccinated their daughters engaged in discussion about 
sexuality than mothers who had not vaccinated and that embarrassment and shame 
ascribed to sexuality were significantly associated with negative attitudes toward 
cancer screening.
Cancer research studies often collect biospecimens as part of the research par-
ticipation process, and it is important that Hispanics are not underrepresented. 
Rodriguez and Erwin describe the Hoy y Mañana (HyM) study as a model of a 
novel application of a community-based approach to biobanking and biospecimen 
research. These studies developed and tested community-based interventions in a 
Northeast Hispanic population to identify factors that influence participation in bio-
specimen donation to a biorepository for future cancer research. The authors use the 
development of the HyM study as an example to highlight critical steps for engag-
ing Hispanic communities in cancer research.
 Conclusion
Basic scientists and clinicians as well as policy makers and public health profes-
sionals gathered in San Antonio to tackle Latino cancer disparities on numerous 
fronts—from basic research on biological differences behind disparities to 
community- level interventions that aim to overcome barriers to cancer care and 
address the unique needs of Latino populations. Unlike past conferences on cancer 
health disparities that focused primarily on policy and public health issues, 
Advancing the Science of Cancer in Latinos incorporated perspectives from a vari-
ety of disciplines with the view that collaboration among diverse professionals is 
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what is necessary now to move the field forward. The papers and posters presented 
here represent just a beginning, and the hope is that the dialog and collaboration that 
started here will continue into the future, providing new solutions for the elimina-
tion of cancer health disparities among Latino populations.
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Chapter 2
Disaggregated Hispanic Groups 




Hispanics living in the United States are heterogeneous: US-born and foreign-born; 
Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, 
and a small number from Spain; wealthy and impoverished; English and/or Spanish 
speaking; residing in the North, South, East, or West; situated in cities or rural areas. 
These varying socioeconomic circumstances, nativity and/or immigration experi-
ences, and cultural values and practices are strongly associated with cancer risk 
factors and thus impact cancer outcomes.
 Epidemiology of Cancer in Hispanics: Aggregated
Cancer is the leading cause of death of all Hispanics combined [1], with the annual 
number of new cases diagnosed in 2014 exceeding 128,000 [2]. To address the 
increasing cancer burden of the burgeoning Hispanic population, including the 
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development of cancer prevention and control strategies, all stakeholders, from cli-
nicians to researchers to policymakers, must have timely and accurate population- 
based cancer indicators, namely incidence, survival, and mortality. Incidence 
patterns are routinely reported by the North American Association of Central Cancer 
Registries (NAACCR) in their Cancer in North American (CiNA) Annual Reports 
[3] and the Annual Reports on Cancer, which group data from the Surveillance, 
Epidemiology, and End Results Program (SEER) and the National Program for 
Cancer Registries (NPCR) [4]. In addition, SEER provides data available for sur-
vival estimates of Hispanics [5], and mortality data are provided by the National 
Center for Health Statistics within the Centers for Disease Control and Prevention 
(CDC) [6].
However, accurate indicators for Hispanics are affected by specific problems. 
Hispanics are known to be undercounted at the cancer registry level [7, 8], largely 
due to incompleteness of the ethnicity variable. NAACCR protocols for the calcula-
tion of incidence rates reduce this undercount by using the NAACCR Hispanic 
Identification Algorithm (NHIA) which relies partly on Hispanic surname [9]. 
Mortality data also suffer from some degree of undercount, potentially up to 5% 
[10]; however, routine use of similar algorithms does not take place. Nonetheless, 
Hispanic incidence and mortality estimates are generally consistent with each other 
and show that US Hispanics in aggregate have lower cancer incidence and mortality 
rates (overall and for the most common cancers) than the non-Hispanic white 
(NHW) referent group [1]. Important and well-known exceptions to this pattern are 
infection-related cancers, in particular cervix, liver, and stomach, for which 
Hispanics, examined in aggregate, have shown consistently higher rates than NHWs 
[1]. For survival, follow-up for foreign-born in general and Hispanics in particular 
can be difficult to perform, especially in comparison to NHWs and non-Hispanic 
Blacks [11]. However, SEER registries show that for all stages combined, cancer 
survival of Hispanics is similar or only slightly lower than NHWs, depending on 
cancer site [5].
Given the lower incidence, lower mortality, and relatively comparable survival 
among Hispanics in relation to NHWs, cancer has been frequently cited as another 
example of the “Hispanic Paradox,” whereby Hispanics have positive health out-
comes despite documented challenges with lower socioeconomic status and access 
to quality health care [12]. Another often cited positive characteristic in the study 
of health outcomes for Hispanics is the Healthy Immigrant Effect [13] (whereby 
immigrants are healthier on average than both their counterparts at home and the 
populations in the host countries) as a sizable portion of Hispanics are immigrants 
to the United States. The reality, however, may well be more complicated. Evidence 
from Fenelon et al. [14] has shown that the “Paradox” in terms of cancer mortality 
(and thus incidence) may largely be tobacco-related, and analyses of the potential 
survival parity or advantage for Hispanics on a population basis may be in part 
artifactual, a problem addressed later in this manuscript [11, 15–17]. Additionally, 
cancer patterns among US-born Hispanics in relation to NHWs are not nearly as 
favorable as their foreign-born counterparts in the United States [18], offering a 
persuasive counterargument to the contention that any advantage stems from being 
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Hispanic per se; rather, the advantage is at least partly being foreign-born, an 
advantage not exclusive to Hispanics, but also present among foreign-born Asians 
and Blacks [19, 20].
Such complexities are challenging, justifying the need for a distinct focus on 
cancer among Hispanics. Hispanics are demographically young, considerably het-
erogeneous, and, by and large, recent arrivals, as shown by the sevenfold increase in 
the Mexican Hispanic population between 1970 and 2010 [21]. Thus, they differ 
from the more established NHW and non-Hispanic Black populations and need a 
more critical and refined evaluation of their cancer indicators for a full understand-
ing of their epidemiological patterns. Simply stated, aggregate estimates for all 
Hispanics that do not consider birthplace and the distinct Hispanic groups are mask-
ing considerable variation, with poor cancer outcomes seen among some segments 
of the Hispanic population that deserve additional targeted efforts to reduce dispari-
ties. Equally compelling is that careful examination of the determinants of these 
vast differences, whether risk or protective factors, can provide crucial information 
needed for effective public health and clinical intervention. In addition, any existing 
survival advantages among Hispanics could be hypothesis-generating and/or pro-
vide insights into improving cancer outcomes for other populations. Lastly, we 
demonstrate that specific Hispanic group analyses can provide new insights into the 
etiology of some cancers, insights only revealed by examining patterns among dis-
tinct Hispanic groups.
 Epidemiology of Cancer in Disaggregated Hispanic Groups
 Challenges in the Data
Cancer Registry Data (Incidence and Survival) Given their heterogeneity, much 
can be learned from examining the unique cancer profiles of all sizable Hispanic 
groups in the United States. These can be divided into 35 million Mexicans, 5.5 
million Central Americans, 5.3 million Puerto Ricans, 4.1 million South Americans, 
2.1 million Cubans, and 1.8 million Dominicans as of 2015 [22]. Additionally, 
examining differences between US-born and foreign-born (FB) groups adds clarity 
to the profiles, albeit only feasible with Mexican and Puerto Rican populations (for 
whom birth on the island is often analyzed as equivalent to FB), because of the 
sparsity of US-born cancer cases among the other Hispanic groups. NAACCR stan-
dards currently include the following specific categories of Hispanic ethnicity 
(group) for cancer cases: Mexican, Puerto Rican, Cuban, Dominican, and a single 
category for Central/South American, a convenient aggregation of very diffuse pop-
ulations, despite having sociodemographic characteristics that are substantially dif-
ferent between the two. In addition, there are categories for other specified Hispanics 
including those from Spain, Hispanics by surname only, and Hispanics not other-
wise specified (NOS) [3].
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Overall, population-based analyses of cancer outcomes by Hispanic group and 
birthplace are obviously dependent on the completeness of these two data pieces. 
Unfortunately, both variables are substantially incomplete in cancer surveillance 
data required for incidence and survival statistics. In the most recent CiNA report 
released by NAACCR in 2017 [3], known specific group for 2010–2014 among 
Hispanic cancer cases was as low as 32% in Texas and only 58% in New York and 
New Jersey, all states with high Hispanic populations. Birthplace was only 50% 
complete for registry data in California (CA) [23] and 43% in Florida (FL) [24], 
ideal states for studying differences between US-born and FB Mexican Hispanics 
(CA) and specific Hispanic groups (FL).
Mostly because the underlying data is complex and because of this considerable 
incompleteness, incidence rates of Hispanic groups have been estimated only a few 
times. Some researchers assigned groups ecologically at the county level, for exam-
ple, Puerto Rican for all Hispanic cases residing in counties in New  York City, 
Mexican for all Hispanics in Los Angeles County, and Cuban for all Hispanics in 
Miami-Dade and Broward counties in Florida [25, 26]. However, these methods are 
subject to substantial misclassification of Hispanic group at the individual level, 
leading to inflated estimates for some groups and underestimates for others. Other 
researchers assessed heterogeneity in risk among Hispanic groups using propor-
tional incidence ratios (PIRs) [27, 28]; however, because PIRs do not depict the 
actual incidence of disease and are highly dependent on the relative frequency 
weight of each cancer, they have the potential to be misleading. To date, the only 
incidence rates for Hispanic groups calculated with individual level data was deter-
mined based on three years of Florida data (1999–2001) and included imputation of 
32% of Hispanic cases to specific groups based on county of residence, cancer site, 
age and sex [29]. The study found that Mexicans in Florida had low cancer risk for 
most cancers except liver, cervical, and stomach, while Cubans and Puerto Ricans 
shared higher cancer risk compared to other Hispanic groups and had rates of endo-
metrial, prostate, and colorectal cancer similar to NHWs [29]. Cubans more closely 
resembled NHWs with lower cervical and stomach cancers than other Hispanics, 
yet they surpassed NHWs for colorectal cancer, while Puerto Rican males showed 
particularly high liver cancer rates [29]. Some of these relative patterns observed for 
incidence are similar to current mortality analyses [30], suggesting that the underly-
ing risk factors for each of these populations have not substantially changed in the 
last decade and attesting to their persistence in the respective Hispanic populations. 
Since then, no other study has attempted to estimate population-based incidence 
rates for Hispanic groups.
Like incidence research, and owing to many of the same shortcomings, few stud-
ies have analyzed differential cancer survival by Hispanic group. These projects 
were mostly conducted in Florida [15, 31], the state with sufficient heterogeneity 
and numerically sizeable Hispanic groups to conduct such studies, but were subject 
to some important biases, as discussed in more detail below. SEER provides sur-
vival statistics for Hispanics, which are predominantly reflective of the experience 
of Mexican Hispanics given the overwhelming proportion of this group in the SEER 
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coverage area [5]. However, because of incompleteness of place of birth, SEER 
survival statistics reports do not make a distinction between US- and foreign-born 
Hispanics [5]. Overall, the consequence of this obstacle in the data and its conse-
quences (see below) is a virtual dearth of knowledge regarding differences in sur-
vival among specific Hispanic groups and compared to other non-Hispanic 
populations.
Vital Statistics Data (Mortality) In contrast to surveillance data (used for inci-
dence and survival), mortality data, particularly when obtained directly from states, 
can be assembled to achieve near completeness for Hispanic specific groups. 
Another advantage of mortality data is that with additional work using specific 
place of birth and text fields, it is possible to study Central Americans and South 
Americans separately, which is not possible in cancer registry data. Thus, mortality 
data are optimal to analyze Hispanic heterogeneity in detail.
While the National Vital Statistics System data from the CDC [6] have the advan-
tage of covering the entire nation, the available data lack sufficient detail on some 
key variables, such as specific country of birth and ethnicity text fields. These fed-
eral datasets are compiled from each state’s data and rely on broader variables (e.g., 
US versus foreign birthplace, South/Central American ethnicity) which inevitably 
leads to some degree of misclassification [6]. As an example, for cancer deaths that 
occurred between 2010 and 2016 in the diverse state of Florida, 29%, 24%, 17%, 
10%, and 9% of individuals born in Paraguay, Spain, Argentina, Venezuela, and 
Honduras, respectively, were coded as non-Hispanic [32]. Furthermore, of all 
Argentinians categorized as Hispanic, coded Argentina by birthplace and/or text 
fields, 38% were not correctly categorized in the South/Central American category, 
most likely falling into the Ethnicity Other category. The pattern continued with at 
least 20% of those who were known to be from Central/South America (Nicaraguans, 
Colombians, etc.) and not found in the South/Central American grouping category 
[32]. On the other hand, individuals born in countries such as Brazil, Italy, and 
Portugal have substantial proportions recorded as Hispanic ethnicity, when this does 
not correlate with the US Office of Management and Budget (OMB) definition of 
Hispanic [33]. While this misclassification results in some underestimation of 
Hispanics as a whole, its final effect on estimated rates is more pronounced when 
studying specific Hispanic groups, with misclassification across groups as well as a 
variable proportion of Not Otherwise Specified Hispanic cases (NOS).
However, at the state level, mortality data for some states contains the necessary 
detailed information that allows for accurate specific group classification based on 
codes for ethnic groups and specific birthplace, augmented with revealing text 
descriptive for otherwise incompatible or incomplete cases. In our studies [18, 30, 
34], we found data in three states (California, New York, and Florida) to be more 
than 97% complete with a traceable specific Hispanic group leaving only 3% of 
cases as Hispanic NOS. Notably, the availability of ethnicity group, birthplace, and 
text fields was partial for other states (Texas) and unavailable for Maryland and New 
Jersey, limiting their use for this purpose.
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 Challenges in the Analyses
Primary to the accurate disaggregation of Hispanics into unique groups is the iden-
tification of all those in the population who are indeed Hispanic. While acknowledg-
ing that race and ethnicity are social constructs that vary by geography across the 
globe, within the United States, disparities research has followed the OMB-defined 
division [33] of races into four mutually exclusive categories (and mixed race) while 
ethnicity is coded as Hispanic or Latino, via a binary Yes/No. Once a case is coded 
Hispanic, then depending upon the data source and how it is collected, specific 
group allocation follows. One of the greatest challenges in population-based studies 
is how to best handle those persons who cannot be allocated definitively to a group, 
commonly referred to as Not Otherwise Specified, or Hispanic NOS. Importantly, 
these persons do not constitute an actual distinct group, as each case logically 
belongs to a specific group (or combination of groups) at some point whether in the 
present or by heritage from past generations. Despite that, a minority of cases 
(mostly US-born) self-identify as Hispanic only. However, a comparison of inci-
dence data (low completeness of Hispanic specified group) to mortality data (very 
high completeness of Hispanic specified group) shows that more often, specific 
group information is known to the individual case, but is not asked, not known, or 
not available to those who record the data. Thus, assignment to the Hispanic NOS 
category is commonly a result of incomplete information. How researchers attend to 
these cases determines the accuracy of resulting calculated indicators.
Incidence and Mortality Rate Problems for Disaggregated Hispanic 
Groups Management of Hispanic NOS cases varies between the sources of data 
used for calculating cancer outcomes. Cancer registry data for cancer incidence and 
death data for mortality rates are used in the numerators, and census-based popula-
tion data are used in the denominators. Census reports have traditionally grouped 
Hispanics into five categories, with only three corresponding to specific groups: 
Mexicans, Puerto Ricans, and Cubans. Other Specified Hispanics (which includes 
any specified group such as Dominican, Central American, South American, 
Spaniard, etc.) make up a fourth group, and a very sizeable Hispanic NOS group is 
the last. Thus, Hispanic NOS cases in the numerator, whether derived from incom-
plete incidence data or more complete mortality data, do not correspond to the NOS 
cases in the denominator, which raises a critical compatibility issue. When estimat-
ing rates for these specific groups, the lack of proper handling of NOS cases with 
the correction of this imbalance can truly confound our understanding of patterns 
among Hispanics.
Mortality rates are a good example. Without attending to the fact that the total 
number of NOS cases in census data logically includes Hispanics from potentially 
all groups (including Mexican, Puerto Rican, and Cuban) [35], people will be miss-
ing from the denominator for the three groups that are specified: Mexican, Puerto 
Rican, and Cuban. Another common problem arises in studies which combine the 
fourth (Other Specified, i.e., South and Central Americans, Dominicans) and fifth 
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census groups (Hispanic NOS) into one denominator group and combine all non- 
Mexican, non-Puerto Rican, and non-Cuban cancer cases into one numerator group. 
These NOS mismatches between numerators and denominators result in an overes-
timation of death rates for the Mexican, Puerto Rican, and Cuban groups, with a 
meaningless underestimation of the Hispanic NOS mortality rates (often labeled as 
Other Hispanics or South and Central American, more for convenience than accu-
racy). For incidence rates, the problem is even worse because the specific group 
information in the numerator is substantially less complete than mortality data; and 
without accounting for the Hispanic NOS, these group-specific rates are inevitably 
underestimated. Sadly, some research published in reputable journals fail to meet 
the basic logical tenet that the sum of the parts should equals the whole; rather these 
studies present disaggregated results where the sum of the weighted rates for each 
group does not correspond to the total All Hispanics rate. Errors of this nature arise 
from the complexity of managing the Hispanic NOS cases; treating NOS cases as 
an included unique group and excluding them are both problematic. Thus, as in our 
research, exhaustive ascertainment of specific group in both the cancer data and the 
denominator data from available detailed sources [22], followed by treatment of the 
remaining (hopefully minimal) NOS cases via appropriate partition and/or imputa-
tion strategies, is essential for the presentation of the true cancer incidence and 
mortality rates in Hispanic groups. In addition, the partition and/or imputation 
should always take into account birthplace distributions [36] in both the cancer data 
and the population data.
 Survival Estimation Problems for Disaggregated Hispanic 
Groups
Hispanic NOS Survival estimates on a population level are derived from one data 
source, cancer registries, and thus theoretically should avoid the problem of numer-
ator/denominator mismatch. Survival denominators are all the cancer cases, while 
numerators are those who have survived up until a certain designated period of time. 
However, a crucially important methodological barrier to calculate accurate survival 
for groups also includes the “nebulous” Hispanic NOS category and who it repre-
sents. In cancer surveillance data (registries), a proper specific group is more likely 
specified when the death has occurred because extra information on ethnicity and/
or birthplace is available from direct access to and/or linkages with death certificate 
data. Consequently, having a specified Hispanic group in registry data is positively 
correlated with death, the exact outcome of interest in survival analysis [16, 17]. 
Conversely, if a Hispanic case is not deceased, the information available for precise 
group and birthplace is much less available, making it more likely to be ascribed as 
Hispanic NOS, rather than Mexican, Cuban, etc. The resulting survival estimates 
for the specified Hispanic groups will thus be underestimated, or lower than reality, 
precisely because those who are alive from any given specific group are more likely 
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to be coded NOS while those who are dead are more likely to have a specified group 
[16, 17]. In practical terms, this results in a specific group likely appearing to have 
worse (lower) survival than reality, while the Hispanic NOS survival will have bet-
ter (higher) survival than that seen for all Hispanics combined, as these NOS cases 
are more likely to appear alive [16, 17]. Thus, exclusion of Hispanic NOS cases in 
survival analysis, under the false assumption that membership in the NOS group is 
random, results in highly biased results, with a specified group having biased low 
survival compared to other non-Hispanic groups (e.g., NHWs), since some alive 
cases are being excluded. Additionally, even if Hispanic NOS cases are excluded 
and analysis is restricted to Hispanic known groups only, survival comparisons will 
still be biased. This is because Puerto Ricans and Cubans are two groups for which 
death matches are more complete than Mexicans and Central and South Americans, 
given the higher proportion among Puerto Ricans and Cubans of a workable social 
security number, the essential variable for death linkages [11, 15]. As it stands, on a 
population basis, exclusion of NOS cases misses the population-based characteris-
tics of the data for each of the Hispanic groups and results in making their outcomes 
look worse than reality.
Disproportionate Loss to Follow-up Survival studies have identified artifactual 
factors impacting death linkages to cancer registry data, particularly for minority 
groups with substantial proportions that are foreign-born such as Hispanics [11, 15]. 
Linkage problems arise from an inability to match social security numbers (SSN) 
because of diverse reasons including lack of SSNs, incorrect SSNs resulting in non- 
matches, or different structure of surnames or misspellings, common among 
Hispanics as well as among Asians from countries with non-Roman alphabets [11]. 
Missed deaths also arise from cases that are diagnosed in the United States but die 
in another country. These may be non-residents who are falsely coded as resident 
when coming to the United States solely for diagnosis and treatment, often referred 
to as “medical tourism.” Others may be residents who are diagnosed here but return 
to their home countries to die, a phenomenon referred to as the “Salmon Bias” [37].
In all the described scenarios, persons from minority populations, especially 
those with late stage disease, are disproportionately lost to follow-up [11]. This may 
bias their survival upward (better than reality), especially in non-SEER states with 
registries associated with the CDC’s National Program of Cancer Registries 
(NPCR). The difference between the registry types arises because SEER registries 
benefit from the requirement of a minimum of 95% of cases having a precise date 
of alive contact over time [38]. Unfortunately, this requirement is not specific to 
ethnicity or birthplace; thus, the remaining 5% are alive/living cases, disproportion-
ately foreign-born and minority cases. By accruing more accurate survival time, 
SEER substantially reduces the potential for bias from non-random censoring 
among the foreign-born. However, in NPCR registries, no date of last alive contact 
is recorded, and if a specific patient does not match any record in a mortality list at 
a given date, then that patient is presumed alive at that date, which is called the 
“presumed alive” assumption of survival [11]. The following example illustrates the 
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current difference between SEER and NPCR survival data: Mrs. X is a US resident 
of Venezuelan origin who had lung cancer diagnosed in the United States. After 4 
months of treatment in the United States, she returns to her birth country and subse-
quently passes away in Venezuela. The death data for Mrs. X never reaches mortal-
ity records in the United States. In SEER registries, her vital status would be counted 
as alive, but only for 4 months of survival time, based on her last medical encounter 
recorded in the United States. In NPCR registries, she would be presumed alive 
until the date of cut-off for the survival estimation, often 5 years. Thus, the NPCR 
registry would have substantially more months of survival for Venezuelans than the 
SEER registry. Similarly, having an unworkable SSN or a misspelled last name 
(both problems more prevalent among the foreign-born) would work the same way 
even if there was no return to Venezuela, because they could more likely result in a 
missed death after routine death linkages. Compared to other groups, deaths of 
Puerto Ricans and Cubans are more likely to be fully captured and linked in cancer 
data [15]. This is because Puerto Ricans are US citizens, and Cubans have lower 
likelihood of returning to Cuba and historically greater facility in acquiring legal 
status in the United States. While on a population basis the proportion of missed 
deaths is small, these missed deaths, particularly for poor prognosis cancers, in 
Hispanic groups that are largely foreign-born (especially Central and South 
Americans [15] and Mexicans born in Mexico), result in inflation of survival esti-
mates, making comparisons inaccurate [11]. To make things even more confusing, 
the combined effect of these biases—Hispanic NOS and higher loss to follow-up—
can send survival estimates in any direction away from reality depending on which 
one is stronger or just balance each other out.
 Current Knowledge: Cancer in Hispanic Groups, Based 
on Mortality Data
Using mortality data, we conducted research that either addressed or bypassed the 
common deficiencies in the literature for disaggregated Hispanic groups. We used 
death certificate data and carefully assembled multiple race/ethnicity fields, text fields, 
and available birthplace variables to accurately classify Hispanic group. Here we sum-
marize our findings from population-based studies using disaggregated Hispanic 
groups, highlighting four examples to show the importance of disaggregation.
Mexicans and Puerto Ricans in the United States Compared to Those in Mexico 
and Puerto Rico Mexicans and Puerto Ricans are the largest US Hispanic groups 
traceable to a single country of origin. (The island of Puerto Rico, although an 
American territory, is considered here as a country of origin for convenience.) Using 
methodology from other studies, we compared cancer rates for these specific groups 
in the states where they are most populous, California for Mexicans and New York 
for Puerto Ricans, to cancer rates among their counterparts in Mexico and Puerto 
Rico, respectively (Table 2.1) [34, 39].
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For the vast majority of cancers, mortality during the studied time period (2008–
2012 in California and 2008–2014 in New York) was higher in the Hispanic groups 
residing in the United States than in their countries of origin [40, 41] (Table 2.1). 
Given that cancer survival is higher in the continental United States than in Mexico 
and Puerto Rico [42], higher mortality suggests that cancer incidence must be sub-
stantially higher in the United States for the majority of cancers. Differences in risk 
among genetically and culturally similar populations such as these are commonly 
attributed to a higher prevalence of lifestyle risk factors in the United States, includ-
ing smoking, obesity, alcohol, and other substance abuse [43]. Thus, results show-
ing higher mortality in the United States are not surprising for many cancers 
including lung and other tobacco-related cancers; breast cancer, linked to obesity 
but also likely to differences in fertility patterns; liver cancer, linked to obesity and 
chronic infection with the hepatitis C virus (HCV); and other obesity-related can-
cers such as kidney and endometrial. The significantly higher pancreas and non- 
Hodgkin lymphoma mortality patterns are more intriguing, given how little 
etiological knowledge is known for these cancers that could be explained logically 
on a population basis. For a few cancers, mortality rates are lower in the United 
States among the Mexican and Puerto Rican groups compared to their country-of- 
origin counterparts. These include prostate cancer, an interesting pattern seen in 
other migration studies [20, 39, 44] and likely reflective of better survival in the 
United States including more aggressive treatment in older ages and more access to 
varied and complex treatment regimens, notwithstanding the potential effect of the 
comparatively higher PSA screening patterns in the United States.
Interesting patterns that emerge between these two distinct Hispanic groups 
include Mexican American women seeming to escape the adverse HCV impact, 
with lower liver cancer rates than women in Mexico. Also, excesses in colorectal 
cancer for Mexican American men compared to Mexico are not mirrored in Puerto 
Rican patterns. Conversely, the gains seen among Mexican Americans for cervical 
and stomach cancers are not realized among Puerto Ricans in New York, who share 
similar high mortality with their island counterparts (Table  2.1). Some findings 
from similar analyses using available data from US minorities and their countries of 
origin extend to childhood cancer: for instance, Mexican American children have 
higher rates (incidence and mortality) of brain cancer and neuroblastoma compared 
to Mexican children in Mexico [39], which raises provocative questions about an 
increased risk for these cancers in the US environment. Yet, very few of these ques-
tions have received attention from the research community.
Differential Cancer Patterns over the Lifespan (Based on Birthplace) among 
Hispanics in the United States Of the 35 million Hispanics in the US Mexican 
group, 22 million are US-born and 13 million are foreign-born [45]. Leveraging this 
distribution in analyses disaggregated by birthplace provides additional insights 
into the role of environmental factors in the development of cancers. While birth-
place is by no means a perfect indicator of residential history or indeed any risk 
factors for cancer, on a population basis, it is the most complete proxy of early life 
environmental influences, as most immigrants arrive as adults [45]. Using mortality 
data from California and Texas, we showed that cancer patterns of Hispanics vastly 
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differ by birthplace [18]. Contrary to the purported Hispanic advantage portrayed 
when rates are calculated in aggregate, overall cancer mortality rates for US-born 
Hispanic males are for the most part no better than non-Hispanic whites, albeit with 
site-specific variation including lower rates of tobacco-related cancers such as lung 
and bladder cancers and higher rates of liver, stomach, colorectal, and kidney can-
cers [18]. Conversely, foreign-born Hispanics are a relatively low-risk group, bur-
dened only with higher rates of stomach, cervix, and prostate cancers than their 
US-born counterparts [18], a finding further confirmed when analyzing Mexican 
Hispanic populations alone [39]. Most striking are the excesses seen for male 
colorectal, kidney, and liver cancers, likely reflecting higher prevalence of obesity 
and HCV infection among US-born Mexicans than their foreign-born counterparts. 
Barring ascertainment of detailed risk factor information, virtually impossible at the 
individual-level on a population basis, these patterns may be the best evidence we 
have so far of the impact of spending formative years in a US environment charac-
terized by overconsumption of fats and sugars, sedentary lifestyle, and low age of 
experimentation with drugs and alcohol as well as unique stressors associated with 
discrimination [43]. Moreover, disaggregated rates by birthplace provide opportuni-
ties to identify protective factors seen in foreign-born populations, identify strate-
gies to maintain these protective factors, and potentially use this information in risk 
reduction strategies among US-born populations.
Puerto Ricans and Divergence from Favorable Aggregated Hispanic 
Patterns Using mortality data from New York State (NYS) [34], we revealed con-
siderable cancer mortality disparities for Puerto Ricans compared both to the major-
ity NHW population and to other Hispanic groups [34]. These disparities, which 
should be addressed by targeted cancer prevention and control programs, were 
largely masked by the presentation of Hispanic cancer mortality rates in aggregate.
Puerto Ricans are the largest Hispanic group in NYS [22]; moreover, most can-
cer deaths (81%) in this group occurred among Puerto Ricans born in the continen-
tal United States [34]. Thus, examination of this group in this state provides a unique 
lens with which to examine the influence of extended acculturation as a minority in 
the United States. Three prominent findings emerged from our study. First, similar 
to US-born Hispanic males in California and Texas, overall cancer mortality rates of 
Puerto Rican males in NYS are not lower than, but rather similar to rates of the 
majority NHW reference group. Again, different cancer sites afflict the two popula-
tions: tobacco-related bladder and lung cancer mortality are higher among NHWs; 
infection-related cancers (stomach, liver and cervix) are higher among Puerto 
Ricans [34]. Secondly, the disparity between Puerto Ricans and NHWs for these 
infection-related cancers, more commonly associated with developing countries, is 
consistent with patterns seen for another socio-economically deprived US minority: 
the US-born black population [34]. Prior assumptions that the high burden among 
Hispanics in aggregate for infection-related cancers was being driven by the foreign- 
born (carrying their risk from developing countries) should be urgently re- examined. 
This evidence from disaggregation of rates suggests US poverty, proportionately 
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higher in NYS among Puerto Rican and US-born blacks, is driving the burden, and 
thus appropriate resources should be shifted to eliminate this disparity. Lastly, 
Puerto Rican males in NYS have significantly higher mortality than any other 
Hispanic group for oral, esophageal, colorectal, lung, bladder, and especially liver 
cancer, while Puerto Rican females have higher mortality from colorectal, lung, 
postmenopausal breast, liver, and cervix cancers [34]. With the exception of colorec-
tal and breast cancers, these are the cancers associated with low SES [46]. Thus, 
these patterns, revealed only because of disaggregation, not only are consonant with 
the negative effects often associated with acculturation, but also correlate with pre-
vailing economic disparities that adversely impact health possibly more acutely in 
second-generation immigrants [34].
Liver Cancer: Etiological Insights from Disaggregation of Hispanic Groups Our 
fourth and final example illustrating the importance of disaggregation focuses spe-
cifically on liver cancer, drawing again from our study conducted in NYS [34]. As a 
multi-causal disease [47], liver cancer incidence and mortality are difficult to inter-
pret given disparate etiological factors, including HCV, obesity, heavy alcohol con-
sumption, diabetes, and chronic infection with the hepatitis B virus, the latter 
especially among Asians and the foreign-born [48]. We examined Hispanics as a 
whole and disaggregated: Puerto Rican male liver cancer rates were higher than 
other analyzed groups in NYS, including Asians and blacks [34]. Within the 1945–
1965 birth cohort, known for its high prevalence of HCV infection [49], excesses in 
liver cancer mortality were exceedingly high among not only male but also female 
Puerto Ricans. Patterns were similar to US-born blacks, but diverged completely 
from other Hispanic groups in New York, which include overwhelmingly foreign- 
born Hispanics (Dominicans, Central Americans, South Americans, etc.) as well as 
non-Hispanic blacks born in the Caribbean; all showing relatively low mortality for 
liver cancer [34]. Differences are more pronounced in males and within the birth 
cohort of 1945–1965, suggesting just from a descriptive analysis that socially and 
economically deprived minority populations physically present in NYS during the 
1960s–1980s (when transmission of HCV was likely caused by IV drug use and 
needle sharing) who also share disproportionately high rates of incarceration [50], 
linked to HCV transmission [51], are particularly prone to higher mortality from 
liver cancer. While undeniably other etiological factors contribute to the excess of 
liver cancer among Hispanics in general, especially in older populations, the exist-
ing patterns suggest a compelling association between the known high prevalence 
of HCV [52] and liver cancer [34] in the Puerto Rican population, even in relation 
to NHWs within the same birth cohort, who are also considered high-risk. Notably, 
neither Hispanics overall nor Puerto Ricans specifically are currently considered a 
priority population for viral hepatitis control programs [53]; yet, our finding, which 
would have been totally missed had it not been for the disaggregation of Hispanics, 
suggests that HCV testing and viral hepatitis control could help alleviate this 
 disparity particularly for Puerto Ricans. Further study of the etiology of liver cancer 
by disaggregated groups will provide additional clarification into the specific etio-
logical forces driving high cancer rates among other Hispanic groups, particularly 
in older populations.
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 Conclusions
US Hispanics number 55 million, which is 17% of the total US population [22]; 
they are highly heterogeneous, with unique genetic admixtures and widely variant 
socioeconomic profiles [45, 46]. While the population structure of Hispanics is rela-
tively young, these currently younger Hispanics will soon reach the ages at which 
cancer is more common. Prevention strategies are needed now to meet this need. 
Special attention should be directed to the distinct disparities among US-born 
Hispanics, whose cancer numbers are rapidly trending upwards and who may not 
profit from the same protective health benefits of their first-generation immigrant 
counterparts. Accurate incidence, survival, and mortality rates of Hispanics by spe-
cific group are critical because aggregation provides at best a fuzzy picture and at 
worst a lie. Not all Hispanics are doing well, as would be suggested by aggregated 
rates. There are many challenges to studying population-based cancer indicators by 
disaggregated Hispanic groups, especially for incidence and survival, which we 
described above. Yet, overcoming these challenges can provide critical insights, as 
we demonstrated here through a synthesis of our results from several recent 
studies.
While cancer surveillance and vital statistics data have the advantage of being 
available on an individual level for entire populations, they are limited to basic 
demographic information. Certainly, while our findings are hypothesis-generating, 
further research that incorporates individual-level risk factor information will be 
required to substantiate and further explain these findings for Hispanic groups, 
including prevalence of obesity, smoking, diabetes, age at immigration, and length 
of time residing in the United States (for immigrants). Studies should also examine 
other social, economic, and cultural factors that impact access to health care and 
attitudes toward health, which may differ substantially by specific Hispanic group. 
Moreover, finding answers to the innumerous questions arising from these compari-
sons will require the inclusion of biological characteristics of tumors, including 
genetic and molecular subtypes.
Continued epidemiological research on the intra-ethnic cancer experience among 
Hispanics in the United States is imperative, not only to identify and address dis-
parities, but also because this highly heterogeneous population provides opportuni-
ties through specific group analyses to further explore the etiology of cancers and 
discover potential avenues for cancer prevention and control efforts.
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Chapter 3
Colorectal Cancer Disparities in Latinos: 
Genes vs. Environment
Maria Gonzalez-Pons and Marcia Cruz-Correa
 Overview of Colorectal Cancer Disparities in Hispanics
For many years, science has been moving toward a better understanding of factors 
that contribute to colorectal cancer (CRC) health disparities. In 2012, CRC was the 
third most diagnosed cancer (1.4 million cases) and the fourth most common cause 
of cancer-related death causing 694,000 deaths worldwide [1]. An analysis of 
Globocan 2012 data shows that among countries in the Americas with the highest 
age-standardized rates (ASR) for CRC incidence, Canada ranks first with the high-
est ASR, closely followed by the United States (US) and Puerto Rico which rank 
fourth and fifth, respectively [1]. In the US, CRC is the third most commonly diag-
nosed malignancy and the third leading cause of cancer-related death [2]; however, 
marked differences in incidence and mortality have been noted among racial/ethnic 
groups [3].
It is important to note that US mainland Hispanics comprise a heterogeneous 
group of Hispanic subgroups from various countries in Central and South America. 
Hispanics are the result of more than 500 years of admixture of European, Indigenous 
American, and African individuals [4], and the extent of admixture varies according 
to the country of origin. CRC incidence rates among US mainland Hispanics 
also vary according to their country of origin, which supports the hypothesis that 
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differences in ancestry may contribute to the variability of CRC incidence. Moreover, 
after Hispanic subgroups move to the US, the CRC incidence among them is higher 
than in their native country, supporting the idea that interactions between ancestry 
and environmental exposures resulting from acculturation are a major risk factor for 
the development of CRC [5]. Disparities in the age of onset of CRC have been 
reported between Hispanic subgroups. From 1993 to 2007, the overall incidence of 
CRC declined in Hispanics, but a dramatic 45% increase was reported 
among Hispanics younger than 50 years of age (early-onset CRC) [6]. The increase 
in incidence of early-onset CRC was markedly greater in Hispanics than in non- 
Hispanic Whites (NHW) and African Americans (AA), which increased 27% and 
15%, respectively [6]. In a study investigating the demographic and clinical charac-
teristics of 36,133 US mainland Hispanics with CRC living in California during 
1995–2011, differences were observed in age at diagnosis according to the country 
of origin [7]. A statistically significant higher number of early-onset CRC was diag-
nosed in Hispanics (16%) compared to NHW (7%). Mexican and Puerto Rican 
Hispanics (PRH) were among the subgroups with the highest proportion of CRC 
cases among individuals <50 years old (20% and 9%, respectively). When compar-
ing all Hispanic subgroups with NHW, a higher number of Hispanics were diag-
nosed at advanced stages.
 Factors Contributing to Colorectal Cancer Disparities 
in Puerto Rican Hispanics
In order to better understand CRC health disparities in Puerto Rico, our research 
team has worked on various transdisciplinary projects examining the epidemiologi-
cal, environmental, and genetic factors that contribute to the CRC health inequities 
observed in this population.
 Epidemiology
In a comparison of age-adjusted CRC incidence in the US and Puerto Rico from 
2009 to 2013, AA and PRH men had the highest rates with 59.2 and 51.6 per 
100,000, respectively. US mainland Hispanic men had the second lowest age- 
adjusted CRC incidence rates during the same time period. However, in a compari-
son of age-adjusted CRC incidence rates among women during the same time 
period, AA women had markedly higher rates (44.8 per 100,000) than the other 
racial/ethnic groups (<36.8 per 100,000). A comparison of age-adjusted CRC mor-
tality rates during the same time period shows a similar trend among AA and PRH 
men, who had the two highest mortality rates; however, age-adjusted mortality rates 
are comparable among women in all racial/ethnic groups. We recently reported the 
M. Gonzalez-Pons and M. Cruz-Correa
37
baseline CRC survival for PRH living in Puerto Rico [8]. Our study compared rela-
tive survival rates to those from racial/ethnic groups in the US, and found that PRH 
had the lowest survival rates in regional cancers and were the only racial/ethnic 
group in which there was a marked 5-year survival advantage among females 
(66.0%) compared to males (60.3%). Similar to the findings reported in California, 
9.0% of the total CRC cases and 6.7% of total CRC deaths correspond to patients 
with early-onset CRC in Puerto Rico. These are  nearly twice the percentages 
reported in the overall US population, thereby demonstrating a high burden of early- 
onset CRC in Puerto Rico [9]. Moreover, a comparison of 5-year survivorship 
according to age at CRC diagnosis during 2005–2010 showed that early-onset CRC 
patients in Puerto Rico had worse survival (57%) than CRC patients diagnosed at 
50–64 years (66%) and ≥65 years of age (62%) [10]. In this same study, 5-year 
survival was also analyzed according to the type of health insurance coverage (gov-
ernment vs. non-government health plan). When combining all age groups, CRC 
diagnosis at advanced stages was more common in patients with the government 
health plan than those with non-government plans (44.3% vs. 40.2% diagnosed at 
regional stages, and 13.6% vs. 10.4% diagnosed at distant stages, respectively). 
Patients with the government health plan aged 50–64 (RR  =  6.59; CI: 2.85–15.24) 
and ≥65 (RR  =  2.4; CI: 1.72–4.04) years were at greater excess risk of death than 
patients with non-government health plans.
 Environmental Factors
CRC still remains a major public health problem. However, very few CRC preven-
tion strategies are available other than routine screening. In addition to genomic 
alterations, dietary and environmental factors are believed to contribute to colorec-
tal carcinogenesis [11]. Factors that may increase the risk of CRC include physical 
inactivity, obesity, alcohol consumption, smoking, gut microbiome composition, 
and diet [12]. Dietary patterns are widely believed to act as pro- and anti-tumor risk 
modifiers across the entire multistep process of colorectal carcinogenesis, and they 
have also been shown to have a pivotal role in modulating the gut microbiota [13, 
14]. Moreover, in 2015 the International Agency for Research on Cancer (IARC) 
concluded that high red meat consumption is a risk factor for CRC [15].
Accumulating evidence supports the hypothesis that changes in gut microbiota 
composition may contribute to the development of CRC [16], but the specific mech-
anisms by which the gut microbiota contribute to colorectal carcinogenesis are not 
fully understood. Differences in gut microbiota composition among ethnic/racial 
groups, as well as between African American and rural Africans, have been reported 
[17, 18]. Differences in bacterial community profiles and metabolites have been 
studied, but in our laboratory we are spearheading a study evaluating the association 
between dietary patterns, presence of bacterial toxins in stool and colonic mucosa, 
and colorectal neoplasia. Using a case–control study design, we examined the asso-
ciation between the presence of bacterial toxin genes (pks, tcpC, gelE, cnf-1, murB, 
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and usp) in stool and colorectal neoplasia using samples from individuals from the 
US and Puerto Rico [19]. These bacterial toxins promote inflammation, cell prolif-
eration, and/or DNA damage, all of which are hallmarks of cancer. Differences were 
observed in the prevalence of these bacterial toxin genes between stool samples 
from individuals in the US and Puerto Rico. Moreover, stronger associations were 
observed between the presence of >2 bacterial toxin genes in stool and the likeli-
hood of having colorectal neoplasia in PRH. In stool samples from the mainland 
US, individuals with ≥2 of the genes in the panel were 9.33 times more likely to 
have colorectal neoplasia than individuals without these bacterial toxin genes. PRH 
individuals with ≥2 of the genes were 11.3 times more likely to have colorectal 
neoplasia and 24 times more likely to have colorectal adenomas than individuals 
without these bacterial genes.
 Genetics
Significant advances have been made toward a better understanding of the molecu-
lar landscape of colorectal tumors. The TCGA’s effort is significant because it pro-
vides a comprehensive molecular characterization of tumors from the colon and 
rectum, and this study demonstrated the molecular similarities between colorectal 
tumors regardless of their location (colon vs. rectum) [20]. In this genome-scale 
analysis of 276 samples, 16% of colorectal carcinomas were found to be hypermu-
tated. Although a wealth of molecular information is available on the tumors 
included in the TCGA, it is important to note that there are very few tumors from 
ethnic/racial minorities (12% Black, 3% Asian, and 3% Hispanic) [21]. To better 
understand the molecular pathways that may contribute to the CRC health dispari-
ties observed among Hispanics, our group analyzed somatic molecular markers in 
PRH tumors (n  =  488).  We found that most tumors were microsatellite stable 
(98.4%), CIMP-low (92.1%), and had wild-type KRAS (68.8%) and BRAF (90.8%) 
genes. When compared to other US ethnic/racial groups, Hispanic CRC tumors had 
a lower percentage of microsatellite instability (MSI), lower incidence of CIMP- 
high tumors, and lower mutation rates for both the KRAS and BRAF genes. A 
recent genome-wide association study (GWAS) reported 17 variants across four 
independent regions that merit further investigation because of suggestive CRC 
associations [22]. There is limited information regarding ethnic-specific risk varia-
tion in Hispanics. Our group recently collaborated with colleagues at the National 
Cancer Institute in order to elucidate risk variants for CRC among PRH. In another 
effort to understand germline genetic predisposition for CRC among Puerto Ricans, 
we spearheaded a study evaluating the association between ancestry and increased 
cancer risk in 425 controls, 99 adenomas, and 414 CRC cases. Previous studies 
reported that Hispanics with adenomas and CRC have higher African mean ances-
try; positive associations between African ancestry and adenomas were observed 
[23]. However, in our PRH cohort, we observed a trend of increased risk of CRC 
with increasing levels of European ancestry. Puerto Rican individuals with higher 
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than mean levels of West African ancestry were at increased risk of presenting with 
CRC tumors that are located in the distal colon, had moderate or low differentiation, 
and had BRAF mutations. Individuals who consumed high amounts of processed 
meat had 2 times higher CRC risk regardless of genetic ancestry.
 Summary
• CRC health disparities have been reported among Hispanic subgroups, including 
PRH.
• CRC is the leading cause of cancer death in Puerto Rico. PRH had the lowest 
survival rates in regional cancers and were the only racial/ethnic group where a 
marked 5-year survival advantage was observed among females (66.0%) com-
pared to males (60.3%).
• Marked disparities were observed according to age at CRC diagnosis and type of 
medical insurance within the Puerto Rican population.
• Dietary patterns are widely believed to act as pro- and anti-tumor risk modifiers 
across the entire multistep process of colorectal carcinogenesis and also play a 
pivotal role in modulating the gut microbiota.
• Differences were observed in the prevalence of bacterial toxin genes between 
stool samples from individuals in the US and Puerto Rico. Associations between 
having ≥2 bacterial toxin genes in stool and the likelihood of having colorectal 
neoplasia were stronger among PRH.
• PRH colorectal tumors were mostly microsatellite stable (98.4%), CIMP-low 
(92.1%), and had wild-type KRAS (68.8%) and BRAF (90.8%) genes. When 
compared to other US ethnic/racial groups, PRH CRC tumors had a lower per-
centage of MSI, lower incidence of CIMP-high tumors, and lower mutation rates 
for both the KRAS and BRAF genes.
• In our PRH cohort, we observed a trend of increased risk of CRC with increasing 
levels of European ancestry.
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Chapter 4
Breast Cancer Risk and Mortality 
in Women of Latin American Origin
Laura Fejerman, Silvia J. Serrano-Gómez, and Lizeth I. Tamayo
 Introduction
The categories of Hispanic or Latino refer to individuals of diverse national origin 
(Mexico and all countries in the Caribbean, Central and South America), place of 
birth (individuals born in the United States whose ancestors were born in Latin 
America or individuals born in Latin America), and continental ancestral back-
grounds (mostly European, Indigenous American (IA), and African, but also includ-
ing Asian and other minor components). This diversity had not been systematically 
addressed in cancer epidemiology until recent years, and the lack of extensive data-
sets with detailed information about subgroups of Latinos has resulted in the plac-
ing of a very diverse set of individuals into one category. This is surprising given 
that Hispanics/Latinos represent the second largest US census racial/ethnic category 
including ~17% of the US population (50 million individuals) [1].
Breast cancer is the most common cancer in US Latinas [2], but compared to 
other population groups, incidence is relatively low. Age-adjusted breast cancer 
incidence rates based on 2010–2014 cases were 127.7 in non-Latina Whites (NLWs), 
125.1 in non-Latina Blacks (NLBs), 98.5 in Asians/Pacific Islanders, 93.1 in Latinas, 
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and 82.2 in Native Americans/Alaskan Natives [3]. Some studies have shown that 
despite the lower incidence of breast cancer in Latinas, their mortality risk is higher 
than NLW women, even after adjustment for tumor characteristics and socioeco-
nomic status [4–8]. However, this observation is not consistent across studies, with 
several reporting lower risk of breast cancer-specific mortality for Latinas compared 
to other population groups [9–12]. In addition, Latinas have been reported to have a 
higher risk of developing aggressive subtypes [13] and of being diagnosed at more 
advanced stages of the disease [12, 14].
This chapter summarizes works conducted by our group and others on breast 
cancer risk, characteristics, and survival, in women of Latin American origin, with 
particular emphasis on observed differences among Latino subgroups.
 Breast Cancer Risk in Women of Latin American Origin
The group usually designated by the category of Hispanics/Latinos is not homoge-
neous, and the risk of developing breast cancer among these women varies by 
national origin [15], place of birth (US-born vs. foreign-born) [16, 17], and genetic 
ancestry [18, 19].
A study that was based on cancer registry data from Florida, including diagnosis 
between the years 1999 and 2001 and ~30,000 Latinas, reported overall age-adjusted 
incidence rates of 106.4 (100.8–112.3) in this group, 140.4 (137.6–143.2) in NLWs, 
and 104.9 (98.5–111.7) in NLBs. Incidence rates varied greatly among Latinas by 
national origin, with Puerto Ricans having the highest rates (116.9; 103.7–131.4), 
followed by Cubans (108.0; 96.7–120.3) and Mexicans (71.9; 53.1–95.2). The inci-
dence of breast cancer in Caribbean women was markedly higher than that in AAs 
[15]. The 2000 and 2005 National Health Interview Survey (NHIS) Cancer Control 
Modules observed a higher 5-year absolute risk in Cubans/Cuban-Americans com-
pared to Mexican/Mexican-Americans and a higher lifetime risk in Dominicans 
compared to Mexican/Mexican-Americans [20].
Studies have reported that foreign-born Latinas have lower breast cancer inci-
dence than their US-born counterpart [16, 17]. In California, foreign-born Latinas 
have lower risk of developing breast cancer than US-born [17], with increasing risk 
with longer US residency [16]. The study based on the Florida Cancer Registry also 
reported marked differences in incidence between Latinas residing in the United 
States and those in their countries of origin. Breast cancer incidence rates were 
reported to be twice or even three times higher in US women of Latin American 
origin, as in the case of Cubans (31 per 100,000 in Cuba vs. 78 in Florida) [15]. 
Concordant with these results, a study that compared cancer incidence between 
Puerto Ricans in the United States and in those residing in the Island found a signifi-
cantly lower breast cancer incidence among Puerto Rican women who reside in 
Puerto Rico [21]. Differences in risk of breast cancer by place of birth could be 
explained by lifestyle changes related to the adoption of a more westernized repro-
ductive behavior (i.e., lower parity, shorter duration of breast-feeding, and later age 
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at first full-term pregnancy) and dietary or other lifestyle choices (i.e., more fast 
food, higher alcohol intake, less exercise) [16, 22].
Genetic ancestry also varies among Latinas, and it has been reported that women 
with high IA ancestry have lower risk of developing breast cancer than those with 
high European ancestry. This difference was statistically significant after control-
ling for most established risk factors that are known to differ between Latina and 
NLW women [18, 19]. The inverse association between IA ancestry and breast can-
cer risk was partly explained by a genetic variant located near the estrogen receptor 
1 gene (ESR1), shown to be of relatively high frequency in women with IA ancestry 
[23]. In Colombia, patients diagnosed with estrogen receptor-negative breast cancer 
(HER2-enriched, basal-like, and non-basal triple negative) had the highest African 
ancestry [24]; however, the role of African ancestry in defining breast cancer risk by 
Latina national origin has not been fully examined.
 Breast Cancer Mortality in Women of Latin American Origin
The described heterogeneity among Latinas not only translates into differences in 
breast cancer risk but also mortality. Cubans and Puerto Ricans have the highest 
mortality rates [25], while Mexicans, Central Americans, South Americans, and 
Dominicans have lower breast cancer mortality rates [25].
Few studies have analyzed differences in cancer mortality by genetic ancestry in 
women of Latin American origin. In 2013, Fejerman et al. analyzed the association 
between genetic ancestry and survival in Latina women from the San Francisco Bay 
area and reported higher mortality hazard in women with more than 50% of IA 
ancestry compared to women with 50% or less of IA ancestry [26]. Nevertheless, 
when the association was re-tested in women with uniform access to healthcare, the 
previously observed disparity in breast cancer-specific mortality was no longer 
apparent [27].
Ellis et al. showed that stage at diagnosis explained 11% of the survival dispari-
ties in Latina women compared to NLW women [28]. Socioeconomic status is an 
important contributor to health disparities in breast cancer outcomes as reduced 
screening, diagnostic delays and barriers to comprehensive treatment can lead to 
later stage at diagnosis [29]. Latina women are less likely to use mammography 
screening compared to NLW women [29–31]. In addition, delays in the diagnostic 
biopsy after an abnormal screening study might contribute to the more advanced 
stages at presentation [29] and delays in treatment initiation [12]. Results of a study 
based in Chicago showed an inverse association between European genetic ancestry 
and the risk of late stage at diagnosis (OR 0.70, 95% CI: 0.54–0.92) among Latina 
patients even after adjusting for multiple social and behavioral risk factors [32].
While breast cancer incidence is relatively low in foreign-born Latinas, they are 
more likely to be diagnosed with breast cancer at more advanced stages, initiate 
treatment later, and are less likely to receive guidelines-concordant treatment when 
compared to US-born Latinas [17]. Some studies have reported that even though 
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foreign-born Latinas are more likely to be diagnosed with more advanced stages, 
they have better survival than US-born Latinas [17, 33, 34]. This is a well-known 
phenomenon called the immigrant paradox that refers to the better health outcomes 
observed for certain immigrant populations in the United States compared to non- 
immigrant individuals of similar socioeconomic background [35]. The fact that 
Latina women experience survival advantages can be related in part to the lifestyles 
adopted in Latino enclaves, in which they may promote better health attitudes and 
behaviors such as healthier diets and social support [17, 34, 36]. These enclaves are 
neighborhoods with dense US-born Latino or Latino immigrant populations that 
hold certain cultural norms and practices [33, 35]. It is important to mention that the 
better survival of foreign-born Latinas could be partly an artifact related to the 
return of these women to their native countries leading to an under-ascertainment of 
deaths [33, 36].
 Breast Tumor Subtypes in Women of Latin American Origin
Breast cancer is a complex and heterogeneous disease that has been classified into 
four main intrinsic subtypes based on gene expression profiles: luminal A, luminal 
B, HER2-enriched, and basal-like [37, 38]. Luminal subtypes belong to the estrogen 
receptor-positive (ER+) group and are characterized by the expression of genes 
such as the estrogen receptor gene (ESR1) and genes regulated by estrogen such as 
GATA3 [39]. Although globally, luminal subtypes show the best outcomes, luminal 
B have a more aggressive phenotype as they express higher levels of proliferation- 
related genes and growth factor receptors such as HER2 [40, 41]. HER2-enriched 
and basal-like subtypes are ER-negative (ER−) subtypes. HER2-enriched tumors 
express ERBB2 and genes in the 17q22.24 locus [39, 42, 43] while basal-like sub-
type express basement membrane cytokeratins and lack the expression of ESR1 and 
its co-expressed genes [39]. ER− subtypes have the poorest prognosis when com-
pared to luminal subtypes [44].
The distribution of breast cancer intrinsic subtypes varies among women from 
different populations, and Latina women have a higher proportion of more aggres-
sive intrinsic subtypes such as ER− tumors than NLW women [13]. This is very 
important as these subtypes of disease have fewer treatment options and a poorer 
prognosis than other subtypes [3, 6, 45–48].
This differential distribution of subtypes in Latina compared to NLW women has 
been shown not only in population-based studies but also in hospital/clinical-based 
studies in Latin America. In population-based studies from the United States [49–
60], the proportion of the triple-negative subtype in Latinas ranged between 10 and 
18%, while in NLW women, it ranged between 8 and 15%. On the other hand, HER- 
enriched tumors ranged between 4 and 24% in Latinas and between 3 and 17% in 
NLW women. Not only US Latinas, but also Latin American women more gener-
ally, have a 20–40% higher risk of developing ER−/PR− and triple-negative breast 
cancers (TNBC) than NLW women [19, 54, 61–67].
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Most studies performed in Latin America are hospital-based [24, 65, 68–73]. The 
reported proportion of triple-negative subtype in Latin America ranged between 12 
and 24% and between 7 and 24% for the HER2-enriched subtype [47] (Fig. 4.1). 
Countries such as Mexico [47], Peru, and Colombia have higher relative frequency 
of triple-negative tumors (23%, 21%, and 21%, respectively) compared to other 
countries in Latin America such as Costa Rica (17%) [69], Brazil (17%) [65], and 
Puerto Rico (17%) [70]. When comparing hospital-based studies with those per-
formed at national referral centers such as the National Cancer Institutes from each 
country, differences are also observed. For example, a hospital-based study in Peru 
reported that the proportion of triple-negative breast cancer was 17% [73] while in 
the study from The National Cancer Institute from Peru, it was 23% [71]. A similar 
scenario was observed in Colombia where a hospital-based study reported a propor-
tion of 12% [72], while the Colombian National Cancer Institute reported a propor-
tion of 21% [24] (Fig. 4.1). More studies are needed to decipher the distribution of 
intrinsic subtypes in a population-based scenario in Latin America and also to ana-
lyze the relationship between genetic ancestry tumor subtype.
The heterogeneity in the distribution of breast cancer subtypes in women of 
Latin American origin can be partly attributed to the differences in the source of 
Fig. 4.1 Prevalence of triple-negative and HER2-enriched breast cancers in women of Latin 
American origin. Differences in the prevalence of these subtypes are noted between the different 
Latin American countries and also within the same country according to the source used, hospital- 
based, or reference center
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information. National Cancer Institutes in Latin America are usually reference cen-
ters that receive patients that could not be adequately served by local hospitals/
clinics, likely because of their advanced stage at diagnosis and tumor aggressive-
ness. Additionally, differences could result from the surrogates used to classify 
breast cancer into intrinsic subtypes (PAM50 or St. Gallen surrogates), although 
most studies used the basic classification that includes the evaluation of ER, PR, and 
HER2 [13].
Recent studies suggested that genetic ancestry could be acting as a modulator of 
gene expression and a risk modifier for the development of specific subtypes of 
breast cancer in Latina women [74]. Serrano-Gómez et al. reported that Colombian 
breast cancer patients with higher IA ancestry showed higher expression of the 
ERBB2/GRB7/MIEN1 genes in breast tumors of luminal B subtype [74]. These 
three genes, located in the same region of chromosome 17, have been reported as 
co-amplified in breast cancer and this event has been associated with poor prognosis 
[42, 75–77].
 Gaps: Do We Have the Right Data to Learn to Predict, 
Prevent, and Treat Breast Cancer in Women of Latin 
American Origin?
Genomic technologies have offered new perspectives to expand and improve human 
health [78]. However, it has been shown that the proportion of samples from minor-
ity populations included in large-scale genomic studies remains low [79, 80]. 
Individuals of Latin American origin only represent 0.54% of the samples included 
in genome-wide association analyses compared to 81% for those of European 
ancestry [80]. A similar scenario was observed in The Cancer Genome Atlas 
(TCGA) where only 3% of the samples are from Latino patients [79]. Increasing the 
representation of diverse populations in future “omics” research efforts will improve 
our understanding of the drivers of aggressive tumor biology across different popu-
lation groups and subgroups [79].
The need for cancer control in Latin America has received significant attention, 
with specific recommendations to increase investment in cancer registration, given 
that cancer registration covers approximately 7% of the populations in Latin 
America, while the equivalent coverage is 83% in North America and 32% in 
Europe [78, 81].
To assure comprehensive registries, the implementation of population-based 
cancer registries (PBCR) in Latin America require government support in order to 
incorporate all sources of information such as data from social security and the 
private sector [82, 83]. Biorepositories in Latin America hold diverse tissue samples 
that could enrich our knowledge of the molecular diversity of cancer in Latinos 
from different regions, but they tend to lack the resources to conduct the research. 
Therefore, it is through international collaborations, including support from US 
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institutions and investigators, that we can begin to generate the complex data that 
we need to better understand cancer risk and outcomes with the consideration of 
biological, environmental, cultural, and access-related factors in individuals of 
Latin American origin.
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Chapter 5
Prostate Cancer in US Latinos: What Have 
We Learned and Where Should We Focus 
Our Attention
Mariana C. Stern
 Prostate Cancer Among Latinos
After skin cancer, prostate cancer (PCa) is the most commonly diagnosed cancer 
among Latino men, with approximately 13,000 cases diagnosed every year in the 
United States; 1800 Latino men die of PCa every year, making it the fourth leading 
cause of cancer death among Latinos [1]. PCa is also the most common cancer 
among non-Latino men, although the incidence rates are higher among non-Latino 
White (NLW) men and highest among non-Latino Black (NLB) men. In spite of the 
high burden of PCa in the United States and many other Western countries, there are 
few established risk factors, and even fewer are modifiable and can be targeted for 
cancer prevention. Most PCa will be diagnosed in men with localized disease (~80% 
of men), most of whom will have indolent disease, although a small minority will 
not. Distinguishing clinically significant from clinically insignificant cancer is one 
of the key challenges that men with prostate cancer face [2–4]. Across the contin-
uum from PCa etiology to PCa survival, there are several other challenges and 
knowledge gaps, which overall are larger for Latino men, who are greatly under-
studied. We summarize below some of the salient findings about the characteristics 
of PCa in US Latinos along this continuum and highlight the unique challenges 
faced by this population and that deserve further study.
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 Prostate Cancer Incidence and Etiology
The incidence of PCa in US Latino men is ~9% lower than NLW men; however, the 
incidence observed among US Latino men is higher than the incidence among men 
in most Latin American countries, which show wide differences in incidence and 
mortality across countries [5]. Studies done among various migrant populations 
have shown increases of PCa among US immigrants in comparison with their coun-
tries of origin [6]. It is not clear whether these increases are exclusively due to 
increased detection of PCa in the United States or changes in environmental factors 
or a combination of both.
Few established risk factors for PCa are age, African ancestry, family history of 
PCa, and genetic susceptibility markers identified among NLW and NLB popula-
tions [7, 8]. However, all these factors together explain a very small proportion of 
the variability of PCa incidence. Several modifiable risk factors have been reported 
for which the evidence is still inconclusive; however, they deserve consideration as 
probable PCa risk factors. Among them are body fatness [9], red meat [10], calcium, 
vitamin D, and lycopene [11]. Less than 2000 Latinos have been included in epide-
miological studies in the United States; thus, the knowledge gap for PCa etiology in 
Latinos is larger than for other racial/ethnic groups. Among the few studies that 
included Latino men, positive associations were reported for some of the same risk 
factors reported among non-Latino individuals such as obesity [12], alcohol [13], 
genetic variants [14], and diets high in red meat cooked at high temperatures and 
meat mutagens [15]. In addition, positive associations were reported uniquely 
among Latinos, such as exposure to agrichemicals and PCa risk [12, 16], and inverse 
associations between high intake of legumes and soy products were stronger among 
Latinos [13, 17].
Most PCa diagnoses are triggered by elevated PSA detected through routine 
screening, although the landscape of PCa detection is currently changing given the 
original 2012 recommendation against PSA-based screening from the U.S. Preventive 
Services Task Force (USPSTF), which in 2018 has evolved into mutual decision 
between patients and their doctors [18]. These newer recommendations are directly 
aligned with what the American Urologic Association (AUA) has recommended 
since 2012 which is sharing decision-making for men aged 55–69 years considering 
PSA screening, taking into account individual risk factors (e.g., African American, 
positive family history) [19, 20]. Thus, even though PSA testing nationwide has 
decreased, debate on the value of PSA screening continues, and the effects of its 
reduction in use are still too early to detect with current cancer registries data. 
Importantly, Latino men show lower rates of use of PSA screening [21–23] than 
NLW men, associated with these lower rates of screening are low PCa literacy and 
overall low educational status [24, 25], as well as specific Latino values (e.g., fatal-
ism) [25] and lack of health insurance [26]. It is not clear if lower screening alone 
can explain the reduced incidence of PCa compared to NLW men. To consider, 
disparities in incidence are also observed when considering aggressive disease only, 
which is less likely to be detected by PSA, suggesting that other factors may explain 
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the reduced incidence among Latinos and remain to be uncovered [27]. 
Socioeconomic status (SES) is an important modifier of PCa risk, with men in the 
lowest SES categories having the lowest PCa incidence and differences being more 
pronounced for Latinos [27].
A key challenge in understanding cancer determinants among US Latinos is the 
fact that they constitute a highly heterogeneous population. Latinos are a highly 
admixed population given the history of colonization of the Americas; all Latinos 
are descendants from generations of admixture among European, Amerindian, and/
or African ancestral populations, with varying degrees of admixture across different 
Latin American countries. Further, there are differences due to local traditions, cul-
ture, lifestyle, and prevalence of various environmental agents [28, 29]. In the 
United States, this heterogeneity is greater, because US Latinos might be foreign- 
born with various degrees of acculturation to the US lifestyle, or they might be 
US-born first or subsequent generation with Latino parents or grandparents of same 
or different Latino origin or with only one Latino parent/grandparent. Therefore, 
Latinos are likely to be among the most heterogeneous ethnic groups in the United 
States. In spite of this, they are typically considered as one single group in cancer 
studies. Therefore, estimates of incidence and cancer characteristics might not be 
representative of all US Latinos [29].
There is accumulating evidence that cancer incidence differs by Latino subpopu-
lations defined by country/region of origin [30–33] or genetic ancestry [29]. 
Specifically for PCa, Latinos of Mexican origin have been reported to have the low-
est incidence among Latinos, and definitively lower than NLW. Caribbean Latinos, 
such as Cuban and Puerto Rican Latinos, have higher incidence; in fact, Puerto 
Ricans in Florida were reported to have higher incidence than NLWs [31–33]. 
Moreover, Latinos living in Florida were reported to have higher incidence of PCa 
than their counterparts living in their countries or regions of ancestral origin [32]. 
Similarly, Puerto Ricans living in the island were reported to have lower PCa inci-
dence rates than those living in the mainland United States [34] and lower than US 
Latinos overall [35]. Recently, we conducted analyses of PCa among Latinos living 
in California using California Cancer Registry, and in agreement with previous find-
ings, we observed that PCa incidence rates were lowest among Mexican and Central 
American Latinos and highest among South American Latinos (unpublished 
results). In agreement with previous findings considering SES, Mexican and Central 
American Latinos in California have greater proportion of low SES, whereas South 
Americans have greater proportion of higher SES. However, estimates by country 
or region of origin must be interpreted with caution. Whereas algorithms that cap-
ture Latino status in cancer registry data are efficient and have good specificity [36, 
37], and algorithms are available to obtain nativity status (US- vs. foreign-born 
status) [38], data for country of origin is missing for a large subset of Latinos identi-
fied in cancer registries. Some of this might be due to lack of inquiry from health 
professionals at the time of diagnosis and treatment, and some might be due to the 
fact that US-born Latinos, who might be fully acculturated to US lifestyle and might 
be several generations of US Latinos, might no longer identify with one particular 
Latin American country of origin, and thus this information might not come up 
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 during their cancer diagnosis and care. In addition, some foreign-born Latinos may 
not volunteer this information due to fears triggered by their immigration status. In 
the California Cancer Registry, more than 70% of Latinos with missing country of 
origin were US-born Latinos [30]. If missingness is independent of country/region 
of origin, and systematic across all Latinos, then the disparities observed across 
Latino subpopulations would still be true. However, if missingness differed by 
country/region of origin, this could lead to biases in incidence rates and artifactual 
disparities by country/region of origin. The lack of systematic efforts to enrich data 
collection of Latino origin in cancer registries is an important gap that needs to be 
addressed to facilitate studies of cancer patterns in Latinos. For Asian populations, 
some cancer registries currently track subpopulation information by country of ori-
gin. Similar approaches could be developed for Latino subpopulations.
Few studies have interrogated the role of genetic ancestry and PCa risk among 
US Latinos. One study done in Puerto Rico reported a lack of association between 
global African ancestry and PCa risk; however, they replicated an association 
between a single-nucleotide polymorphism (SNP) of African ancestral origin and 
PCa risk, suggesting possible associations with African local ancestry and PCa risk 
that deserve further investigation [39]. To our knowledge, no studies have investi-
gated the role of Indigenous American ancestry and PCa risk, and whether the pres-
ence of specific alleles of Indigenous American origin might explain the lower risk 
of PCa among some Latinos, as it has been reported for breast cancer [40].
 Clinical Presentation of PCa Among Latinos
Most PCa tumors are diagnosed by 12-core systematic random prostate needle diag-
nostic biopsy, which can miss areas of more advanced disease already present in the 
prostate in as high as 30% of patients, thus introducing under-staging and under- 
grading error at the time of diagnosis [41–43]. PCa biopsies are used not only for 
cancer staging but also for treatment decision-making [44]. Patients diagnosed with 
clinically insignificant disease, typically Gleason 6 and no biopsy core with more 
than 5 mm of cancer, will likely be offered to avoid treatment and enroll in active 
surveillance, whereas those with clinically significant cancer, those with Gleason 7 
or higher or any Gleason with biopsy cores with more than 5 mm of cancer, will be 
offered definitive treatment. If the diagnostic biopsy missed the most aggressive 
part of the tumor, patients diagnosed with clinically insignificant cancer might be at 
risk by not choosing adequate treatment. The rate of misclassification of PCa biopsy 
has been reported to be higher among African-American men compared to NLW 
men [45, 46], and it has been proposed that this could be due to higher proportion 
of anterior tumors, which are more likely to be missed by random systematic biop-
sies [46, 47]. The proportion of anterior tumors and rate of biopsy misclassification 
among Latinos are understudied. One study, of modest sample size, compared the 
Gleason grade at biopsy to the one obtained at surgery and reported that the rate of 
misclassification in PCa biopsy among Latinos was ~36%, which was in between 
M. C. Stern
61
the rate in NLWs (27%) and NLBs (~52%) [48]. Interestingly, the majority of 
tumors with misclassification had anterior localization [48]. Recently, in analyses 
done with data from the California Cancer Registry from 1995 to 2012, we observed 
that foreign-born Latinos had higher rate of upgrade from biopsy to resection than 
NLWs and even NLBs, with Mexicans showing the highest proportion of misclas-
sification (~30%) and Caribbean Latinos showing a proportion that was even lower 
than NLWs (~18%) (unpublished results). These results are intriguing and deserve 
further investigation. If a higher proportion of anterior tumors localization was con-
firmed among Latinos, along with higher rate of misclassification on biopsy, this 
would strongly advocate for a greater proportion of Latinos receiving more accurate 
biopsies coupled with imaging, such as magnetic resonance imaging (MRI)-guided 
targeted biopsies, which can more accurately identify clinically significant cancer 
and sampling error [49–51]. However, these procedures are currently costly and are 
only available at specialized centers. Given that a great proportion of US Latinos 
have low SES, they may lack insurance, or their insurance may not cover these pro-
cedures, which are not yet standard of care. More research in this area is needed to 
advocate for changes in healthcare coverage.
Analyses done with California Cancer Registry data showed that foreign-born 
Latinos had greater proportion of advanced stage at diagnosis than US-born Latinos 
[52]. Moreover, our recent analyses in the same California registry (1995–2012) 
showed comparable proportion of high grade at diagnosis, positive lymph nodes, 
and metastasis as NLBs, with disparities observed by country of origin among for-
eign born (unpublished results). A separate report using SEER data showed that 
Latinos had higher proportion of metastatic disease at diagnosis than NLBs and 
NLWs [53].
 PCa Treatment Patterns Among Latinos
The Prostate Cancer Outcomes Study reported that Latinos received radical prosta-
tectomy in greater proportions than NLWs and NLBs and received radiation therapy 
in lower proportion [54]. Among Latinos in California, foreign-born Latinos were 
reported to be more likely to undergo surgery than US-born Latinos and less likely 
to receive radiation [52]. Our own analyses within the California Cancer Registry 
showed that foreign-born Latinos, Mexicans, Central Americans, and South 
Americans had the highest proportion of surgery utilization (unpublished findings). 
In contrast, a study done in Texas reported that Latinos were less likely to receive 
radical prostatectomy, or radiation therapy, than NLWs [55]. Further, a study done 
using data from the National Cancer Database reported that a lower proportion of 
Latinos than NLWs received radical prostatectomy and that a greater proportion 
than NLWs received radiation or androgen deprivation therapy [56]. The different 
conclusions between these studies might be partially driven by different definitions 
of Latino status and consideration of nativity.
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Our analyses also showed that Latinos, especially foreign-born, had a greater 
proportion of men without any treatment reported (unpublished results). This might 
be indicative of higher proportion of men choosing active surveillance, although we 
cannot confirm this. Analyses using SEER data show that along with NLBs, Latinos 
are more likely to enroll in active surveillance instead of choosing treatment [57–
59], and an association has been reported between low-income patients and selec-
tion of watchful waiting [60, 61]. Alarmingly, Latinos under active surveillance 
seem to be less likely to receive medical monitoring [57, 62], and we recently 
reported that Latinos under active surveillance were more likely to be lost to follow-
 up than NLWs [63]. These findings are concerning and require additional studies to 
identify determinants of lack of adherence to active surveillance in order to reduce 
loss to follow-up and possible disparities in overall survival.
 Survival and Mortality
Historically, US Latinos have been reported to have lower mortality rates from PCa 
than NLWs [1]. However, this finding might be heavily influenced by the heteroge-
neity within Latinos and may not accurately reflect the experience of all Latinos in 
the United States. In Florida, Latinos from the Dominican Republic were reported 
to have the highest PCa mortality rates, followed by South Americans, Central 
Americans, Cubans, Puerto Ricans, NLWs, and then Mexicans [64]. A recent study 
from California and Texas focused exclusively on US-born Latinos and reported 
mortality rates for PCa that were comparable to those among NLWs in both states 
[65]. These studies highlight the importance of considering Latino national origin 
and the biases that are introduced when this consideration is not given. Disparities 
have been reported between US and foreign-born Latinos; foreign-born Latinos liv-
ing in high enclave neighborhoods had better survival than US-born Latinos in simi-
lar neighborhoods, whereas both had comparable survival if they lived in low 
enclave/higher SES neighborhoods [52]. It is possible that among foreign-born 
Latinos, specially low SES Latinos, there might be missing data on mortality if 
many of them return to their home countries (“salmon hypothesis”) to seek care or 
to die back home, or if missing social security numbers impair proper tracking of 
death via vital statistics. These and other related circumstances may bias estimates 
of mortality among Latinos yielding the false notion that survival patterns are more 
favorable, as discussed by Pinheiro et al. in previous studies [64, 65] and in Chap. 2 
in this same issue.
In terms of survival patterns, a study done with SEER data, taking into account 
possible clinical determinants, concluded that when considering all Latino men 
combined, there were no differences in survival with NLWs; however, when consid-
ering country of origin, several disparities emerged, with Puerto Ricans having less 
favorable survival than NLWs [66]. In recent analyses using the California Cancer 
Registry, we did not find differences in survival between Caribbean Latinos and 
NLWs, or between US-born Latinos and NLWs, and we only observed marginally 
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improved survival for South American Latinos (unpublished results). Lack of con-
sideration of nativity may explain these disparate results between studies. Overall, 
results from foreign-born Latinos need to be interpreted with caution given the large 
number of missing data, potential issues with missing social security numbers, and 
uncertainty over final place of death.
 Final Conclusions and Key Knowledge Gaps to Address
Research on PCa in Latinos lags behind our current knowledge for other racial/
ethnic groups. This is a disparity of great public health relevance given that PCa is 
the number one cancer that affects Latino men and that Latinos are the largest and 
fastest growing minority population in the United States, and majority population in 
some US regions, such as California. Among the key knowledge gaps we need to 
address are the following:
• Great need for more epidemiological studies with adequate risk factor data 
including Latinos; currently, there are less than 2000 individuals ascertained 
across studies in the United States.
• Data collection on Latino national origin needs to be improved at all levels so 
that cancer registries can allow for more accurate analyses taking into account 
Latino heterogeneity.
• Analyses of the role of genetic ancestry and PCa risk among Latinos are needed, 
as these studies may help inform some of the cancer incidence findings.
• The tumor landscape of Latino men is largely unknown, as scarcely any Latinos 
have been included in ongoing efforts such as The Cancer Genome Atlas. 
Moreover, patterns of tumor localization need to be understood in order to 
improve PCa detection strategies among Latinos accordingly.
• More studies are needed on patterns of care and adherence to active surveillance 
among Latinos, with emphasis on their determinants, to design culturally- 
sensitive interventions to address any disparities.
• Similar to other cancers, clinical trials focused on novel treatments for advanced 
PCa need to include more Latinos.
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As summarized in the third expert report of the World Cancer Research Fund/
American Institute for Cancer Research (WCRF/AICR), there is accumulating evi-
dence regarding the importance of diet to cancer risk [1]. Because new research is 
making contributions at a rapid pace, WCRF/AICR instituted the “Continuous 
Update Project” to report advances in real time. Tremendous gains in new under-
standing of how nutrients affect gene expression through epigenetic regulation, cell 
signaling, and DNA damage and repair promise to clarify the important roles of 
foods and nutrients on risk and course of different cancers. Important conditions 
affected by diet that contribute to risk include inflammation and oxidative stress. 
What is not well covered at this time, however, is an understanding of the dietary and 
biological differences across populations with diverse cultural backgrounds, which 
may help to explain differences in patterns of cancer incidence and mortality. In the 
United States, Mexican Americans and Puerto Ricans are the two largest subgroups 
among Latinos, yet little research has been done to address the potential differences 
in risk for these or other Hispanic groups. This is important, particularly as the Latino 
population is expected to make up 25% of the total US population by 2050 [2].
 Cancer Incidence Varies by Ethnicity and Gender
Cancer is the second leading cause of death in the United States [3], and thus it is imper-
ative that preventative dietary measures be taken to lessen its occurrence. In the United 
States, cancer incidence is known to vary by ethnicity and gender. Between 1999 and 
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2014 total cancer incidence rates were estimated to be about 475/100,000/year in 
Hispanic males, and 350/100,000/year in Hispanic females. Both of these statistics fall 
into the middle of incidence rates among different ethnicities in the United States, higher 
than that of American Indians/Alaskan Natives or Asians/Pacific Islanders, but lower 
than that of non-Hispanic whites or African Americans [4]. However, the incidence of 
specific cancers varies across groups. Latinos have higher incidence rates of liver, stom-
ach, and gallbladder cancers, compared to non-Hispanic whites, and Latino women 
have among the highest incidence rates of cervical cancer [4, 5].
Although overall cancer rates tend to be lower among Latinos than non-Hispanic 
whites, cancer remains a major cause of death in this group, often discovered at later 
stages with higher mortality. For example, the Surveillance, Epidemiology, and End 
Results Program (SEER) [6] noted that, for most cancers, the incidence of localized 
cancers are lower for Hispanics than non-Hispanic whites, yet later stage and/or more 
aggressive regional or distant cancers are more common among Hispanics than non-
Hispanic whites for lung, colorectal, melanoma, prostate, and female breast cancers [7].
Further, risk differences exist across Latino subgroups. For example, colorectal 
cancer mortality is higher among Puerto Ricans than Mexican Americans, while 
stomach cancer mortality is higher among Mexican Americans than Puerto Ricans 
[7]. The likelihood that these differences may be due to modifiable exposures rather 
than genetic factors is suggested by differences in incidence with migration. In a 
comparison of age-standardized rate ratios for Puerto Ricans living on the island of 
Puerto Rico with Puerto Ricans living on the mainland United States, mainland 
Puerto Ricans had significantly higher cancer risk than island Puerto Ricans. For all 
sites among island Puerto Ricans, standardized rate ratios (SRR) were 0.66 (95% 
CI = 0.61–0.70) for men and 0.64 (95% CI = 0.60–0.68) for women, with most 
significantly lower risk on the island for liver, prostate, and colorectal cancer among 
men and for breast and colorectal cancer among women [8]. Similarly, Mexican 
Americans have higher mortality from cancer than do Mexicans living in Mexico, 
including for colorectal, pancreatic, kidney, liver, and esophageal cancers. There is 
evidence that immigrants adopt unhealthy behaviors the longer that they are in the 
United States [9]. Among these unhealthy behaviors are declines in dietary quality.
 Dietary Factors and Cancer Risk
Dietary factors have been noted to be one of the main contributing risk factors for 
cancer, particularly for colon, breast, and prostate cancers [10]. Up to one third of 
cancers in Western countries have been estimated to be associated with dietary fac-
tors [11]. A recent review [12] estimated that 42% of all cancers and 45% of cancer 
deaths in the United States may be attributed to preventable risk factors. The propor-
tion of cancer cases attributable to specific nutrition-related risk factors were esti-
mated to be obesity (8%), excess alcohol (6%), low fruit and vegetable intake (2%), 
low fiber intake (1%), and processed meat intake (1%), with lower contributions 
from red meat and low calcium intake.
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Alcohol intake is one of many modifiable dietary factors that has been associated 
with cancer risk. The definition of an alcoholic beverage is 12 oz of beer, 5 oz of 
wine, or 1.5 oz of distilled spirits. There is evidence that heavy drinkers (more than 
one drink/day for women or two drinks/day for men) have significantly increased 
risk for mouth, larynx, esophagus, liver, and breast cancers. In one study, heavy 
drinkers had a 15% increase of lung cancer risk in comparison to occasional drink-
ers or those who did not consume any alcohol [13]. Two thirds of adults in the 
United States report exceeding the moderate amount at least once per month [4].
Fruits and vegetables pose many health benefits in relation to preventing disease 
and maintaining overall health. High fruit and vegetable intake has been associated 
with lower risk of lung, colorectal, breast, esophageal, stomach, pancreatic, uterine, 
cervical, and ovarian cancers. Cruciferous vegetables, for example, contain phyto-
chemicals that are thought to reduce colorectal cancer risk [14, 15]. In one study 
assessing the relationship between fruit and vegetable intake and the onset of colorec-
tal cancer, however, there was a statistically significant association between the 
decreased risk of prevalent colorectal adenomas only in participants who had higher 
intake of fruits, but not vegetables. Those authors suggested that the fiber present in 
fruits may be protective against colorectal adenoma and ultimately protect against 
colorectal cancer [16]. Antioxidant nutrients in fruits and vegetables including vita-
min C, vitamin E, selenium, carotenoids, and other phytochemicals also protect 
against tissue damage from oxidative stress. However, several trials of antioxidant 
supplements did not show protection [17], demonstrating that it is important to obtain 
these nutrients in their natural combinations within the food matrix.
The impact of certain B vitamins is also of interest for cancer prevention, with 
considerable evidence for folate. Folate is required for DNA methylation and cellular 
repair, and low folate has been related particularly to colorectal cancer [13, 18]. 
Other research has suggested a relationship between folate deficiency and lung, cer-
vical, breast, and brain cancers [19]. Food sources of folate include leafy greens, 
citrus fruits, legumes, nuts, seeds, and whole grains. Vitamin B6 has also been associ-
ated with cancer prevention; this nutrient is involved in more than 100 metabolic 
reactions, including those involving DNA synthesis and methylation, reducing 
inflammation, and reducing oxidative stress. Vitamin B6 is present in a variety of 
whole quality foods, such as beans, grains, meat, poultry, fish, and certain fruits and 
vegetables, including potatoes, bananas, and avocados. Higher vitamin B6 status, 
measured by pyridoxal 5′-phosphate (PLP), a vitamin B6 biomarker, has been associ-
ated with the reduced risk of colorectal cancer [20, 21]. A systematic review and 
meta-analysis found that observational data supported a strong inverse association 
between both vitamin B6 dietary intake and PLP blood concentration and the risk of 
all cancers: diet (RR = 0.78, 95% CI = 0.73–0.84), PLP (RR = 0.66, 95% CI = 0.58–
0.76). The most prominent finding among 45 studies was the relationship between 
gastrointestinal cancers and vitamin B6, particularly colorectal carcinoma [22].
Red and processed meats have been identified as particular foods that contribute 
to carcinogenic processes. Nitrites in processed meats may be converted in the 
stomach to carcinogenic nitrosamines [23]. Importantly, diets high in fruits and 
vegetables, with vitamin C and phytochemicals, may slow this conversion. The 
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way in which one cooks meat and how much preservatives it contains could be the 
potential identifiable characteristics of interest. In particular, frying, broiling, or 
grilling meats at high temperature creates chemicals that increase cancer risk, mak-
ing braising or stewing a better choice [24]. High consumption of red and pro-
cessed meats may also affect serum obesity-related inflammatory markers, and 
elevated iron composition in meat may be carcinogenic because it is cooked at high 
temperatures [25].
Another controversial nutrient for cancer risk is calcium. On the one hand, foods 
high in calcium may reduce the risk for colorectal cancer [26]. On the other hand, 
high calcium intake has also been associated with prostate cancer risk. Several 
meta-analyses, for example, have related high calcium intake to risk of prostate 
cancer [27]. Roderick and Cook [28] explain how Ca2+, the physiologically active 
derivative of calcium, contributes to cell growth in the body. They note that, because 
Ca2+ is regulated by proteins which exist in cancerous cells to protect the cell, it 
could be detrimental to cancer progression.
 Dietary Patterns and Cancer Risk
Although specific nutrients have received the most attention in the past, newer stud-
ies focus on the totality of dietary patterns and dietary quality in relation to cancer 
risk. One dietary pattern, in particular, has been found to be protective of many 
aspects of health—the Mediterranean diet. A study by Benetou et al. [29] specifi-
cally assessed adherence to a Mediterranean diet in relation to cancer risk among 
25,623 participants from Greece. A 10-point scale, based on data from a food fre-
quency questionnaire, was used to assess compliance with a Mediterranean diet. 
Results showed that those who most thoroughly followed a Mediterranean diet had 
significantly lower incidence of cancer. Important aspects of the Mediterranean diet 
include abundant use of fruits, vegetables, beans, nuts, and seeds, and olive oil as 
the major source of fat, with moderate use of dairy and limited use of red meat. This 
study noted that, within this population, specifically reducing intake of meat, 
increasing intake of legumes and vegetables, and replacing butter with olive oil 
yielded a 12% decrease in the incidence of cancer [29].
While evidence for the importance of these nutritional risk factors continues to 
grow, most studies have been conducted with non-Hispanic whites. Understanding 
the specifics of Mexican and Puerto Rican American dietary habits and sources of 
these nutrients may help improve the overall diet of Latinos as well as prevent 
chronic illnesses like cancer. One factor that has hindered research on Latino diets 
and cancer has been the use of general food frequency questionnaires (FFQ) in the 
United States in large cancer studies. These questionnaires, including the Block and 
Willett, do not contain many Latino foods of importance. In addition, they do not 
consider portion sizes or recipes that are important to nutrient intakes of these 
groups. For this reason, when studying the Puerto Rican population in Massachusetts, 
we developed an FFQ to specifically include their foods, portions, and recipes [30]. 
K. L. Tucker and K. Flanagan
73
Some lessons learned from this include the need to include foods that are widely 
consumed by a specific group, as well as the recipes. For example, Puerto Ricans 
season their rice dishes with tomato sauce and a mixture of onions and green pep-
pers, which contribute vegetables and phytonutrients that may otherwise be over-
looked. They also have significantly larger servings of white rice and lower servings 
of most vegetables than is assumed in the most widely used FFQ. For that reason, 
we added the main rice dishes to our questionnaire. Another major food for 
Caribbean Latinos that is completely missing in most FFQ is plantains, a starchy 
vegetable that contributes considerably to energy and fat intake. When compared to 
24 h recalls, we found that our FFQ, relative to the Block FFQ improved intraclass 
correlations considerably; for example, the correlation for vitamin A improved from 
0.04 to 0.36 and for folate from 0.31 to 0.79. Importantly, when foods consumed 
heavily by a subgroup in a population are missing from the FFQ or portion sizes are 
grossly underestimated, there is not only poorer correlation, but actual bias in esti-
mation compared with other groups [31].
Given the scientific evidence of the potential role that these dietary factors play 
in cancer incidence, it is important that an accurate assessment is taken into consid-
eration for intervention purposes. Moreover, it is important to consider different 
ethnic and cultural backgrounds with relation to dietary habits. By understanding 
the typical diet of Mexican and Puerto Rican Americans, health professionals may 
be able to offer advice and other mediations in order to decrease cancer incidence in 
these populations.
There are also considerable differences in dietary quality across Latino sub-
groups. A large study was conducted in 2014 to assess the overall dietary patterns of 
the Hispanic and Latino communities, known as the Hispanic Community Health 
Study/Study of Latinos (HCHS/SOL). In 2011, these ethnic minority groups made 
up 16% of the total US population. Puerto Ricans, Mexicans, Dominicans, and 
Central Americans in general lived in the United States for longer periods of time in 
relation to Cubans [31]. Two 24-h dietary recalls were administered to assess dietary 
patterns among Puerto Ricans, Dominicans, Mexicans, and Central Americans. 
Puerto Ricans were reported to have the highest prevalence of obesity and higher 
intake of saturated fatty acids and sugar-sweetened beverages; lower intake of 
potassium, total fruits and vegetables, and fiber; and lowest intake of vitamins A and 
C, folate, calcium, and iron than other groups. Puerto Ricans and Mexican- 
Americans were second in relation to Cubans for total fat intake. Mexican- 
Americans also had higher intakes of vitamins A and C, potassium, and fiber than 
other Latino groups [31].
Data from the Boston Puerto Rican Health Study support the idea that Puerto 
Ricans have a relatively lower nutritional status. In our earlier studies [32, 33], we 
noted low intakes of fruits and vegetables, whole grains, dietary fiber, folate, vita-
min B6, vitamin C, and calcium, relative to recommendations, with high intakes of 
refined carbohydrates. The low vitamin B status was confirmed with plasma con-
centrations; 8% were below 5  ng/mL in folate intake, and 28% were below 
30 nmol/L in PLP (vitamin B6). Further, in relation to neighborhood-based non- 
Hispanic whites, Puerto Ricans had lower intake and plasma concentration of most 
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carotenoids, particularly lutein-zeaxanthin (which comes mainly from green leafy 
vegetables), but slightly higher intake of lycopene (from tomato sauce added fre-
quently to recipes) [34].
Food acculturation is the concept of one’s dietary habits in relation to how accul-
turated they are with the Western diet. Batis et al. [35] used the Mexican Nutrition 
Survey of 1999 and the NHANES in the United States to assess Mexican dietary 
patterns. Mexican Americans born in Mexico had higher intakes of fruits, vegeta-
bles, and fruit juices related to all other subpopulations, with evidence of declining 
quality with years in the United States and even more so with the subsequent gen-
eration [35]. In contrast, evidence from Puerto Ricans shows a different pattern, at 
least among Puerto Ricans living in the US mainland, with higher acculturation 
(based on orientation to US society and English usage) associated with better, rather 
than worse, dietary quality [36].
The American Cancer Society recommends a healthful diet for decreasing the 
risk of cancer. The ideal preventative dietary intakes include at least two and a half 
cups of fruits and vegetables per day, reduced intakes of red and processed meat, use 
of whole grains instead of refined grains, and limiting intake of sugars [37] 
(Table 6.1). The evidence clearly suggests that most Latino groups, and particularly 
Puerto Ricans, are falling far short of these recommendations. Improving dietary 
intake in these groups will require greater attention to cultural dietary patterns, 
emphasizing traditional healthy foods to reduce risk of cancer along with other 
metabolic outcomes. Further research with appropriate dietary assessment in longi-
tudinal studies with cancer outcomes are needed in these understudied populations 
to reduce the current risk and to prevent the potential for widening risk with increas-
ing use of Western diet patterns in these groups.
Table 6.1 American Cancer Society (ACS) guidelines on nutrition and physical activity for cancer 
prevention [38]
ACS recommendations for individual choices
Achieve and maintain a healthy weight throughout life
 • Be as lean as possible throughout life without being underweight
 • Avoid excess weight gain at all ages. For those who are currently overweight or obese, losing 
even a small amount of weight has health benefits and is a good place to start
 • Engage in regular physical activity and limit consumption of high-calorie foods and 
beverages as key strategies for maintaining a healthy weight
Adopt a physically active lifestyle
 • Adults should engage in at least 150 min of moderate intensity or 75 min of vigorous 
intensity activities each week, or an equivalent combination, preferably spread throughout the 
week
 • Children and adolescents should engage in at least 1 h of moderate or vigorous intensity 
activity each day, with vigorous intensity activity occurring at least 3 days each week
 • Limit sedentary behavior such as sitting, lying down, watching television, or other forms of 
screen-based entertainment
 • Doing some physical activities above usual activities, no matter what one’s level of activity, 
can have many health benefits
(continued)
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Despite decreasing incidence in the last 50 years, gastric cancer remains the fifth 
most common cancer in the world, representing 6.8% of the total global cancer 
cases [1], and ranks third as the most common cause of cancer-related death in men. 
Almost one million new cases of stomach cancer were estimated to have occurred 
in 2012 [1, 2]. There is a wide geographic variation in gastric cancer incidence and 
mortality rates, with more than 70% of gastric cancer cases occurring in less devel-
oped countries [1]. In Eastern Asia and South and Central America, gastric cancer 
is a significant health burden [1, 2]. In addition, both gastric cancer incidence and 
mortality vary widely among different race/ethnic groups in the United States. 
Asian, Hispanic, non-Hispanic black, and Native American populations have up to 
50% higher risk for gastric cancer than non-Hispanic white populations [3–5]. 
Similarly, gastric cancer survival is better in Asians than in Caucasian Americans, 
African Americans, and Hispanics [4, 6, 7]. Hispanics are younger and more often 
with stage IV disease when gastric cancer is diagnosed, and they present a shorter 
survival time than non-Hispanic whites [8]. Lower survival rates for non-Hispanic 
blacks compared to non-Hispanic whites have also been reported [9].
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Helicobacter pylori (H. pylori) is among several factors associated with non-cardia 
intestinal-type gastric cancer development. It is the primary cause the in initiation of 
the disease and has been classified as a class I carcinogen [10]. Infection with 
H. pylori occurs mainly during childhood [11], and in a proportion of those chroni-
cally infected, it results in the transformation of the normal gastric mucosa into 
non-atrophic gastritis (NAG), followed by multifocal atrophic gastritis without 
intestinal metaplasia (MAG), intestinal metaplasia (IM), dysplasia, and finally can-
cer [12, 13].
Current estimates of H. pylori prevalence in the world range from 24 to 79% 
[14]. The highest prevalence is in Africa (79%) and Latin America and the 
Caribbean region (63.4%), and the lowest in Oceania (24.4%) and Northern 
America (37.1%). In regions of South and Central America, which include 
those with high gastric cancer risk, H. pylori prevalence can reach up to 
80–85%, some of the highest prevalence in the world [15]. In the United States, 
the estimated H. pylori prevalence is 30% [15]. However, while H. pylori prev-
alence ranges from 18.4 to 26.9% in non-Hispanic whites, it can be as high as 
51.1%, 57.9%, and 75% in non- Hispanic blacks, Hispanics, and Alaskan Native 
Americans, respectively [14, 16, 17]. This high prevalence likely contributes to 
the high incidence and mortality from gastric cancer in non-Hispanic blacks 
and Hispanics. Despite this high prevalence of infection, it is estimated that 
approximately 1% of those chronically infected with H. pylori will develop 
gastric cancer [18, 19]. In fact, the majority of the population will remain 
asymptomatic.
In the last decades, H. pylori prevalence has decreased around the world, 
especially in the more developed regions, mostly due to improved hygienic 
conditions, improved diet and food preservation, and broader access to antibi-
otics [2]. Recently, Hooi et al. [14] compared H. pylori prevalence from two 
time periods (1970–1999 and 2000–2016) and found that from one time period 
to the next, H. pylori prevalence significantly decreased in Europe (from 48.8 
to 39.8%), Northern America (from 42.7 to 26.6%), and Oceania (from 26.6 to 
18.7%) [14]. In contrast, H. pylori prevalence remained similar during the 
same periods in Asia (53.6% vs. 54.3%) and Latin America (62.8% vs. 60.2%) 
[14]. This geographical variability in H. pylori prevalence explains in part the 
higher gastric cancer incidence and mortality observed in Latin American 
countries compared to more developed countries as the United States. 
Furthermore, Porras et al. in a recent study of the epidemiology of H. pylori 
infection in six countries of Latin America did not observe any significant 
changes in H. pylori prevalence between the oldest and youngest participants 
in their study, suggesting that gastric cancer incidence is not going to decrease 
in those countries in the near future [15].
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 Environmental Factors
Even though infection with H. pylori is considered necessary for the development 
of gastric cancer, it is not determinant; just 1–3% of those infected with H. pylori 
will develop gastric cancer in their lifetime [18, 19]. Additional environmental fac-
tors are associated with gastric cancer risk, including smoking, alcohol use, and a 
diet low in fresh produce and high in meats and salt [20]. In a recent meta-analysis, 
Bonequi et al. found that in Latin America, smoking and alcohol use were associ-
ated with a 47% and 61% increase of gastric cancer risk, respectively [21]. Regarding 
diet, the same study found that consumption of red and processed meats were asso-
ciated with a 73% and 64% increase of gastric cancer risk, respectively. High salt 
intake was associated with 2.24-fold increase. In contrast, consumption of fruits and 
vegetables were associated with a 32% and 42% reduction of gastric cancer risk, 
respectively [21]. There is a high prevalence of smoking and alcohol use in Latin 
American populations [22, 23], and in regions with high gastric cancer rates as in 
the Andean mountains, the diet is poor in fruits and vegetables and excessively high 
in consumption of salt [24]. Data from the US National Health Interview Survey 
indicate that Hispanics have the lowest prevalence of smoking in all racial/ethnic 
populations and the highest consumption of fresh fruits and vegetables [25]. These 
habits are not in concordance with their gastric cancer incidence and mortality rates.
 Genetic Bases of the Gastric Inflammatory Cascade (Correa’s 
Cascade)
 Single-Nucleotide Polymorphisms (SNPs)
In 1975, Correa et al. analyzed 1500 stomachs obtained at autopsy to estimate the 
prevalence of intestinal metaplasia [26]. As a result of that analysis and later updates, 
Correa et al. proposed that gastric adenocarcinoma is the final stage of an inflamma-
tory cascade that leads the normal gastric epithelia to non-atrophic gastritis (NAG), 
multifocal atrophic gastritis (MAG), complete intestinal metaplasia (IM), incom-
plete intestinal metaplasia, dysplasia, and cancer [13, 27–30]. It was shown that 
single-nucleotide polymorphisms (SNPs) in the cytokine gene encoding 
interleukin-1β (IL1B) are associated with the risk of gastric cancer [31]. Since then, 
others have shown the association of cytokine SNPs with gastric cancer risk in sev-
eral populations [32–36]; however, very few works have centered on defining the 
association of cytokine SNPs and the presence of advanced gastric lesions as pre-
cursors of gastric cancer. Our work has led to the identification of SNPs and haplo-
types in the IL1B gene associated with advanced gastric premalignant stages in 
African American and Caucasian individuals [37, 38]. Our studies have shown that 
African American individuals have a higher prevalence of MAG as well as a higher 
rate of H. pylori infection [37, 38]. Using DNA samples from healthy African 
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American and Caucasian newborns, we performed additional analyses of cytokine 
SNPs and haplotypes in cytokine genes which showed that there is a differential 
distribution of proinflammatory SNPs and haplotypes between these two ethnic 
groups [39]. In the case of IL1B gene, there is a strong linkage disequilibrium 
among the SNPs analyzed [39].
 Stage-Specific and Evolution-Associated Gene Profiles
The pioneer studies by Correa et al. led to the identification of a premalignant cas-
cade suggested to precede gastric carcinogenesis [27]. However, the molecular basis 
for the intricate relationship between the different stages and their evolution over 
time is not fully known. Using baseline and 6-year follow-up samples from a cohort 
study established by Correa et al. in Colombia [40], we extracted RNA and per-
formed a microarray analysis to find genes associated with stage and progression of 
premalignant lesions. Analyzing the genomics of lesion evolution over time, we 
found that the genes CD44, NUMA, and LCN2 were associated with progression 
[41]. Interestingly, these three genes have been associated with several types of 
cancer and with advanced premalignant lesions [42–46]. Using mouse models of 
H. pylori infection in wild-type and Cd44−/− H. pylori mice, we found a significant 
activation of immune-related pathways in response to the infection, among them 
was the IFNγ pathway [41]. Interestingly, the gastric mucosa of Cd44−/− mice had 
significantly lower expression of Ifng and Ifng-related genes including Irf7, Ifit3, 
Ifit2, Nos2, and Stat1 [41]. Reduction in Stat1 expression was paralleled with reduc-
tion in phosphorylation of the Stat1 protein [41]. In order to correlate the differences 
found in global and immune gene expression with pathological changes in the gas-
tric mucosa, we determined and compared the presence of gastric lesions between 
wild-type and Cd44−/− H. pylori-infected mice. We found that compared to the wild- 
type mice, the H. pylori infection did not induce tissue damage in the gastric mucosa 
of Cd44−/− H. pylori-infected mice. These data suggest that this gene, and the pro-
tein encoded by it, is essential to mount the Th1 responses associated with tissue 
damage induced by the infection [41, 47–49].
Using baseline samples from the same cohort of individuals described for our 
work with CD44 [40], we identified 37 samples with MAG, 25 with IM, and 12 with 
dysplasia. Using the less advanced gastric precancerous lesion as reference (MAG), 
we identified 16 genes with at least a 30% change in their expression levels when 
compared with dysplasia [50]. However, the only one showing significantly higher 
expression was the gene Deleted in Malignant Brain Tumor 1 (DMBT1), which was 
able to separate most dysplasia from MAG cases [50]. Interestingly, gastric tissue 
from African American and Caucasian individuals with advanced gastric lesions 
also had increased levels of expression of the gene [50], suggesting that this response 
is conserved across ethnicities. We also found that the expression of the DMBT1 
gene was significantly higher in individuals with advanced gastric lesions who also 
had infection with H. pylori, which highlights the role of the DMBT1 protein as an 
agglutinin [51–53]. Mouse models of H. pylori infection show that this gene acts as 
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a tumor suppressor by limiting tissue damage in response to the infection and 
through the activation of interleukin 33 (IL33) and pERK [50].
In summary, gastric cancer is a disease of disparities, with minority groups hav-
ing increased prevalence and mortality of the disease. We have shown that precan-
cerous lesions and their evolution over time are associated with specific patterns of 
genes that may be used as the basis to devise strategies for the prediction of disease 
aggressiveness and outcome.
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Chapter 8
Molecular Subtypes and Driver Mutations 




 Gastric Cancer Is a Common Malignancy with Poor 
Outcomes
Worldwide, gastric cancer (GC) is the third leading cause of cancer mortality [1]. 
Each year ~1 million new gastric cancer (GC) cases are diagnosed and >720,000 
patients die of GC [2, 3]. GC prognosis is dismal because early-stage tumors, where 
survival is high, are clinically silent and difficult to detect. Most GCs are detected in 
late stages and have 5-year survival rates <10% [2, 4, 5]. To improve GC outcomes, 
major limitations need to be addressed. First, new prevention and early detection 
tools must be developed, including the identification of susceptibility genes that 
allow the identification of high-risk individuals. Until recently, E-cadherin (also 
known as CDH1) was the only known GC gene; it accounts for ~40% of cases with 
hereditary diffuse GC (HDGC) syndrome and a very small fraction of non-HDGC 
cases [2, 6, 7]. We recently identified a second familial GC form, involving germline 
mutations in recombination DNA repair genes, which account for ~2–6% of all 
cases [1, 8, 9]. Even though this recent gene discovery represents an important 
advance, few individuals currently benefit from genetic-guided prevention. Another 
major limitation is the need to develop effective therapies to improve GC outcomes. 
The Cancer Genome Atlas (TCGA) study found that >70% of all GCs have muta-
tions that can be targeted with existing drugs [10]. Despite this large fraction of 
“druggable” mutations, only two GC-targeted therapies have been approved by the 
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Food and Drug Administration (FDA) [11, 12]. Hence, major advances in etiologi-
cal and translational research are needed to improve GC outcomes through preven-
tion, early detection, and better treatments.
 Gastric Cancer in Latinos
GC exemplifies a malignancy with strong disparities in incidence, mortality, and 
survival that disproportionately affects Latinos, the largest and youngest US minor-
ity population [13–16]. Table 8.1 shows incidence and mortality rates (per 100,000 
people) in NLW, Latinos, and their associated disparities [15]. Latinos are between 
1.7- and 2.2-fold more likely than NHWs to be diagnosed with GC and between 
2.0- and 2.3-fold more likely to die when diagnosed. These disparities are among 
the highest in the country and are not fully accounted for by differences in the preva-
lence of known risk factors or access to healthcare. Addressing these disparities 
should be a priority in etiological and outcome research in the country.
 Genomic and Genetic Research Disparities
Relative to NLW, very limited GC genetic or genomic research has been carried out 
in Latino populations. All published GC genome-wide association studies (GWAS) 
have been carried out in Asians [17–20] or NLW [21], and no data are available on 
the risk that GWAS variants confer in Latino populations. Furthermore, all gastric 
tumor whole exome or whole genome sequencing studies carried out to date have 
only involved either Asian [22–28] or, as in the TCGA, predominantly NLW [10]. 
Table 8.2 shows the ethnic/racial composition of the TCGA patients, where Latinos 
represent only 1% of the participants. It is unfortunate that the minority population 
with the highest GC burden in the country was not fully represented in such an 
important study. To my knowledge, there is no published Latino data on the preva-
lence of the four TCGA molecular subtypes (Epstein–Barr virus associated, EBV; 
microsatellite instable, MSI; genomically stable, GS; and chromosomally instable, 
CIN) or of the mutation prevalence of the TCGA driver genes. Investigating Latino 
GC genomics is needed, because many somatic alterations are druggable and the 
TCGA new molecular subtypes show important differences in prognosis and 
response to therapy [29]. Having such information on population-specific molecular 
Table 8.1 Disparities in gastric cancer incidence and mortality in Latinos and in non-Latino 
whites (NLW ) (data from the American Cancer Society report [15])
Incidence per 100,000 individuals Mortality per 100,000 individuals
Latinos NLW Disparity ratio Latinos NLW Disparity ratio
Men 13.5 7.8 1.7 7.2 3.6 2.0
Women 7.8 3.5 2.2 4.2 1.8 2.3
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profiles will empower studies aimed at improving GC outcomes in this minority 
population. Furthermore, Latino-focused genomic research efforts will help avoid 
widening the pervasive gap in cancer disparities [30].
 The Unique Epidemiology of Gastric Cancer in Latinos
Table 8.3 presents GC incidence and mortality data for Latinos and NLWs from 
California. These data are interesting because GC profiles show important popula-
tion differences. Latinos have a higher fraction of women with GC (44% vs. 34% in 
NLWs) and more GC patients with lower socioeconomic status (37% vs. 14% in 
NLWs). Furthermore, Latinos are more often diagnosed with GC by age 50 years 
(23% vs. 8% in NLWs), diffuse tumors (38% vs. 23% in NLWs), and regional and 
distant metastasis (77% vs. 62% in NLWs). These data therefore suggest that the 
epidemiology of GC in Latinos is unique and highlights the need for research that 
uncovers etiological differences between Latinos and other populations.
Table 8.2 The racial/ethnic 
composition of the GC 
patients included in TCGA 
[10]
Race/ethnicity






Table 8.3 Epidemiological 
profiles of gastric cancers in 
Latinos and NLWs from 







Men 2166 (56%) 3048 (66%)
Women 1713 (44%) 1564 (34%)
Age
Early onset (≤50 years) 880 (23%) 363 (8%)
Late onset (>50 years) 2999 (77%) 4249 (92%)
Socioeconomic status
Lowest 1285 (37%) 435 (14%)
Medium/high 2145 (63%) 2736 (86%)
Histology
Intestinal 1929 (62%) 2739 (77%)
Diffuse 1187 (38%) 828 (23%)
Stage
Localized 887 (23%) 1282 (38%)
Regional/remote 2580 (77%) 2895 (62%)
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 Molecular GC Profiles in Latinos Are Unique
The new TCGA GC molecular classification is important, because some of these 
subtypes have been associated with the prognosis or with response to therapy. 
Specifically, GC patients with EBV subtype tumors have excellent prognoses, while 
those with the GS subtype have poorer outcomes [29]. A recent study by Sohn et al. 
[29] also showed that patients with GS tumors do not benefit from chemotherapy, 
highlighting the need for research aiming at developing effective therapies for this 
subtype. To establish the prevalence of GC molecular subtypes in Latinos, our group 
recently carried out a pilot study of targeted sequencing in 30 tumors from Latino 
patients. Relative to TCGA, our unpublished study found that Latinos have a lower 
prevalence of CIN (33% vs. 49%) tumors and a higher prevalence of the GS (39% 
vs. 19%) subtype. We also found that the prevalence of mutations in driver genes is 
very different in Latinos (see Table 8.4 for some examples). These unpublished data 
suggest that the molecular profiles of GCs in Latinos are unique and highlight the 
need for larger and more comprehensive tumor genomic studies in the population.
 Conclusions
Latinos have the highest GC burden in the United States. Published data and ongo-
ing research suggest that the epidemiology of GC in Latinos is unique. It is now 
critically important to carry out studies that help us understand the etiology of GC 
in this minority population and that further characterize genetic and genomic pat-
terns in GC patients of Latino ancestry. Furthermore, the unique molecular patterns 
in Latino GCs warrants future preclinical and translation studies in driver genes and 
molecular subtypes that are more prevalent in this minority population.
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Chapter 9
The Biology of Breast Cancer Disparities 




The Hispanic population in the United States has been steadily increasing over the 
last decades, and it currently represents over 54 million people or approximately 
19% of the US population (U.S. Census Bureau data, 2014). Breast cancer is the 
most common cancer in Hispanics and also has the highest mortality; therefore, 
addressing disparities in breast cancer outcomes is a critical healthcare issue. Data 
from national databases clearly show that non-Hispanic whites (NHW) have a 
higher population-based incidence and mortality from breast cancer than Hispanic 
women (incidence NHW 128.1/100,000 vs. 91.9 in Hispanics; mortality NHW 21.9 
vs. 14.5 in Hispanics, ACS 2015 data) [1]. On the other hand, Hispanic women with 
breast cancer are more likely to be younger, to present with advanced stage disease, 
and are more likely to have aggressive subtypes (triple negative and HER2 positive) 
than NHW. As a result of this, Hispanic women with breast cancer have higher mor-
tality rates than NHW [2].
 Factors Contributing to Higher Breast Cancer Mortality 
Among Hispanics
It has been shown that socioeconomic factors including low socioeconomic status 
(SES) and lack of insurance or under-insurance are the main contributors to the 
observed outcome disparities among Hispanic women with breast cancer [2]. A 
higher prevalence of obesity among Hispanics is another factor contributing to these 
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disparities [3, 4]. Also, the prevalence of inherited BRCA mutations among differ-
ent subsets of Hispanic women has been correlated with the presence of European 
ancestry [5]. These data suggest that the higher prevalence of aggressive subtypes of 
breast cancers among Hispanic women may result from interactions between envi-
ronmental and genetic factors.
 Recent Data Elucidating the Causes of Breast Cancer 
Disparities Among Hispanics
Martinez and colleagues evaluated California Cancer Registry data that consists 
of 29,626 Hispanics and 99,862 NHW women with invasive breast cancer who 
were diagnosed between 2004 and 2014 [2]. They analyzed the prevalence of 
different breast cancer subtypes and found that triple-negative breast cancer and 
HER2- positive breast cancers were more common in Hispanics (HR 1.29 and 
1.19, respectively). Hispanic women also had a higher mortality rate ratio (MMR) 
of 1.24. Multivariable analysis showed that neighborhood SES and health insur-
ance status accounted for most of the differences in mortality. The percentage of 
Hispanic breast cancer women aged less than 50 years was twice that of NHW. 
Hispanics had a higher percentage of patients living in low SES neighborhoods 
(52.7 vs. 21.1%) and a higher percentage of patients with Medicaid insurance 
(30.8 vs. 17%). Hispanics also had more advanced (stages 3–4) disease and less 
stage 1 disease (39.2 vs. 28.4% and 39.8% vs. 51.1%) and were more likely to 
present with positive nodes (41.1% vs. 31.5%). Hispanics had higher TN and 
HER2-positive subtypes (TN: OR 1.29; ER neg HER2 pos: OR 1.31; ER pos 
HER2 pos: OR 1.19). In a model that included all variables, mortality among 
Hispanics was significantly lower than among NHW (MRR 0.90, CI 0.87–0.94). 
Younger women had a higher risk of dying than older women (p < 0.001), and 
mortality differences between Hispanics and NHW were greatest in the younger 
group (MRR 1.42 vs. 1.13).
Fejerman et al. showed that European ancestry is associated with increased 
risk of breast cancer among Hispanics in the San Francisco area (OR 1.79, CI 
1.28–2.79) [5]. Among Mexican women, the risk of breast cancer increases with 
every 25% increase in European ancestry (OR 1.20, CI 1.03–1.41) [6]. They 
also showed that 50% or more Native American ancestry in Hispanic women 
with breast cancer is associated with a doubling of mortality [7]. Engmann and 
colleagues in Fejerman’s group recently analyzed data from the Pathways Study, 
a prospective study of 506 Latina women with breast cancer cared for in the 
Kaiser Permanente Health System. They found that equal access to care as part 
of the Kaiser System eliminates the association between Indigenous American 
ancestry and breast cancer recurrence and mortality [8].
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 Breast Cancer in Young Hispanic Women: The Subset 
with the Greatest Disparities in Outcomes
Even though breast cancers are most common in women in their fifth and sixth 
decades of life, breast cancer in women younger than 50 years is a significant health 
issue. For example, among US women aged 35–40 years, breast cancer is the num-
ber one cause of death and the number one cancer. Among women aged 25–34 years, 
breast cancer is the number two cause of death behind accidents. If we consider 
women aged 25–40  years, breast cancer accounts for 23% of all cancer deaths. 
Keegan et al. reviewed data from 5605 women aged 15–39 years that were diag-
nosed with breast cancer in the United States between 2005 and 2009. They found 
that Hispanic women had a 3.25 RR and African American (AA) women had a 1.65 
RR relative to NHW women [9]. It was also found that in this age group, women 
with breast cancer are more likely to have triple-negative and HER2-positive dis-
ease as well as more likely to present with stages 3–4 and be Hispanic, AA, or 
Native American (NA) [9].
 Conclusions from Recent Data
We can conclude from the recent data that breast cancer outcome disparities are 
greatest in the young age group (age less than 40 years) and that there is a need for 
more studies on the interplay between genetic and environmental factors. There is 
also a need for breast cancer preventive interventions in the young age group (age 
less than 40  years). Since low SES neighborhoods and uninsured/under-insured 
patients account for most of the disparities, efforts need to emphasize interventions 
in these populations.
 Hypothesis for the Causes of Early Onset Breast Cancer 
Disparities and the Potential Role of Childhood Obesity
Figure 9.1 summarizes a working hypothesis for possible factors contributing to 
early onset breast cancer disparities. We hypothesize that low SES factors lead to 
increased stress and poor dietary habits, which in turn leads to childhood obesity. 
Childhood obesity leads to increased production of adipokines and IL-6 with 
increased transcription of aromatase in the adipose tissue leading to increased estro-
gen and increased genotoxic estrogen metabolites. This results in increased DNA 
damage, particularly in patients with DNA repair defects, leading to early onset 
breast cancer with its worse prognosis.
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 Childhood Obesity: A Likely Contributor to Breast Cancer 
Disparities
The prevalence of obesity in US children and adolescents has tripled over the last 
30 years [4, 10]. The prevalence of childhood obesity is highest in non-White children 
with 30% AA children and 20% Mexican American children being obese as com-
pared to 11% NHW [4]. Recent data also shows that obesity in childhood predicts for 
adult obesity. Among 2400 obese 5–14 year olds followed for 17 years, 83% AA vs. 
68% NHW were obese as adults [11]. Finally, low income is associated with higher 
obesity and with a higher consumption of fast foods, snacks, and soft drinks [4].
 Possible Linkage of Childhood Obesity with Breast Cancer: 
The Third Harvard Growth Study
The Third Harvard Growth Study was a longitudinal study of more than 3000 school 
children performed by the Harvard School of Education from 1922 to 1935 [12]. 
The subjects were first- and second-grade public school students enrolled in 1922–
1923 from three middle-class cities in the north of Boston. Subjects were measured 
annually through high school, and those with at least eight height and weight 
Low SES
Discrimination & Increased Stress
Childhood Obesity
Increased IL-6 & TNFα
Increased Aromatase
Increased Estrogen
Increased Genotoxic Metabolites Early Onset Breast Cancer
Poor Dietary Habits
Increased Cortisol
Fig. 9.1 Hispanic breast cancer outcome disparities are greatest in the early onset breast cancer 
subset. We speculate that this is likely a result of genetic factors and disparities in the prevalence 
of obesity among low SES Hispanics with its effects on estrogen metabolism
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measurements were included in this study. Subjects were contacted in 1968 and 
1988. A total of 1877 subjects were included in the analysis, including 858 women. 
Ever been overweight before puberty was associated with a 2.7 times risk of breast 
cancer mortality in females. Previous studies had yielded conflicting results regard-
ing the risk of breast cancer associated with childhood obesity, but these studies 
were dependent on patients’ recollection of their childhood weights [12].
 Childhood Obesity: A Proinflammatory State with High 
Estrogen and Genotoxic Estrogen Levels
Mauras et al. evaluated a cohort of obese and lean pre-pubertal girls. In the obese 
girls, they found a significant increase in levels of proinflammatory cytokines, 
including IL-6 as well as evidence of elevated prothrombotic proteins (PAI-1 and 
fibrinogen) [13]. These findings show that obesity in childhood, prior to the onset of 
clinically evident metabolic syndrome, is associated with a significant proinflam-
matory and prothrombotic state. In addition, using the same cohort of patients, they 
showed that childhood obesity is associated with significantly higher levels of estra-
diol and its genotoxic metabolites (16-OH-E1, 2-OH-E1, 2-OH-E2, 4-OH-E1 and 
4-OH-E2) with greatest elevations in the 16-OH-E1 levels and a significantly lower 
ratio of 2-OH-E1/16-OH-E1, values that had been directly and reciprocally related 
to the subsequent risk of breast cancer in postmenopausal women by Fuhrman et al. 
[14]. The elevations of estradiol and its metabolites in the obese group correlated 
with the elevation of IL-6.
 Contemporary Hormonal Contraception Is Associated 
with a Higher Risk of Breast Cancer
Morch et al. recently reported a detailed epidemiologic analysis of the effects of 
hormonal contraceptive use on the prevalence of breast cancer. This was a prospec-
tive study of 1.8 million Danish women aged 15–49 years followed for an average 
of 10.9 years [15]. More than 10 years of hormonal contraceptive use was associ-
ated with a 1.38 RR for breast cancer in this population.
 Oral Versus Transdermal Estrogen Replacement and Its 
Effects on Estrogen Metabolism
Estrogen is converted into its oxidative metabolites in the liver, and it is conceivable 
that oral estrogens may be associated with a greater generation of these metabolites 
than the transdermal estrogens. In a prospective randomized study of hypogonadal 
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girls with Turner syndrome, Dr. Mauras’ team administered estradiol orally versus 
transdermally at doses that resulted in similar serum-free estradiol levels [12]. 
Measurements of total estradiol and its metabolites after 12 months of therapy were 
obtained. The oral estradiol group was associated with higher generation of geno-
toxic estrogen metabolites than normal post-pubertal girls and the transdermal 
estradiol group [16]. This may explain the higher risks of breast cancer associated 
with oral hormonal contraception reported by Morch et al. [15] and suggests that a 
switch from oral estrogen to transdermal estrogen contraception could potentially 
decrease breast cancer and ameliorate breast cancer disparities.
 Future Research on Genotoxic Estrogen Metabolites 
and Breast Cancer Disparities
Additional studies aimed at determining if obesity in Hispanic young women is 
associated with higher levels of genotoxic estrogen metabolites will be of interest. 
Evaluating possible interactions between BRCA mutations (or other pathogenic 
DNA repair mutations) and genotoxic estrogen metabolism in Hispanics may iden-
tify mechanisms involved in early onset breast cancer. Short-term diet and exercise 
interventions may alter genotoxic estrogen metabolite generation in pre-pubertal 
obese girls, and measuring the effects of dietary manipulations on these metabolites 
may be of clinical value.
 Conclusions
In summary, Hispanic women overall have lower prevalence and mortality from breast 
cancer than NHW. On the other hand, breast cancer in Hispanics develops at a younger 
age, is more likely triple-negative or HER2-positive, presents in advanced stage and 
has a worse prognosis. Data is emerging on the potential roles of stress from low SES 
status, childhood obesity, genotoxic estrogen metabolites, exogenous oral estrogens, 
and genetics on breast cancer, particularly early onset breast cancer and its associated 
disparities in Latinas. Further studies are needed to elucidate the biological factors 
accounting for disparities in outcome among Latinas with breast cancer.
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Chapter 10
Molecular Profiles of Breast Cancer 
in Hispanic/Latina
Silvia J. Serrano-Gómez, Maria C. Sanabria, Jone Garai, Li Li, 
Melody Baddoo, Lucio Miele, Laura Fejerman, and Jovanny Zabaleta
 Introduction
Breast cancer is the most common cancer in women worldwide and is the second 
leading cause of cancer death among women in the United States [1]. Although it is 
the most incident cancer at the global level, its incidence and mortality rates vary 
among the population groups in the United States [2]. African American (AA) and 
Hispanic/Latina (H/L) women have a lower incidence of breast cancer (125.5 per 
100,000 and 91.9 per 100,000, respectively) compared to non-Hispanic White 
(NHW) women (128.7 per 100,000) [2]. Mortality rates for breast cancer are higher 
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in AA women (29.5 per 100,000) and lower in H/L women (14.2 per 100,000) when 
compared to NHW women (20.8 per 100,000) [2].
 Breast Cancer Intrinsic Subtypes
Breast cancer is a complex and heterogeneous disease in terms of histology, thera-
peutic response, metastatic patterns, and outcomes [3]. In 2000, Perou et al. pub-
lished the first classification of breast cancer into intrinsic subtypes based on data 
from gene expression microarrays [4]. They used complementary DNA (cDNA) 
microarrays to analyze breast cancer tissue from 65 surgical specimens of human 
breast tumors from 42 different patients. These samples were collected at Stanford 
University California, or at the Haukeland University Hospital in Bergen, Norway, 
so presumably included women of mostly European descent. Gene expression anal-
ysis separated intrinsic subtypes of breast cancer into two main groups based on the 
expression of estrogen receptor (ER). Within these two groups, four intrinsic sub-
types were identified: luminal A and luminal B subtypes, which are positive for the 
ER expression (ER+); and HER2-enriched and basal-like, both ER negative (ER−) 
[5, 6]. One year later, Sorlie et al. [7] analyzed the clinical implications of this new 
classification of breast cancer [8] and reported differences in breast cancer out-
comes between the intrinsic subtypes [7].
 Genetic Ancestry and Breast Cancer Characteristics
Each Latin American country shows variations in the proportions of European, 
African, and Native American ancestries, and countries such as Mexico, Peru, and 
Bolivia are predominantly indigenous while Argentina and Uruguay are predomi-
nantly European [9]; there are differences not only in genetic ancestry but also in 
lifestyles and exposures of breast cancer [10].
Increasing evidence shows that breast cancer characteristics differ according to 
genetic ancestry. European ancestry in H/L women has been associated with an 
increased risk for breast cancer in women from the San Francisco Bay area [11], and 
this finding was replicated in women from Mexico [12]. Also, Fejerman et al. [11] 
did not find any associations between genetic ancestry and tumor characteristics 
such as hormone receptor status. Al-Alem et al. [13], however, studied the associa-
tion between genetic ancestry and breast cancer characteristics in a group of 656 
women (255 NHW, 277 AA, and 124 H/L) from the “Breast Cancer Care in Chicago” 
study and found that higher European ancestry was protective for later stage at diag-
nosis in H/L women (OR 0.70, 95% CI 0.54–0.92) and that Indigenous American 
ancestry (IAA) was associated with later stage at diagnosis (OR 1.36, 95% CI 1.04–
1.79). The lack of concordance between the last two studies can be explained by the 
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variation in the case populations. The study by Fejerman et al. [12] included women 
from the San Francisco Bay area, presumably of Mexican origin while the Al-Alem 
et al. study [13] included a larger proportion of women from the Caribbean. This 
highlights and reinforces the idea that results found in one Hispanic population can-
not be generalized for all Latinos and that there is a need to include genetic ancestry 
in the studies [13].
Growing evidence suggests that differences in gene expression profiles of breast 
cancer can be influenced by the genetic architecture of the individual’s genome 
[14–17]. These studies have compared gene expression profiles from NHW and AA 
women with breast cancer in an effort to explain health disparities in the tumor biol-
ogy context. Martin et al. [16] compared breast tumors from 18 AA and 17 NHW 
women, and over the 400 differentially expressed genes, they found two genes that 
could distinguish between the two population groups, CRYBB2 and PSPHL. Similar 
findings were reported by Field et al. [14] who analyzed 52 matched patients (26 
AA and 26 NHW) and compared the gene expression profile between the two popu-
lation groups. They found 22 differentially expressed genes, including CRYBB2 and 
PSPHL. Stewart et al. [17], using data from The Cancer Genome Atlas (TCGA) 
compared gene expression profiles of 574 NHW and 53 AA patients and found 674 
differentially expressed genes. Among those, resistin (RETN), a gene associated 
with obesity and diabetes [18], was the most changed. CRYBB2 was also found to 
be overexpressed in AA patients [17]. Grunda et al. [15] analyzed the expression of 
84 genes involved in breast cancer prognosis associated with therapy, estrogen sig-
naling, and tumor aggressiveness in 11 AA and 11 NHW patients and identified 20 
genes that participate in regulatory processes such as G1/S transition, cell adhesion, 
and estrogen pathway targets. The results suggest that there may be some differ-
ences in the gene expression profile as a consequence of ancestry. None of these 
studies included H/L women in the analysis. More importantly, ancestry was 
assessed by self-identification, and genetic ancestry was not analyzed.
There is one study from Chavez-MacGregor et al. [19] that investigated the dif-
ferences in gene and protein expression within each molecular subtype as a conse-
quence of ancestry. They analyzed a group of 376 women belonging to different 
racial groups (AA, NHW, H/L, and others) and did not find differences in gene and 
protein expression between racial/ethnic groups. As they discuss in the paper, to 
perform a more accurate analysis in an admixed population, it is important to ana-
lyze their genetic ancestry, as it could lead to misclassification of the population. 
Even though the latter work did not find ancestry-modulated genes in breast cancer, 
more studies are needed to answer that question.
Few studies have explored genetic ancestry to assess gene expression differ-
ences. Huo et al. [20] analyzed genetic ancestry in 930 patients with breast cancer 
who were grouped into the categories genomic black (≥50% African ancestry) or 
genomic white (≥90% European ancestry). After adjusting for intrinsic subtypes, 
they found 142 differentially expressed genes, with LOC90784 and CRYBB2 being 
the top two most differentially expressed. This result is consistent with previous 
studies where genetic ancestry was not analyzed [14, 16, 17]. This finding can be 
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explained by the fact that the genetic ancestry in patients who self-identify as NHW 
and AA is more uniform, with dominant ancestries being European and African, 
respectively [20].
Our recent work identified luminal B as the most prevalent subtype in Colombian 
women with breast cancer [21]. In the context of genetic ancestry, we analyzed gene 
expression profiles of 42 Colombian women with breast cancer (21 luminal A and 
21 luminal B) based on 80 ancestry-informative markers (AIMs) [22]. The patients 
were categorized according to luminal subtype and to the proportion of European or 
Native American ancestry. Differential expression analysis was performed accord-
ing to intrinsic subtype and by ancestry category. We found five genes potentially 
modulated by genetic ancestry: ERBB2, GRB7, GSDMB, MIEN1, and ONECUT2. 
Further studies are needed to explore the prognostic value of this finding and to 
replicate it in other Latin-American patients.
Other studies have analyzed gene expression profile in H/L women without 
determining genetic ancestry. DNA repair capacity (DRC) has been previously 
described as a breast cancer risk factor [23, 24]. DRC can be measured by the host- 
cell reactivation (HCR) assay that quantifies the capacity of a lymphocyte to repair 
exogenous DNA [25, 26]. Ramos et al. [27] reported that a low DRC is a breast 
cancer risk factor in H/L. They compared the DRC in 33 breast cancer patients and 
47 healthy controls from Puerto Rico and found that for every 1% decrease in the 
DRC, there was a 22% increase in breast cancer risk. Matta et al. in 2012 [28] ana-
lyzed the DRC from 824 women (285 breast cancer patients and 539 controls) and 
also found that the DRC was lower in breast cancer patients. One year later, the 
same group [29] performed microarrays to analyze the expression level of DNA 
repair genes in women with breast cancer from Puerto Rico compared to controls to 
explore how DNA repair was dysregulated in breast cancer. They found 21 genes 
differentially expressed between breast cancer patients and controls: CHEK2, EME1 
(MMS4L), ERCC3 (XPB), FANCM, H2AFX (H2AX), HMGB1, HUS1, MBD4, 
NEIL3, PCNA, RAD1, RAD23B, RAD51, RAD54B, RDM1 (RAD52B), SHFM1 
(DSS1), TP1, UBE2N (UBC13), and XRCC5 (Ku80). Moreover, they analyzed DRC 
using the HCR test and found three genes positively associated with the DRC level, 
RAD51, FANCB, and FANCA. This study is important because the use of inhibitors 
of DNA repair pathways can interfere with the ability of the cells to survive DNA 
damage induced by chemotherapeutic agents [27, 30, 31]. The results in Matta et al. 
[29] and Ramos et al. [27] provide evidence regarding dysregulation of DNA repair 
capacity at the gene expression level in H/L women with breast cancer. Similar 
results have been reported in NHW women [32, 33].
Analysis of gene expression profiling has also been used to develop gene signa-
tures to estimate recurrence risk and to better select patients who will benefit from 
chemotherapy [34–37]. These signatures have been developed and validated in 
samples of NHW women and have been used in H/L patients with the assumption 
that the molecular profile would be similar. Kalinsky et al. [38] compared the pro-
liferation index of ER(+)/HER2(−) early stage tumors based on the Oncotype DX 
gene expression signature in H/L and NHW women and found that tumors from 
H/L women showed higher proliferation scores than tumors from NHW women.
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 Conclusions
Hispanic/Latinas are underrepresented in breast cancer studies and usually are ana-
lyzed as a whole group. However, the genetic make-up of H/L women may create a 
bias in genetic association studies and generate false-positive or false-negative asso-
ciations. It is thus advisable to properly classify genetic ancestry in admixed popu-
lations, like Hispanic/Latinos, to better understand the real contribution of genetics 
to disease susceptibility and to provide this ethnic group the benefits of recent treat-
ment advances.
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Chapter 11
Biomarkers and Precision Medicine 
in Oncology Practice and Clinical Trials
Edith A. Perez
 Introduction: Biomarkers in Clinical Care and Research
 Biomarker-Based Precision Medicine
Biomarker-based precision medicine is now often the standard of care for patients 
diagnosed with cancer. Industry and government have invested heavily in the devel-
opment of precision medicine, and as improved diagnostics, testing, and biomarkers 
become more common, existing barriers to the use of precision medicine will be 
eliminated. To make this happen, there must be clear scientific communication that 
enhances understanding and influences clinical practice. One concern is the high 
cost of new precision medicines available for patients, which should be offset by 
efficiency and overall value provided to patients with cancer. Additionally, rather 
than testing tumor specimens just once, there will be increased reliance on dynamic 
biomarkers in the continuum of cancer care. This will influence existing guidelines 
and procedures in many hospitals, clinical practices, and insurance companies, so 
that patients can access the best medicine for them.
 Biomarkers for Decision Support
It is increasingly evident that the introduction of targeted therapies has revolution-
ized the management of patients with cancer. Integration of biomarkers, in the 
tumor and stroma, in addition to clinical characteristics, helps healthcare profes-
sionals optimize diagnosis and treatment recommendations. However, when should 
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a physician consider the use of biomarkers for decision support in the continuum of 
cancer care? Biomarker testing can be used to help assess cancer risk, best diagnose 
a particular malignancy, select treatment, and/or assess the treatment response. 
There are many decisions that physicians must make when they use biomarker test-
ing, not the least of which is what tests to choose from the many now available. And 
once the results are in, how does the physician interpret the sometimes massive 
amount of information and report them in an understandable way? How should the 
results be applied to patient care? Will patients be reimbursed for this selected ther-
apy? Ultimately, physicians are increasingly expected to consider these issues in the 
context of biomarker testing in the continuum of cancer care.
 Biomarker Properties
Biomarkers, which are measureable indicators of biological processes, may be 
prognostic or predictive. A prognostic biomarker demonstrates the relationship 
between the biomarker and response in a control group (patients receiving standard 
of care); it predicts disease aggressiveness regardless of the experimental study 
treatment. A prognostic biomarker can be evaluated by comparing a control group 
response in patients who have the positive biomarker (Dx+) with patients who do not 
have the positive biomarker (Dx−). A predictive biomarker demonstrates the rela-
tionship between the biomarker and treatment effect; it differentiates between 
patients who are likely to benefit from a particular treatment (relative to those in a 
control) and patients who are not. Sometimes a predictive biomarker helps identify 
patients who will benefit the most from a treatment; however, it does not necessarily 
preclude patients without the biomarker from also receiving treatment benefits. This 
scenario often occurs in the context of new cancer immunotherapies and the use of 
PD-L1 testing or tumor mutational burden biomarker analyses. These concepts are 
further clarified in Figs. 11.1, 11.2, 11.3, and 11.4; note that depending upon the 
circumstance, biomarkers may be both prognostic and predictive.
 Considerations in Biomarker-Driven Trial Design
Because the analysis of biomarker studies can be complex and challenging, it is rec-
ommended that a knowledgeable statistician be consulted for high-level biostatistics 
guidance. When designing a trial, it is best if all hypotheses are prespecified and 
ranked to guide interpretation and that appropriate analytical strategies are used to 
minimize bias. Also, it is best if the experimental design does not have a large num-
ber of analytical covariates, because it can decrease confidence in the results. An 
additional general consideration in trial design is having respect for the patients par-
ticipating in the study and understanding that their time is valuable. Thus, it is critical 
to develop the best clinical or translational trial possible. Obviously, one size design 
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strategy does not fit all, but strategies based on the three pillars of time, cost, and risk 
still serve as a good guiding principle for biomarker-driven drug development.
There are some unique challenges in biomarker research that require special con-
sideration in trial design. Sometimes there is a need to shorten the timeline from 
specimen collection to having the biomarker report available for clinical decisions, 
because patients are waiting for the information needed to improve (as well as 
lengthen) their lives. In this case, it is possible to use a clinical trial design that is 
adaptive—having the ability to change the design or hypotheses in an ongoing study 
based on early results from the same study or on biomarker data from other studies. 
Fig. 11.1 Average patient response versus the value of a pretreatment personalized healthcare 
biomarker (PHC) in a single arm trial. While there appears to be a correlation between response 
and biomarker value, it is not possible to determine whether the biomarker is prognostic or predic-
tive without a control group for comparison
Fig. 11.2 Average patient response versus biomarker value in a randomized trial. The biomarker 
is prognostic, because the benefit is similar for all biomarker values irrespective of the treatment
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For example, when phase II and III studies run in parallel, the data from phase II 
may be used to adjust the phase III study design while the study is still ongoing, thus 
shortening the time it takes to get results. The opportunities or triggers for adapta-
tion are prespecified in the initial design to protect the integrity of the phase III 
study.
Fig. 11.3 Average patient response versus biomarker value. This example shows a biomarker that 
is both prognostic and predictive. Patients in the treatment group (red line) with higher biomarker 
values showed a better response. For the control group (blue line), the biomarker gives some prog-
nostic information and shows that patients with lower biomarker values receive the greatest benefit 
of treatment




 Tumor Sequencing for the Near Future
Looking to the future, one projection is that tumor sequencing will become standard 
clinical practice in the next few years, and the question is when should this tumor 
sequencing occur? Should it occur right after initial diagnosis? Should it occur after 
patients have received initial therapy and then develop refractory disease for us to 
identify potential biomarkers or to think about novel approaches?
It is also likely that liquid biopsy technology will be developed. Blood tests used 
to follow patients in the past are based on single proteins, such as CEA, CA 125, CA 
19-9, but in the last few years there has been much interest in new technology to 
sample circulating cell-free tumor DNA (ctDNA). The ability to detect mutations in 
tumor DNA from a blood sample rather than from multiple tumor biopsies would be 
a huge improvement for patients. The isolation and subsequent analysis of ctDNA 
is viewed as a powerful tool with considerable potential to facilitate and improve 
clinical outcomes across multiple cancer types. This technology is promising, but 
still has limitations such as its inability to examine a large number of genes. Accurate 
blood sample collection, handling, and storage procedures are essential for reliable 
ctDNA extraction and molecular analyses. The conditions in which the blood sam-
ples are stored and shipped, as well as the amount of time that elapses between 
blood drawing and plasma extraction, are just some of the factors that may influence 
the accuracy of ctDNA analysis. Both clinical practitioners and researchers should 
be particularly attuned to these steps to maximize progress. In addition to screening 
for cancer, circulating tumor DNA technology can become part of the assessment of 
patients receiving cancer therapy. A positive finding of an actionable mutation in 
ctDNA (if using valid procedures and assays) could represent sufficient evidence to 
initiate targeted therapies. If the patient, for example, has had mutations detected in 
their tumor with next-generation gene sequencing, the physician can sample circu-
lating tumor DNA during and after treatment to follow these mutations and other 
molecular changes over time—and do so without performing invasive tumor biop-
sies. The role of sensitivity, specificity, and concordance rates among various tech-
niques will be important to elucidate in the next few years.
Cancer taxonomy is expected to become molecular-based; however, it is likely 
that tumor classification is going to be based on a combination of tumor location 
and molecular diagnosis. This field is evolving quickly, for example, there are thera-
pies that have been approved for patients with melanoma whose tumors have the 
BRAF mutation. Many of these medicines have already been approved by the FDA 
including some combinations such as a BRAF inhibitor and a MEK inhibitor that 
work better than monotherapy. The future may be for an increasing tumor-agnostic 
biomarker strategy to manage patients. Two of these approvals have been recently 
granted by the FDA and other regulatory agencies, based on the analysis of somatic 
microsatellite instability (MSI) and the other NTRK fusion alterations. Basket trials 
and biomarker testing in various tumor types will help us gain more insights that 
will be relevant to the inclusion of new therapeutic strategies by the FDA, guideline, 
and pathway development groups. As an example of a recent development, the 
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Southwest Oncology Group conducted a study in which they used a BRAF inhibitor 
(which had only been approved by the FDA for melanoma) in patients with refrac-
tory colon cancer whose tumors have the BRAF mutation. The impressive results of 
that trial led to an NCCN (National Comprehensive Cancer Network) designation, 
so that patients with colorectal cancer whose tumors have the BRAF mutation, may 
gain access to BRAF treatment, even though not yet approved by the FDA for the 
treatment of colorectal cancer. Another type of biomarker testing is the one of germ-
line alterations, or alterations of homologous recombination, with therapies such as 
PARP inhibitors being either approved or under study. For clinicians and healthcare 
professionals, it is significant that this type of research is being done, because of its 
impact to improve options for patients.
Finally, clinical trials in oncology will increasingly use sequencing at enrollment 
and follow-up. This is already the standard of care for many current research stud-
ies. Earlier intervention and prevention strategies will facilitate adoption of gene 
and protein testing and will require better trial designs and statistical plans. As a 
consequence, people will have more access to these genomic technologies, regula-
tory approval will become adaptive, and early phase clinical trials will reflect a 
genomic approach.
 FDA Approvals of Next-Generation Gene Sequencing (NGS) 
Panels and In Vitro Diagnostics (IVDs)
Many companies offer next-generation gene sequencing, but in addition, many 
healthcare facilities have developed their own panels. There are probably about 
20,000 genes in our genome, but only a portion of those actually encode protein. In 
the context of cancer, the question is how many genes should be tested for clinical 
practice versus clinical research, because they have different purposes. For exam-
ple, some hospitals have a 46-gene panel, 50-gene panel, and 200-gene panel, and it 
is not known which is best.
The FDA now considers not only safety but also efficacy as a way to regulate 
approvals, and the good news is that the FDA has given regulatory approval and 
clearance for some next-generation sequence, multigene marker tests. On June 23, 
2017, the FDA approved the Oncomine Diagnostic Target Test, a 23-gene next- 
generation assay for patients with non-small cell lung cancer. On November 15, 
2017, the FDA gave clearance (not approval) to the Memorial Sloan Kettering 
Cancer Center (MSKCC) for IMPACT—a tumor profiling test based on next- 
generation gene sequencing. To do this, the FDA developed a mechanism to approve 
diagnostic tests in addition to medicines. In this case, they accredited the New York 
State Department of Health (NYSDOH) as an FDA third party reviewer of in vitro 
diagnostic (IVD) tests. This resulted in the establishment of a Class II regulatory 
pathway for the review of other NGS-based tumor profiling tests, making these tests 
eligible for the 510(k) clearance process by applying either to the FDA directly or 
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through an accredited third party reviewer like the NYSDOH. The cleared IMPACT 
test analyzes 468 genes and captures somatic mutations (e.g., point mutations, 
insertions, deletions) and microsatellite instability. This test, however, does not 
detect gene copy number alterations or rearrangements.
On November 30, 2017, the FDA and the Center for Medicare approved another 
multigene marker test, FoundationOne from Foundation Medicine (FMI). The 
approval was somewhat different from the other diagnostic tests, because it is a 
companion diagnostic (CDx) used to predict and inform therapy decisions. This is 
the first time there has been an FDA approval of a test that also considers what 
therapeutic drug can be used based on the patient’s test results. This test analyzes 
324 genes and can be used for any tumor; it detects four genomic alterations (base 
pair substitutions, insertions and deletions, copy number alterations, and rearrange-
ments), tumor mutational burden, and microsatellite instability.  Other tumor 
sequencing platforms and the so-called liquid biopsies, such as the Guardant test, 
have more recently received regulatory approval.
A new type of test that is available for clinical testing is tumor mutational burden 
(TMB)—a genomic biomarker for cancer immunotherapy that measures the num-
ber of mutations in a tumor’s genome. There is research evidence that there is a 
correlation between the amount of tumor mutational burden and responsiveness to 
checkpoint inhibitors, a fairly new class of immunotherapies for patients with can-
cer. Thus, TMB may be an important predictive marker for patients who are being 
considered for this new type of immunotherapy. In addition to strengthening the 
correlation between TMB and benefit to checkpoint inhibitors, further research 
must answer two questions. One, who can do the most accurate and reliable test? 
And second, what should be the cutoff for tumor mutation burden and decision for 
patient treatment? Most recently, tests that allow for comprehensive genomic results 
from a blood draw have started gaining FDA approval, which could be instrumental 
to help move beyond the limitations of tissue biopsies to match patients to best per-
sonalized treatments.
 Designing Clinical Trials to Support FDA Approval
Suggestions for designing biomarker trials that support FDA approval include 
design trials that make sense in the context of the United States; ask clinically mean-
ingful questions; select and refine drug dose; think about biomarkers early and 
often; and include more patient-related outcomes and do them well. What is an ideal 
biomarker trial? It should inform about the in vitro diagnostic (IVD), the drug, and 
their interaction. To determine whether an IVD can be used to select a therapy, there 
must be knowledge about sensitivity determined by the fraction of responders that 
are marker-positive; specificity determined by the fraction of non-responders that 
are marker-negative; positive predictive value (PPV) based on the fraction of 
marker-positive patients who respond; negative predictive value (NPV) determined 
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by the fraction of marker-negative patients who do not respond; and cutoff point for 
positivity.
A further consideration when designing biomarker trials is to include diverse 
ethnic patient participation, because it provides the most comprehensive ability to 
apply data to the general population. The issue is what is a sufficient number of 
diverse patients to adequately do the analysis? Finally, one additional caveat is 
that limiting a study to marker-positive patients may characterize the drug/diag-
nostic poorly. Sometimes researchers incorrectly assume that a biomarker is 
required for a response and may thus deny effective therapy to marker-negative 
patients.
 Cancer Immunotherapy (CIT) Biomarkers
 General Concepts
The use of cancer immunotherapy (CIT) biomarkers for a variety of malignancies is 
revolutionizing oncology. The number of drugs approved by the FDA is rapidly 
growing, added to unprecedented opportunities to better understand biology and 
offer better treatments for patients with various malignancies.
Many different types of cells and molecules are necessary for the immune system 
to work properly. These include T-cell lymphocytes such as CD4+ and CD8+ T cells, 
natural killer (NK) cells, dendritic cells, macrophages, and a myriad of regulatory 
cells and proteins that influence immune mechanisms. Because the immune response 
is so complex and each individual’s response unique, there are many challenges to 
develop effective CIT biomarkers. For example, researchers must first be able to 
answer some fundamental questions such as which cells are important for the 
immune system, how to test whether cells are functioning properly, and how to test 
whether they are activated or not. It is also critical to know specifically which of the 
many proteins (and their spatial localization) are important for elucidating the role 
of biomarkers as predictors for immunotherapy, as well as how to identify patients 
who are most likely to benefit from these cancer immunotherapies.
There are a variety of immunotherapy biomarkers currently being researched and 
used in cancer management. One is a measure of tumor infiltrating lymphocytes 
(TILs); in many tumors, there is a correlation between infiltration of T cells into the 
tumor (e.g., CD8+ T cells) and patient outcome. However, validation studies are still 
required before incorporation for therapeutic decisions. The biomarker most 
advanced to help predict the likelihood of benefit to checkpoint inhibition is the 
expression of an immune checkpoint protein, programmed death ligand (PD-L1); 
although it is not a binary marker (in other words, high expression predicts for 
greater likelihood of response), it does not mean that responses will not be seen in 
patients whose tumors do not express the protein. Combined expression patterns of 
multiple genes such as T-effector gene expression signatures as well as mutational 
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load across targeted genes may be used to evaluate the predictability of  clinical 
benefit to immune therapies. One promising note is that, in the past, mutational 
burden was measured from tumor biopsies, but now there is the potential to measure 
it from blood (liquid biopsy). A future goal is to identify neoantigens—tumor- 
specific antigens that may be detected and targeted by T cells (e.g., CD4+ and CD8+). 
Whole transcriptome sequencing can now be used to identify neoantigens and 
T-specific subsets in a given patient. One current avenue for research is to identify 
neoantigens that may help predict benefit to therapy and those that may be helpful 
to develop new vaccines. There are multiple companies worldwide that are develop-
ing vaccines for patients with cancer, and this neoantigen approach is one of the 
most promising (added to focused trials using protein-based vaccine approaches).
 Program for Accelerated Cancer Therapies (PACT): 
An Example of Multidisciplinary Collaboration to Elucidate 
Relevant Biomarkers in Oncology
A new Program for Accelerated Cancer Therapies (PACT) has been initiated in col-
laboration with NIH, NCI, and biopharma. It emerged from the importance of work-
ing together to solve the problem of understanding biomarkers in the area of cancer 
immunotherapy. The overall goal is to provide a systematic approach to immune 
and related oncology biomarker investigation in clinical trials by supporting the 
development of standardized biomarkers and assays. This project will leverage NCI 
investments in its Cancer Immune Monitoring and Analysis Centers (CIMACs) and 
Cancer Immunologic Data Commons (CIDC) Network to select biomarkers for uni-
form clinical applications, to validate and standardize biomarker assays, to incorpo-
rate biomarkers as standards in clinical trials, and to create a comprehensive 
database, integrating biomarker, and clinical data to enable pre-competitive correla-
tive biomarker analyses. Also, PACT will engage the FDA in its biomarker stan-
dardization and harmonization efforts in order to enhance regulatory decision 
making. This important project will help develop standardized biomarkers for 
immunoprofiling and exploratory biomarkers of high relevance to patient care.
 Challenges and Opportunities to Improve Biomarker-Based 
Trials
There is growing pressure on many fronts to accelerate the pace at which new medi-
cines are launched and made available for patients, but bringing biomarker-based 
trials to patients is challenging. A major hurdle is that investigators are reluctant to 
run extensive molecular profiling panels if only a small fraction of patients will be 
eligible to participate in their clinical trial. Thus, there is a need for a more efficient 
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way to connect patients with genomic information to a clinical study, because high 
screen failure rates make trials more costly and time consuming. For example, if a 
marker is present perhaps in one out of 500 patients, it is really difficult for a clini-
cian or institution to order 500 tests to find only one patient who might be enrolled 
in that particular clinical trial. This has slowed down the progress. Thinking about 
this scenario in more detail brings to light another issue—accountability to the 
patient. Increasing screen fail rate in clinical trials not only makes a large number of 
screenings necessary but also leaves many patients with no accountability. For 
example, imagine a patient with refractory ovarian cancer who wants to join a clini-
cal trial testing a promising new drug for a particular alteration, and the patient is 
screened only to find that her tumor is negative for the marker. This is very tough on 
the patient who at this point wants to try everything that might help.
One way to address both of these issues is to link patient screening to a set of 
trials with an algorithm that assigns patients to the most relevant study. For exam-
ple, consider a scenario with five trials A through E. If it is found on screening that 
a patient has a particular abnormality based on the biomarker A, the patient can 
enroll in trial A. If a patient does not have the biomarker for trial A, the patient can 
be considered for one of the other trials (B, C, D, or E) with one screening and 
patient consent. If screened patients do not have any of the abnormalities for the five 
trials, they can be enrolled in an all-comer trial. Thus, this theoretical initiative is a 
win-win scenario because patients will always have access to a clinical trial with 
new options, and cancer centers and institutions will have more efficient recruitment 
into their clinical trials. This type of solution requires both collaboration and the 
analysis of thousands of annotated biospecimens. There are many of these projects 
in the United States, such as PACT and the GENIE program sponsored by AACR 
that now have data on more than 100,000 patients. A collaborative strategy will 
catalyze biomarker precision medicine and precision oncology by linking clinical 
retrospective and prospective cancer genomic and proteomic data with longitudinal 
clinical outcomes. Data aggregation will benefit patients through the validation of 
biomarkers; drug repositioning or repurposing; addition of new mutations to exist-
ing drug labels; and identification of new targets and new biomarkers enabling the 
development of better therapies for patients.
In summary, cancer is composed of a broad spectrum of biologically distinct 
subtypes with overlapping or unique molecular alterations. We will need to increas-
ingly expand biomarker development in various populations, incorporate biomarker 
testing, as well as consider clinical, ethnic, and socioeconomic factors to optimize 
patients’ lives. We are on this path.
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Chapter 12
Overcoming Barriers for Latinos 
on Cancer Clinical Trials
Ruben A. Mesa and Amelie G. Ramirez
 Increasing Complexity of Accrual in Clinical Trials for All 
Populations
The concept of clinical trials has expanded over the years from straightforward 
drug-based interventional studies to those that recognize the breadth of the human 
experience. We are now focusing on preventing cancer, expanding research into 
screening, primary prevention, active prevention, and behavioral modification in 
ways that would not have been done before. Still clearly concerned about treatment, 
we are also concerned about symptom control and how to deliver the care itself, as 
well as with issues of health economics and survivorship such as healthcare out-
comes and post-therapy care. Now, with the complexity of clinical trials, testing 
whether interventions can make a difference relies on rigorous, well-conducted 
clinical trials to either support the case or, sometimes just as importantly, demon-
strate that the intervention does not work.
In the era of individualized medicine, enrolling patients in clinical trials has 
become much more difficult because of narrowed eligibility criteria, such as the case 
where patients must have a particular mutation before they can be enrolled. Another 
issue is the requirement for randomization. The enthusiasm of patients to be random-
ized has clearly decreased. Availability of information on the Internet means that 
individuals learn and question more, and for some, the concept of not being able to 
select their therapy is very uncomfortable. Being in the placebo group is a frighten-
ing thought for most patients; if included, it typically has to be for a finite amount of 
time, with a fair amount of confidence that they will then be able to receive the 
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therapy they seek. Another hurdle to recruitment is that there are now many nonex-
perimental treatment options, so the patient has to weigh the benefits of standard care 
against the inconvenience of entering a trial. Other barriers to recruitment are that 
patients may be wary of becoming a guinea pig for research or of taking experimen-
tal drugs they fear will have greater toxicity and adverse effects. Also, patients receive 
a river of information and misinformation daily from the Internet, television, and the 
lay press that may give them unrealistic expectations for miracle cancer cures.
There is also the issue of expense of participating in a clinical trial. There is the 
direct standard of care expense, but there are also expenses that are often not consid-
ered. For example, is the experimental drug going to be more expensive? Usually the 
answer is no, but it may be more expensive to be in a clinical trial in other ways. There 
may be more travel, more time away from work, and more standard of care expenses. 
A significant barrier may not be a new experimental therapy, but rather the use of 
standard of care therapies that are in the control arm and would have to be covered. 
There are clearly also barriers of third-party payers having significant concerns around 
trials. Some of that is protected through healthcare policy, but not completely.
There are additional barriers to recruiting racial and ethnic minorities from 
underserved populations. In 2013, Brown et  al. conducted semi-structured audio 
interviews with 22 African American patients who refused to participate in clinical 
trials in order to gain insights into their perceptions of clinical trials and reasons for 
refusal [1]. Most participants refused because of fear of treatment-related burdens 
and fear of adverse effects. Some refused out of mistrust. Many patients and family 
members misunderstood the purpose and benefits of the clinical trial, and family 
members were mostly against participation. However, most patients indicated that 
they would participate if given access to a decision aid and the ability to discuss 
their concerns with a provider. In other interventions, these researchers found that 
with sufficient information, patients felt they could overcome some of these barri-
ers. Other barriers they identified include additional patient burden; in addition to 
the burden of the disease itself, patients reported their reluctance to undergo more 
testing and more office visits. Lost time at work and trouble finding transportation 
were cited most often. Also, patients expressed the fear of participating in an 
“experiment.” Frequently, there was a lack of understanding about the benefits of 
clinical trials; many patients did not understand that they would continue to treat 
their cancer and receive high-quality care throughout the clinical trial. Also, most 
patients were frightened about possible side effects from clinical trials, though, in 
some cases, the effects were the same as those associated with the standard of care.
 Barriers That May Disproportionately Impact Latino Patient 
Enrollment
What are some barriers that may disproportionately affect Latino patient enroll-
ment in clinical trials? In an effort to answer that question, scientists from the 
Institute for Health Promotion Research and the Mays Cancer Center at UT 
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Health San Antonio interviewed patients from south Texas who were receiving 
treatment at the cancer center. This study explored, from the patients’ perspec-
tive, both promoting factors and barriers to participation in early phase clinical 
trials [2]. They found that more Latinos than non-Hispanic whites decline early 
phase clinical trials and were more likely to be concerned with symptom improve-
ment. On the positive side, Latinos surveyed were more concerned that treatment 
would improve symptoms, decrease hospitalizations, and have the potential for 
better outcomes than standard of care. Barriers to participation included greater 
fear of uncertainty over experimental treatment efficacy and poor communication 
with their doctor and poor understanding of the purpose of the clinical trial. 
Exploring this further, Ramirez et  al. examined if there was an association 
between the attitudes and practices of Latino physicians and clinical trial partici-
pation [3]. They found that Latino physicians were less connected to and saw less 
value in clinical trials. The authors identified this as an opportunity for education 
and engagement with physicians to better promote clinical trial recruitment 
among Latinos. Langford et  al. examined eligibility, refusal rates, and clinical 
trial participation among patients at sites in the National Cancer Institute’s 
Community Cancer Centers Program [4]. One question they asked was whether 
minorities have a lower rate of enrollment because they have more comorbidities, 
such as diabetes, obesity, and hypertension. They found that the odds of comor-
bidity were higher with older age, males, and non-Hispanic blacks, but not for 
Hispanics. They also found that consent readability was a factor for refusal across 
the board and that in this community center setting, there were no racial/ethnic 
differences in clinical trial enrollment.
One recent study examined underrepresentation of Hispanics in clinical trials 
from the perspective of clinical trial recruiters [5]. They conducted focus groups 
with professional recruiters and described how to adapt to potential participants’ 
language competency and literacy levels. One issue that emerged is the consent 
form, the legal document designed to protect the institution but not necessarily to 
communicate clearly. Additionally, translating the form from English to Spanish 
does not necessarily enhance understanding; communicating the general con-
cepts is what is needed. It is also important for recruiters to engage in culturally 
appropriate verbal and non-verbal communication; establish a sense of connec-
tion between recruiters and patients; accommodate socioeconomic concerns; 
adapt to contextual factors; and respond to potential participants’ mistrust of 
medical research.
Are there differences between urban and rural residents in their willingness to 
participate in a clinical trial? The results of a telephone survey of South Carolina 
residents showed no significant differences between the two groups [6]. The 
researchers who performed the study found that distrust and fear of clinical trials 
were barriers in both groups. However, clinical trial participation is lower among 
the rural population, and they attribute this to perceive limited access to clinical tri-
als and a greater lack of knowledge about clinical trials.
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 Strategies to Facilitate Clinical Trial Participation
How do we augment the enrollment of Latinos into cancer clinical trials? And why 
do we want to do so? The answer is that cancer clinical trials must reflect the popu-
lation that we are studying, so that we can capture differences among ethnic groups 
and make inferences that are generalizable. We (Hispanics/Latinos) may be differ-
ent in how we process drugs, the genetic profile of disease, or the risk factors we 
possess. For example, Hispanics/Latinos in the United States have a higher rate and 
worse outcomes of acute lymphoblastic leukemia than the general population. Why 
is this so? Do they have a worse molecular profile? Do they have worse cytogenet-
ics? Are they more likely to develop neutropenic fever? If they develop neutropenic 
fever, are they more likely to take longer to go into the hospital? Do they have more 
port infections because they do not have family members who are able to assist 
them with their port? Really delving into these issues is the key to understanding.
An active area of research is determining how to improve accrual into clinical 
trials. Drs. Iruku and Kaklamani from UC Health Colorado Springs and UT Health 
San Antonio, respectively, are developing a predictive model of trial accrual. Based 
on an analysis of 297 trials carried out at the Mays Cancer Center in San Antonio 
(formerly the CTRC), they found that certain variables—the type of sponsor, author 
of the trial, and the type of intervention—were significantly associated with accrual. 
Trials that were observational, interventional, industry-sponsored, and authored by 
the local PI were more likely to meet accrual goals.
Experience has taught us that it is important for staff involved in clinical trials to 
be knowledgeable about the study and to have a strong stake in the trial. Having 
staff such as the nurses, cancer navigators, or clinical trial coordinators who under-
stand the settings around the studies is incredibly important. Dr. Vanessa Sheppard 
reports a similar approach used at the Massey Cancer Center at Virginia 
Commonwealth University. Their strategy to improve trial accrual includes using 
dedicated resource specialists; clinical social workers help patients identify 
resources, including alternative transportation grants, childcare, or legal assistance, 
freeing the clinical research nurses to better focus on patient care and treatment. 
There is also a dedicated insurance authorization coordinator who explains insur-
ance policies to determine coverage and financial obligations. Further, Massey 
offers communications training not only to physicians but also to nurses. Our expe-
rience has been that appropriate communications are important even in terms of the 
discussion between the infusion nurses or the pharmacy and the patients as well. 
How one phrases something might have a very significant impact on patients. 
Finally, another strategy that Massey uses to improve accrual is to build awareness 
of clinical trials through marketing; it actively promotes its trials in clinics, at com-
munity events and within the larger health system.
Enhancing accrual and addressing underrepresentation in clinical trials begin 
with the process of matching patients with appropriate trials. Our experience is that 
we are much more likely to have a successful discussion around trials if patients 
have the preconceived notion that a clinical trial is something positive and that the 
R. A. Mesa and A. G. Ramirez
129
physician is someone who might be able to connect them with a study that helps. 
Determining eligibility is a necessary step to minimize bias in the results from the 
clinical trial, but it can be a tedious, slow process. Penberthy et al. from the Massey 
Cancer Center at Virginia Commonwealth University have attempted to automate 
the process by using matching software; when patients register they can be poten-
tially matched up with a clinical trial [7]. Not only does the automated process 
reduce the time for eligibility screening, but it also assures patients that there might 
be a clinical trial for them. The earlier in the process patients become aware that 
clinical trials are available and might be beneficial, the more likely they are to 
participate.
At the Mays Cancer Center, we have the mandate to decrease the burden of can-
cer in our catchment area, which is from San Antonio down to the border. It is a 
sizable area that is 69% Hispanic, 24% non-Hispanic white, 4% African-American, 
and 3% other. Our collective efforts reflect this largely Hispanic population, which 
includes developing a minority recruitment plan for cancer clinical trials. How did 
we do this? Our first step was to identify the potential resources. A Minority Clinical 
Trial Accrual Committee was established to try to reduce barriers for accrual and to 
implement strategies to enhance minority recruitment. A Coordinator of Minority 
Programs was hired to oversee these activities, which included developing a minor-
ity accrual plan required for all clinical trials. As part of this effort, Trevino et al. 
developed a toolbox to help investigators create a minority recruitment plan and 
meet those goals [8]. Barriers to minority enrollment were identified through 
research, focus groups, interviews, and physician outreach. Strategies and materials 
were then developed including virtual connections with physicians in remote areas 
in South Texas; Spanish translations of signs, brochures, and consent forms; and 
expanded media outreach with Spanish-language television (Univision), a Spanish- 
language daily newspaper in San Antonio (La Prensa), and others. The minority 
accrual plan (MAP) toolbox thus includes activities that build awareness and 
improve health literacy. Since its inception in 2013, this group has helped at least 50 
clinical trials per year with the goal of improving enrollment in cancer clinical trials. 
Prior to its implementation, the enrollment of Hispanics into our interventional 
studies was 46%; now it is 56%. Accrual of Hispanics into interventional non- 
treatment studies has fluctuated over the years, but in 2017 it was 59%. If we look 
at non-intervention, observational ancillary-correlative studies, the accrual numbers 
are lower (37% in 2017). Even within our own Latino communities, when therapy 
is taken out of the equation, interest in participation wanes. We must communicate 
better how important the biospecimen study is to inform future research, even 
though it does not center on immediate therapy.
A research team from the Institute for Health Promotion Research and the Mays 
Cancer Center at UT Health San Antonio conducted a pilot study to test whether 
CHOICES, a bilingual multi-component intervention, would empower Latina 
patients with breast cancer to make informed decisions about clinical trials [9]. The 
CHOICES intervention included an educational interactive video, a low-literacy 
booklet, and care coordination by a patient navigator. This randomized controlled 
study compared the CHOICES intervention group with a control group that received 
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general clinical trial information. They found that the intervention was more effec-
tive than the control in increasing patients’ perception of understanding clinical 
trials and their consideration of a clinical trial as a treatment option.
 Next Steps
In conclusion, key opportunities for increasing accrual of Hispanics/Latinos in clin-
ical trials include the education of registering physicians to better promote enroll-
ment in clinical trials. It also includes building general awareness among Hispanic/
Latino populations of the role of clinical trials in improving cancer care. The more 
that it becomes the collective impression, the more successful accrual will be. For 
example, only a minority of adult patients with cancer goes into clinical trials, but 
there is a very different experience that exists with pediatric patients. In the pediatric 
world, it has become by culture, from physicians, staff, and parents that clinical tri-
als are the standard of care for their disease. Almost all patients go into clinical tri-
als; they have been incredibly successful, making great advances in pediatric cancer 
research. If we can accomplish a similar culture among Hispanic/Latino patients 
that clinical trials are considered to be a good thing, accrual should improve. Another 
opportunity to increase accrual is enhancing care navigation to better support the 
role of cancer clinical trials in treatment planning, including matching up the right 
patient with the right study. Clearly the issue of language and culture cannot be 
overstated; there must be language- and culture-appropriate materials, education, 
and clinical trial coordination. Finally, a key opportunity exists in the sharing of 
lessons learned between centers and investigators committed to this mission.
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Chapter 13
Breast Cancer Precision Medicine 
in Hispanics/Latinas: Focus on Luminal B 
Tumors
Jovanny Zabaleta, Silvia J. Serrano-Gómez, Laura Fejerman, 
Teresita Muñoz-Antonia, Doug Cress, Cathy Meade, and Lucio Miele
 Introduction
Breast cancer risk assessment and treatment are increasingly guided by genetic and 
transcriptomic information. In addition to the few well-known genes associated 
with high risk of breast cancer that are routinely tested in the clinic [1], the recent 
description of polygenic risk scores [2, 3] has further complicated the picture of 
genetic risk evaluation for breast cancer. Gene expression-based tests such as 
Oncotype DX [4] and MammaPrint/BluePrint [5] have demonstrated clinical value 
in predicting the risk of recurrence for early stage breast cancers. Among these, 
PAM50 [6] and BluePrint [5] can be used to assign breast cancers to one of the most 
common molecular subtypes.
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The first molecular classification of breast cancer based on gene expression pro-
filing was proposed in 2000 by Perou et  al. [7]. This classification has been 
 subsequently refined, and the most commonly accepted subtypes today include 
luminal A and B, both estrogen receptor alpha (ER)-positive, as well as Her2-
enriched, basal- like and “non-basal triple-negative” (“normal-like” in some classifi-
cations) [8, 9]. Luminal A tumors are the most common among non-Hispanic 
Whites, and they typically carry a better prognosis than luminal B or non-luminal 
tumors, particularly when diagnosed and treated early. “Triple-negative” tumors, 
immunohistochemically “negative” by standardized pathological criteria for ER 
and progesterone receptor (PR) and not carrying Her2 amplification, are often con-
flated with the basal-like molecular subtype. However, not all basal-like tumors are 
triple-negative and not all triple-negative tumors are basal-like. Indeed, triple-nega-
tive tumors may include as many as four molecular subtypes (basal-like 1 and 2, 
mesenchymal, and androgen receptor luminal-like) with different biology and prog-
nosis [10]. Significant molecular heterogeneity exists even within the recognized 
subgroups, with a variety of low-frequency driver mutations [11]. Higher-dimension 
classifications including mutations, copy number variations, and gene expression 
profiling are being developed [12].
Despite nearly 20 years of genomic and transcriptomic studies of breast cancer, 
our understanding of the molecular portraits of breast cancer remains based on 
tumors overwhelmingly derived from European or European-American (non- 
Hispanic White) patients. The representation of patients of non-European ethnicity 
in public molecular datasets remains limited. As of December 2018, only 37 out of 
3650 cases of breast cancer whose molecular portraits are available through The 
Cancer Genome Atlas (TCGA) portal are from women who declared a Hispanic/
Latina ethnicity. Hence, it is fair to assume that we currently do not know to what 
extent the information gathered to date on the genetics and transcriptomics of breast 
cancer applies to Hispanic/Latina patients.
Hispanic/Latinos share a broad linguistic identity, but they are culturally diverse 
and genetically highly heterogeneous, with ancestry mixtures that vary among and 
within different countries. This makes the study of gene–environment and gene–
gene interactions particularly challenging. Most of the populations commonly 
referred to as ethnically “Hispanic” are the result of admixture of three ancestral 
populations: European, Indigenous American, and African. Yet, there is consider-
able variability in the proportion of each ancestral genetic background within and 
across those populations [13]. A recent seminal paper by Conomos et  al. [14] 
explored the genetic diversity of a large cohort (12,803 individuals genotyped using 
a high-density SNP chip) from four US metropolitan areas, the Hispanic Community 
Health Study/Study of Latinos (HCHS/SOL). Using principal component analysis 
(PCA), this group identified substantial genetic differentiation within and among 
six self-identified background groups (Cuban, Dominican, Puerto Rican, Mexican, 
and Central and South American). These authors used a multidimensional cluster-
ing method to define “genetic-analysis groups” that retain many properties of self- 
identified background groups while achieving substantially greater within-group 
genetic homogeneity. Remarkably, these “genetic-analysis groups” accounted for 
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significant trait variation in 8 of 22 clinically measurable phenotypic traits. These 
authors argue that “genetic analysis groups” are a more useful covariate for genetic 
association studies than self-identified ethnic background groups. This underlying 
genetic complexity highlights the inadequacy of using self-reported “Hispanic” eth-
nicity for genetic and genomic studies.
 Hispanics/Latinas and Breast Cancer: A Complex 
Relationship
Age-adjusted breast cancer incidence in the United States is approximately 25% 
lower in Hispanic/Latina women than among non-Hispanic Whites [15]. The rea-
sons for this “Hispanic Paradox” are most likely multifactorial and may include 
lifestyle (e.g., number and timing of pregnancies, diet), socioeconomic factors, and 
genetic factors. It is well established that high Indigenous American (IA) ancestry 
correlates with reduced risk of breast cancer, and at least one protective variant only 
found in high IA ancestry individuals has been identified [16]. That said, breast 
cancer risk varies among Hispanics/Latinas of different geographic origins and 
between US-born and foreign-born Hispanics/Latinas. This lower risk does not nec-
essarily translate into better outcomes for patients who do develop breast cancer 
[17]. In fact, California Hispanics/Latinas with over 50% IA ancestry have a risk of 
breast cancer mortality that is twice as high as that of California Hispanics/Latinas 
with less than 50% IA ancestry. This may be because of socioeconomic factors, 
access to health care, late stage at diagnosis, and hitherto unknown biological fac-
tors. To our knowledge, the “genetic analysis groups” proposed by Conomos et al. 
[14] have not yet been studied as covariates for breast cancer risk. The interpretation 
of epidemiological studies is complicated by the fact that in most studies not only 
are Hispanics/Latinas considered a single group but “breast cancer” is treated as a 
single disease. Given the remarkable molecular heterogeneity of breast cancer, it is 
possible that part of the increased mortality risk observed among Hispanics/Latinas, 
despite their overall lower risk of disease, may be due to differences in the preva-
lence of specific breast cancer subtypes or due to molecular differences within the 
subtypes themselves. For instance, the protective variant identified in individuals 
with high IA ancestry is near the ESR1 gene, which encodes the estrogen receptor α 
[16]. We do not know whether it protects against all breast cancer molecular sub-
types, including ER-negative ones. In a large molecular epidemiology study of the 
LACE/pathways combined cohort, Sweeney et al. [18] examined the distribution of 
breast cancer subtypes as determined by the PAM50 gene expression test among 
racial and ethnic groups. This study confirmed that Basal-like tumors are far more 
common among African-Americans (AA) than among other ethnicities. Additionally, 
Hispanic/Latina patients had a lower incidence of luminal A tumors compared to 
non-Hispanic Whites (44.2% vs. 55.2%) and a correspondingly higher incidence of 
luminal B tumors (24% vs. 20.9%). Her2-enriched and Basal-like tumors were also 
slightly more common among Hispanic/Latina patients than among non-Hispanic 
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Whites. These differences did not reach statistical significance, given the relatively 
small number of Hispanics/Latinas in the combined cohort. Hispanics/Latinas in 
this study were not stratified by national origin, IA ancestry, or “genetic analysis 
group.” If these findings are confirmed, it is possible that despite their overall lower 
incidence of breast cancer, Hispanic/Latina patients may suffer from higher-risk, 
non-luminal A breast cancer subtypes than non-Hispanic Whites.
 Luminal B Breast Cancer in Colombians
Among luminal/ERα-positive tumors, luminal B cancers are a distinct biological 
entity compared to luminal A tumors. These tumors are clinically more aggressive, 
with worse prognosis than luminal A tumors, similar to the basal-like and Her2- 
enriched tumors. They tend to have lower expression of nuclear hormone receptors, 
higher expression of Her2/Neu and proliferation markers such as Ki67, and a lower 
likelihood of responding to endocrine therapy with aromatase inhibitors, selective 
estrogen receptor modulators (SERM) or selective estrogen receptor disruptors 
(SERD) [19]. Luminal B tumors have distinctive molecular characteristics from all 
other subtypes. In the METABRIC multiparameter molecular classification of 
breast cancers [12], luminal B tumors fall within four clusters (IntClusts 1, 2, 6, and 
9). Among recurrent mutations in these tumors are loss of PPP2R2A (protein phos-
phatase 2 subunit), TP53 mutations, and a hypermethylated profile. Conversely, 
PIK3CA mutations are less common in this subtype than in luminal A tumors [19]. 
Moreover, luminal B tumors have higher risk of de novo resistance to endocrine 
therapies [6, 11]. At the transcriptomic level, they are characterized by increased 
expression of cell proliferation genes or cell cycle regulators such as MKI67 and 
AURKA [20]. Luminal B tumors are usually characterized by high recurrence 
scores based on the Oncotype DX gene expression signature and are more likely to 
benefit from cytotoxic chemotherapy, reaching higher percentages of pathologic 
complete response (pCR) compared to luminal A tumors [19]. Interestingly, in a 
study of 219 women with early stage luminal breast cancers who received an 
Oncotype DX test, Hispanic/Latina patients had a significantly higher Proliferation 
Axis score, driven by higher expression of CCNB1 (cyclin B1) and AURKA (Aurora 
Kinase A) [21]. These authors suggest that biological differences between luminal 
tumors in Hispanic/Latinas and non-Hispanic Whites may contribute to the higher 
mortality observed among Hispanics/Latinas. Limitations of this study included its 
relatively small size, which did not allow stratification of Hispanics/Latinas by 
ancestry, geographic origin or “genetic analysis group,” and the limited number of 
informative genes in the Oncotype DX test. Studies using larger panels, such as the 
150-gene MammaPrint/BluePrint combined test, and larger, well-characterized 
Hispanic/Latina populations would be highly informative.
To begin to address this knowledge gap, the Zabaleta group studied a cohort of 
301 Colombian breast cancer patients diagnosed and treated at the same institution, 
the National Cancer Institute in Bogota [22]. Using immunohistochemical markers 
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and the 2013 St. Gallen consensus criteria for surrogate subtype assignment [23], 
Serrano-Gomez et al. found a higher prevalence of luminal B tumors than luminal 
A (40.86% vs. 22.59% or 37.21%, vs. 26.25%, using 14% and 20% cutoff values for 
Ki67, respectively). This result was confirmed using the 2011 St. Gallen criteria. 
Interestingly, when Ki67 was excluded from the analysis and subtype assignment 
was based on ER, PR, and Ki67 alone, the prevalence of luminal B tumors decreased 
dramatically to 15.95% versus 52.49% luminal A, a subtype distribution more typi-
cal of US-based non-Hispanic Whites. The difference in subtype breakdown among 
different immunohistochemical criteria may hold biological clues. The St. Gallen 
consensus criteria for surrogate subtype assignment include Ki67, a proliferation 
marker, in addition to ER, PR, and Her2/Neu. Hence, luminal tumors in Colombian 
patients appeared to be characterized by higher proliferative activity, consistent 
with the Oncotype DX findings reported by Kalinsky et al. [21]. The tumors classi-
fied as luminal B based on St. Gallen 2013 or 2011 tended to be of higher histologi-
cal grade, larger size, and higher stage at diagnosis, similar to molecularly confirmed 
luminal B tumors in US-based patients (Table 13.1). No significant association was 
found in this study between genetic ancestries established using 80 Ancestry 
Informative Markers (AIMs) and St. Gallen subtype distribution. Similar results 
were obtained by Gomez et al. in an independent study of a Colombian cohort [24].
Following up on these intriguing observations, the same group performed whole- 
transcriptome RNASeq on 21 immunohistochemically defined luminal A and 21 
luminal B tumors from the same 301-patient cohort. Serrano-Gomez et  al. [25] 
found 67 differentially expressed genes (p < 0.05) from which 39 were upregulated 
and 28 downregulated in the luminal B subtype (Fig. 13.1). Unsupervised hierarchi-
cal clustering showed that using these genes, luminal B tumors clustered together 
and separated from luminal A tumors. Pathway analysis showed that top upregu-
lated genes participate in biological processes such as mitosis and cell cycle regula-
tion (CDK1, CDC6, CCNB2, BUB1, CENPF, ANLN, CENPE, CCNA2, ASPM, 
MKI67) and downregulated genes mostly encode phosphoproteins (KCND3, 
RALBP1, RCAN3, ABCA3, RBBP8, PAIP2B, STARD13, ELOVL5, HIPK2, 
NTRK2, KDM4B, BAI2, FGD3). Another upregulated gene in luminal B tumors 
was CYP19A1. This gene encodes aromatase, the enzyme that catalyzes the rate- 
limiting step in estrogen biosynthesis, aromatization of androstenedione and testos-
terone to estrone and estradiol, respectively. Aromatase is a major therapeutic target 
in luminal tumors. This result may suggest that these luminal B tumors can produce 
estradiol endogenously. Whether the CYP19A1 mRNA derived from tumor cells or 
tumor-associated adipocytes is unclear. Another gene overexpressed in luminal B 
compared to luminal A tumors in this study is TOP2A, the gene encoding DNA 
topoisomerase IIA. Sparano et al. [26] suggested that in breast cancer patients with 
ER-positive, Her2-normal (hence, luminal) tumors, high levels of TOP2A may be 
associated with resistance to anthracycline-based chemotherapy. Higher expression 
of TOP2A correlated with poor tumor grade and high recurrence score based on the 
Oncotype DX signature. Romero et al. [27] also found higher expression of TOP2A 
in luminal B, HER2-enriched and basal-like tumors when compared to Luminal 
A. Consistent with immunohistochemical results, several proliferation-associated 
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genes, including CDK1, BUB1, CENPF, and MKI67 (the gene encoding Ki67) 
were overexpressed in luminal B versus luminal A tumors in this Colombian cohort. 
Taken together, these results support the hypothesis that, at least in this population 
of Hispanic/Latina patients, proliferative activity may be higher in luminal tumors 
compared to similar tumors occurring in non-Hispanic White patients.
When gene expression was correlated with ancestry, these authors identified five 
genes differentially expressed between luminal B and luminal A tumors that are 
potentially modulated by genetic ancestry: ERBB2 (log2FC = 2.367, padj < 0.01), 
GRB7 (log2FC  =  2.327, padj  <  0.01), GSDMB (log2FC  =  1.723, padj  <  0.01), 
MIEN1 (log2FC = 2.195, padj < 0.01), and ONECUT2 (log2FC = 2.204, padj < 0.01). 
These results were confirmed by RT-PCR. In the replication set, the authors found a 
statistically significant association between ERBB2 expression with IA ancestry 
(p = 0.02, B = 3.11) [25]. Again, these statistical correlations may reveal biological 
clues. ERBB2 (the gene encoding Her2/Neu, a clinically informative and therapeuti-
cally targetable gene), GRB7 (the gene encoding a molecular adaptor in the Her2/
Neu pathway), and MIEN1 (a putative oncogene) are physically contiguous, occupy-
ing a region of approximately 60,000 bp on Chromosome 17q12. These genes are 
usually co-amplified in Her2-enriched tumors and are located near a common 
Fig. 13.1 Gene expression profile of 42 luminal breast cancer samples. (a) Unsupervised hierar-
chical clustering with 67 differentially expressed genes between IHC-defined luminal B and lumi-
nal A tumors. (b) Most relevant signaling pathways associated with 67 differentially expressed 
genes in luminal B tumors from Colombian women. (c) Diseases associated with differentially 
expressed genes in luminal B. Reproduced from Ref. [25]
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enhancer. There are multiple possible explanations for an association of IA ancestry 
with high expression of these genes. Factors associated with IA ancestry may control 
the epigenetic regulation of the chromatin region encompassing these genes or the 
expression of transcription factors or non-coding RNAs regulating the transcription 
of this chromosomal region. Alternatively, the relatively high expression of 
Chromosome 17q12 transcripts may be due to the subclonal structure of the tumors; 
that is, to the presence of clonal populations within tumors containing copy number 
variants (CNV) in this chromosomal region. The appearance of these clones may be 
indirectly promoted by factors linked to IA ancestry. Ongoing investigations are 
exploring these potential mechanisms in other Hispanic/Latina populations.
 Discussion
Our understanding of the “Hispanic Paradox” in breast cancer remains woefully 
inadequate. Lower risk of breast cancer, likely due to a combination of ancestry, 
socioeconomic, and lifestyle factors, contrasts with increased mortality, most likely 
due to a similarly multifactorial etiology. Hints emerging from the relatively few 
studies that have investigated the molecular portraits of breast cancer in Hispanic/
Latinas suggest that the most common group of breast cancers, the luminal tumors, 
may be biologically different in Hispanic/Latinas than in other ethnic groups. 
Results from Oncotype-DX-based studies [21] and immunohistochemistry-based 
studies [22] suggest that genes associated with proliferation may be expressed at 
higher levels in breast cancers from Hispanics/Latinas. This putative difference 
does not appear to be associated with genetic ancestry and may be related to life-
style, socioeconomic, hormonal, or dietary factors. Higher expression of Ki67 
accounts for the higher prevalence of luminal B tumors among Colombian patients 
as defined by St. Gallen 2013 consensus immunohistochemical criteria. This is con-
sistent with differences in gene expression profiling, which revealed differential 
expression of multiple genes linked to the cell cycle, including MKI67. The higher 
expression of aromatase in luminal B tumors suggests a possible role for endoge-
nous estrogen in driving proliferation.
Conversely, the IA ancestry-associated expression of five genes, notably includ-
ing ERBB2 and two of its genomic neighbors, may suggest that IA ancestry is 
associated with an ERBB2-driven phenotype in luminal tumors. ERBB2-encoded 
Her2/Neu signaling is among the several well-characterized mechanisms of endo-
crine resistance [28]. Whether these tumors might benefit from Her2/Neu-targeted 
treatment with trastuzumab, lapatinib, or other agents remains to be determined.
The studies we describe herein have significant limitations. The number of tumors 
molecularly profiled is still relatively small, as is the number of subjects studied. 
These findings must be replicated in larger population of Hispanics/Latinas of differ-
ent geographic origin and ideally, in different “genetic analysis groups.” Larger num-
bers of tumors need to be molecularly profiled, and the gene sets  examined by 
clinically used gene expression-based molecular panels need to be examined in detail.
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The possibility that luminal tumors in Hispanic/Latinas may have distinctive 
biology, due to non-genetic and/or ancestry-linked factors deserves further investi-
gation. The interpretation of gene expression-based molecular tests, and thus the 
treatment choices made on the basis of gene expression results may have to take 
Hispanic/Latina ethnicity and/or genetic ancestry into consideration.
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Chapter 14
Is Precision Medicine Widening Cancer 
Care Disparities in Latino Populations? 




In 2016, people of Latino ancestry comprised 17.8% (57,398,719) of the total esti-
mated US population (323,127,515) [1]. The states with the highest percentages of 
people of Latino ancestry include New Mexico, Texas, California, Arizona, and 
Nevada, with New Jersey ranking eighth. However, these data reflect an ethnicity 
that is far from homogenous. The term “Latino” encompasses a wide range of 
people from a large geographical area. Varying elements, such as culture, 
environment, and genetic makeup, foster diversity among people of Latino ancestry.
Precision medicine focuses on treating cancer based on the molecular alterations 
and dysfunctions within a tumor, not solely on the tumor type itself. It provides a 
more streamlined approach to cancer care, allowing an individual patient’s tumor to 
be specifically targeted with available treatments, some of which may be FDA- 
approved for other diseases or tumors.
There is a great potential to treat cancer patients using precision medicine; how-
ever, research shows that its implementation in the Latino population is limited. For 
example, Latino representation in The Cancer Genome Atlas is <3%. In a 2016 
analysis of genome-wide association studies, Popejoy and Fullerton showed that 
while nearly 20% of participants were of non-European descent, less than 1% were 
Latino [2]. While the data show that physicians have been less likely to offer 
genomic testing (including germline BRCA1/2 testing for breast cancer) to Latino 
versus white non-Latino women, there is evidence that Latino patients have positive 
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attitudes and the willingness to participate in testing [3, 4]. The diversity among 
Latinos lends itself to the application of this targeted method of cancer care, but 
concern exists over whether a gap in the practice of precision medicine exists in this 
population.
 Background
 Latino Populations in the United States
Based on data from the US Census Bureau, 2016 American Community Survey 
(1-Year Estimates), the top 10 states with the highest percentages of people of 
Latino ancestry included New Mexico (48.5%), Texas (39.1%), California (38.9%), 
Arizona (30.9%), Nevada (28.5%), Florida (24.9%), Colorado (21.3%), New Jersey 
(20.0%), New York (19.0%), and Illinois (17.0%) [5]. Among these states, the most 
prevalent subpopulations of ethnicities varied from Mexican in New Mexico, Texas, 
California, Arizona, Nevada, Colorado, and Illinois to Cuban in Florida and to 
Puerto Rican in New Jersey and New York [5].
 Latino Populations in New Jersey
Based on data from the US Census Bureau, 2016 American Community Survey 
(1-Year Estimates), ancestries within the Latino populations in New Jersey were 
26.3% Puerto Rican, followed by Dominican (15.2%), Mexican (13.7%), Colombian 
(7.0%), Ecuadorian (6.7%), Peruvian (5.5%), Cuban (4.8%), and Salvadoran (4.6%) 
[6]. New Jersey is home to a diverse array of people of Latino ancestry, providing a 
unique opportunity for the Rutgers Cancer Institute of New Jersey (RCINJ), an 
NCI-designated comprehensive cancer center, to understand precision medicine and 
potential cancer-care disparities within the Latino population.
 Targeted Therapies as Standard of Care
With a growing focus on cancer therapies that target dysregulated proteins along 
signaling pathways, guidelines for standard of care treatments for a wide array of 
cancer types have begun incorporating targeted agents into their clinical 
recommendations. For example, bevacizumab, a VEGF inhibitor has been 
recommended in National Comprehensive Cancer Network (NCCN) guidelines for 
some brain and CNS cancers, such as anaplastic gliomas and glioblastomas [7]. The 
NCCN guidelines have also incorporated targeted agents into their clinical guide-
lines for such cancer types as ovarian, thyroid, breast, and colorectal cancers [8–11].
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 Cancer Incidence and Mortality Rates Among Patients of Latino 
Ancestry
Among brain and CNS cancers, ovarian cancer, thyroid cancer, breast cancer, and 
colorectal cancer, data on 5-year (2010–2014), age-adjusted incidence rates (cases 
per 100,000) and death rates (deaths per 100,000) from the US Department of 
Health and Human Services on State Cancer Profiles show the following [12].
Brain and CNS Cancers The highest incidence rates of brain and CNS cancers 
among Latinos are reported in Florida (6.1), Connecticut (6.1), Rhode Island (6.0), 
and New Jersey (6.0). Nonetheless, the incidence rates of cancers of the brain and 
CNS in each of these states are higher in non-Latino whites who also suffer higher 
mortality rates for brain and CNS cancers than Latinos in these states.
Breast Cancer The highest incidence rates of breast cancer among Latinos are 
reported in Hawaii (151.6), Montana (134.3), Connecticut (127.5), and Oklahoma 
and Colorado (tied at 104.4). Of these five states, incidence rates of this cancer type 
in non-Latino whites are higher in Connecticut, Oklahoma, and Colorado. In each 
of the aforementioned states, non-Latino whites have higher mortality rates for 
breast cancer than Latinos.
Ovarian Cancer The highest incidence rates of ovarian cancer among Latinos are 
reported in Oklahoma (15.7), Colorado (12), Wisconsin (11.2), and Virginia and 
New Mexico (tied at 11.1). Of these five states, incidence rates of this cancer type 
in non-Latino whites are higher in Wisconsin, Virginia, and New Mexico. This pop-
ulation also has higher mortality rates for ovarian cancer than Latinos in each of the 
aforementioned states.
Colorectal Cancer The highest incidence rates of colorectal cancer among Latinos 
are reported in Hawaii (43.3), Connecticut (42.9), Montana (42), and New Jersey 
(38.9). Incidence rates of this cancer type in non-Latino whites are lower in each of 
these four states. In all of the aforementioned states except Hawaii, non-Latino 
whites have higher mortality rates for colorectal cancer than Latinos.
Thyroid Cancer The highest incidence rates of thyroid cancer among Latinos are 
reported in Connecticut (21.2), Utah (19.6), New Hampshire (18.7), and Montana 
(18.3). Of these four states, incidence rates of this cancer type in non-Latino whites 
are all lower. In each of the four aforementioned states, the mortality rates are higher 
among non-Latino whites.
 Our Experience
At the Rutgers Cancer Institute of New Jersey (RCINJ), we designed a protocol that 
longitudinally follows patients with rare or refractory tumors who underwent tumor 
genomic profiling (NCT02688517). Patients provided their informed consent to 
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participate in this study, which was approved by the Rutgers University New 
Brunswick Health Sciences IRB (Pro2012002075).
Using precision medicine at RCINJ, we analyzed readily available data from 
selected tumor groups to determine if disparities exist between Latino patients and 
non-Latino whites. Initial analysis of 93 patients shows that 43 patients were of 
Latino ancestry, while 50 patients were non-Latino white (Table  14.1). Cancer 
groups included breast, central nervous system (CNS), colorectal, gastrointestinal, 
genitourinary, gynecologic, thyroid, pulmonary, skin, unknown primary, and other 
cancers. The median ages for Latino patients and non-Latino white patients were 50 
and 60.5 years, respectively.
 Next-Generation Sequencing (NGS)
Formalin-fixed, paraffin-embedded tumor specimens were sent to a Clinical 
Laboratory Improvement Amendments (CLIA)-approved, laboratory for next- 
generation sequencing. Sequencing included the entire coding regions of cancer- 
related genes as well as introns of genes involved in fusions.
 Results
Thirty-three percent of Latino ancestry patients and 30% of non-Latino white 
patients received targeted therapy. Interestingly, patients of Latino ancestry who 
received targeted therapy survived an average of 10 months longer than their white 
counterparts. In addition, Latino ancestry patients who did not receive targeted 
therapy survived an average of 4 months longer than their non-Latino white 
counterparts. Paradoxically, the Latino ancestry patients had more advanced disease 
(higher stage) at the time of diagnosis.
 Discussion
Precision medicine in cancer care provides physicians with the ability to offer tar-
geted treatment options to patients based on the molecular makeup of the individu-
als’ tumor. Given disparities in cancer healthcare in Latino populations and the cost 
and effort involved in genomic testing, we hypothesized that precision medicine has 
the potential to increase disparities in care for Latino ancestry patients and may 
hinder the progress of precision-based medicine in this population. In this study, we 
found that, at our institution, there may not be a disparity between Latino ancestry 
patients and non-Latino white patients with regard to the implementation of preci-




Total number of patients, n 43 50
Age (years)
  Median 50 60.5
  Mean 43 60
  Range (5–80) (16–79)
Gender
  Female 34 29
  Male 9 17
Cancer groups Histologies
Breast 11 9
  Stage II–IV cases 6 6
  Mean age 51 57
CNS 11 6
  Stage II–IV—WHO grade case 8 3
  Mean age 35 49
Colorectal 2 3
  Stage III cases 2 –
  Stage IV cases – 2
  Mean age 64 46
CUP a 2
  Stage IV cases – 1
  Mean age – 48
Genitourinary a 9
  Stage I–IV cases – 5
  Mean age – 66
GI 4 a
  Stage IV cases 2 –
  Mean age 56 –
GYN 4 10
  Stage I–IV cases – 10
  Stage II–IV cases 4 –
  Mean age 50 63
Thyroid 5 a
  Stage II–IV cases 5 –
  Mean age 51 –
Other 6 5
  Stage I cases – 1
  Stage III–IV cases 3 –
  Mean age 42 69
Pulmonary a 3
  Stage I–III cases – 2
  Mean age – 65
Skin a 3
  Stage II cases – 3
  Mean age – 65
aLow number of patients, counted in other
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size. Having a larger sample size may affect the outcome of our analysis, and an 
ongoing analysis will contribute to our final conclusions.
The Cancer Genome Atlas (TCGA) provides a large repository for data on 
genomic characteristics of tumors, which have been de-identified but made publicly 
available [13, 14]. Hispanics were recently shown to represent <3% (N  =  5729, 
n = 149) of the patients included in the TCGA database [15]. This finding reflects 
the underrepresentation of Latinos on larger and broader genome studies.
Targeted treatments are being recommended as standard of care for many cancer 
types. For example, the guidelines of the National Comprehensive Cancer Network 
(NCCN) recommend the immune checkpoint inhibitors, nivolumab or 
pembrolizumab, for colon and rectal cancers that are mismatch repair deficient or 
have microsatellite instability, and agents targeting receptor tyrosine kinases (e.g., 
vandetanib, cabozantinib, lenvatinib, and sorafenib) in some thyroid cancer types 
[8, 9]. Given the higher incidence rates of these two cancers in Latinos, it is crucial 
to ensure that this population has access to tumor molecular analysis.
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Chapter 15
A Vision for Improving Quality of Life 




Latinas are at higher risk than non-Latino white women of psychosocial and physi-
cal sequelae of breast cancer. Latinas report higher rates of anxiety, depression, fear 
of recurrence, fatigue, and pain; they also have worse health-related quality of life 
(HrQoL) and shorter disease-free survival [1–3]. Spanish-speaking Latina immi-
grant breast cancer survivors, in particular, experience worse quality of life and 
emotional well-being than their English-speaking and White counterparts [2]. 
Multiple synergistic factors place many Latinas with breast cancer at increased risk 
of chronic elevated stress; these factors include limited English proficiency (LEP), 
low literacy, lack of access to culturally and linguistically appropriate clinicians and 
information about their illness and treatment, limited employment and insurance 
coverage, lack of transportation, unfamiliarity with the health care system, greater 
existential concerns and fear, more symptoms, and later stage at diagnosis and more 
aggressive disease [4–6]. Compared to White, African American, and English- 
speaking Latinas, Spanish-speaking Latinas are significantly more likely to report 
difficulty understanding treatment information and to need help with written materi-
als they receive from their treatment team [5].
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 State of the Science on Behavioral Interventions to Improve 
Health-Related Quality of Life Among Latino Cancer 
Survivors
Among White women with breast cancer, stress management interventions improve 
health-related quality-of-life (HrQoL), reduce stress and anxiety [7], and may 
reduce chances of recurrence by decreasing inflammation and improving immune 
responses [7, 8]. However, a limited number of studies of the effectiveness of stress 
management programs have included Latinas with breast cancer and rural popula-
tions. Furthermore, stress management programs for cancer patients are primarily 
delivered by mental health professionals in large cancer centers. Widespread adop-
tion of stress management programs could be enhanced if they were translated for 
more vulnerable, ethnically diverse patient groups and for delivery in community 
settings by trained peers. Similarly, physical activity interventions have resulted in 
improved mood among women with breast cancer [9].
A comprehensive systematic review identified 15 intervention studies designed 
to improve HrQoL among Latino cancer survivors; most of these studies were pilot 
or feasibility studies, and nine were randomized controlled trials (RCTs) [3]. Half 
of these studies involved mixed ethnic groups and, thus, were not specifically tai-
lored for Latinos, and very few engaged community partners. Interventions were 
largely psychosocial (6), followed by educational (4), exercise/dietary (4), and navi-
gational (1). The authors concluded that the science of interventions among Latino 
cancer survivors is nascent and in great need of further development. Although this 
review found that interventions are feasible and acceptable among Latinos and that 
early results are promising, there is insufficient evidence on which to base further 
translation and dissemination efforts to reduce psychosocial health disparities and 
improve HrQoL among Latinas with breast cancer.
 The Nuevo Amanecer Program and Translation Methods
 Rationale
Our research program focuses on developing community-based interventions to 
equip Spanish-speaking Latina breast cancer survivors with the information and 
tools to manage their disease. This research aims to reduce psychosocial and symp-
tom disparities experienced by underserved cancer survivors. We focus on 
community- based self-care approaches for several reasons. First, many underserved 
communities have limited access to cancer support services and oncology special-
ists, especially in rural areas [10]. Second, a shortage of cancer specialists, includ-
ing psycho-oncologists, is projected to worsen with the growth of the older 
population [11]. Third, two influential reports by the National Academy of Sciences 
have led to recommendations by several regulatory and advocacy bodies that cancer 
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care address survivors’ comprehensive needs including surveillance, late effects of 
treatment, distress screening, psychosocial care, and healthy lifestyles, as well as 
attention to the transition from active treatment to survivorship [12, 13]. Fourth, 
over 75% of cancer patients are followed up in primary care, but primary care physi-
cians often lack the necessary training and confidence that they possess the specific 
expertise required to manage the health care needs of cancer survivors [14]. Finally, 
as health care in this country moves to accountable care organizations responsible 
for managing the health of populations, integration of cancer support services with 
health care systems will be critical, including establishing linkages among oncolo-
gists, primary care providers, and community-based cancer support services.
 Translation of the Nuevo Amanecer Program
Working with community partners, we developed an extensive research program to 
address these gaps. We conducted extensive formative research and developed 
Nuevo Amanecer (A New Dawn), a new 8-week, peer-delivered cognitive- behavioral 
stress management (CBSM) program for Spanish-speaking Latinas. Using 
community- based participatory research methods, we applied an innovative transla-
tional process model appropriate for minority and underserved populations (we 
integrated an evidence-based intervention, a community best-practices program, 
and formative research results) resulting in a program that could be delivered by 
trained breast cancer survivors (peers) [15]. We tested Nuevo Amanecer in a ran-
domized controlled trial (RCT) of urban Latinas who were newly diagnosed with 
breast cancer; results indicate that it effectively improved several quality-of-life 
domains and decreased breast cancer concerns and depressive and bodily symptoms 
[16]. In the words of a participant, “The program changed me. It made me happier 
and helped me think positive thoughts so I could push forward and fight.”
Cognitive-behavioral stress management interventions such as Nuevo Amanecer 
and culturally tailored physical activity interventions have tremendous value for 
giving disenfranchised patient populations the tools to help manage their cancer and 
gain control over what many perceive as an untenable situation. CBSM skills train-
ing delivered early in the cancer care trajectory can reduce the most common symp-
toms experienced by Latinas with limited access to culturally and linguistically 
appropriate psychosocial services [16].
Throughout rural California, Latinos are concentrated in communities with agri-
cultural jobs; in these communities, we find more Latinos living in poverty, fewer 
with a high school degree or some college, and lower per capita community reve-
nues and expenditures [17]. Cancer patients in rural areas suffer greater disparities 
related to lack of access to cancer supportive services, including informational and 
psychosocial support [18]. Barriers to cancer support services among rural women 
with breast cancer include distance, lack of transportation, low income, and low 
literacy. In the Central Valley of California, geographic isolation, distance to health 
care providers, and language barriers are risk factors for poor health [19]. Effective 
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psychosocial health programs for rural Latinas with breast cancer could reduce 
these disparities. Because the broader Latina population in California includes 
many in rural settings and with limited literacy, a necessary step prior to full-scale 
dissemination is to adapt Nuevo Amanecer for more vulnerable subgroups and test 
it in these new populations. In addition, community organizations need resources to 
facilitate incorporating such programs into their settings. Thus, we embarked on 
Nuevo Amanecer-II, a study in which we are translating and testing the program in 
three rural, low-income communities in California. We trained a new set of com-
munity health workers (CHWs) to deliver the program. Recruitment for the study 
has closed, and intervention delivery and follow-up assessments should be com-
pleted by September 2018.
Baseline breast cancer-specific quality-of-life data from our Nuevo Amanecer 
and Nuevo Amanecer-II RCTs demonstrate that compared to norms based on white 
breast cancer survivors, Latinas do worse on every domain. Using the Functional 
Assessment of Cancer Therapy measures that include a subscale on breast cancer 
concerns (FACT-B), we found that urban and rural Spanish-speaking Latinas 
reported worse overall quality of life, physical well-being, emotional well-being, 
social/family well-being, and functional well-being compared to norms from a sam-
ple of 400 White women with breast cancer. Spanish-speaking Latinas scored about 
60% lower (indicating poor quality of life). These results are consistent with prior 
studies, although these studies are few in number [1, 2].
Development of these programs occurs in partnership with community organiza-
tions, Latina breast cancer survivors, and clinicians using an integrative approach 
that synthesizes scientific evidence with community knowledge, while taking into 
account the local context [15]. We utilize mixed methods to obtain data that informs 
program development (e.g., semi-structured interviews and surveys with survivors, 
clinicians, and social service providers). We embed these programs in the commu-
nity by training community-based organizations to deliver them in a fashion that 
they have determined works with the populations they serve. We have described this 
implementation model and the features that make it especially suitable for transla-
tion of programs for delivery in health disparity communities [15].
 A Conceptual Framework to Guide Research on Behavioral 
Interventions for Latino Cancer Survivors
Based on this program of community-based participatory research (CBPR), we 
developed a conceptual framework of survivorship needs, types of programs that 
would address these needs, and the hypothesized mediators and outcomes that 
would be affected by these programs [20]. According to Spanish-speaking breast 
cancer survivors, their needs focus on four general areas: symptom management, 
psychosocial health, coordination of post-treatment care including the transition 
from immediate diagnosis to survivorship, and healthy lifestyles. Based on the 
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 literature, the types of interventions that help include (1) skills training on symp-
toms, stress management, and communication with family and clinicians; (2) infor-
mation on symptoms and treatment side effects, recommended follow-up care, signs 
of recurrence, healthy lifestyles (physical activity and nutrition), and community 
resources; and (3) social support. These types of interventions have been shown to 
improve self-efficacy for managing symptoms, stress, and communication; improve 
knowledge; and increase perceptions of social support. Improvements in these 
mediators lead to decreased stress and distress and improved health-related quality 
of life [20].
Spanish-speaking Latinas experience limited access to culturally and linguisti-
cally appropriate cancer survivorship care. Cancer centers are often ill-equipped to 
meet the needs of cancer patients who are limited-English proficient and low 
income, especially in rural areas. Such women often fall through the cracks and may 
not receive high quality care for breast cancer into the acute and survivorship phases. 
Community-based models that utilize CHWs and peers are proven methods for 
reaching underserved populations, resulting in improved health outcomes [21]. 
CHW-delivered cancer support programs could be a low-cost, effective method for 
meeting the psychosocial needs of underserved Spanish-speaking cancer survivors.
 Gaps and Opportunities for Future Research
Clearly, we need stronger evidence for the effectiveness of behavioral interventions 
for improving the HrQoL of Latino cancer survivors. Once culturally appropriate 
cancer support programs are found to be effective in diverse populations, we will 
need effective methods for disseminating these evidence-based programs. Although 
there are platforms for dissemination of evidence-based behavioral interventions, 
including cancer-related programs, these are largely only known to and used by 
researchers. Researchers can address such service delivery gaps by developing an 
integrated program of research focused on translation and dissemination of 
evidence- based behavioral interventions for underserved cancer survivors.
Importantly, in our Nuevo Amanecer-II study, we added the collection of bio-
specimens (hair and saliva samples) to examine the effects of the program on corti-
sol levels (a biomarker of stress). Minority populations in the United States are less 
likely than Whites to donate biospecimens [22], and there is almost no evidence on 
the effectiveness of methods employed by researchers to collect biospecimens 
among Latinos. In the context of this study, our CHWs successfully collected the 
biospecimens. However, we were unable to secure the cooperation from one partner 
community-based organization; thus, we were not able to offer women from that 
community the choice of providing saliva and hair samples. To inform future efforts, 
we will report on the unique issues we have faced with collection of biospecimens 
among Spanish-speaking Latina breast cancer survivors. Such evidence is critical so 
that vulnerable populations can accrue the benefits of precision  medicine. 
Deployment of targeted resources will be necessary to include minority populations 
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in large, multicomponent cohort studies that require biospecimens, such as the “All 
of Us” program, a national initiative to enroll a diverse and representative cohort of 
one million Americans to advance precision medicine for all diseases [23]. Inclusion 
of vulnerable populations in all phases of this research is imperative, if we are to 
reduce health disparities and assure communities that the results will be relevant for 
and accessible to them.
A promising avenue for delivering behavioral interventions to minority commu-
nities, including Latinos, is technology-assisted community health worker interven-
tions. In other translation efforts, we recently developed and conducted a pilot test 
of a Spanish-language mobile phone application to provide women with breast can-
cer survivorship planning and physical activity promotion tools. We combined the 
mobile phone application with telephone-delivered health coaching. Data analyses 
are in process, but preliminary results suggest that the tool was acceptable to women, 
increased their self-efficacy to manage their illness, and increased their daily aver-
age steps. In another study, we developed a prototype of an English and Spanish 
mobile phone application that adapted the core stress management components of 
the Nuevo Amanecer program for use among low-income women undergoing che-
motherapy for breast cancer. We hope to test this mobile phone application in a 
future RCT that will incorporate telephone health coaching as well. Finally, we are 
providing technical assistance to another investigator-community stakeholder 
research team on a project that is translating our program for use among under-
served, rural white women using a telehealth modality delivered by peers (rural 
breast cancer survivors). Thus, we are translating effective programs for new popu-
lations and delivery methods that have potential for broad-based dissemination.
 Conclusions
As cancer centers strain to meet the needs of the burgeoning cancer survivor popula-
tion, alternative service models that capitalize on community resources and inte-
grate CHWs and families into the health care delivery system will be needed. 
Working with disparities communities, investigators can integrate evidence-based 
programs with community knowledge and best practices to test and disseminate co- 
developed programs to meet the needs of vulnerable cancer survivors. Working 
together, academic-community partners can develop acceptable, effective, and 
potentially more sustainable programs to reduce disparities. With such an approach, 
the intervention development process is incomplete “until an intervention is opti-
mally efficacious and implementable with fidelity by practitioners in the commu-
nity” [24].
Through Nuevo Amanecer-II we are testing whether the program meets the 
needs of vulnerable and low literacy Latinas in rural areas. This will ensure that the 
program is appropriate for rural and urban Latinas and results in a transportable 
program and implementation guide for community-based organizations prior to 
widespread dissemination. Because of the extensive involvement of community 
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advocates, survivors, and cancer care providers throughout translation, broad pro-
gram dissemination should reduce ethnic disparities in psychosocial health. Our 
Nuevo Amanecer process evaluation indicates that it was precisely this careful inte-
gration of community input that resulted in a program that effectively reduced dis-
parities in the psychosocial health of vulnerable Latinas in the study by meeting 
their needs and anticipating implementation barriers [25]. On study completion, we 
will post our program products on Internet sites to further disseminate them and to 
maximize the community benefit derived from these studies. Our vision is to see 
this practical, culturally relevant program widely adopted to eliminate psychosocial 
health disparities in vulnerable Latinas with breast cancer.
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Chapter 16
Research Democracy in a Randomized 
Controlled Trial: Engaging Multiple 
Stakeholders in Patient-Centered 
Outcomes Research
Charlene Kuo, Christina Rush, Abigail Montero, Claudia Campos, 
Gloria Elliott, Ivis Febus-Sampayo, Ysabel Duron, Migdalia Torres, 
Margaret Darling, and Kristi D. Graves
 Introduction
Patient-centered outcomes research (PCOR) addresses issues and measures out-
comes that are meaningful to patients and other stakeholders. PCOR emphasizes 
involving patients and other interested stakeholder groups such as clinicians, advo-
cates and caregivers in the research process [1–4]. Some funding agencies, such as 
the Patient-Centered Outcomes Research Institute (PCORI), require the “active 
incorporation of perspectives beyond those of the researchers” throughout the entire 
project [1]. Understanding factors that contribute to successful collaborations is a 
critical component to better serve our patient populations and forge stronger part-
nerships in PCOR.  The involvement of engaged and enthusiastic team members 
with diverse perspectives is one of the factors important for PCOR.
C. Kuo · A. Montero · K. D. Graves (*) 
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
e-mail: Kristi.Graves@georgetown.edu 
C. Rush 
Department of Psychology, University of Colorado, Denver, CO, USA 
C. Campos · G. Elliott 
Nueva Vida, Inc., Alexandria, VA, USA 
I. Febus-Sampayo 
LatinaSHARE, New York, NY, USA 
Y. Duron 
The Latino Cancer Institute, San Jose, CA, USA 
M. Torres 
Gilda’s Club New York City, New York, NY, USA 
M. Darling 
Humphrey School of Public Affairs, University of Minnesota, Minneapolis, MN, USA
168
The benefits of engagement are demonstrated through the effective management 
of partnerships concerned with health and social welfare [4, 5]. True engagement 
yields better work performance among team members. Improved work performance 
among teams is supported by creating an environment in which team members can 
fulfill and exceed expected roles and apply creativity to problem-solving to achieve 
or exceed the desired outcomes [4]. Similar contexts among health care teams can 
increase patient-centered care [6].
For teams conducting PCOR, one approach that may work to promote involve-
ment among stakeholders with diverse perspectives and experiences is research 
democracy—a process in which individuals involved in research (e.g., team mem-
bers, participants, advisors) have a vote and a voice in the decisions that are made 
and the procedures that are used to conduct the research. Elements of research 
democracy include opportunities for sharing opinions, casting votes, discussing out-
comes, and identifying areas for improvement. We expand upon ideas presented in 
the limited literature on team engagement in PCOR [7–9] and provide examples of 
effective communication to keep each member updated and informed [9–11]. 
Research democracy can also provide a process for fostering creativity, innovation, 
and synergy among team members [9, 12, 13].
The purpose of this chapter is to describe research democracy in a PCORI- 
sponsored project, the Nueva Vida Intervention, and illustrate how such research 
democracy may promote PCOR. The literature on team engagement in research and 
public health interventions is limited [7–9]. To address these gaps, we present 
research democracy applications (Table  16.1), team member satisfaction 
(Table 16.2), barriers (Table 16.3), and benefits (Table 16.4) to conducting research 
in a PCOR context.
 Methods
The Nueva Vida Intervention is a dyadic intervention that aimed to improve quality 
of life outcomes among Latina breast cancer survivors and their caregivers (PCORI 
AD12-11-5365) [14]. The Nueva Vida Intervention was evaluated in a randomized 
controlled trial, and the study team was composed of four community-based orga-
nizations (CBOs), scientific investigators from the Lombardi Comprehensive 
Cancer Center at Georgetown University, clinical and research consultants, an advi-
sory board that included Latina cancer survivors and caregivers, and a data safety 
and monitoring board [14]. The intervention consisted of eight group-based ses-
sions in which survivors and caregivers learned coping and communication skills in 
separate rooms and then joined together for discussion and a meal [14]. Throughout 
the process of study design, intervention refinement, protocol implementation, and 
follow-up, we collected data on team engagement through informal observations, 
direct discussions during team meetings, and survey assessments.
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Table 16.1 PCOR elements and research democracy approaches in the Nueva Vida Intervention 
project
PCOR element Research Democracy Approaches in the Nueva Vida Intervention
Clear expectations 
[9, 11]
  • Maintained detailed records of every phone call and meeting
  • Set a goal and deadline for each (new) action item
  • Reiterated expected deliverables from team members for each 
deadline
  • Followed up with one another as deadlines approached
  • Allowed time for expression of differences of opinion related to 
identified goals
Delegation [9]   • Each site recognized and understood their responsibilities to meet 
their own goals as well as the larger overall team goals. Individual team 
members were tasked with different responsibilities as appropriate for 
each site.
  • Newsletter writing was divided so that each Community Based 
Organization (CBO) authored one newsletter and the Georgetown 
University Medical Center team edited each issue





Structural elements of communication
  • Team members were invited to specific telephone calls based on their 
tasks. Most calls were open to all members, including bi-weekly phone 
calls between the principal investigator and project directors at each 
CBO, and monthly teleconference calls with the entire study team
  • We held separate monthly interventionist supervision telephone calls 
for only the interventionists and our team clinical supervisors (CC; GE). 
The decision to restrict these calls to only the interventionists was at the 
suggestion of a team member; this decision promoted confidentiality of 
the participants and also promoted further autonomy and sense of 
connection among the team interventionists
  • Georgetown University Medical Center sent team emails with project 
updates and other items, such as webinars and articles, at least once per 
month to the entire study team
  • Polls and team surveys were conducted as an additional means of 
collecting team member ideas and opinions about the implementation 
and progress of the project
  • Annual meetings featured diverse discussion methods. Both large 
group discussions and small break-out sessions were organized and 
implemented
Process elements of communication
  • Communication was conducted in an accepting, considerate 
environment to accommodate and value different personalities and 
interpersonal styles, creating balanced but diverse discussions
  • Each person was asked for input during monthly teleconferences and 
annual meetings; each CBO site was asked for group input
  • Each site shared ideas, successes, and difficulties during recruitment
  • Team members were offered support and reassurance throughout the 
process
(continued)
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Table 16.1 (continued)
PCOR element Research Democracy Approaches in the Nueva Vida Intervention
Establishment of 
shared goals; [12]
  • Voting to identify intervention topics
  • All team members shared a passion for improving outcomes among 
the target population of Latina breast cancer survivors and their 
caregivers
  • During proposal planning and writing, team members identified 
initial shared goals for improving quality of life among Latina breast 
cancer survivors and their caregivers
  • During intervention adaptation and planning, team members voted on 
which intervention topics were most relevant to the “core” five session 
content areas out of eight total sessions
  • During implementation, team members identified and acted upon 
shared goals for recruitment; intervention implementation; and quality of 
communication among team members and with participants, including 
dissemination of results. These goals were determined through 
discussions that engaged all team members
  • At the first intervention session with each new group, participants 
(Latina breast cancer survivors and their caregivers) voted on topics for 
3 sessions (out of a possible 6 elective session topics). This ensured that 
interventions received by the participants were appropriate to their 
interests and needs. For example, some groups consisted of caregivers 
who were adult children of the survivors, while other groups consisted 
of spouses or partners of the survivors
Establishment of 
mutual trust [12]
  • Site principal investigators emphasized mutual trust and were 
receptive and responsive to difficulties encountered by team members 
without causing fear of penalty or embarrassment, thus promoting a 
culture of transparency with meeting expectations
Promotion of team 
pride [9]
  • A team logo and motto were developed as a team and used in team 
materials across sites
  • Each phone, email, or meeting communication began with sharing 
team or individual members’ study-related accomplishments




  • Created a basic study structure that could easily be adapted based on 
team member feedback and community interactions
  • Team members suggested that the research be prioritized over 
peripheral tasks or that requests be made in smaller, more manageable 
steps
  • Created a press kit based on one site’s previous experience
  • Gifts sent to participants were chosen as a team
  • Changed newsletter format and delivery
  • Created an introductory video used for participant recruitment
  • Sites hosted events to accomplish a number of goals to:
  (a) Educate the desired target population about the importance of 
clinical research
  (b) Share the outcomes of the research as a way to disseminate results 
and show the research team’s appreciation for participant involvement
(continued)
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Table 16.1 (continued)
PCOR element Research Democracy Approaches in the Nueva Vida Intervention
  (c) Encourage participants and team members to feel proud of how 
their engagement made success possible
  (d) Provide participants an opportunity to share what important things 
they learned in the process and what ideas they had for future research
  • Creative thinking helped clarify consultant roles and responsibilities. 
For example, one consultant with expertise in clinical aspects of 
supporting caregivers was invited to facilitate a discussion about 
caregiver needs in a conference call and to provide an update to the team 
during one of our annual team meetings
  • At a recruiter’s suggestion, we created a ‘recruitment flipbook’ that 
consisted of photos only (no text) to convey steps of study involvement 
for community members with low literacy





  • Two sites in New York hosted an event emphasizing the importance 
of Latino participation in cancer research. Two other sites adopted that 
idea and hosted an event in the DC metropolitan area
  • One CBO site principal investigator shared that work on the PCORI 
Nueva Vida Intervention generated greater internal team cohesiveness. 
Other team members (a CBO site principal investigator; advisory board 
member) identified and followed through on opportunities to submit an 
abstract as first author and co-present an invited presentation
  • One site had its entire team complete HIPAA and Human Subjects 
Research training
Promotion and 
practice of cultural 
humility [13]
  • Some research team members acknowledged lack of familiarity with 
cultural norms
  • Some community partners acknowledged lack of familiarity with 
research
  • The minimum inclusion age was changed from 21 (often the norm in 
research studies) to 18 when we realized that young caregivers are 
common among the patient population
  • Stopped using the word “study” when publicizing and recruiting, 
because community partners informed us that the word “study” elicited 
images of blood being drawn
Connecting your 
team to resources 
[9]
  • Provided human subjects training to community partners using 
CERTification, a training approved by our IRB that is designed for 
community-based partners; adapted training into Spanish
  • Included professional development opportunities in team emails
  • Leveraged existing meeting schedules to maximize learning 
opportunities and make attendance more convenient. For example, one 
annual meeting was scheduled around the National Latino Cancer 
Summit and another was scheduled around a survivorship conference in 
DC
  • Minimized administrative burdens such as secure file sharing across 
sites. Ultimately we simplified data requests and input from site team 
members and increased data input among the Georgetown PI’s study 
team to lessen CBO team member burden
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Table 16.2 Team member satisfaction and experiences survey results
Item text
Please circle a response to indicate if the following 
changes have occurred since joining the team:
% of team members who reported 
“increased”
My willingness to express my point of view has increased 45
Trust between the group members has increased 81
Please circle a response below to indicate your level of 
satisfaction with the following:
% of team members who reported 
“satisfied” or “extremely 
satisfied”
The impact of study involvement on my agency 100
The amount of influence I have over team decisions 95
Based on your experience with the Nueva Vida 
Intervention study, please circle a response to indicate 
how likely are you to:
% of team members who reported 
“likely” or “extremely likely”
Collaborate in other research 100
Seek out new research collaborations 100
Table 16.3 Barriers identified during work on the Nueva Vida Intervention study
Category Barrier
Communication “Organizational barriers/limitations to understanding/complying with research 
practices and communicating to potential participants”
“Labor intensive, [lack of] clarity in startup conversations, time [zone] 
difference[s]”
“Staff mobility and communication issues”
Recruitment “Recruitment and retention barriers were expected”
“[Difficulty with] Caregiver recruitment”
Other “Some language barriers but resolved”
“Progression of disease as a hindrance to participation”
“[Difficulty understanding and accepting] Randomization”
Table 16.4 Benefits identified during work on the Nueva Vida Intervention study
Category Benefits
Collaboration “Collaboration”
“Collaboration with other subcontractors”
“Wonderful collaboration, organizational structure and team 
spirit”
“Collaboration with other organizations and working with Kristi 
[Graves] and her team”
Learning about the research 
process
“Internal abilities to collect and disseminate lessons learned 
throughout the research process
“[Ability to] Participate in research study”
“Great model for staff to learn how such a project works”
Other “Could not be happier!”
“I feel my work with A[frican] A[merican] community and other 
advocacy work contributes”
“Closer connection with all sites”
“Learning about caregiving”
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 Results
Table 16.1 illustrates how we applied elements of PCOR using research democracy 
approaches during the randomized controlled trial to evaluate the Nueva Vida 
Intervention. We identified these elements based on evidence from studies of 
employee engagement, team engagement, and community-based participatory 
research [13, 14].
During the study period at one of the annual in-person team meetings, we admin-
istered a survey to assess team member satisfaction and experiences (see Table 16.2 
for a summary of survey results). Team member feedback on this survey helped set 
the agenda and procedures for upcoming team calls. We specifically asked for bar-
riers and benefits to individual team member’s success and involvement with the 
study. By eliciting input during open communication on team calls and also through 
a survey, we obtained feedback about team procedures so that adjustments could be 
made, as needed. We presented results to team members to promote transparency 
and open communication. Team members identified barriers (Table 16.3) and ben-
efits (Table 16.4) during the Nueva Vida Intervention Study.
Sites also reported enhanced team engagement within their own organizations. 
One site principal investigator reported that participation in the project contributed 
to restructured roles, unified people as a team pursuing a common goal, and fostered 
creativity and collaboration. The methods used to promote team engagement thus 
appeared to be advantageous not only for the larger research team but also for the 
individual community-based organizations. A critical component to whether part-
ners on a research team can thrive involves recognition of their time and expertise 
through appropriate compensation for time and inclusion in the dissemination of 
results.
 Discussion
Research democracy, a process by which all members of a research team (patients, 
CBOs, scientific investigators, and other stakeholders) are engaged, valued, 
respected, and heard through both direct voting and open communication, resulted 
in a successful PCOR project, the Nueva Vida Intervention study. The management 
strategies employed kept the study running efficiently and effectively and estab-
lished mutual trust. Setting clear expectations provided opportunities to foster such 
trust, and listening to team member concerns promoted transparency and sharing of 
information in a safe environment. Transparency and effective communication 
alerts a site to events occurring at other sites which may disrupt study flow such as 
staff turnover, staff illness, site moves, or other obligations. Team cohesion, devel-
oped using the elements of team engagement, generated enthusiasm for the research 
project among the team members. The diversity of the team was an asset, contribut-
ing to the goals of team members individually and the research project as a whole. 
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For example, flexibility during implementation of the study and dissemination of 
information to the community was particularly important, because the CBOs were 
more familiar with the community and culture than the researchers. Elements of 
team engagement that value each person may be more likely to promote community 
members’ participation in future research. These preliminary results suggest that 
active application of research democracy elements may promote team engagement 
and satisfaction as well as awareness of project barriers and benefits, which may, in 
turn, strengthen and promote PCOR.  Future research can systematically explore 
approaches for how to best assess team engagement to strengthen and pro-
mote PCOR.
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Chapter 17
Es Tiempo: Engaging Latinas in Cervical 
Cancer Research
Lourdes Baezconde-Garbanati, Carol Y. Ochoa, Sheila T. Murphy, 
Megan B. Moran, Yaneth L. Rodriguez, Rosa Barahona, and Lizette Garcia
 Overview of Community-Driven Research
Community health science is an approach that takes science to the community and 
ensures that the community participates in the scientific process in order to improve 
quality of life [1]. It is the development of a two-way street between communities 
and academia that helps solve some of the most challenging scientific health prob-
lems at the community level. Academic–community partnerships provide one 
mechanism to facilitate engagement of communities in research. The goal is to 
improve access to services, research participation, access to technology, and infor-
mation/knowledge transfer or faster dissemination of information. As the Latino 
community ages, grows, and spreads throughout the United States, bridging the gap 
between science and practice becomes more urgent, especially among older seg-
ments of the Latino population whose cancer risk profile may be increasing. This is 
needed especially in cancer prevention and control, if Latinos are to benefit from 
new and emerging technological advances and engage in precision medicine 
more fully.
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In the United States, Latino communities are changing demographically and cul-
turally. Latinos are not a monolithic unit, but are instead a very heterogeneous group 
with differences in acculturation, immigration, documentation status, country of 
origin, and racial/ethnic make-up. In spite of this heterogeneity, their connection 
with each other is central to the Latino community. The values that Latinos share are 
central to the essence and culture of being Latino. Most share in the Spanish lan-
guage, except Brazilians who speak Portuguese and some indigenous communities 
from Central and South America who predominantly speak an indigenous language, 
even if they have learned Spanish. Common to the culture is an emphasis on person-
alismo, familismo, simpatia, collectivism, harmony, and cooperation in the group 
[2, 3]. These characteristics have often been found to be protective and have served 
as deterrents to unhealthy life styles, such as alcohol, drug, and tobacco use in some 
segments of the Latino community. Although other groups may share in similar 
values, solutions found for other cultural/ethnic and racial groups may not necessar-
ily apply to Latinos and to Latinas in particular. For example, the Latino 
Epidemiologic Paradox shows that in spite of living in poverty and having low edu-
cational attainment, some segments of the Latino population have very positive 
health outcomes on specific indicators and have shown important gains in life 
expectancy.
Unfortunately, Latino populations are not always well informed of recent 
advances in research, nor do they benefit equally from scientific discoveries as other 
populations. On average, research can take 17 years to go from bench to bedside [4], 
which is why community-based models are needed; these models engage partici-
pants in research, not just as subjects but also as planners, implementers, and dis-
seminators of information, so information can be transferred more quickly. 
Community-based participatory models can decrease this time gap by utilizing 
patient-centered approaches and by including patient advocates, citizen scientists, 
and community health workers, who are trusted by their respective communities to 
research and deliver life-saving information and accelerate knowledge transfer. 
These programs work best through the establishment of equal power-sharing part-
nerships, which effectively accelerate health improvements that more quickly 
achieve health equity [5]. The World Health Organization (WHO) defines equity as 
“the absence of avoidable or remediable differences among groups of people, 
whether groups are defined socially, economically, demographically, or geographi-
cally” [6]. In our research, we strive to achieve health equity in cancer-related dis-
eases and to adequately reduce risk factors via participation in research and more 
timely dissemination of information to the Latino community.
Israel et al. [7] described key principles for community engagement which we 
utilize in our research with Latinos. These include (1) engaging community partners 
from the beginning stages; (2) working on the principle of shared equity and 
decision- making; (3) engaging in mutual learning in all stages of research; (4) nego-
tiating a common vision, goals, values, priorities; (5) compensating community 
partners; (6) hiring staff from the local community; (7) training community health 
workers/promotoras de salud; (8) allowing community partners to influence pro-
gram direction; (9) sharing equal power among partners; (10) planning jointly with 
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partners; and (11) working with partners on dissemination of information. These are 
principles that form part of community-based participatory research (CBPR). Even 
though it is not always possible to implement all CBPR principles in cancer research, 
some cancer research can still be community driven and abide by many of the prin-
ciples described above.
Our over 25 years of experience show that to actively engage Latinas in cervical 
cancer and other cancer-related research, it is critical to build strong relationships in 
the Latino community over time. We build community trust by establishing several 
partnerships that are still in effect years later. Further, we engage Latino communi-
ties and Latinas, in particular, directly and indirectly in the research. Latinos are 
engaged as participants and as community scientists. Once the research is finalized, 
we give information back to these communities. Further, we follow up in terms of 
policy or services that are needed to further community goals, and we work with 
volunteer organizations, such as the American Lung Association and the American 
Cancer Society in policy and advocacy.
One important mechanism we have utilized is the establishment of community 
advisory boards/committees (CABs/CACs) [8]. Through our CABs we have 
engaged key community members in guiding the research from its initial stages 
through to its dissemination [9]. This implies that the CABs are truly heard and that 
academic researchers recognize the importance of their contributions from concep-
tualization to decisions on analysis and information dissemination. We have also 
engaged patient advocates, community scientists, citizen scientists, and/or commu-
nity health workers (CHWs) and promotores de salud as vehicles for listening to 
community voices. These key community representatives do not necessarily have a 
formal science or research background, but they contribute time, effort, and 
resources toward scientific research. Citizen scientists work often with professional 
scientists or alone [10]. Citizen scientists and patient advocates are helping to bridge 
gaps in research, as everyday people contribute to the scientific enterprise. In these 
days of Big Data, they can contribute to data collection by accumulating photo-
graphs and videos of their environment and by providing context for interpretation 
of data from these large datasets. Ability to help culturally interpret findings is 
critical.
 Current Work
Although much has been accomplished in reducing morbidity and mortality from 
cancer, cervical cancer remains a serious health threat for Latinas in Los Angeles. 
In LA County, the incidence of cervical cancer is as high as 8.0 per 100,000 among 
Latinas, compared to 6.3 per 100,000 among Asian/Pacific Islander women, 10.5 
per 100,000 among African American women, and 7.3 per 100,000 among non- 
Hispanic White women [11]. These statistics are particularly worrisome, especially 
for Los Angeles, a county heavily populated by Latinos. Women present them-
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selves to local clinics with advanced stage of disease and limited survival and treat-
ment options.
 Past Interventions
A multidisciplinary team at the University of Southern California (USC) conducted 
12 focus groups [12], which resulted in the development of two research/interven-
tion programs: Tamale Lesson (Murphy/Baezconde-Garbanati, NCI-
R01CA144052), Es Tiempo (California Community Foundation, the Norris 
Comprehensive Cancer Center, P30 CA01408939S4), and the SC Clinical 
Translation Science Institute (CTSI-UL1TROOO130).
 Tamale Lesson: Transforming Cancer Information Through Narrative
For Tamale Lesson, we developed two 11-min English films with the goal of reduc-
ing the burden of cervical cancer. Tamale Lesson was also translated and adapted 
into Spanish. Tamale Lesson was produced using a culturally tailored narrative for-
mat which aimed to provide information on the human papillomavirus (HPV), the 
virus that causes cervical cancer; cervical cancer prevention via vaccination; and 
cervical cancer detection via Pap test screening and new genetic tests. The second 
film, It’s Time, was developed as a non-fictional, non-narrative alternative to Tamale 
Lesson and also included similar information. Details of development are presented 
elsewhere [13]. Short 3-min clips of these videos are available on YouTube, as well 
as longer versions on DVD. A sample of 900 European American, African American, 
and Mexican American women living in Los Angeles were recruited through ran-
dom digit dialing (RDD) and were randomly assigned to receive either the narrative 
or the non-narrative film in the mail. All women were surveyed to assess their level 
of cervical cancer-related knowledge, attitudes, and behavior before receiving the 
film, 2 weeks and 6 months after viewing the film. Latinas participated in many 
aspects of the research. They were active participants in the focus groups, and also 
participated in focus groups that viewed and edited the films to make them more 
culturally specific. Through funding from the SC CTSI, promotoras de salud were 
included. They participated in the research via the formation of a community advi-
sory board that produced the Spanish language version of Tamale Lesson. Findings 
from the study revealed that the narrative and non-narrative films were successful 
interventions in both the short-term at posttest and long-term at 6-month follow-up 
[14]. The narrative film was more effective in increasing cervical cancer-related 
knowledge and attitudes at posttest than the non-narrative. Moreover, the narrative 
film reduced cervical cancer screening disparities for Mexican American women 
from pretest to the 6-month follow-up. Fifty percent of non-Hispanic whites, 32% 
of Mexican Americans, and 36% of African Americans did not need a Pap test at 
baseline. Within 6 months after viewing the Tamale Lesson, the disparity  disappeared, 
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and 78% of non-Hispanic whites, 83% of Mexican Americans, and 77% of African 
Americans had a Pap test or made an appointment for cancer screening [14]. The 
program has been disseminated not only throughout California but also across sev-
eral countries in the Caribbean and Latin America, including Colombia, Mexico, 
Panama, Costa Rica, and Argentina through Buena Salud America of the National 
Alliance for Hispanic Health and the Healthy Americas Institute. In Panama, the 
Ministry of Health is distributing Tamale Lesson throughout 900 jurisdictions, 
including rural indigenous areas.
 Es Tiempo: The Jacaranda Initiative
Our multidisciplinary team at USC developed Es Tiempo—a stunningly beautiful 
and innovative campaign to prevent cervical cancer among Latinas. It was built on 
the 12 Latina focus groups [13] and environmental scans conducted by students in 
the Designmatters Program at the ArtCenter College of Design. Es Tiempo uses the 
annual blooming of the purple jacaranda tree in Los Angeles to remind us all that we 
can prevent cervical cancer and to remind women to vaccinate their sons and daugh-
ters from HPV. Es Tiempo’s design elements were created by students from the 
ArtCenter College of Design, Designmatters Program and developed and tested by 
investigators from the Norris Comprehensive Cancer Center, Institute for Health 
Promotion and Disease Prevention Research, Department of Preventive Medicine, 
Keck School of Medicine of USC, and the Annenberg School for Communication 
and Journalism. The program was pilot tested and launched with cooperation from 
community clinics, Clínicas Monseñor Oscar Romero (Pico Union and Boyle 
Heights). We obtained support from the Office of Women’s Health (OWH) at the 
L. A. County Department of Public Health.
The bilingual Es Tiempo campaign has three components: (1) an outdoor media 
educational campaign; (2) a clinic intervention in partnership with Clínicas 
Monseñor Oscar A. Romero in Boyle Heights and Pico Union; and (3) a community 
component, where promotoras de salud deliver community educational workshops 
and collect intercept surveys to measure knowledge increases at the community 
level. Latinas are and have been engaged in this project from its creation all the way 
through to its implementation and dissemination in the community. Outdoor media 
materials include billboards, bus benches, and light post banners with the OWH 
cervical cancer helpline number. When Latinas call the helpline, trained callers 
make appointments and referrals for free or low-cost cervical cancer screening and 
HPV vaccinations for qualifying women. Intervention clinics mail postcards to 
women who have not had a Pap test in the last 3 years (based on current guidelines), 
and clinic banners remind women to schedule their cervical cancer screening or 
vaccinate their sons and daughters. OWH and the clinics report the number of 
women who call or make appointments pre- and post-intervention. In addition, pro-
motoras de salud conduct community workshops which have a pre- and post-survey 
of knowledge on cervical cancer and the HPV vaccine. At the end of the workshop, 
participants are provided with referrals, places where they can receive low or no 
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cost screening and HPV vaccinations. Also, women are encouraged to follow-up if 
they have abnormal Pap test results. Lastly, intercept community surveys are con-
ducted to assess the campaign and understanding of the material; knowledge-related 
questions pertaining to cervical cancer, the HPV vaccine, and Pap test; format in 
which they have received health information; and how they would like to receive 
health information in the future.
Clínicas Monseñor Oscar Romero (community partner in Es Tiempo) reported 
that 1428 women were eligible for Pap tests in the community intervention clinic 
and 745 women were eligible from a control clinic located in another area of the 
city. Our findings show that there was a statistically significant difference in percent 
of women who became compliant during the intervention period. The percentage of 
women in the Boyle Heights intervention clinic was higher than the Pico Union no 
intervention (46% vs. 33%, p < 0.01). Also, there was a statistically significant dif-
ference in percent of women who received a Pap test based on the type of interven-
tion they received. Women in the Boyle Heights clinic who received a postcard at 
home with the same imagery as the outdoor media had higher rates of Pap testing 
than women in Pico Union who received only the postcard (65% vs. 34%, p < 0.001). 
Our findings demonstrate the effectiveness of a multicomponent intervention to pro-
mote screening for cervical cancer that incorporates Latinas in various aspects of 
the program.
 Identified Gaps
There continues to be a need for the inclusion of Latinas in cancer prevention and 
control research. Latina involvement in our research helped us develop interven-
tions that include social and cultural assets, which are essential elements that can 
make a difference in the elimination of health disparities in cervical cancer screen-
ing and in HPV prevention and control. For example, our research shows that 
Latinas respond well to narrative or storytelling in an educational campaign such as 
Tamale Lesson. Feeling transported into a storyline, being able to identify with the 
characters, and being emotionally impacted by the narrative [14] will go a long way 
to help eliminate cancer disparities. There is also a need to target a more diverse 
population (e.g., region and age), because cultural elements that resonate best with 
one Latino community may not resonate best for others, such as El Paso, Chicago, 
Watsonville, or Miami.
 Future Research
Greater engagement of Latinas in cervical cancer research may provide opportuni-
ties for eliminating this cancer health disparity. Working in partnership with Latino- 
driven clinics, community-based organizations, and volunteer agencies, our 
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researchers can commit to the translation of research into policies and public health 
initiatives that have the potential for making a difference at the community level. In 
order to engage Latinas in cervical cancer research, we can work with the commu-
nity and not only engage in research but also in its translation and dissemination, so 
it can reach our various communities more quickly. Es Tiempo and Tamale Lesson 
demonstrate ways in which we can provide a research environment that is more 
conducive to participation and engagement. Our campaigns and intervention pro-
grams model cultural strategies that can be used not just for cervical cancer but also 
for other diseases. Community-level interventions that are conceptualized, devel-
oped, and implemented using community-based participatory principles and that 
engage Latinas from the beginning of the research through the dissemination of 
data, have the potential of increasing Latina research engagement, helping to reduce 
cancer disparities and save lives.
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Chapter 18
Reaching Latinos Through Social Media 
and SMS for Smoking Cessation
Patricia Chalela, Alfred L. McAlister, Edgar Muñoz, Cliff Despres, 
David Akopian, Sahak Kaghyan, Andrea Fernandez, Pramod Sukumaran, 
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 Background
Smoking is the leading cause of premature, preventable death in the country, 
accounting for about 480,000 deaths per year, including 41,000 from secondhand 
smoke. This means that one in five deaths per year are due to cigarette smoking. 
Tobacco’s impact on cancer and heart/lung disease is well known [1, 2]. Of all 
smoking-related premature deaths, about 36% are due to cancer, 39% due to heart 
disease, and 24% due to lung disease. In general, mortality among smokers is three 
times higher than that among nonsmokers. On average, smokers die 10 years earlier 
than nonsmokers and cost billions of dollars to the nation, including $170 billion in 
direct medical care; more than $156 billion in lost productivity due to tobacco- 
related diseases and disability, of which $5.6 billion are due to secondhand smoke 
exposure [2–4].
In Texas, smoking kills more than 25,000 people per year and 3000 of those are 
in South Texas [5]. Almost 90% of adult smokers start smoking by age 18, and 
almost all (99%) of daily tobacco users try their first cigarette by age 26 [2]. Smoking 
prevalence is highest (23.5%) among US young adults aged 18–29 and even higher 
among those with less than a high school education (28.7%) and those living at or 
below the poverty level (25.5%) [1, 2, 6–8]. About 24% of Latinos aged 18–39 in 
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the program areas are current smokers [6]. Among young adult Latinos aged 
18–29  in the study areas, smoking rates are similar to those in this age group 
 nationally and the state overall [7]. Smoking rates are low among older Latinos in 
Texas, and notably higher among young adult Latino men than women.
For young adults, particularly among lower-income Latinos, mobile and social 
media are increasingly viable communication choices [9–12]. Nine out of ten Latino 
adults own a smartphone [9] and have a Facebook account, making Facebook the 
most frequently used social media platform in this group [10, 11]. Latino young 
adults are heavy users of mobile-only texting, apps, and Internet, and trends in use 
of mobile-only social media are rapidly rising among lower-income Latinos [11]. 
Smartphone social media interventions are an innovative, evidence-based, recom-
mended approach for promoting healthy behavior changes among young people 
[13–18].
Telephone counseling is a well-studied service with strong evidence of effective-
ness [19], particularly among younger smokers—among whom rates of cessation 
are more than doubled by telephone counseling [20–23]. However, telephone coun-
seling services reach only 1–2% of smokers annually and only 0.9% of Latinos [24, 
25]. Online and mobile applications have also been validated by research indicating 
similar levels of effect on cessation rates at much lower unit costs [13, 14, 26–28]. 
Smartphones have the potential to provide personalized smoking cessation support. 
Research has shown that support delivered via mobile phone text messaging dou-
bled rates of biochemically validated smoking cessation rates at 6 months over con-
trols (10.7% vs. 4.9%) [13]. More recent studies, including a Cochrane Review 
[26], concluded unambiguously that texting interventions can significantly increase 
odds of successful smoking cessation, with a pooled RR of 1.7, with some studies 
performing even better [26]. Motivational messages and behavior-change methods 
in phone or face-to-face smoking cessation support can be modified for delivery via 
text messaging combined with social media with content tailored to the quitter’s 
gender, ethnicity, and age [13, 27, 28]. Thus, support can be delivered where the 
person is located without them having to attend services, providing anonymity peo-
ple like, and it can be interactive, allowing participants to get extra help if needed 
[13, 27, 28]. Text messaging can also include embedded links to videos and other 
content to offer peer modeling for cessation behaviors [29]. Its usefulness can be 
further increased by adding connections to social media and obtaining user profiles 
to personalize messages to gender and marital and parental status [30]. Young smok-
ers, and particularly lower-income Spanish-speaking young adults for whom mobile 
devices are a primary point of Internet access, can be effectively served by text mes-
saging cessation program methodology [13, 14, 27–29, 31].
We present results from Quitxt, a text-messaging tobacco cessation program pro-
moted via social media to reach young adult Latinos aged 18–29 in South Texas, a 
marginalized population with low access to cessation services.
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 Methods
The Quitxt geographic area is South Texas, a 53,000-square-mile area that borders 
Mexico and contains 4.9 million people. This region includes the Rio Grande Valley, 
one of the most medically underserved and impoverished areas in the nation, char-
acterized by gaps in public health services, poor access to health care, significant 
environmental health concerns, and elevated chronic disease rates. About 72% of 
young adults in this region are Latino [32]. Of this region’s 38 counties, 25 are rural 
and 21 are Health Professional Shortage Areas. The region’s population is more 
than 30% uninsured, younger and less educated than the state average, and experi-
ences high poverty rates (23.6%). About 70% of residents in this region speak 
Spanish at home [32, 33].
 Program Development
Formative research took place during the first 6 months of the program, including 
review of existing evidence-based short message service (SMS) cessation services 
(i.e., smokefree.gov) and focus groups with young adults (English and Spanish) 
from San Antonio and the South Texas border area, to ensure that the program mes-
sage library was culturally and linguistically appropriate.
 Pretesting
With input from focus groups, we developed preliminary content and protocols for 
our intervention and constructed beta versions of all key promotional messages and 
protocol elements for pretesting. To identify any potential technical issue prior to 
program launch, we conducted beta testing of the program with young adult smok-
ers who enrolled in the program via Facebook, received texts, and responded to 
social media and video links embedded in texts.
 Process
To enroll in the program participants must be 18 years of age or older, current smok-
ers, willing to set a quit date within 14 days, and provide baseline data. The program 
responds to text codes with a sequence of interactive messages beginning with col-
lection of baseline data that includes basic demographics (i.e., age, ethnicity, gender), 
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number of cigarettes smoked per day, e-cigarette use, and binge drinking behavior. 
Participants are then prompted to choose either “quit tomorrow” or set a “quit date” 
within 2 weeks. Based on the selection, a specific message sequence follows. The 
program provides motivational messages, tips to manage cravings and difficult situ-
ations, and support 24/7. After their quit date, enrollees are also encouraged to text 
“help” if they are having difficulty avoiding cigarettes; when they text “help,” the 
system texts to ask if the help needed is due to “stress” or “mood,” and depending 
on their text reply, they are then sent either a prompt and link to breathing exercises 
(for stress) or a message with links to diverting, humorous videos (for mood). When 
enrollees fail to reply to texted questions at any point in the protocol, the system is 
designed to repeat the question twice before moving forward with the messaging 
sequence whether replies are received or not. Texts also include links to mobile 
webpages with short videos, music, and other fun and helpful content. These pages 
(Fig. 18.1) correspond to primary elements of the text messaging component: (1) 
reasons and motivation for quitting; (2) obtaining social support; (3) nicotine 
replacement therapy; (4) increasing physical activity; (5) breathing exercises for 
managing stress; (6) things to do instead of smoking; (7) avoiding relapse by talking 
yourself out of smoking; (8) predicting, planning, and practicing for difficult situa-
tions; and (9) avoiding binge drinking (Fig. 18.1). The messaging system was built 
and operated by the Software Communication and Navigation Systems Laboratory 
at the University of Texas at San Antonio.
Fig. 18.1 Screenshots of webpages. (Reproduced with permission of Quitxt/Institute for Health 
Promotion Research, UT Health San Antonio; © 2018 Quitxt/Institute for Health Promotion 
Research, UT Health San Antonio. All rights reserved)
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 Program Promotion
Program enrollment is promoted using mainly social media (i.e., Facebook, 
Instagram, Twitter), in addition to local mass media publicity and outreach at col-
leges, universities, trade schools, and other venues attended by young adults. The 
program uses social media ads with different themes (i.e., disgust, confidence in 
quitting) and styles (cowboy, metro, punk, graphic novel). Participants are prompted 
to click on the ad to visit the program homepage for more information or to text a 
code corresponding to the channel of recruitment (Fig. 18.2).
 Results and Discussion
This was not an experimental trial, and no data were collected to control for use of 
pharmacological or other behavioral interventions, but we did collect data on enroll-
ment, continuation of service utilization, and self-reported cessation status. 
Fig. 18.2 Sample of social media ads. (Reproduced with permission of Quitxt/Institute for Health 
Promotion Research, UT Health San Antonio; © 2018 Quitxt/Institute for Health Pro-motion 
Research, UT Health San Antonio. All rights reserved)
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Cessation success was assessed with a question texted from the service 222 days 
(7 months) following the enrollees’ selected quit dates that measured 24-h point 
prevalence abstinence (no smoking in the past day). This measure of cessation 
yields estimated cessation rates that are highly correlated with abstinence assessed 
for longer intervals, and the question can be answered more accurately than ques-
tions about smoking in the past week or month [34]. If this were a clinical trial, 
more extensive measures of cessation success would be warranted, but guidelines 
for research on cessation do not call for biochemical validation of self-reported 
abstinence in texted or other low-response demand measurement contexts [35].
A total of 798 enrollees are included in the present group assessment. Participants 
were recruited from October 2015 to January 2016, with 70% (555) texting in 
response to Facebook advertising, 14% (111) responding to publicity, 9% (70) 
responding to outreach, and 8% (62) responding to Twitter or Pandora Internet 
Radio. Facebook advertising with a theme of confidence and the metro/urban style 
was the most productive recruitment source and yielded enrollees at a cost of 
approximately $120 each.
Chi-square tests and multivariate analyses were used to determine the statistical 
significance of differences between program user groups. The mean age of Quitxt 
participants was 29.3, and 55% were below the age of 30 (Table 18.1). More men 
(57%) than women (43%) enrolled in the program, and 36% identified themselves 
as Hispanic or Latino. The mean number of cigarettes smoked per day was 11.5. 
Table 18.1 Quitxt participant characteristics and cessation rates
Characteristic Frequency (%) Cessation (%) OR
Age
≤29 398 (55.1) 23.9 Ref
≥30 324 (44.9) 23.5 0.90
Gender
Male 400 (56.5) 23.7 Ref
Female 308 (43.5) 24.7 1.05
Ethnicity
Hispanic/Latino 246 (35.5) 25.2 1.18
Non-Hispanic/Latino 446 (64.5) 24.4 Ref
Cigarettes smoked per day
<10 cigs/day 308 (46.4) 26.3 Ref
≥10 cigs/day 356 (53.6) 25.3 0.97
Use of e-Cigs (ever)
Yes 302 (49.6) 19.9 0.34∗
No 307 (50.4) 36.2 Ref
Binge drinking
Yes 385 (64.1) 23.4 0.37∗
No 216 (35.9) 37.5 Ref
∗p < 0.001
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Approximately half (302) of the 609 enrollees who replied to the question about 
e-cigarette use reported that they were using e-cigarettes to help reduce their ciga-
rette smoking. Among the 601 enrollees who texted a reply to the question about 
alcohol use, 64% (385) reported binge drinking (4 or more drinks on a single occa-
sion in the past month among women, 5 or more among men).
Regarding cessation rates, 21.4% of participants (171/798) reported 24-h point 
prevalence abstinence from smoking 7 months after their selected quit date. There 
were no significant differences in cessation rates between males and females, 
younger and older enrollees, or Latino enrollees and others. Participants who 
reported use of e-cigarettes were less likely to report smoking cessation at 7 months 
than those who did not report e-cigarette use: 20% (60/302) versus 36% (111/307; 
chi-square test, p < 0.001). Those who reported binge drinking were less likely to 
report smoking cessation at 7 months than those who did not report binge drinking: 
23% (90/385) versus 37% (81/216; chi-square test, p < 0.001).
Smoking cessation rates reported here are higher than the rates reported in previ-
ous studies of mobile cessation services [26], but are consistent with research on 
telephone counseling for young adults [20]. Measurement of point prevalence of 
24-h abstinence yields cessation rate estimates that are slightly higher than 
 longer- reported intervals of abstinence [34]. In addition, enrollees in this service 
were mostly light to moderate smokers (mean consumption 11.5 cigarettes per day at 
baseline), which may have contributed to the relatively high cessation rates achieved.
 Conclusion
Texting and mobile media services for smoking cessation can be effectively deliv-
ered to young adults in South Texas. Support can be delivered 24/7 wherever the 
person is located, providing the anonymity people like, and it can be interactive, 
allowing participants to obtain help when it is most needed. This is a highly scalable 
service, which makes mobile personalized smoking cessation advice/support an 
affordable approach to reach disadvantaged population groups, produce a public 
health impact, reduce health service costs, and reduce smoking-related health 
disparities.
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Chapter 19
The Need for a Holistic Approach 
to Prevent Reproductive Cancers Among 
US Latinas: The Potential Impact 




US Latina women are disproportionately affected by cervical cancer incidence 
compared to non-Latina white women. The cervical cancer incidence rate among 
US Latinas is estimated at 9.9/100,000 compared to the 7.7/100,000 estimated rate 
of non-Latina white women [1]. Compared to non-Latina white women, Latinas are 
less likely to screen for cervical cancer, more likely to get a cervical cancer diagno-
sis later in the course of the disease, and less likely to receive follow-up treatment 
services after a positive diagnosis, leading to increased risk of mortality [2].
Research suggests that a myriad of factors, operating at multiple levels of influ-
ence, negatively influence cervical cancer screening and receipt of follow-up treat-
ment in a timely fashion. Factors at the individual level include low knowledge 
about the causes of cervical cancer and forms of prevention, screening, and treat-
ment [3] and demographic factors such as low acculturation, foreign birth, and low 
income and educational attainment [4, 5]. Other factors operating at the individual 
level include adherence to Latino cultural beliefs and norms such as dignity, respect, 
fatalism, and traditional gender norms [6]. At the structural level, factors such as 
lack of access to health care services and logistical barriers to accessing services 
such as lack of transportation and childcare have been shown to affect screening and 
receipt of follow-up treatment [7, 8].
To promote cervical cancer screening and treatment, a literature review was con-
ducted on interventions; several gaps were identified, including few interventions 
uniquely targeting Latinas and a dearth of interventions informed by theories explicating 
the manner in which culture may affect screening and treatment, such as the PEN-3 
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model of cultural influence [9]. Specifically, most cervical cancer screening promotion 
interventions have been informed by health–behavior change theories prominent in psy-
chology, such as the Health Belief Model, Theory of Reasoned Action, Transtheoretical 
Model, Social Learning Theory, Social Cognitive Theory, and Social Influence Theory. 
The literature review clearly identified a need for interventions that simultaneously tar-
get factors operating at multiple levels of influence and for a broadening of focus beyond 
cancer screening as end outcomes to include improvements in sexual and reproductive 
health, broadly speaking [9]. Using a theoretical lens accounting for the complex inter-
play of factors affecting human behavior, a closer look at research findings and interven-
tion efforts undertaken in other domains of Latino sexual and reproductive health may 
promote the development of interventions targeting multiple levels of influence, includ-
ing structural-level factors beyond individual-level precursors of behavior change.
A closer look at disparities in sexual and reproductive health among Latinos 
indicates that Latinos experience negative health outcomes in multiple domains of 
sexual and reproductive health, not only cervical cancer. For example, Latinas are 
less likely to screen for breast cancer and are at increased risk of mortality com-
pared to non-Latina white women [10]. Furthermore, the rate of sexually transmit-
ted infections (STIs) including HIV and unintended teen pregnancies among Latinos 
is double the rate of non-Latino whites [1, 2, 11]. These statistics underscore the 
need to develop and test interventions aimed at targeting root causes of disparities 
in sexual and reproductive health.
We argue that there is the need to conduct research informed by theories which con-
ceptualize the individual as nested in complex systems, to further understand the manner 
in which contextual and individual-level factors interact and influence adoption of sex-
ual and reproductive health preventative behaviors across domains. Culture is a powerful 
system that influences human behavior. According to the socioecological model by 
Bronfenbrenner [12], culture is a macrosystem in which individuals are nested; it can be 
conceptualized as institutional and familial socialization practices that transmit values, 
norms, and behavioral expectations through generations. Past research has examined the 
effect of culture on various domains of sexual and reproductive health among Latinos. 
However, when considering how culture may influence various systems in which the 
individual is embedded and how it may ultimately lead to individual differences in sex-
ual and reproductive health decision-making, there is a need to operationalize it and its 
effects in a more complex way. Here we present findings from two separate studies that 
highlight the influence of two important cultural factors operating at the macro and 
micro levels of influence: embarrassment and shame ascribed to sexuality (macro level) 
and communication about sexuality among members of a social network (micro level).
 Study 1
The purpose of the first study was to understand the influence of communication 
about sexuality in adoption of the HPV vaccine—a three-dose vaccine recommended 
for children and pre-adolescents between the ages of 11 and 12. Catch-up vaccina-
tion is recommended for adolescents who were not vaccinated at the recommended 
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age. Our study sample consisted of 65 mother–daughter dyads who self-identified as 
Latino. We purposefully sampled 50% of daughters who had received at least one 
dose of the HPV vaccine and employed a mixed methods qualitative dominant 
sequential design.
 Materials, Procedure, and Approach to Analysis
Participants were recruited from a variety of venues including churches, schools, and 
supermarkets. Mothers and daughters were interviewed separately. Mother was asked 
to sign an informed consent form for her and daughter, and daughter was assented 
separately. Participants answered open-ended questions as part of the qualitative por-
tion of the study followed by a brief demographic survey, which also assessed whether 
mother had engaged in the discussions about sexuality with daughter and the specific 
sexuality-related topics discussed. We content analyzed open-ended responses, com-
puted chi-square tests of association, and performed a logistic regression analysis. We 
computed a chi-square test to assess the association between having engaged in dis-
cussions about sexuality with daughter and vaccination uptake. We computed a step-
wise blocked logistic regression to understand which sexuality-related topics were 
significantly associated with vaccination uptake. In the first block of the regression 
equation, we entered the daughters’ age. In the second block we entered specific sex-
uality-related topics using the stepwise procedure. Our goal was to assess which of 
these variables would emerge as significantly associated with vaccination uptake.
 Results
A larger proportion of mothers who had vaccinated their daughters (64%) reported to 
have engaged in discussions about sexuality with daughter compared to mothers who 
had not vaccinated (36%) (χ2 = 5.38, p = 0.02). Content analysis of the responses 
suggested that the content of sexuality-related discussions differed between those 
who had and had not vaccinated. Specifically, the content of discussions between 
mothers and their daughters who had been vaccinated seemed to encompass a variety 
of topics related to sexual health including anatomy, puberty, appropriate timing of 
initiation of sexual relations, and the importance of engaging in behaviors to protect 
oneself against STIs. In contrast, the majority of mothers of daughters who had not 
been vaccinated conveyed feeling uncomfortable and embarrassed about speaking 
with daughter about sexual health, and the content of their communication was 
value-based including admonishing daughter about the inappropriateness of initiat-
ing sexual relations before marriage. Table 19.1 presents the results of the last step of 
the logistic regression analysis. Daughters’ age emerged as a significant predictor of 
uptake; the older the daughter the more likely she is to be vaccinated. Furthermore, 
engaging in discussions about birth control emerged as significantly associated with 
uptake, predicting 40% of the variance in vaccination uptake.
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 Study 2
The purpose of the second study was to understand the sociocultural factors associ-
ated with attitudes toward cancer screening in a sample of US Latinas. A cross- 
sectional survey was administered to a sample of 85 US Latinas as part of a larger 
study designed to test the effect of a community-based, participatory, sexual-health 
intervention delivered by community health workers.
 Materials, Procedure, and Approach to Analysis
Community health workers (CHWs) recruited participants in locations where Latinos 
congregate regularly (e.g., supermarkets and churches). To be eligible to participate, 
participants had to be 18 years old and self-identify as Latina. Participants who volun-
teered to participate were asked to answer a survey asking demographic questions 
including age, household income, and whether they had ever had a Pap smear test and/
or mammogram if eligible. The survey also included questions assessing negative atti-
tudes toward cancer screening and sociocultural constructs such as shame and embar-
rassment ascribed to sexuality. To understand whether sociocultural factors such as 
shame and embarrassment ascribed to sexuality would emerge as significant predictors 
of attitudes toward cancer screening, we computed a hierarchical multivariate linear 
regression analysis. In the first block of the  equation we entered demographic variables 
including age, income, and whether the participant had ever had a Pap smear test and/
or mammogram using the enter procedure. In the second block of the regression equa-
tion, we entered sociocultural variables using the stepwise procedure.
 Results
Table 19.2 presents the results of the last step of the regression model. The sociocul-
tural variable shame and embarrassment ascribed to sexuality was significantly 
associated with negative attitudes toward cancer screening above and beyond demo-
graphic variables typically associated with access to health care and predicted an 
additional 30% of variability in negative attitudes toward cancer screening.
Table 19.1 Factors associated with vaccination uptake
Variable B SE OR 95% CI
Wald
statistic p
Daughter’s age 0.50 0.21 1.65 1.09, 2.50 5.68 0.01
Talk birth control 1.71 0.77 5.56 1.21, 25.50 4.87 0.02
Note: Data is for mothers (N = 65). Talk birth control = extent to which mothers reported having 
discussed birth control methods with daughters. Talking about birth control with daughters alone 
predicted 40% of the variance in vaccination uptake
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 Discussion
Operating at multiple levels of influence, culture is a key factor to be considered in 
order to move the field forward and reduce Latino health disparities in sexual and 
reproductive health broadly speaking. Our argument is put forth in light of several 
factors. First, the majority of the prominent behavior change theories which have 
dominated health promotion and intervention research rest on the assumption that 
the most powerful determinants of behavior are personally derived attitudes and 
cognitions about the health behavior in question, such as perceived benefits and 
consequences of the behavior [13]. This assumption is questionable as research with 
individuals who conceptualize the self as an extension of the in-group (i.e., Latinos) 
compared with individuals who conceptualize the self as separate from others (i.e., 
non-Latino whites) [14] suggests that the function of behavior is to fulfill social 
obligations [15]; and self-efficacy is more the product of support from important 
members of the social network than volitional control [16]. Second, sexual and 
reproductive health behaviors around the world are heavily influenced by societal 
level norms and expectations; consequently, developing interventions that target 
multiple levels of influence with culture considered as a central piece could yield 
interventions that target root causes of disparities and yield sustainable behav-
ior change.
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Chapter 20
Critical Steps for Engaging Hispanics 
in Cancer Research: Building Capacity 




The disproportionately lower number of certain subpopulations participating in 
clinical and prevention research has a significant impact on the representativeness 
of scientific outcomes and results in social and clinical injustices [1]. A sequential 
set of community-based studies were conducted to engage diverse medically under-
served populations in biospecimen donation for cancer genomic research [2, 3]. 
This chapter is organized around three critical steps of community engagement that 
are relevant to participatory research as applied to novel and formative efforts 
focused on biospecimen science that were used in the Hoy y Mañana (translated to 
Today and Tomorrow) study. Specifically, these studies developed and tested 
community- based interventions to identify influential factors regarding participa-
tion in biospecimen donation to a biorepository at a cancer center in upstate 
New  York for future cancer research from a Northeast Hispanic, predominantly 
Puerto Rican population [4].
 Three Critical Steps for Engaging Hispanics in Cancer 
Research
Community engagement is an essential component to reaching and including 
diverse and\or hard-to-reach populations in biomedical research with a focus on 
reducing health disparities and improving individual health. There are three over-
arching steps that can be applied when working at the community level that  facilitate 
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engaged approaches to research and enhance the relevance of research as an oppor-
tunity to build capacity and increase health equity. The following steps are not 
exclusive to biospecimen research studies but can be applied to a variety of public 
health issues and research topics targeting efforts at a community level.
 Step 1: Know the Community
The first step is to know the community. Knowing the community requires an in- 
depth understanding of community members and stakeholders, barriers and assets, 
population demographics, and community context. The Community Development 
Model for Public Health Applications is a comprehensive model that integrates the 
factors essential to knowing a community as the primary unit of analysis and can be 
used as a framework to guide community-engaged research efforts [5]. Additionally, 
Community-Based Participatory Research (CBPR) principles and methods also 
serve as a foundation for collaborative approaches to research that enhance and sup-
port community engagement research activities across a variety of topics and 
disciplines.
Involving the community at the earliest stages of the research process can better 
ensure acceptability and relevance to the population of interest. The Hoy y Mañana 
(HyM) study focused on the opportunity to build capacity with preexisting com-
munity partners around the topic of biospecimen donation for future cancer research 
[3]. Capacity building is a key component of the CBPR principles that values skill 
building and co-learning [6]. Community partners played an integral role in linking 
the pilot research project to the community and vice versa. Transparent and consis-
tent communication was an important factor throughout the process and contributed 
to an effective partnership process in engaging the community and assessing feasi-
bility to conduct community-based cancer research involving the collection of 
biospecimens.
Formative research including structured in-person interviews and focus groups 
were completed with Hispanic community leaders, staff from the biorepository at 
the cancer center, and Hispanic participants from the community. Table 20.1 pro-
vides examples of the qualitative methods employed in the HyM study to illustrate 
the process used to gain the community perspective regarding biospecimen dona-
tion for cancer research and how the data informed each step of the research. The 
key informant interviews with Hispanic community leaders were part of the first 
level of community data collection. These individuals are best described as com-
munity leaders (e.g., pastors, civic leaders, and clinicians who practice in the com-
munity). They are trusted individuals who often assume an informal gatekeeper role 
in the community because of their established relationships with members of the 
community at large. Knowledge of the community facilitates an understanding of 
who these respected and trusted leaders are and the potential impact they can have 
in linking the community to collaborative research opportunities. Rodriguez et al. 
describe the methods and community-engaged research process in detail as well as 
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the resultant findings from a predominantly Puerto Rican population with regard to 
their self-reported awareness and interest in biospecimen donation for cancer 
research [3].
 Step 2: Know the Goal of Engagement Activities
Community-engaged research efforts often require understanding and commitment 
to an iterative process; however, the goal of engagement activities should be trans-
parent and mutually agreed upon prior to research implementation to ensure accep-
tance and commitment to the process. In the HyM study, the objective of this first 
step was to better understand the community’s awareness, knowledge, attitudes, and 
interest in biospecimen donation for cancer research. The results from the formative 
research were shared with stakeholders including the Community Advisory Board 
(CAB) members during a partner education component of the study to finalize con-
cepts to be covered in the biospecimen science education program. Dissemination 
activities require thoughtful planning, because there may be different audiences 
(e.g., CAB and community members) and time points within the research process 
that require their own feedback loops for sharing information as it is developed and 
analyzed. Likewise, how information is developed and analyzed requires 
Table 20.1 Summary of formative research methods used in the Hoy y Mañana study
Objective n Method Findings (examples)







How are specimens used?
Never asked to donate
Integration/application:
These findings informed focus group 
topics with broader community
Gain perspective of 





Identified staffing needs to ensure 
community competence
Integration/application:
Informed protocol for collecting 
samples in the community to maintain 
scientific rigor while enhancing 
community access to participation in 
biospecimen donation
Identify barriers and assets in 
recruiting diverse populations 
to biospecimen donation 
(e.g., Hispanic community)





Interest in research opportunities
Need for translated materials and 
consent process
Integration/application:
Disseminated results to community 
advisors and informed the design of a 
community-based pilot
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 consideration of the goal and transparency in why and how specific partners are 
included throughout the research process.
The HyM study involved multiple phases that fed into each other and led to the 
testing of a mobile lab unit that could be used to collect and process biospecimen 
donations from willing community members at onsite events in the community. 
Each phase of the research included specific activities and processes that were 
meant to assess, deliver, or support the intended research goals of the study 
(Fig. 20.1).
 Step 3: Design Activities Using Best Practice Strategies
As with any type of research, there is an emphasis on scientific rigor and the process 
applied to draw conclusions from study findings. Community-based research will 
often vary with respect to the level of community partner involvement, and this is 
unique to each collaboration; however, in studies that apply CBPR methodology, 
there are accepted and best practice strategies that can be used to ensure scientific 
rigor while addressing the issues most relevant to the community [6]. Best practice 
strategies should be applied at all phases of the research process and considered as 
an opportunity to further integrate community partners as citizen scientists who are 
the rightful experts with respect to the communities they live in.
Fig. 20.1 Study schematic describing examples during each phase of the research process: (1) 
Formative phase: assess awareness; (2) development phase: create a culturally appropriate bio-
specimen science education program to deliver in the community; (3) implementation: test the 
education program and feasibility of mobile lab unit to facilitate community participation in bio-
specimen donation for cancer research
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The HyM study applied best practice strategies throughout each component of 
the research process from study design to public dissemination (Table 20.2). The 
CBPR principles were followed from the onset of the grant writing process and 
applied to all steps of the educational tool development, implementation, and dis-
semination processes [7]. Ultimately the application of a CBPR approach served to 
broker communication among scientists and community stakeholders and members 
throughout the biospecimen science co-learning process. An important implication 
included a detailed understanding of methods for introducing biospecimen science 
to diverse communities such as the Hispanic community engaged in the HyM study.
 Discussion and Lessons Learned
Hispanics represent a significant proportion of the diverse minority populations that 
make up the United States and are underrepresented in biomedical research studies 
and even more so in biospecimen banks [8, 9]. A growing number of cancer research 
studies include the collection of biospecimens as part of the research participation 
process. It is important that this rapidly evolving field of cancer research as it relates 
to precision medicine and/or immunotherapy not contribute to further gaps and dis-
parities across the cancer care and research spectrum. The HyM study sought to 
engage and partner with an underserved Hispanic community to (1) understand 
their awareness and interest in biospecimen science (2) develop a community-based 
education program to increase awareness and facilitate informed decision-making 
with regard to biospecimen donation and (3) test the feasibility of community- 
engaged culturally appropriate approaches in recruiting diverse and underserved 
Table 20.2 Application of best practices in the Hoy y Mañana (HyM) study
HyM study 
component Best practice strategies applied
Study design Community-Based Participatory Research (CBPR) Approach




Culture and literacy All program materials were translated to Spanish to meet community 
language needs and preferences
An Audience Response System was used to engage the community 




Revisions were made after multiple pilot programs
Spanish translation and verification process
Process measures were collected on efficacy of the community pilot 
including implementation of tools and the mobile unit
Public 
dissemination
Hispanic newspapers and radio
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community participants to biospecimen donation for cancer research using a mobile 
lab unit for onsite collection and processing of biospecimen donations.
Most Hispanic groups do not have a historical context of mistrust with regard to 
the medical community. Other studies including Hispanics have also found that lack 
of awareness regarding biospecimen science and/or not having been asked to par-
ticipate in cancer research are the primary reasons cited by this population regarding 
their lack of participation in biospecimen donation [2, 4, 9]. Cancer research oppor-
tunities inclusive of Hispanics are critical to understand the molecular differences in 
cancer cells compared to populations that have been better studied and represented 
in research [10]. Community-engaged studies have shown that several Hispanic 
groups indicate a willingness to donate biospecimens for cancer research and also 
support the use of trained non-medical staff to obtain consent for the biospecimen 
request [2, 11]. Engaging Hispanic communities in a culturally appropriate manner 
at the very beginning is necessary and essential to the collection of biospecimens for 
cancer research. This research requires a commitment to collaboration across disci-
plines and values community engagement as part of the research process.
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Chapter 21
Emerging Policies in US Health Care
Amelie G. Ramirez and Edward J. Trapido
Many of the issues discussed at the conference, such as testing, clinical product 
rules, drug approvals, and funding for research, clearly touch the arena of public 
policy. At the close of the conference, Dr. Ruben Mesa, Director of the Mays Cancer 
Center at UT Health San Antonio, chaired a panel discussion on emerging policies 
in US health care. The diverse, expert panel offered different perspectives on emerg-
ing health policy. The panel included:
• Congressman Joaquin Castro, Representative from the 20th Congressional 
District in Bexar County, Texas
• Dr. Esteban López, Chief Medical Officer, Clinical Strategy and Innovation at 
Blue Cross and Blue Shield of Texas
• Dr. Robert Croyle, Director, Division of Cancer Control and Population Sciences 
at the National Cancer Institute
• Dr. Elena Rios, President and CEO of the National Hispanic Medical Association
 Congressman Joaquin Castro, Representative from the 20th 
Congressional District in Bexar County, Texas
Congressman Castro began the session by stating that cancer and heart disease are 
the two diseases that claim the most lives of Latino Americans. In Texas, that prob-
lem is especially pernicious. Congressman Castro pointed out that he is very much 
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involved in public policy that supports the research that many of the researchers at 
the conference are doing—research that will help save the lives, not only of many 
Latinos, but of all Americans. His main message to researchers was to advocate for 
their own work and educate policy makers in Congress of its value in helping people 
and saving lives. In doing so, he suggested that researchers should be persistent 
because lawmakers are juggling many issues in addition to healthcare and may need 
reminding to refocus their attention. He reminded the audience that there was an 
infusion of new money earmarked for cancer research, with Vice President Biden’s 
MoonShot Initiative funded through the 21st Century Cures Act, but warned that 
National Cancer Institute would still need to cut their operating budget and deal 
with increasing requests for research funding. Congressman Castro has been speak-
ing out about the need to increase funding for cancer research and not back away 
from that commitment.
Ruben Mesa, Director, Mays Cancer Center at UT Health San Antonio asked, 
“What opportunities are there for being the voice in getting important policies 
implemented related to issues regarding cancer in Latinos?”
Congressman Castro responded that there is an incredible opportunity for 
researchers and community leaders and many members of Congress and state legis-
latures to make an impact in funding and policies passed by legislative bodies. For 
example, the Tri-Caucus, which comprises the Congressional Asian Pacific 
American Caucus (CAPAC), the Congressional Black Caucus (CBC), and the 
Congressional Hispanic Caucus (CHC), led legislation efforts in previous years that 
would improve cancer funding and cancer research among minority groups. But 
that legislation did not move in Congress the way it was expected. Therefore, there 
is a great need for advocates to come to Washington and make the case that this is 
important work.
We must also protect the Affordable Care Act because one part of it, the indi-
vidual mandate, has been recently removed. Latinos were the biggest beneficiaries 
of the Affordable Care Act; more Latinos than any other group were able to receive 
insurance coverage because of that act, so researchers and community members 
must make sure that it is not eroded any more. One other important issue that must 
be addressed is the environmental quality of many Latino communities. This is 
deeply challenging in places like Texas. For example, the environmental agency that 
regulates companies in Texas is the Texas Commission on Environmental Quality 
(TCEQ). It is charged with enforcing air, water, and waste management violations. 
Over a multi-year period, the state agency found only a fraction of the air and water 
violations from different polluters. As a consequence, there are huge Latino com-
munities that are exposed to damaging environmental factors because of weak 
enforcement in certain states like Texas. This is important when one considers the 
health effects of the environment on cancer and other illnesses. Thus, everyone must 
be mindful, not only of Congress and the federal government, but also of state and 
local jurisdictions.
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 Dr. Esteban López, Chief Medical Officer, Clinical Strategy 
and Innovation at Blue Cross and Blue Shield of Texas
Dr. Lopez spoke about Understanding Drivers and Barriers for Latinos in Cancer 
Care; he began by addressing the difference between “Equal and Equitable.” While 
physicians may try to treat patients in an equal manner and offer equal care, equal 
care is not necessarily equitable, because patients face different challenges to 
receive the care that they need. Blue Cross wants to not only give patients access to 
care but also address social indicators of health that prevent patients from receiving 
their highest potential level of care.
Addressing cancer disparities among Latinos first requires knowledge about 
what health challenges Latinos face. In addition to using published research, Blue 
Cross is using online research to see how Latinos are communicating online. Blue 
Cross partnered with a vendor who mines and structures qualitative data; examines 
who is talking, where users are talking and what they are talking about in reference 
to cancer; and determines underlying drivers and barriers. Blue Cross wants to 
know what the barriers and attitudes are, so they can understand in real time what 
their Latino members are experiencing. Using breast cancer as an example, he 
described the following strategies for offering culturally relevant care:
• There is a crucial need for early detection. Breast cancer is the most common 
cancer in Hispanic women. As a population, Hispanic women are reactive to 
care; they seek medical care when they are sick but do not necessarily go to a 
physician to seek preventative care. To encourage proactive screening, there is a 
need to go where they are, such as their places of business, with mobile mam-
mography; and we must find other methods to ensure screening as we continue 
to educate the Latino population.
• Respect cultural differences. Latinos online show less knowledge about breast 
cancer and express the competing priorities of job and family in relation to get-
ting mammograms. In terms of Latino care, we must include the whole concept 
of family and community. We have a call to action to design dedicated strategies, 
interventions, and activations that tackle the specific unmet needs and cultural 
nuances of Hispanic breast cancer patients and their caregivers.
• Target both patients and caregivers, including male caregivers. Latinos tend to 
be collectivistic, so the caregivers are influential in the lives of patients with can-
cer. The goal is to create a two-pronged approach that involves and educates the 
caregiver as well as the patient.
• Target primary care physicians. Primary care physicians (PCPs) can be the num-
ber one driver or barrier for proper cancer care and adherence to treatment. 
 Latinos tend to be deferential to their physician and may not question a treatment 
that will be given. Because a small percentage of physicians are Latinos, we must 
empower non-Latino physician partners with cultural competence to enhance 
their relationship with breast cancer patients and their caregivers.
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• Foster advocacy within the community. Data from social media and chat rooms 
show that while there are many conversations happening online, there is a lack of 
advocacy for Latino cancer survivors. There is a need to involve Latino cancer 
survivors in advocacy, sharing the issues they faced. The powerful voice of sur-
vivors can be leveraged to motivate women to seek breast cancer screening.
• Leverage online channels. Many Latinos actively use social media and smart 
phones, and they go to online communities for information about cancer care. 
So, health care systems must give out information where Latinos are going first. 
We must also look beyond Facebook and Twitter to online chat communities and 
message boards. Because the Internet is a powerful channel for Hispanics to find 
information and support, there is a call to action to think holistically and include 
online as another channel along the path to treatment.
• Protect patients through local policy. Physicians, health care systems and insur-
ance companies must step up to advocate for the communities they serve. For 
example, Blue Cross and Blue Shield of Texas helped to raise the minimum age 
to buy tobacco to 21 in Bexar County and San Antonio. While the Latino health 
care population is younger and often has good health habits, once Latinos are 
treated for a chronic condition, unfortunately they often experience higher inci-
dence of complication and death. And so, advocacy is important.
 Dr. Robert Croyle, Director, Division of Cancer Control 
and Population Sciences at the National Cancer Institute
The field of health disparities research is evolving. Ten years ago, much of the dis-
parity research was pigeon-holed into work on documenting gaps in access to care. 
It was important to document, understand, and explain health disparities, but the 
next generation of health disparity researchers is now focusing on disparities across 
the board, regardless of which community is being studied. That is, the science has 
moved from documenting what is wrong to raising aspirations and goals to what is 
possible. What is really compelling and exciting about this meeting is how much 
solution-focused research is now being done including interventions that are work-
ing, risk reductions that are happening, solutions around the uninsured and distance 
to care, use of technology, culturally appropriate care, building bridges between 
specialty and oncology care and primary care, and the expansion of navigation.
At NCI we need feedback, criticism, and honest talk. We need to know about 
many of the great innovations that occur at the local level in your communities, so 
that we can scale them up at a national level. So, in terms of raising our aspirations, 
one of the ways we do that is through the tremendous research infrastructure that the 
NCI supports along with NIH. This depends upon an adequate budget, and so at 
NCI, we feel fortunate because we have been told that the very last bipartisan area 
of agreement on the Hill is NIH. One of the ways we try to raise the bar across the 
whole span of basic, clinical, and population research in cancer is recognizing that 
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all domains of this research need to be revolutionized to better inform Latino health. 
At this meeting, we heard about basic science and the acquisition of biospecimens, 
genomics, molecular epidemiology, and the need for the representation of biologi-
cal specimens from all communities—without which you can make erroneous infer-
ences and conclusions.
Clinical research still has a long way to go in terms of underrepresentation of 
Latinos in cancer clinical trials. One of the barriers to Latino accrual is the use of 
comorbidities, such as hypertension and obesity, as exclusion criteria for enrollment 
in clinical trials. So, one question we are asking in our clinical research community 
and the NCI is: Are all these exclusion criteria really necessary in terms of eligibil-
ity to clinical trial enrollment? Some of these exclusion criteria are not even neces-
sarily evidence-based. Researchers are being very cautious, trying to understand 
and reduce toxicity and side effects. But if you are excluding a very large proportion 
of our population for not a very thorough and sound evidence-based reason, we 
need to revisit it.
NCI has a large research infrastructure; we are proud of the 69 NCI-designated 
cancer centers around the country, but they do not reach all parts of the country yet. 
As a federal agency that funds grants, NCI has been raising the criteria, expecta-
tions, and standards to fund these cancer centers over the past several years. For 
example, community outreach engagement in our cancer centers is a requirement 
that has been enhanced in our funding guidelines. That has had a great spillover 
effect; many cancer centers now have associate directors of community outreach 
engagement. NCI will continue this strategy by adjusting criteria every year. More 
recently, NCI asked cancer centers to clearly define their population catchment area. 
Have some ownership, have some engagement, and describe who you think you are 
serving in your community. It is no longer acceptable for cancer centers to say, 
“these are the people in trials, because these are the people who can afford to travel, 
who can come to our center and stay here in a hotel for a week.” So NCI has raised 
the bar in expectations and provided the additional money to do that. It is one thing 
to change the rules, but we want to avoid unfunded mandates as well.
Another important role that NCI plays is through its cancer registry systems, 
which have been discussed throughout the conference. The way NCI tries to vali-
date its cancer statistics is by branching cancer registry data and linking it to census 
data. The census is where people self-report their race and ethnicity, so it is viewed 
as the gold standard. Data linkage is really of key importance, and without a good 
census, we cannot track progress in cancer at a national level. The census is not only 
the key denominator to cancer but also for other diseases that reach across the coun-
try. So we are proud of our cancer registry system, our surveillance system in the 
United States. This is our national report card. We are going to be finishing our next 
annual report on the nature of cancer shortly, focusing on prostate cancer. This is a 
data quality issue, so if you want to support cancer research, support a good census. 
And that means not including elements that deter people from participating.
Finally, there is the issue of cultural competence of non-Latino physicians in 
Latino communities. One of the most common complaints we still receive from 
cancer patients is poor communication. “I don’t understand my treatment.” “I don’t 
21 Emerging Policies in US Health Care
218
understand the diagnosis.” “I don’t understand the prospects for recurrence.” 
“What’s going to happen to me next?” “What are my side effects?” In response to 
this, NCI has been trying to contribute to a solution in a small way by translating the 
patient-reported outcome system we use for clinical trials into 14 different lan-
guages. So the measures we use in our research have to be available in Spanish 
language and must be carefully done and carefully validated.
 Dr. Elena Rios, President and CEO of the National Hispanic 
Medical Association
Dr. Rios spoke about cancer and Hispanic Advocacy. There are two important trends 
from current health policy issues that impact all of us. The first is that the size of the 
Latino population is growing; in 2015, 1  in 5 people in the United States were 
Hispanic, and by 2045, the ratio is projected to be 1 in 4 [1]. This growing demo-
graphic has the potential to use the power of the vote to shape public policy. The 
second trend is that the uninsured rate for Hispanics declined significantly after the 
Affordable Care Act (ACA)—the most transformative law in healthcare policy 
since Medicare for the elderly and Medicaid for the poor. The ACA gave Hispanic 
communities access to doctors, clinics, and hospitals with less financial burden, 
because insurance pays not only for medical and hospital care, but also medications. 
However, even though Hispanics have gained the most in terms of having more 
insurance, they still face many disparities. Thus, health care policy, for Hispanics, is 
important.
 Congressional Legislation in the 115th Congress (January 3, 
2017 to January 3, 2019)
The National Hispanic Medical Association is interested in advocacy; it is co-chair 
for the National Hispanic Leadership Agenda that includes the top 40 Hispanic 
organizations in the country, and it works with other coalitions for minority health. 
Some of the most important issues that need advocacy include:
Health Insurance Reform The Affordable Care Act (ACA) is the law of the land. 
Even though the individual mandate has been taken away, there are still essential 
benefits, consumer protections, and state marketplaces where competition drives the 
prices down. An important advocate, the Congressional Tri-Caucus, has influenced 
health care policy by promoting the need to address disparities in health care among 
minorities; they have introduced legislation every year for the last decade and have 
supported major parts of the ACA.
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Research The 21st Century Cures Act provides funding to the FDA and NIH for 
expediting the development and delivery of new medical advances to patients who 
have hard to treat diseases such as cancer and Alzheimer’s. The NIH earmarked 
funding from this bill for a program known as All of Us, which includes three initia-
tives—Beau Biden Cancer Moonshot Initiative, Brain Initiative, and Precision 
Medicine Initiative. The intent is to involve a diverse cohort of one million volun-
teers to provide personal health data and biological specimens for research. The 
NHMA is a national partner with the All of Us Research program and is interested 
in finding ways to involve the next generation of doctors in sharing the idea that 
more patients should become involved in clinical trials. Finally, there is the second 
study period of the Study of Latinos—a large NIH community-based, longitudinal, 
cohort study of Hispanics/Latinos in the United States.
CDC Cancer Prevention Programs Advocacy groups and coalitions, such as One 
Voice Against Cancer (OVAC), actively lobby Congress to appropriate funds to the 
Centers for Disease Control to conduct or support cancer research. The CDC 
Division of Cancer Prevention and Control has many cancer prevention programs 
that offer grant money including National Comprehensive Cancer Control Program, 
National Program of Cancer Registries, National Breast and Cervical Cancer Early 
Detection Program, Colorectal Cancer Control Program, National Skin cancer 
Prevention Education Program, Prostate Cancer awareness Campaign, Ovarian 
Cancer Control Initiative, Gynecologic Cancer and education and Awareness 
(Johanna’s Law), and Cancer Survivorship Resource Center.
Health Workforce Programs: HRSA and Department of Education Health 
workforce programs of the Health Resources and Services Administration (HRSA) 
and Department of Education include funding for diversity recruitment and training, 
faculty development, and scholarships. On the House side, the Health and Education 
Workforce agreed with NHMA Summit recommendations for President Obama’s 
STEM initiative, a major goal of which is to increase the diversity of underrepre-
sented groups within science, technology, and mathematics. Also, it is time for reau-
thorization of the Higher Education Act (HEA). The NHMA has worked for years 
with Congressional offices to reauthorize HEA, which is a federal aid program 
administered by the Department of Education that supports students seeking post- 
secondary education. The hope is that there will be more opportunities for students 
in high school and college to become students for medical, nursing and dental 
schools, or to become STEM researchers of the future. Congressmen Raul Ruiz 
(D-CA) and Ruben Hinojosa (D-TX) have introduced bills to give more flexibility 
to Hispanic-serving institutions so that they may use their HEA grant funds for 
mentoring and advising students to enroll in medical and graduate programs that 
prepare students for health care occupations. As a result, more Hispanic students 
may enter the pipeline for health care professions, because their eyes will be open 
to the opportunity.
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Minority Health: HEAA 2018 in Progress A large coalition has formed around 
Minority Health that is broader in scope than ethnic minorities; it also includes the 
disabled, women’s health, and the LGBT communities. They are all working on a 
bill with the Tri-Caucus, which is called the Health Equity and Education Act 
(HEAA). This comprehensive bill aims to improve the quality of health care and 
eliminate disparities. It will address culturally and linguistically appropriate and 
value-based health care, as well as promote research and data collection on health 
needs and outcomes in diverse communities.
 Health Policy Trends
There is polarization in Congress with more people at the extremes, so we must find 
a way to bridge the gap in order to make progress in addressing health care issues 
and disparities. For example, Democrats are promoting Medicare for All, a univer-
sal health insurance that is paid for with taxes; Republicans are proposing block 
grants, a set amount of money given to states to administer Medicaid that would not 
be responsive to changes in demand. However, there is bipartisan support for some 
insurance reforms such as reinsurance programs and subsidies including cost- saving 
reductions (CSRs) that enable insurance companies to help the poor, lower income 
and middle class in the United States. A new low premium/high deductible insur-
ance product, the copper plan, is being proposed to offer more affordable insurance. 
There is also bipartisan support for Medicare Advantage, which is now 30% of the 
Medicare population. It was designed originally to offer a comprehensive insurance 
product with medication coverage before Part D was available.
Another health policy trend at both the federal and state level is the recognition 
that where people are located and the conditions in which they live influences their 
health risks and outcomes. Thus, there is a focus on social determinants of health 
such as poverty and income, housing, food security, transportation, financial liter-
acy, education, employment, behavioral health, homelessness, and being in or hav-
ing been in prison. In Massachusetts, which has been the leader in health reform and 
health insurance, measures of the social determinants of health are now being incor-
porated into research, state programs, Medicaid, Medicare, and the marketplace.
 Health Care Trends: Medicaid
Medicaid is now the largest insurance with a new focus on flexibility at a state level. 
There is a push from the Trump administration to allow states to impose work 
requirements on Medicaid recipients. Ostensibly, the intent is to make recipients 
lead healthier, more productive lives. This is not the first time that work require-
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ments have been part of policy. At the end of the Clinton administration, work 
requirements were imposed during welfare reform as an incentive to find jobs. One 
caveat is that there is no money allocated for child care or transportation.
States are experimenting with other ways to improve health and contain costs. 
For example, some states want to require Medicaid recipients to pay premiums and 
contribute to health savings accounts. If recipients are too poor to make these pay-
ments or do not understand the logistics, they risk losing coverage. To lower drug 
costs, some states are trying to negotiate value-based purchasing agreements with 
drug manufacturers. Some states are requesting waivers to allow providers to require 
participation in wellness programs, and some are allowing Medicaid recipients to 
use telehealth and telemedicine services so that they can receive medical care at 
home, giving access to health care for people who lack transportation or who are 
isolated in rural areas. There is also a move to improve outreach and to measure 
social determinants of health to inform health management policy and better serve 
the needs of low-income Americans.
 Care Management Trends
When we started managed care in this country in the 1970s, it consisted of just 
administration of benefits and financing. Then we moved into an era of provider 
care management, where the emphasis was on the supply side to keep costs down 
and included measures such as utilization review, risk contracting, diagnostic- 
related groupings (DRG), and pay for performance (P4P). Now providers are using 
mainly consumer care management, which emphasizes the demand side, viewing 
patients as consumers who have choices. It focuses on how to change consumer 
behavior, for example, to visit the doctor and practice healthy behavior to prevent 
disease. The strategies for consumer care management are based on factors such as 
consumer centric behavior, work–life balance, population management, and out-
come data. Community care management is a future model of care management that 
is gaining interest, primarily from Medicaid. This model moves the focus beyond 
the individual consumer to the community; the intent is to provide accountable, 
coordinated, whole-person care that will involve not only hospitals and clinics but 
also home care and caregivers. There will be a shift from hospital-based care to 
residence-centered care with decreased hospital stays and readmissions. Community 
budgets will be established for the target population with shared risk strategies 
between providers and the community, and there will be a shift from volume to 
value of care received.
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 Federal Strategic Plans
Some of the federal strategic plans are trendsetters for policies and are thus impor-
tant to understand; a few of the more influential ones are mentioned here. The stra-
tegic plan from the US Department of Health and Human Services (HHS) focuses 
on high-risk populations now. In the new plan, the words diversity and disparities 
have been minimized; Latinos are still considered high risk, but are just not named. 
Another point of note is that every section of the new HHS strategic plan mentions 
giving more funding to religious and faith-based organizations, so researchers seek-
ing funding might consider partnering with these groups.
The HHS Office of Minority Health (OMH) has a National Plan to Eliminate 
Disparities and has continued to support the National Partnership for Action (NPA). 
The OMH also has a history of support for the National Standards for Culturally and 
Linguistically Appropriate Services (CLAS) in Health and Health Care to be 
adopted by hospitals and leaders of our institutions and communities. Since 2003, 
the Agency for Healthcare Research and Quality (AHRQ) has put out an annual 
National Healthcare Quality and Disparities Report. This assessment of the US 
healthcare system points out the strengths, weaknesses, and disparities that exist in 
both quality and access to care. In 1999, the Institute of Medicine (IOM) was asked 
by Congress to examine health care disparities in the United States. In 2002, the 
IOM published Unequal Treatment, an influential report that was the first to docu-
ment widespread health inequities in the United States and to map out general strat-
egies for how to address them, including increasing awareness among the public, 
policy-makers, and health care industry and promoting evidence-based medicine to 
insure consistent, equitable care.
Finally, two other reports that have had important impacts on policy are Healthy 
People and the Report of the Lung Cancer Progress Review Group. Healthy People 
is a federal strategic plan that focuses on disease prevention; it is updated every 
10  years and is administered by the Office of Disease Prevention and Health 
Promotion (ODPHP) at HHS. Healthy People 2020 aims to:
 1. Identify nationwide health improvement priorities
 2. Increase public awareness and understanding of the determinants of health, dis-
ease, and disability and the opportunities for progress
 3. Provide measurable objectives and goals that are applicable at the national, state, 
and local levels
 4. Engage multiple sectors to take actions to strengthen policies and improve prac-
tices that are driven by the best available evidence and knowledge
 5. Identify critical research, evaluation, and data collection needs. (https://www.
healthypeople.gov/2020/About-Healthy-People)
Published by NCI in 2001, the Report of the Lung Cancer Progress Review Group 
presented a vision for cancer research that is more multidisciplinary. Its “highest 
priority” was to foster the creation of integrated, multidisciplinary, multi- institutional 
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research consortia organized around the problem of lung cancer rather than around 
specific research disciplines.
 Future: Cancer and Hispanics
Looking to the future for cancer and Hispanics, the National Hispanic Medical 
Association sees the need to educate policymakers. Each year NHMA has a national 
conference in Washington DC which includes a Lobby Day and a session for doc-
tors, medical students, and others to stress the importance of not only cancer but 
also chronic disease in general in our communities and the need for more doctors. 
There are many issues discussed, but it is always about access for Hispanic com-
munities, cultural competence, research, and whatever else we can do to help. We 
also work with coalitions such as the Tri-Caucus, Healthy Equity and Education 
Workgroup, Medicaid coalitions, Better Medicare Alliance, PhRMA Advisory 
Council, Public Health Institute new community-based coalition, National Hispanic 
Health Agenda, Children’s Health Group, Immigrant Children Committee (AAP), 
and Health Professionals/Nursing Education Coalitions (AAMC). Finally, the 
NHMA supports Political Action Committees such as Hispanic Congressmen 
(GoBold), Poder PAC—Latina Congresswomen, and the Victory Fund started by 
Eva Longoria. It is not necessary to have much money to help political action com-
mittees, because Congressmen have their own mechanisms for generating funds 
which can be directed toward future Congressmen that will champion for cancer 
research. One recommendation for the future is to start a PAC that is just about 
healthy living in general, not just for Hispanics, but for everyone.
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Chapter 22
A Way Forward: The Future of Cancer 
Health Disparities Research in Latinos
Amelie G. Ramirez and Edward J. Trapido
The vision for Advancing the Science of Cancer in Latinos was to bring together 
researchers, scientists, physicians, health care professionals, patient advocates, and 
students from across the nation and beyond, engaging them in open dialogue to 
summarize research advancements to date, identify gaps, and develop actionable 
goals to translate basic research into clinical best practices, effective community 
interventions, and professional training programs to eliminate cancer disparities in 
Latinos.
This conference not only brought together a diverse group of researchers, but it 
also built upon the pioneering work of Redes En Acción: The National Latino 
Cancer Research Network (Redes). The Institute for Health Promotion Research 
established the long-standing network in early 2000 under the National Cancer 
Institute’s (NCI) Center to Reduce Cancer Health Disparities (formerly the Special 
Populations Networks program). Nineteen years later, Redes maintains collabora-
tion with six regional sites (San Antonio, San Francisco, San Diego, Houston, 
Miami, and New York) with a combined network of more than 2000 community 
leaders, researchers, government health agencies, and public advocates, from across 
the nation dedicated to fighting cancer among Latinos through research, training, 
and awareness.
Early on, the Redes network identified cancer issues of greatest relevance to 
Latinos. These identified issues laid the foundation for a national Latino cancer 
agenda, providing a useful tool for individuals and organizations engaged in cancer 
prevention and control efforts among Latino populations [1–4]. The Advancing the 
Science of Cancer in Latinos conference provided a pulse check to see what has 
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been accomplished, what has been learned, what is still unknown, and what is next. 
Toward that end, most of the conference presenters made recommendations for a 
way forward; some of the suggestions are specific to their field of study and others 
are intended to be applied more broadly. The following are some key recommenda-
tions abstracted from their conference presentations.
 Genetics, Environment, Lifestyle, and Cancer
• Cancer prevention strategies are needed now to address changing demo-
graphics in the United States. The US Latino population is growing and is 
projected to double in the next 40 years. Because US Latinos are a young demo-
graphic whose cancer burden will rise as they age, there is an urgent need for 
prevention strategies now, such as promoting cancer screening and altering mod-
ifiable risk factors (Chap. 2; Pinheiro, Callahan, and Kobetz; Chap. 21; Rios).
• Disaggregate Latino cancer data into subgroups. The US Latino population is 
a heterogeneous mix of subgroups that may differ in country of origin, accultura-
tion, nativity, socioeconomic status, and US region in which they reside; these 
factors can influence cancer risk and outcome. Most US cancer data reports on 
Latinos as an aggregate group, obscuring the differences that exist among sub-
groups (Chap. 2: Pinheiro, Callahan, and Kobetz).
• Improve data collection on Latino national origin so that cancer registries 
can account for Latino heterogeneity in their analyses. State death certificates 
can supplement surveillance data (incidence and survival) in order to find Latino- 
specific group and place of birth—key pieces of information needed to analyze 
Latino heterogeneity (Chap. 2: Pinheiro, Callahan, and Kobetz; Chap. 5: Stern).
 Cancer Risk, Prevention, and Screening
• Consider heterogeneity among Latinas when estimating breast cancer risk 
and mortality rates. There is evidence that both the risk of developing breast 
cancer and mortality rate varies among and within Latino subgroups based upon 
country of origin, nativity, and genetic ancestry (Chap. 4: Fejerman, Serrano- 
Gómez, and Tamayo).
• Support international collaborations to access population data and biore-
positories in Latin America. Acquisition of these data will enrich the study of 
the molecular diversity of cancer in Latinos, helping researchers to better under-
stand cancer risk and outcomes related to biological, environmental, cultural, 
and access-related factors in individuals of Latin American origin (Chap. 4: 
Fejerman, Serrano-Gómez, and Tamayo).
• Conduct more epidemiological studies on prostate cancer using adequate 
risk factor data that includes Latinos. Prostate cancer (PCa) is the top cancer 
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that affects Latino men, yet few Latinos have been included in epidemiological 
studies in the United States. Also needed are analyses of genetic ancestry and 
PCa risk among Latinos, which may inform some of the cancer incidence find-
ings; and patterns of tumor localization must still be characterized to improve 
PCa detection among Latinos. Finally, patterns of care and adherence to active 
surveillance must be studied to design culturally-sensitive interventions (Chap. 
5: Stern).
• Consider ethnic and cultural background in the design of research and 
interventions to improve diet among Latino groups. Most Latino groups fall 
short of American Cancer Society recommendations for the ideal preventative 
diet. Incorporate cultural dietary patterns and emphasize traditional healthy 
foods when designing nutritional interventions and research; this will help to 
reduce bias and establish reasonable portion sizes. Conduct longitudinal studies 
of diet and cancer outcomes among understudied Latino populations to reduce 
current cancer risk and prevent widening risk with the adoption of a Western diet 
(Chap. 6: Tucker).
 The Biology of Cancer Health Disparities
• Find biomarkers associated with gastric pre-malignant lesions in Latinos. 
Gastric cancer disproportionately affects Latinos, and because early stage dis-
ease produces no symptoms, this cancer is often diagnosed as stage IV disease 
with low survival. It would be of great benefit to find biomarkers of treatable, 
pre-malignant stages and to devise strategies for the prediction of disease aggres-
siveness and outcome (Chap. 7: Garai, Li, and Zabaleta).
• Conduct comprehensive tumor genomic studies of gastric cancer in Latinos. 
Research suggests that the molecular profiles of gastric cancer in Latinos are 
unique. Thus, there is a need to characterize genetic and genomic patterns of 
gastric cancer in patients of Latino ancestry and to conduct preclinical and trans-
lation studies in driver genes and molecular subtypes that are more prevalent in 
Latinos (Chap. 8: Carvajal-Carmona).
• Elucidate biological factors that promote outcome disparities among Latinas 
with breast cancer. Breast cancer in Latinas develops at a younger age, and 
there is evidence that this early onset disparity may result from genetic, environ-
mental, and biological factors such as altered estrogen metabolism resulting 
from childhood obesity (Chap. 9: Colon-Otero).
• Investigate the role of ethnicity in breast cancer susceptibility. Differences in 
gene expression profiles of breast cancer may be a consequence of ancestry and 
thus may be useful for studying breast cancer susceptibility in Latinos. 
Researchers must properly classify genetic ancestry in admixed Latino popula-
tions not only to understand the role of genetics in disease susceptibility, but also 
to provide Latinos the benefits of recent treatment advances (Chap. 10: Serrano-
Gomez and Zabaleta).
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 Advances in Cancer Therapy and Clinical Trials
• Structure diverse ethnic patient participation in biomarker trials. This will 
provide the most comprehensive ability to apply data to the general population. 
One important issue is determining the sufficient number of diverse patients to 
adequately do the analysis (Chap. 11: Perez).
• Include biomarker-negative patients in clinical trials. Limiting a study to 
marker-positive patients may characterize a drug/diagnostic poorly. Sometimes 
researchers incorrectly assume that a biomarker is required for a response and 
may thus deny effective therapy to marker-negative patients (Chap. 11: Perez).
• Improve Latino recruitment into cancer clinical trials. Latinos are underrep-
resented in cancer research, data registries, and genomic databases; this disparity 
can be addressed by improving Latino accrual into clinical trials. Suggestions are 
to educate physicians to promote enrollment, build awareness among Latinos 
about the role of clinical trials in improving cancer care, enhance care navigation 
for treatment planning; and develop language- and culture-appropriate educa-
tional materials (Chap. 12: Mesa and Ramirez).
• Use comorbidities as exclusion criteria only for sound evidence-based rea-
sons. One of the barriers to Latino accrual in clinical trials is the use of comor-
bidities such as hypertension and obesity. Carefully determine if these exclusion 
criteria are necessary and evidence-based (Chap. 21: Croyle).
• Attract more Latinos into the pipeline for higher education in the health 
professions and medical school. Provide opportunities for Latinos to become 
health professionals or STEM researchers of the future. Try to attract more 
Latinos into the pipeline for higher education and medical school (Chap. 12: 
Mesa and Ramirez; Chap. 21: Rios).
 Cancer in the Era of Precision Medicine
• Include more Latinos in precision medicine research. Genomic and transcrip-
tomic studies are based primarily on tumors from Americans of northern 
European ancestry. Without adequate representation of patient diversity, preci-
sion medicine based on these studies may actually worsen health disparities 
(Chap. 13: Zabaleta et al.).
• Consider ethnicity and genetic ancestry when making cancer treatment 
choices based on gene expression profiles. For example, luminal breast cancers 
in Latinos may have distinctive biology due to non-genetic and/or ancestry- 
linked factors (Chap. 13: Zabaleta et al.).
• Ensure that Latinos have access to tumor molecular analysis for targeted 
cancer therapy. Targeted therapy is recommended as standard of care for 
colorectal and thyroid cancers. Compared to non-Latino whites, Latinos have 
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higher incidence rates of these two cancers, so it is crucial that they have access 
to tumor molecular analysis (Chap. 14: Rodriguez-Rodriguez).
 Cancer Outcomes and Survivorship in Latinos
• Provide access to cancer survivorship care that is linguistically and cultur-
ally appropriate for Spanish-speaking Latinos. Engage Latino communities 
in design and implementation of behavioral interventions that can be delivered in 
community settings and are linked to cancer care systems. Investigators can inte-
grate evidence-based programs with community knowledge and best practices to 
test and disseminate co-developed programs to meet the needs of vulnerable can-
cer survivors (Chap. 15: Nápoles).
• Engage multiple stakeholders in patient-centered outcomes research on 
intervention design. Research democracy, where all stakeholders—including 
patients and their caregivers—have a voice and a vote in research decisions, can 
improve patient-centered outcomes research (PCOR) by promoting team engage-
ment, satisfaction, and awareness of project barriers and benefits (Chap. 16: Kuo 
et al.).
 Engaging Latinos in Cancer Research
• Engage Latinos in cancer prevention and control research. Community-level 
interventions that use community-based participatory research principles and 
that engage Latinos from the beginning of the research through the dissemination 
of data have the potential to reduce cancer disparities and save lives. Latina 
involvement can help researchers develop interventions that include social and 
cultural assets—essential elements that can help to eliminate disparities in can-
cer screening, prevention, and control (Chap. 17: Baezconde-Garbanati et al.).
• Deliver personalized interventions through texting and mobile media ser-
vices. This scalable service makes mobile, personalized advice/support afford-
able; it can reach disadvantaged populations, produce a public health impact, 
reduce health service costs, and reduce health disparities in Latinos. Effectively 
used for smoking cessation, text messaging is interactive and can be delivered 
anonymously wherever the person is located (Chap. 18: Chalela et al.).
• Design cervical cancer interventions that target cultural factors which may 
operate at various levels of influence. Also, broaden the focus of interventions 
beyond cancer screening to improved sexual and reproductive health. Such inter-
ventions can target root causes of disparities and yield sustainable behavior 
change (Chap. 19: Lechuga and Melo).
• Use a community-based approach to increase participation of Latinos in 
biobanking and biospecimen research. Latinos are underrepresented in 
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 biomedical research and biospecimen banks. One solution is to partner with 
Latino communities in a culturally appropriate manner; deliver community-
based education programs to increase awareness and informed decision-making 
about biospecimen donation; and use mobile lab units to collect and process 
biospecimen donations onsite (Chap. 20: Rodriguez and Erwin).
 Emerging Policies in US Health Care
• Researchers who study cancer in Latinos must advocate to Congress for 
their own work and educate policy makers of its value in helping people and 
saving lives. Researchers should be persistent in this effort, because lawmakers 
deal with many issues in addition to health care and may need reminding to refo-
cus their attention (Chap. 21: Castro, Rios).
• Protect the Affordable Care Act. More Latinos than any other group were able 
to receive insurance coverage because of that act, so researchers and community 
members must make sure that it is not completely eroded (Chap. 21: Castro and 
Rios).
• Address the health effects of environmental quality on cancer and other ill-
nesses. Some Latino communities are exposed to damaging environmental fac-
tors because of weak enforcement in certain states. Be mindful not only of 
Congress and the federal government but also of state and local jurisdictions 
(Chap. 21: Castro).
• Empower non-Latino physician partners with cultural competence to 
enhance their relationship with Latino patients and their caregivers. Only a 
small percentage of physicians are Latino, and the primary care physician can be 
the number one driver or barrier for proper cancer care and adherence to treat-
ment (Chap. 21: López and Croyle).
• Foster survivor advocacy within the community. Involve Latino cancer survi-
vors in advocacy, because the powerful voice of survivors can be leveraged to 
motivate Latinos to seek cancer screening (Chap. 21: López).
• Leverage online channels. The Internet is a powerful channel for Latinos to find 
information and additional support along the path to treatment (Chap. 21: López).
• Protect patients through local policy. Physicians, health care systems, and 
insurance companies must advocate for the communities they serve. Latinos 
treated for chronic conditions often experience higher incidence of complication 
and death than their non-Latino counterparts, so advocacy is important (Chap. 
21: López).
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 Charting the Future of Cancer Health Disparities Research 
in Latinos
The purpose of this conference was to move beyond documented health disparities 
in Latinos to set a new agenda for future initiatives that specifically address cancer 
health disparities and improve outcomes in Latino communities. At the close of the 
conference, Drs. Trapido (LSU Stanley Scott Cancer Center), Cruz-Correa 
(University of Puerto Rico Comprehensive Cancer Center), and Stern (University of 
Southern California) moderated a session entitled Charting the Future of Cancer 
Health Disparities Research in Latinos. The group determined research priority 
areas based upon the papers presented at the meeting. Attendees were asked to 
respond to a live poll and select up to three areas they considered top priorities for 
cancer research in Latinos.
The top five priority areas for cancer research in Latinos for Parts II, III, and IV 
were ranked from one to five as follows:
 1. Larger cohort studies on genetics vs. environment in Latinos to understand 
health differences.
 2. Translate effective lifestyle programs to fit the community context and 
population.
 3. Multinational studies comparing native born in countries of origin vs. United 
States.
 4. Investigate ancestry and infectious agents which cause cancer.
 5. Develop and implement interventions for sexual health (i.e., assessment of out-
comes, longitudinal designs, standardization).
The top five priority areas for cancer research in Latinos for Parts V, VI, and 
VII were:
 1. Reduce barriers of enrollment for Latinos in clinical trials and include patient 
reported outcomes and ethnic diversity.
 2. Link databases to catalyze biomarker precision medicine and precision 
oncology.
 3. Examine the relationship of genes/pathways to determine metaplasia that might 
progress to cancer, as well as SNPs in key genes among Latinos.
 4. Mitigate the impact of trial globalization on the relevance of medical products/
drugs to the Latino community.
 5. Evaluate pathways in carcinogenesis in HCC to explore therapies.
The top five priority areas for cancer research in Latinos for Parts VIII and 
IX were:
 1. Conduct long-term follow up in intervention studies.
 2. Include more family system-based approaches.
 3. Improve integration across disciplines.
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 4. Get Latinas and other minorities to participate in cancer research and pay it 
forward.
 5. Measure depression better in Latinos.
This publication describes the beginning of much needed research tailored to 
improve understanding of key contributors to cancer in the Latino population. 
Recommendations from the conference participants give us a direction for future 
research that will advance the science of cancer in Latinos and eventually lead to 
lives saved. And until we reach populations with needed screening, treatment, and 
improved quality of life for cancer survivors, we will not see a decline in cancer 
deaths. Reducing the cancer burden in Latino communities takes all of us working 
together throughout the continuum of cancer.
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 Does Metformin Modify Racial/Ethnic Disparity 
in Hepatocellular Carcinoma?
C. P. Wang, J. Kuhn, L. Tenner, D. P. Shah, S. Schmidt,  
Y. F. Lam, and A. G. Ramirez
UT Health San Antonio, San Antonio, TX, USA
Background: Racial/ethnic disparity in hepatocellular carcinoma (HCC) is well- 
established. However, the extent to which the disparity in HCC is attributed to fac-
tors that are independent of the disparity associated with chronic liver diseases 
(CLD) and type 2 diabetes (T2D) is not clear. This study assessed (1) the race/ethnic 
disparity in HCC incidence among men with T2D but without CLD and (2) whether 
the race/ethnic disparity HCC was modified by the use of T2D medication: 
metformin.
Methods: The study cohort was derived from the electronic medical records in the 
nationwide Veterans Administration Health Care System. Inclusion criteria: 
40–89 years old, male veterans with T2D; without prior diagnosis of cancer, cardio-
vascular diseases, CLD, or renal diseases; without prescription for insulin or thia-
zolidinedione. Logistic regression model was used to compare the HCC incidence 
between race/ethnicity groups under no use of metformin adjusting for covariates 
and propensity scores for race/ethnicity. The generalizability weighting technique 
was incorporated in the logistic regression model to assess the heterogeneity in the 
odds ratio (OR) of HCC associated with metformin use among race/ethnicity 
groups. Covariates adjusted for in the analyses included study duration, social eco-
nomic status, use of statins and beta-blockers, age, LDL, HbA1c, BMI, (alcohol 
related) mental health disorders, abnormal liver functions, obstruction of the gall-
bladder, cholecystectomy, tobacco-related complications, blood transfusion, and 
residency location.
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Results: The study cohort consisted of 84,433 men with T2D but without prior 
CLD; mean follow-up 6.10  ±  2.87  years; 67,065 (79.47%) non-Hispanic white 
(NHW), 13,125 (15.5%) African American (AA), 4243 (5.03%) Hispanics; mean 
age 67.8 ± 9.8 years, mean HbA1c 6.57 ± 0.98%, 121 (0.14%) HCC cases, 31,036 
(36.76%) metformin users, 65,612 (77.71%) statins users, and 46,961 (55.62%) 
beta-blocker users. The IOM concordant disparity measures showed that NHW and 
Hispanic had a similar HCC risk (OR = 0.95 (0.40–2.24)); AA had a 40% lower 
HCC incidence compared to NHW (OR = 0.60 (0.40–0.92)). Metformin use was 
associated with an overall 50% reduced HCC risk (OR  =  0.49 (0.36–0.66)). 
Metformin’s HCC prevention effect was superior among Hispanics compared to 
non-Hispanics: OR associated with metformin use was 0.57 (0.40–0.81) for NHW; 
OR = 0.35 (0.25–0.47) for AA; OR = 0.31 (0.22–0.43) for Hispanics. There was no 
significant synergistic HCC prevention effect associated with the combination use 
of metformin and statin (p = 0.76). For NHW, metformin’s HCC prevention effect 
did not differ by the average daily dose; for AA, higher average daily dose of met-
formin was associated with a less HCC prevention effect (ORs associated with 
≥1000 mg/day (vs. <1000 mg/day) were 3.48 (p = 0.001), 2.68 (p = 0.02), and 2.76 
(p  =  0.02) under ≥90, ≥120, and ≥180  days of prescription, respectively); for 
Hispanics, higher average daily dose of metformin was associated with a greater 
HCC prevention effect (ORs associated with ≥1000 mg/day (vs. <1000 mg/day) 
were 0.11 (p = 0.004), 0.07 (p = 0.002), and 0.07 (p = 0.002) under ≥90, ≥120, and 
≥180  days of prescription, respectively). Significant covariates for NHW were 
statin use (OR = 0.44), age (OR = 1.02), comorbidity (OR = 1.35), BMI (OR = 0.98), 
LDL (OR = 1.01), and poverty (OR = 1.06); significant covariates for AA were 
comorbidity (OR = 1.56), abnormal liver functions (OR = 5.22), and residing in 
south Texas (OR = 42.54); significant covariates for Hispanics included statin use 
(OR  =  0.19), beta-blocker use (OR  =  0.16), age (OR  =  1.13), comorbidity 
(OR = 1.60), and binge drinking (OR = 7.01).
Conclusion: In men with T2D but without CLD, AA had a lower HCC incidence 
compared to NHW or Hispanics; HCC incidence was similar between NHW and 
Hispanics. The similar HCC incidence between Hispanic and NHW observed in this 
cohort suggested that the ethnic disparity in HCC could be mediated by CLD, T2D, 
or other unmeasured factors. The superior HCC prevention effect of metformin use 
among Hispanics could be attributed to the pharmacogenomic heterogeneity. The 
differential HCC prevention effects by metformin, statins, and beta-blockers among 
race/ethnic groups shed some light on the potential interventions to reduce race/
ethnic disparity in HCC.
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 Oxidized Low-Density Lipoprotein Is a Potentially Potent 
Mediator of Proteasome Inhibitor Resistance in Obese 
Multiple Myeloma Patients
J. Esparza, S. R. Polusani, V. Cortez, M. C. Kinney, R. Asmis, and E. A. Medina
Division of Hematopathology, Department of Pathology and Laboratory Medicine, 
UT Health San Antonio, San Antonio, TX, USA
Internal Medicine, Section on Molecular Medicine, Wake Forest School of 
Medicine, Winston-Salem, NC, USA
Background: Multiple myeloma (MM) is a malignancy of plasma cells that accu-
mulate in the bone marrow. While treatment advances, particularly proteasome 
inhibitors (PIs) and immunomodulatory drugs have improved survival, MM is 
incurable. Latinos have the worst overall survival compared with other racial-ethnic 
groups. Obesity is an established risk factor for MM mortality, and because it is 
rampant among Latinos, it may play a role in contributing to this survival disparity. 
Oxidized low-density lipoprotein (OxLDL), a key atherogenic factor that is elevated 
in obesity, has emerged as a risk factor for the development and progression of some 
solid cancers, and it has been shown to stimulate pro-oncogenic signaling; its role 
in MM is unexplored. We evaluated the influence of OxLDL on MM cell killing by 
chemotherapeutics used to treat MM. OxLDL, at concentrations within the range 
reported for patients with metabolic syndrome, suppressed MM cell killing by the 
therapeutic PIs bortezomib and ixazomib. Native LDL (nLDL) did not affect the 
anti-MM effects of these PIs, which suggests that the oxidative modification of 
lipids or apolipoprotein in OxLDL are the mediators of cytoprotection. OxLDL did 
not affect MM cell killing by other agents with distinct targets such as the immuno-
modulatory drug lenalidomide and doxorubicin. OxLDL appeared to restore protea-
some activity as evidenced by its suppression of bortezomib-induced accumulation 
of ubiquitinated proteins and pro-apoptotic unfolded protein response signaling. 
The cytoprotective effects of OxLDL were suppressed when lipid hydroperoxides 
(LOOHs) associated with the lipoprotein were specifically reduced by pretreatment 
with the glutathione-dependent selenoperoxidase mimetic Ebselen. Finally, immu-
nohistochemical analysis of bone marrow biopsy samples from newly diagnosed 
MM patients demonstrated the presence of OxLDL in macrophages/histiocytes 
scattered among MM cells. Our findings suggest that OxLDL may be a potent medi-
ator of chemoresistance to therapeutic PIs in obese MM patients. OxLDL appears 
to counteract the anti-MM effects of PIs through LOOH-mediated restoration of 
proteasome activity. Our findings raise the potential benefit of LDL cholesterol- 
lowering therapy, or pharmacological targeting of intracellular pathways used by 
OxLDL, to increase the efficacy of therapeutic PIs and improve the survival of 
obese MM patients.
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 Mechanisms of Radioprotection in Intestinal Stem Cells
C. M. Ortiz Malave, S. Govindaraju, and C. Taniguchi
School of Medicine, University of Puerto Rico Comprehensive Cancer Center, San 
Juan, Puerto Rico
Department of Experimental Radiation Oncology, The University of Texas MD 
Anderson Cancer Center, Houston, TX, USA
Introduction: Pancreatic cancer is one of the leading causes of cancer mortality in 
developed countries and one of the most lethal malignant neoplasms across the 
world with an overall 5-year survival rate of 6%. The reasons being because there 
are no current screening recommendations, it is diagnosed at later stages, and it 
presents a challenge for treatment. For radiation treatment, this challenge arises 
because of the anatomical position of the pancreas in relation to the small intestine. 
Unfortunately, radiation therapy to the pancreas can lead to toxicity of the duode-
num with lethal consequences. Studies demonstrate HIF2 is radioprotective when 
expressed in all GI epithelial cells. But further studies are needed to demonstrate 
that HIF2 might have key mediators in this protective mechanism. Interestingly, it 
has been shown that Wnt ligand was required for crypt regeneration after injury in 
mice. This work attempts to study the mechanisms of regeneration of intestinal stem 
cells post radiation through Wnt regulated pathways.
Methods: Intestinal stem cells are harvested from mice and pass through a series of 
washes using PBS with EDTA, HBSS with EDTA, and Wash Media. A mixture of 
Matrigel and crypt stem cells is produced for plating in 12-well plates. Conditioned 
medium is prepared from L-WRN cells and added to each well. The conditioned 
medium is changed every 2 days. To study the mechanisms of radioprotection of 
intestinal stem cells, crypt organoids were infected with Cre adenovirus to delete 
Wnt gene and irradiation was performed using 6 Gy. Then, recombinant Wnt was 
added to the conditioned medium, and differences in dose concentration were com-
pared (rWnt: 10,600 and 1200 ng/mL).
Results: Wnt provides protection after radiation treatment to stem cells, and it is 
concentration dependent. Twenty-four hours after radiation, there was no growth in 
the 6Gy  +  adCre+ organoids and an increase in growth in correlation to rWnt 
concentration.
Conclusions: This preliminary data support our hypothesis that Wnt proteins are 
required for intestinal epithelium regeneration and repair after radiation. 
Additionally, it demonstrates that this growth is concentration dependent. These 
results provide information for intestinal epithelium regeneration pathways and 
could potentially lead to future treatments for intestinal protection against radiation 
to the pancreas.
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Future Work
• Optimization of experiments for accurate quantification of cell survival
• Study the role of Wnt receptors in the protective mechanism
• Perform RNA profile studies and promoter analysis for key Wnt targets
 Genetic Markers for Treatment-Related Pancreatitis 
in an Exclusive Cohort of Hispanic Children with ALL
A. Grimes, Y. Chen, H. Bansal, C. Aguilar, L. Perez Prado, and G. Tomlinson
Department of Pediatrics, UT Health San Antonio, San Antonio, TX, USA
Greehey Children’s Cancer Research Institute, UT Health San Antonio, San 
Antonio, TX, USA
Department of Population Health Sciences, UT Health San Antonio, San Antonio, 
TX, USA
Background: Treatment-related pancreatitis (TRP) is a rare but serious complica-
tion impacting up to 18% of children with acute lymphoblastic leukemia (ALL). 
Those affected risk severe organ toxicity and treatment delays impacting outcomes. 
TRP is associated with asparaginase, a backbone therapeutic agent in childhood 
ALL. Native American ancestry, older age, high-risk leukemia, and increased aspar-
aginase are linked to pancreatitis risk. However, dedicated gene studies evaluating 
pancreatitis in childhood ALL include few Hispanics. Thus, there remains a gap in 
understanding the genetic basis for pancreatitis risk among Hispanic children 
with ALL.
Methods: We reviewed children with ALL treated over a 20-year period in South 
Texas (1994–2013) and identified 14, all Hispanic, who developed pancreatitis 
related to asparaginase therapy. Forty-six Hispanic controls, children treated on the 
same regimens without pancreatitis, were selected for comparison. Total DNA iso-
lated from whole blood was utilized for targeted DNA sequencing on 23 selected 
genes including those known to be involved in pancreatitis in other populations and 
those involved in asparagine metabolism.
Results: Non-synonymous polymorphisms and frameshift deletions were identified 
in 15 genes with most TRP cases demonstrating variants in ABAT, ASNS, and 
CFTR. Notably, leukemic children with pancreatitis harbored increased CFTR vari-
ants (71.4%) over controls (39.1%). Among these, V470M (rs213950) was most 
frequent (OR 4.27, p = 0.029).
Conclusion: This is the first study of genetic factors in treatment-related pancreati-
tis for Hispanic children with ALL.  Identifying correlative variants in ethnically 
vulnerable populations may provide an innovative screening method to identify 
those at greatest risk for pancreatitis.
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 Bladder Cancer Cell-Intrinsic PD-L1 Signaling and Its 
Influence on the Bladder Microenvironment
R. Reyes, D. Zhang, N. Mukherjee, R. Svatek, and T. J. Curiel
The Graduate School of Biomedical Sciences, UT Health San Antonio, San 
Antonio, TX, USA
Department of Medicine, UT Health San Antonio, San Antonio, TX, USA
Department of Urology, UT Health San Antonio, San Antonio, TX, USA
UT Health San Antonio Cancer Center, UT Health San Antonio, San Antonio, 
TX, USA
Background/Introduction: Nearly 80,000 new cases of bladder cancer (BC) are 
diagnosed in the US annually. A primarily carcinogen-driven cancer, certain occu-
pational and environmental exposures are known significantly affect BC incidence. 
BC also has the highest lifetime treatment costs per patient of all cancers, owing in 
part to its high recurrence rate. BC particularly affects Latinos because of the high 
prevalence of Latino workers in construction, agricultural, and cleaning/mainte-
nance positions, putting them at risk for persistent BC carcinogen exposure, along 
with the potentially lower income (and thus diminished healthcare access) that can 
be associated with these positions.
The carcinogen-induced progression that results in BC formation increases the 
tumor mutational burden, which can increase the likelihood of response to immune- 
based therapies. The newest immunotherapies in the treatment of BC target the 
programmed death-1 receptor (PD-1) and one of its ligands programmed death 
ligand-1 (PD-L1), and specifically anti-PD-L1 (αPD-1) and αPD-L1 antibodies 
have shown durable responses, yet only 10–30% of patients respond. Optimal pre-
dictors of response are yet to be elucidated, with expression of target molecules 
(e.g., PD-L1) serving only as incomplete markers of treatment response.
Previous immunotherapy studies have focused on the extrinsic effects of tumor PD-L1 
and T-lymphocyte PD-1 interaction. Seminal work from our group has recently 
reported tumor cell-intrinsic PD-L1 effects on cancer immunopathology and immu-
notherapy in multiple cancer types. As we have previously shown the importance of 
the tumor microenvironment in cancer immunotherapy outcomes, we tested the 
hypothesis that BC cell-intrinsic PD-L1 and PD-1 signals drive bladder microenviron-
ment-specific immunity and influence BC immunotherapy responsiveness.
Methods: We used transplantable MB49 BC cells that we engineered to be PD-L1 
null and a carcinogen (BBN)-induced BC model to study BC tumor cell PD-L1. We 
used fluorescence-activated cell sorting, Western blots, PCR, Luminex protein 
detection, and histopathology to assess environmental factors and effects of tumor 
PD-L1. MB49 tumors were engineered to express luciferase to measure tumor 
growth in vivo. Human BC tissues were also studied.
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Results: Our preliminary results suggest that the unique bladder immune microen-
vironment influences immunotherapy treatment outcome in BC through the effects 
of T cells, natural killer cells, and interferon-γ among other factors. BC-intrinsic 
PD-L1 signals affected mTOR, autophagy, and chemokines distinctly from other 
cancers. Ongoing work is assessing effects on treatments.
Conclusion/Significance/Impact: Data from this work can be used to improve BC 
immunotherapy. We hope to use our data as the launching point from which to pur-
sue clinical testing with Latino BC patients in San Antonio and South Texas, filling 
a major unmet medical need to include Latinos in the rapidly advancing world of 
cancer immunotherapy.
 Ancestry-Associated Molecular Portraits of Luminal Breast 
Cancer in Hispanic/Latinas May Have Prognostic 
and Therapeutic Implications
S. J. Serrano-Gomez, J. Garai, M. C. Baddoo, M. C. Sanabria, G. Hernández, 
J. C. Mejía, O. Garcia, L. Fejerman, J. Zabaleta, and L. Miele
Instituto Nacional de Cancerología, Bogotá, DC, Colombia
Stanley S. Scott Cancer Center, Louisiana State University Health Science Center, 
New Orleans, LA, USA
Tulane University School of Medicine, New Orleans, LA, USA
Grupo de Investigación en Biología del Cáncer, Instituto Nacional de 
Cancerología, Bogotá, Colombia
Department of Medicine, Institute of Human Genetics, University of CaliforniaSan 
Francisco, CA, USA
Department of Pediatrics, School of Medicine, Louisiana State University Health 
Science Center, New Orleans, LA, USA
Department of Genetics, Louisiana State University Health Science CenterNew 
Orleans, LA, USA
Hispanic/Latino (H/L) populations are a genetically admixed and heterogeneous 
group, with variable fractions of European and Indigenous American and African 
ancestries. Although breast cancer incidence tends to be highest among non- Hispanic 
whites (NHW) and African Americans, some studies suggest that breast cancer-spe-
cific 5-year survival rate in US H/L is lower than in NHW after adjustment for socio-
economic status and education. This may be due to numerous factors, including 
access to optimal care and the effect of comorbidities such as obesity and diabetes. 
Additionally, there remain significant knowledge gaps on the biology of breast can-
cer in minorities including H/L. The molecular profiles of breast cancer have been 
extensively examined in NHWs but equivalent knowledge is lacking in Hispanic/
Latinas. Importantly, we know little about the validity of gene expression- based 
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molecular tests used to classify breast cancers and predict outcomes in genetically 
admixed H/L patients. We have previously reported that the most prevalent breast 
cancer-intrinsic subtype in Colombian H/L women was luminal B as defined by sur-
rogate St. Gallen criteria. Luminal B tumors tend to have poorer prognosis and 
develop endocrine resistance more frequently than their luminal A counterparts. 
More recently, we explored ancestry-associated differences in molecular profiles of 
luminal B tumors among highly admixed Colombian H/L women. Using whole tran-
scriptome analysis and a set of ancestry-informative markers selected to be most 
informative in H/L patients, we identified genes potentially modulated by genetic 
ancestry: ERBB2, GRB7, GSDMB, MIEN1 and ONECUT2. ERBB2, GRB7, and 
MIEN1 are contiguously located in a region of chromosome 17q that is frequently 
amplified in HER2-enriched breast cancers. Expression of ERBB2 (Her2/Neu) is 
associated with endocrine resistance in luminal cancers. We also observed statisti-
cally a significant association of ERBB2 expression with Indigenous American 
ancestry (p < 0.001, B = 3.82). Our results suggest that genetic ancestry in Hispanic/
Latina women may modify ERBB2 gene expression in luminal breast cancers. These 
results suggest that ERBB2, a gene responsible for endocrine resistance in a signifi-
cant fraction of luminal breast cancers, may be more likely to be highly expressed in 
women with higher Indigenous American ancestry. As ERBB2 is a therapeutically 
important gene, which encodes the target of trastuzumab and other Her2-targeted 
agents, these findings may have important therapeutic implications in Hispanic 
patients with luminal breast cancers. Additionally, we observed considerable discor-
dance between immunohistochemistry and PAM50-assigned intrinsic subtypes in 
our patient population. Only 50% of the patients identified as luminal B by immuno-
histochemistry were accurately classified as luminal B by PAM50. Yet, their clinico-
pathological features and outcomes were consistent with luminal B classification in 
other ethnic groups. Thus, our data suggest that commonly used breast cancer molec-
ular tests should be validated in diverse populations including sufficient numbers of 
Hispanic/Latina patients. Given the considerable genetic heterogeneity of Hispanic/
Latinos, more studies are necessary to confirm these findings in patients from the 
USA and other Central and Southern American countries.
 Latinas and Breast Cancer: Discovery of Mutations 
in Non- BRCA1/2 High- and Moderate-Penetrance Breast 
Cancer Susceptibility Genes
S. L. Neuhausen, J. Weitzel, A. Adamson, S. Tao, C. Ricker, M. Rosenblatt, 
B. Nehoray, D. Senitzer, S. Sand, L. Steele, D. Hu, S. Huntsman, D. Castillo, 
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Background: Breast cancer (BC) is the leading cause of cancer deaths among 
Hispanic women, who represent the largest and fastest-growing minority population 
in the USA, yet genetic susceptibility to BC has been largely understudied. BRCA1 
and BRCA2 (BRCA) mutations explain approximately 25% of familial BC, and the 
proportion associated with other BC susceptibility genes is unknown. We deter-
mined the rate of mutations in 12 additional BC susceptibility genes among Hispanic 
women who tested negative for BRCA mutations.
Methods: BRCA-mutation-negative Hispanic women with familial BC (diagnosis 
of BC under age 50 years, bilateral BC, or both breast and ovarian cancers,  and/or 
with at least two first- or second-degree relatives diagnosed with BC under age 
70  years) were selected from participants in a large registry and whole exome 
sequencing was performed. We analyzed data for 12 known and suspected high- and 
moderate-penetrance BC susceptibility genes (ATM, BRIP1, CDH1, CHEK2, 
NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, and TP53).
Results: We identified 51 (4.8%) pathogenic or likely pathogenic variants (PV) in 
48 of 1058 (4.6%) participants, including 21 frame shift leading to truncation, 19 
missense, 5 nonsense, and 7 splice site variants. The distribution genes with PVs 
were PALB2 (N = 18), CHEK2 (20), ATM (6), and BRIP1(2), TP53 (2), and CDH1, 
NF1, PTEN, and STK11 (all N = 1). No PVs were observed in NBN, RAD51C, or 
RAD51D. Nine participants carried the same PALB2 PV (n = 8; 1.1%) and 14 carried 
the same CHEK2 PV.
Conclusions: Of the 1058 BRCA-negative high-risk Hispanic women, 4.6% carried 
a PV in a BC susceptibility gene. Recurrent PVs in PALB2 and CHEK2 were the 
most frequent findings, representing 45% (23/51) of all PVs; the recurrent muta-
tions likely are due to founder events. PVs in ATM were seen less frequently than in 
non-Hispanic white populations.
 The Role of Six Transmembrane Epithelial Antigen 
of the Prostate 2 in Hepatocellular Carcinoma
C. R. Zeballos, H. Bouamar, G. Zheng, X. Gu, Y. Chen,  
F. G. Cigarroa, and L. Z. Sun
Department of Cell Systems and Anatomy, UT Health San Antonio,  
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Introduction: Hepatocellular carcinoma (HCC) is the most common type of liver 
cancer in adults and the third most common cause of cancer death worldwide. Its 
incidence and mortality rates are two times higher in Latinos than those in the US 
general population with the highest incidence rate among Latinos in the South Texas 
region. The molecular etiology associated with the increased incidence of HCC in 
this population is largely unknown. We performed whole genome RNA sequencing 
in paired HCC tumor and adjacent nontumor tissue total RNA from nine South Texas 
Latino patients. Analysis of differentially expressed genes revealed significant alter-
ations in pathways associated with oxidative stress; most importantly, we found that 
the expression of STEAP2 (Six Transmembrane Epithelial Antigen of the Prostate 2) 
is increased fivefold in HCC tumor tissue compared to adjacent-normal tissue. In com-
parison to a non-Latino population, this finding was unique to South Texas Latinos. 
STEAP2 is a metalloreductase of iron and copper; reduced iron and copper ions can 
mediate the production of hydroxyl radicals resulting in increased oxidative stress, 
which can cause DNA damage and lipid peroxidation. We aim to prove that STEAP2 
through the regulation of iron and copper homeostasis, and an increase in oxidative 
stress, will lead to malignant progression of HCC, including obese hosts.
Materials and Methods: Hispanic paired HCC and adjacent normal tissues were 
collected for RNA sequencing, metal ion measurement, and oxidative stress mark-
ers. STEAP2 RNA and protein expression levels in Hispanic and Caucasian sam-
ples were evaluated by RT-PCR, Western blot, and immunohistochemistry. HCC 
cell lines (SNU398 and HUH7) with knockdown (KD) and overexpression (OE) 
of STEAP2 were created to examine the proliferation, migration, anchorage inde-
pendent growth, and oxidative stress in vitro.
Results: Analysis of RNA sequencing data demonstrated the overexpression of 
STEAP2 in HCC tumors in Hispanic patients, which were validated by RT-PCR and 
Western blot data. Lipid peroxidation product, 4-hydroxynonenal, and copper levels 
were higher in HCC tumor vs. adjacent tissue. KD of STEAP2 in the HCC cell lines 
decreased proliferation, migration, and anchorage-independent growth, while OE of 
STEAP2 increase migration and anchorage-independent growth but not proliferation 
in 2D culture.
Conclusions: STEAP2 is specifically overexpressed in HCC tumors in Hispanics in 
comparison to HCC tumors in non-Hispanic whites and appears to play a malignant- 
promoting role in HCC cells. Further studies on the role of STEAP2 as a novel 
tumor promoter in HCC and the mechanisms by which it promotes carcinogenesis 
are underway. The proposed studies will likely yield mechanistic insights into the 
molecular mechanisms that drive HCC development and progression in South Texas 
Hispanics and potential therapeutic targets.
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The incidence of obesity-related endometrial cancer is increasing in our catchment 
area, Bexar County, and vicinity in South Texas. Strikingly, we observed a sharp 
rise of this disease in Hispanic Latinos between 2005 and 2014, bringing the num-
ber of diagnosed endometrial cancer cases higher than whites, in contrast to the 
previous 10 years. In addition, the death rate in our catchment area was higher than 
the national mortality rate. Further highlighting this disparity is that based on the 
Texas Cancer Registry, Cancer epidemiology and Surveillance Branch, the age at 
diagnosis of Hispanics (mean age ~50 years) in our catchment area is much lower 
than non-Hispanic whites (mean age ~60 years). In this study we examine the epi-
genetics, molecular etiology, and functional biology underlying this unique endo-
metrial cancer in young obese Hispanic patients.
Emerging evidence suggest that adiposity-associated endometrial tumorigenesis 
may be driven in part by adipose stromal cells (ASCs), which are resident precursor 
cells to adipocytes in fat tissue. ASCs may exert their oncogenic effects, which are 
associated with inflammation, on endometrial tissue through paracrine actions, as 
some evidence suggest ASCs are trafficked to tissue sites via chemokine actions. To 
simulate ASC paracrine actions on endometrial epithelial cells (EECs), we pre-
formed co-culture studies exposing EECs to ASCs over a 3-week period. Expression 
profiling revealed extensive transcriptome changes in EECs exposed to ASCs com-
pared to control EECS (no ASCs). Bioinformatics analysis revealed a significant 
repression of gap junction (GJ) genes and related genes involved in the regulation of 
gap junctions. Gap junctions are intercellular channels that allow for electrochemi-
cal communication by transfer of small molecules and ions between cells. 
Deregulation of gap junctions has been shown to be involved in oncogenesis. Our 
studies show that gap junction activity in endometrial cancer cells is stunted, which 
can be restored by epigenetic modification, namely treatment with DNA demethyl-
ation agents. This treatment also led to restoration of gap junction plaques on the 
cell surface of endometrial cancer cells, which was predominantly intracellular 
without treatment. As DNA methylation is a marker of gene silencing, which affects 
tumor suppressor genes during tumorigenesis, we examined DNA methylation 
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patterns in Latino Hispanic endometrial cancer patients in Bexar County (average 
age 42 years) compared to a Midwestern cohort of predominantly white patients 
(average age 60 years). The data reveal distinct and significant elevation of DNA 
methylation in the main gap junction gene GJA1 and a gene coding for a regulator 
kinase (PRKCA) in the young Hispanic cohort.
Additionally, when accounting for comorbidity, both GJA1 and PRKCA exhib-
ited higher methylation levels in obese compared to nonobese patients in 
the Hispanic cohort. This distinction was not evident in the Midwestern cohort. 
Our data suggest that deregulation of GJA1 gap junction cellular communication by 
epigenetic means is a marker for obesity-associated endometrial cancer in young 
Latino patients in South Texas. Further studies are needed to assess if this is appli-
cable to other Latino populations in the USA.
 Novel Use of Estrogen Receptor-β Agonists in the Treatment 
of Endometrial Cancer Cell Lines
C. A. De la Garza, K. Ramasamy, J. M. Richards, R. R. Tekmal,  
and E. R. Kost
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 
UT Health San Antonio, San Antonio, TX, USA
Introduction: Endometrial cancer (EC) is the most common gynecologic malignancy 
in the country, with increasing incidence in premenopausal obese patients. In breast 
cancer, it has been previously reported that ER-β agonists exert antitumor activity. 
ER-β agonists are also being studied for the treatment of vasomotor symptoms, 
ovarian cancer, and brain cancer. However, the role of ER-β in the endometrium and 
in EC is only theorized. Therefore, we evaluated the effectiveness of the ER-β ago-
nists: S-Equol, LY500307 (LY), and Liquiritigenin (LIQ) on two commercially avail-
able human endometrial cancer cell lines. We developed two unique models in which 
we sought to emulate the premenopausal and postmenopausal endometrial environ-
ments. Using media with fetal bovine serum (FBS) known to contain estradiol, we 
emulated the premenopausal environment, and for the  postmenopausal environment, 
we used media with charcoal-stripped serum (CSS) devoid of estradiol.
 Methods
Endometrial cancer cell lines: Premenopausal: Ishikawa (ECACC 99040201). 
Postmenopausal: RL952 (ATCC® CRL1671™).
Cell culture: Cells were maintained in phenol red-free minimum essential media α 
(MEM α) supplemented with 1% penicillin/streptomycin and either 10% FBS or 
10% CSS. Cells using CSS media were incubated 48 h prior to treatment.
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Cell proliferation and vitality assay: Cells were grown in 96-well plates at a den-
sity of 5 × 103 cells/well. Cells were treated with various concentrations of S-Equol, 
LIQ, and LY. Cell viability was detected by MTT assay at 48 and 96 h after treat-
ment. Proliferation rate was obtained by measuring the changes in absorbance at 
595 nm. Optical density was measured by a 96-well microplate reader.
Statistical analysis: Graphpad Prism version 5 (SPSS, Inc., Chicago, IL, USA) was 
used. Paired t-test was used for normally distributed data. Differences were consid-
ered statistically significant at p < 0.05.
Results: Premenopausal cell line Ishikawa expressed ER-α and ER-β protein. Under 
premenopausal (estrogen rich) conditions, both cell lines exhibited antiproliferative 
response to all three ER-β agonists. In postmenopausal (estrogen devoid) condi-
tions, the premenopausal cell line Ishikawa displayed antiproliferative activity with 
S-Equol and LY while postmenopausal cell line RL952 exhibited no antiprolifera-
tive response to any ER-β agonists. LIQ exerted no significant effect on either cell 
line in the postmenopausal model.
Conclusion: This is the first study to suggest a differential effect of ER-β agonists 
based on menopausal status. We hypothesize that ER-β has a greater effect in an 
estrogen rich (premenopausal environment). Results using a postmenopausal envi-
ronment showed greater variability to ER-β agonists, particularly in the postmeno-
pausal cell line. Studies in our lab showed high level of expression of ER-β in 
premenopausal EC cancers. ER-β agonists appear to exert stronger antiproliferative 
effects under premenopausal conditions, our data suggests that ER-β signaling may 
be less effective in the hypoestrogenic postmenopausal environment.
 Intratumoral Environment of Premenopausal Endometrial 
Cancers in South Texas Hispanic Patients
C. A. De la Garza, P. T. Valente, K. Ramasamy, M. Goros, J. Gelfond, 
R. R. Tekmal, and E. R. Kost
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 
UT Health San Antonio, San Antonio, TX, USA
Department of Population Health Sciences, UT Health San Antonio,  
San Antonio, TX, USA
Introduction: There is a high incidence of endometrial cancer (EC) in young 
Hispanic women residing in South Texas. EC is a devastating disease in young 
women who desire childbearing ability. Medical management with progestin ther-
apy is rarely effective treatment. Recent evidence has shown that cancers have a 
unique intratumoral environment which allows them to make their own growth fac-
tors. In this study we sought to characterize the intratumoral environment of EC in 
a cohort of premenopausal patients.
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Introduction: The correlation between obesity and type 1 endometrial cancer (EC) 
is of particular importance in the Latino community given the high obesity rates, 
particularly in premenopausal patients. This has led to an increase in the incidence 
of EC. The role of ER-β in the endometrium and in EC is currently unclear and only 
theorized. Following our previous research, we decided to evaluate the effectiveness 
of the ER-β agonist: LY500307 (LY) and the aromatase inhibitor letrozole (LET) 
independently and in combination with human endometrial cancer tissue. We used 
media supplemented with fetal bovine serum (FBS) known to contain estradiol or 
with charcoal-stripped serum (CSS) known to be devoid of estradiol.
Methods: The study included 114 surgical specimens from women aged 
25–50 years; of which 74 had a diagnosis of EC and 40 had benign pathology (con-
trols). Clinical data were abstracted from the EMR. Immunohistochemistry was 
used to evaluate the expression of estrogen receptors α and β, progesterone recep-
tors A and B, progesterone receptor B alone, aromatase, TNF-α, IL-6, IGF-1, 
IGFR-1, and IGFBP-1. Scores were assigned for proportion (0–5) and intensity of 
staining (0–3), then a total score was determined (0, 2–8). Statistical analysis was 
carried out using Kendall rank correlation coefficient and Kruskal–Wallis test as 
appropriate. P < 0.05 was considered significant.
Results: All patients were of Hispanic ethnicity. Average age was 42 years with a 
mean BMI of 40 kg/m2. The majority of cancers were type 1. ERα and β had high 
levels of expression in cancers, 68.5% and 60.5%, respectively. TNF-α had increased 
expression in the cancers as compared to controls, P = 0.001. Furthermore, TNF-α 
expression was positively correlated with the expression of aromatase and ERβ, 
P = 0.002 and 0.05, respectively. IL-6 expression was also positively correlated with 
the expression of ERβ, P < 0.001.
Conclusion: EC in this young, obese cohort had high levels of expression of hor-
mone receptors, aromatase, and the inflammatory cytokines TNF-α and IL-6. 
Overexpression of intratumoral TNF-α may be a driver of carcinogenesis through 
the induction of aromatase and subsequent increase in  local estrogen production. 
Expression of both TNF-α and IL-6 correlated with increased expression of ERβ. 
Increased levels of ERβ have been associated with good prognosis in EC, suggest-
ing a possible antiproliferative effect. The role of ERβ agonists in the treatment of 
premenopausal EC is an area of active research.
 Effect of Estrogen Receptor-β Agonist in the Treatment 
of Endometrial Cancer
C. A. De la Garza, J. M. Richards, R. R. Tekmal, and E. R. Kost
Division of Gynecologic Oncology, Department of Obstetrics and GynecologyUT 
Health San AntonioSan AntonioTXUSA
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 Methods
Human endometrial cancer: EC was obtained from the UTHSA Ob-Gyn depart-
ment tumor bank following guidelines established by the UTHSA and the University 
Hospital System IRB.
Tissue media: Phenol red-free RPMI media were prepared, one with 10% FBS and 
the other with 10% CSS. Each was supplemented with 1% anti-anti (antibiotic anti-
mycotic), 1% sodium pyruvate, 1% sodium bicarbonate, and 0.1% insulin. In addi-
tion, CSS containing media was supplemented with androstenedione 100 nM before 
treatment.
Tissue maintenance and processing: Once obtained, the fresh EC was divided into 
eight triplicates and plated in two different 24-well plates on gelatin sponges and 
incubated in prepared FBS media for 24 h. After 24 h, plate 1 was kept with FBS 
and treated with LY 5 μM, LET 1 μM, and combination, then incubated for 72 h. 
Plate 2 was then changed to CSS containing media and incubated for 48 h prior to 
treatment. Post incubation, androstenedione was added to plate 2 and then treated 
with LY 5 μM, LET 1 μM, and combination, then incubated for 72 h. Post treatment, 
both sets were evaluated using immunohistochemistry and examining the expres-
sion of ER-α, ER-β, PR, aromatase, and Ki-67.
Scoring: Scoring was based on percent total stain. Classified as weak (<30%), mod-
erate (30–60%), and strong (>60%).
Results: Tissue supplemented with FBS and CSS both had increased ER-β expres-
sion when treated with LY. We observed a decreased expression of ER-α in the FBS 
and CSS group of 40% and 50%, respectively, when treated with the same com-
pound and compared to controls. Ki-67 expression was stronger in the group sup-
plemented with CSS when compared to FBS and controls.
Conclusion: Preliminary results suggest that ER-β activation might have an effect 
on downregulation of ER-α on endometrial cancer, as evidenced by the decreased 
expression of ER-α in both groups (FBS and CSS). Ki-67 expression was increased 
in tissue with CSS + androstenedione suggesting that precursors to estradiol will 
have a greater effect on proliferation versus estradiol supplementation. This may 
indicate that paracrine stimulation of endometrial cells rather than endocrine stimu-
lation could lead to proliferation.
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 The Incidence of Endometrial Cancer in Bexar County 
Hispanics Is Increasing at an Alarming Rate
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Introduction: South Texas has a large Hispanic “minority” population which raises 
the concern for poorer health outcomes. We sought to determine the demographic 
and geographic factors underlying the racial disparity in the incidence of endome-
trial cancer (EC) in South Texas.
Methods: We queried the Texas Cancer Registry (TCR) which is a state-wide pop-
ulation-based tumor registry. We searched the TCR for all cases of uterine cancer 
from 1995 to 2010 and abstracted data on cancer incidence, race, age at diagnosis, 
county of diagnosis, and year of diagnosis. We accessed the Texas Behavioral Risk 
Factor Surveillance System (BRFSS) which provides data on obesity, diabetes, 
physical activity, sleep, drinking and driving, tobacco, and alcohol use, and other 
health-related issues by year and county of origin.
Results: Data from 2008 to 2012 indicates that the incidence of uterine cancer in 
Hispanic females increased by 2.3%, second only to liver and bile duct cancer. From 
1995 to 2010 the incidence of EC in Bexar for Caucasians decreased from 22.7 to 
21.1 per 100,000. During the same time period, the incidence of EC in Hispanics 
increased from 18.7 to 25.4 per 100,000. Data from the BRFSS looking at risk fac-
tors for EC found a marked disparity between Caucasians and Hispanics in multiple 
areas including increased incidence of obesity and diabetes, as well as lower educa-
tion levels and socioeconomic status (SES).
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Background: Hepatitis C virus (HCV) is the leading cause of hepatocellular carci-
noma (HCC), the most common type of primary liver cancer. Mortality from liver 
cancer along the Texas–Mexico border is among the highest in the USA. HCC can be 
prevented with direct-acting antiviral therapy, emphasizing the need for early detec-
tion and treatment of HCV. The US Preventive Services Task Force endorsed one-time 
screening in patients born in 1945–1965 (baby boomers, BBs). However, screening 
rates have risen only slightly in the 5  years since guidelines were published. 
Furthermore, most BBs diagnosed with chronic HCV fail to complete the care con-
tinuum to cure. Novel integrative models of care are needed to diagnose and treat HCV 
in order to prevent HCC, especially for uninsured populations that lack access to care.
Methods: Through an 1115 Medicaid Waiver, the chronic care model (CCM) for 
HCV screening and care was implemented in two Rio Grande Valley federally qual-
ified health centers in FQHC1 and FQHC2 serving Hispanic, uninsured patients. 
The CCM included (1) electronic medical record redesign to support screening; (2) 
registry to monitor chronic HCV patients; (3) quality reports; (4) team-based care 
by a physician champion, licensed vocational nurse, and social services; and (5) 
personalized patient education with navigation. A specialist provided distance sup-
port for onsite management of chronic HCV.  For the uninsured, all tests were 
funded, and free therapy provided through pharmaceutical assistance programs. 
Data are presented from October 2014 to June 2017.
Results: FQHC1 screened 3001 (71.2%) of 4189 eligible BBs while FQHC2 
screened 5051 (34.0%) of 14,866. FQHC1 identified 49 BBs with chronic HCV and 
61  in FQHC2; at both sites >93% received education. In FQHC1 28 (77.6%) of 
Conclusion: Hispanics in Bexar County currently have an incidence of EC which 
exceeds that of Caucasians and is rapidly increasing. We have identified an unequal 
distribution of modifiable risk factors for EC in Hispanics including obesity, diabe-
tes, low education level, and low SES. This marked racial disparity warrants dedi-
cated social and political efforts as many of these risk factors are modifiable.
 Implementing Hepatitis C Screening and Treatment 
of Minority, Uninsured Baby Boomers: Best Practices  
in HCC Prevention Through the Chronic Care Model
A. Rochat, A. Choi, E. Yao, B. Wickwire, H. Imperial, J. Gutierrez,  
and B. J. Turner
Center for Research to Advance Community Health, UT Health San Antonio,  
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Introduction: Texas has the highest age-adjusted incidence of hepatocellular carci-
noma (HCC) in the USA.  One-time screening of baby boomers (BBs, born in 
1945–1965) has been endorsed by the US Preventive Services Task Force to prevent 
HCC and liver disease. Over half of incident HCC cases in Texas are in South Texas 
(S TX) where most residents are Hispanic and many uninsured. Because treatment 
of hepatitis C infection (HCV) reduces the risk of HCC, S TX is a priority location 
for novel approaches to implement HCV screening and linkage to care.
Methods: From June 1, 2016 to August 31, 2017, a program for HCV screening and 
treatment was operationalized in 19 primary care practices within four S TX clinic 
systems. The program includes electronic medical record (EMR) modification; cli-
nician/staff training; patient education; coverage of testing for uninsured; anti-HCV 
antibody testing with reflex HCV RNA testing; case management; and telehealth 
specialty support for onsite direct-acting antiviral (DAA) therapy. We compare 
results of anti-HCV screening and RNA testing for chronic HCV across the four 
systems.
chronically infected BBs received FIB-4 staging, 35 (71.4%) had specialist review, 
22 (44.9%) were treated, and 19 (38.8%) cured at 12  weeks posttreatment. In 
FQHC2, these figures are 32 (52.5%), 36 (59.0%), 13 (21.3%), and 12 (19.7%). 
Notably, all patients who initiated treatment successfully completed it and were 
confirmed cured at 12 weeks posttreatment.
Implications: Both FQHCs outperformed national rates of HCV screening and 
care. Facilitators to higher performance in FQHC1 than FQHC2 include greater 
staff continuity, higher-quality EMR, centralization of services, and increased social 
services support. These data suggest that the CCM offers a valuable infrastructure 
for implementing HCV preventive care; however, coverage for tests and treatment 
is needed for the uninsured. Lessons from this program should be evaluated in other 
settings serving vulnerable populations with higher HCV prevalence.
 Hepatocellular Carcinoma Prevention in the High-Risk 
Region of South Texas Through Baby Boomer Screening 
for Hepatitis C and Linkage to Care
T. V. Melhado, R. Bobadilla, L. Tenner, M. K. Jain, A. G. Singal, J. Guerrero,  
and B. J. Turner
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Background: Hispanic women are more likely to develop and die from cervical 
cancer than non-Hispanic whites. Factors contributing to disparities in morbidity 
and mortality from cervical cancer between Hispanic and non-Hispanic white 
women include low levels of knowledge, limited access to healthcare services, and 
barriers that lead to failure to adhere to screening guidelines or inappropriate fol-
low- up. Culturally targeted interventions are needed that promote the benefits of 
early vaccination against the human papillomavirus (HPV) and of the utilization of 
the Pap test, among women over 26 years of age, who no longer qualify for HPV 
vaccination.
Methods: A randomized controlled telephone trial that surveyed the effectiveness of 
two films on cervical cancer-related knowledge, attitudes, and behaviors of Mexican 
origin women in Los Angeles County was conducted by a team of multidisciplinary 
investigators. A sample of 300 women aged 25–45 years who spoke Spanish were 
recruited using random digit dialing (RDD) procedures. Participants were randomly 
assigned to view either a narrative (Tamale Lesson) or a non- narrative 11 min film 
Results: The clinic system with the highest rate of screening had 275 eligible BBs 
and tested 209 (76%) while the clinic with the lowest had 2336 eligible BBs and 
tested 374 (16%). Anti-HCV+ rates for screened BBs ranged from 5% to 15%. 
Overall for all sites, 78% of anti-HCV+ BBs had follow-up RNA testing. Among all 
1462 anti-HCV tested BBs, 121 (6%) were RNA+ (chronic HCV), varying from 2% 
to 10% by system. Characteristics of BBs with chronic HCV included: mean age 
57 years, 80 (66%) men, 71 (59%) Hispanic, and 68 (56%) uninsured. Primary care 
clinicians received telementoring by a specialist to deliver DAA therapy onsite. As 
of August 31, 2017, 12 BBs completed DAA therapy, 14 were on treatment, 13 had 
had a telehealth review, and 29 were having data collected for review.
Conclusion: In four S TX clinic systems serving low income patients, 16–72% of 
eligible HCV BBs were screened for HCV, all exceeding the reported national rate 
(13%). The yield of screening was high, with 6% of all screened patients diagnosed 
with chronic HCV. Of all 121 BBs diagnosed with HCV, 21% have been or are 
being treated and 35% in the process of gaining access to treatment.
 Using a Culturally Tailored Narrative to Increase Cervical 
Cancer Detection Among Spanish-Speaking Mexican 
American Women
C. Ochoa, S. T. Murphy, and L. A. Baezconde-Garbanati
Division of Health Behavior, University of Southern California, Los Angeles,  
CA, USA
Annenberg School for Communication and Journalism, University of Southern 
California, Los Angeles, CA, USA
Appendix B: Cancer Epidemiology and Prevention
253
(It’s Time) that contained information about cervical cancer prevention via the HPV 
vaccine and early detection via regular screenings. Data was collected by phone at 
baseline, 2 weeks after, and 6 months after viewing either film. Descriptive statistics 
were performed to analyze and summarize demographic and health information. 
Analysis of covariance will be conducted to examine if there was a main effect on 
cervical cancer-related knowledge, attitudes toward Pap tests and HPV vaccine, and 
behavioral intentions of getting a Pap test based on film condition (narrative vs non-
narrative), after adjusting for specific variables. We hypothesize that women who 
view the narrative film will have increased knowledge, more positive attitudes, and 
increased behavioral intention to get a Pap test than the identical information pre-
sented in a nonnarrative film.
Results: A total of 140 women completed the three surveys. At baseline, 74% of the 
women were foreign born, 30.1% had some college education, 30.5% had a high-
school education, and 39.3% had completed less than high school education. 62.1% 
of the women were married, and 42.1% of the women were employed either full- or 
part-time. Over 66% of the women found the narrative film to be either excellent or 
very good; 49.6% of the women stated they learned something about Pap tests; 
45.9% of the women stated they learned something about the HPV vaccine; 51.5% 
stated they learned something about cervical cancer in general.
Conclusion: Findings support the use of a culturally tailored narrative/storytelling 
to inform and engage high-risk women in cancer screening. This contributes sub-
stantially to a better understanding of how to both facilitate and maintain behavior 
change. A narrative format is a useful tool for eliminating cervical cancer health 
disparities, and a preferred tool over fact based, non-narrative, especially among 
less acculturated Spanish-speaking women. These findings have implications for 
health education delivery methods, helping to save lives.
 “Nuestra Pareja” [Our Partner]: Together Against Cervical 
Cancer: Interim Results
B. E. Flores, L. Arévalo-Flechas, M. Martinez, M. Tobar, M. W. Goros, 
Gelfond JAL, D. Patel, and D. Parra-Medina
School of Nursing, UT Health San Antonio, San Antonio, TX, USA
South Texas Veterans Health Care System, San Antonio, TX, USA
Institute for Health Promotion Research, UT Health San Antonio, San Antonio, 
TX, USA
Department of Population Health Sciences, UT Health San Antonio,  
San Antonio, TX, USA
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Introduction: Cervical cancer incidence and mortality are higher for Hispanic 
women in Texas compared to non-Hispanic whites (13.9 vs. 8.2 per 100,000). The 
majority of deaths are preventable through early detection and screening. Cervical 
cancer screening is recommended every 3 years for women 21–65 years old and 
HPV co-testing starting at age 30 years every 5 years. However, Hispanic women in 
Texas are under screened. Reported barriers to cervical cancer screening among 
Hispanic women include cultural beliefs, socioeconomic status, education level, 
limited English proficiency and health literacy. We seek to investigate the links 
between health literacy, socio-demographic variables, access and utilization of care, 
culture, and language related to cervical cancer screening practices among 
Hispanic women.
Methods: A mixed-method community-based study using focus group interviews 
and survey data with Hispanic males and females is being conducted. Using the 
Paasche-Orlow and Wolf (2007) model linking health literacy to health outcomes, 
we aim to identify individual level factors that influence cervical cancer screening 
behaviors. Focus group discussions were led by bilingual/bicultural researchers, 
audio-recorded, and transcribed verbatim. Survey data includes cervical cancer 
knowledge, attitudes, beliefs, self-efficacy, health literacy, and acculturation.
Results: Eleven focus groups and 100 surveys (n = 74 females and n = 26 males) 
have been collected thus far with Hispanic males and females in South Texas. The 
majority were Mexican-American (50%) and Mexican (35%), and the mean age 
was 51  years (SD 13). The majority (93%) of females reported having a Pap 
smear; however, 50% of these same women had not had a Pap smear in 3 years or 
more, potentially exceeding the recommended interval. In addition, participants 
did not know if they had HPV co-testing (45%). A majority of participants (55%) 
reported primarily receiving medical information from the doctor’s office. Focus 
group narratives were analyzed using thematic content analysis. The preliminary 
theme from female focus group interviews is “include males” in cervical cancer 
prevention education. The overreaching theme from male focus group is a “clash 
of cultures” or navigating between scientific knowledge and expected Hispanic 
cultural norms.
Conclusion: These results suggest the need for concerted efforts to improve consis-
tent, regular recommended cervical cancer screening and the importance of provider 
recommendation for cervical cancer screening. Community-based, culturally com-
petent cervical cancer screening intervention strategies including male partners are 
needed to decrease Hispanic cervical cancer health disparities in Texas.
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Introduction: Cervical cancer is the most common HPV-associated cancer among 
Hispanic women. In the Hidalgo County, women experience higher incidence and 
mortality from cervical cancer compared to the state and nation. Prevention of cer-
vical cancer is possible using the HPV vaccine, which the Advisory Committee on 
Immunization Practices recommends for males and females aged 11–26  years. 
Despite this recommendation, uptake of the HPV vaccine remains low for Hispanic 
adolescents and young adults in Texas. The Entre Familia (EF) program integrates 
a community education component (public education and health professional train-
ing/education) and clinic component (provider-directed intervention and healthcare 
system-based intervention) to increase HPV vaccine initiation and completion rates 
in Hidalgo County.
Methods: Community health workers (CHWs) at community and clinic sites recruit 
parents of Hispanic adolescents (aged 11–17  years) and young adults (aged 
18–26 years) who have not initiated or completed the vaccine series. As part of the 
community component of EF, CHWs engage in county-wide outreach activities, 
delivering group health education sessions using a flipchart and one-on-one sessions 
with an educational brochure. This component also provides education and training 
for community-based healthcare providers. The clinical component of EF will edu-
cate and train healthcare providers to implement evidence-based strategies to increase 
vaccination rates and to make strong recommendations for the HPV vaccine to their 
patients. CHWs will implement healthcare system-based interventions (e.g., clinic-
based patient education and patient reminders) selected by the lead clinical provider 
at each site to increase vaccination rates.
Results: The EF program is currently underway. We expect EF to increase HPV 
immunization rates (initiation and completion) through the implementation of clinic 
and community components in Hidalgo County. From March 2017 to May 2017, 
we (1) reached 1157 adult residents of Hidalgo County through outreach, (2) edu-
cated 349 adult residents of Hidalgo County using EF’s evidence-based education 
sessions and brochures, (3) educated 109 healthcare professionals, (4) served 46 
vaccine-eligible clinical patients through the clinic CHWs. We also plan to (5) edu-
cate 60 healthcare providers on evidence-based HPV vaccination practices, (6) 
increase over baseline the proportion of healthcare providers that routinely offer the 
HPV vaccine, and (7) meet or exceed Texas’ vaccine initiation (39%/16%) and 
completion (20%/8%) rates for adolescents and young adults using clinic electronic 
medical records.
 An Evidenced-Based Services Program to Increase HPV 
Vaccination Rates
E. K. Villarreal, D. Y. Morales-Campos, L. C. Crocker, M. V. Morales, N. Silva, 
C. Rohr-Allegrini, L. Trevino, A. Lopez, C. Leal, and I. Garcia
Latino Research Initiative, College of Liberal Arts, University of Texas at Austin, 
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Introduction: Cervical cancer is the most common human papillomavirus (HPV) 
associated cancer among Hispanic women. Prevention of cervical cancer is possible 
through the HPV vaccine; however, HPV vaccination rates for Hispanic adolescents 
in Texas remain low. Studies show that a strong provider recommendation is a factor 
influencing HPV vaccination. Academic detailing (AD), which uses brief, facilitator- 
led face-to-face evidence-based education sessions with providers, is one method 
for increasing provider recommendation for the HPV vaccine. Our two projects are 
using a provider-directed intervention (PDI) using AD sessions, which we designed 
to give providers key evidence-based messages to use with patients. The purpose of 
the PDI is to improve vaccination initiation and completion rates for adolescents 
aged 11–18 years in five rural counties in south Texas.
Methods: Research staff collected baseline data including clinical reports on HPV 
vaccination, initiation, and completion rates; clinical staff surveys on knowledge 
and attitudes regarding the vaccine; and provider interviews about HPV vaccina-
tion. Additionally, the study team developed an AD booklet with supplemental 
materials using the Centers for Disease Control and Prevention’s “You are the Key 
to HPV Cancer Prevention” curriculum, the Immunization Schedule for Preteens 
and Teens, and The Community Guide. Clinical facilitators will deliver 4 monthly 
AD sessions to providers followed by two sessions to develop a strategic plan. Each 
session will last 30–60 min and give providers Continuing Medical Education cred-
its for their participation. The AD sessions cover the following themes: (1) under-
standing the burden of HPV infection and disease; (2) evidence-based strategies to 
HPV disease prevention; (3) talking about HPV vaccine to patients; and (4) strate-
gies to improve HPV vaccine coverage.
Results: Eleven clinics in five Texas counties are participating in the PDI. Two 
clinical facilitators are collecting baseline data and implementing the PDI in two 
distinct territories. Reports summarizing baseline data have been shared with the 
lead provider at four participating clinics, while baseline data is being finalized for 
four other sites.
Conclusion: By increasing vaccine initiation and completion among adolescents 
and young adults, EF has the potential to reduce cervical cancer incidence and 
mortality among Hispanic women in Hidalgo County.
 Increasing Providers’ Recommendation for HPV Vaccination 
Using Academic Detailing in South Texas
R. L. Romero, L. C. Crocker, B. Flores, E. K. Villarreal, D. Parra-Medina,  
and D. Y. Morales-Campos
Institute for Health Promotion Research, UT Health San Antonio, San Antonio, 
TX, USA
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Background: Initiatives targeting the uptake of human papillomavirus (HPV) vac-
cination have improved rates nationally; however, HPV-related diseases remain a 
significant health concern. Childhood cancer survivors (CCS) are uniquely vulner-
able to HPV-related second malignancies. Female CCS are 40% more likely and 
male CCS are 150% more likely to develop an HPV-related malignancy compared 
to their age-matched peers without a history of cancer. This increased risk is even 
more pronounced among CCS who received allogeneic stem cell transplantation, 
which is a common therapy for a subset of childhood cancer patients. Despite higher 
risks, a recent survey found that CCS have very low rates of HPV vaccination. Little 
is known about HPV vaccination rates among Hispanic CCS.
Objectives: Study aims included evaluation of (1) HPV vaccination rates among 
pediatric cancer survivors in South Texas and (2) HPV vaccination rates by demo-
graphic and clinical factors in this population.
Methods: Medical records of childhood cancer survivors treated at the South Texas 
Children’s Cancer and Blood Disorders Center in San Antonio, Texas, were retro-
spectively reviewed to identify all patients potentially eligible to receive the HPV 
vaccine (age 11–26 years during 2006–2016). Review of vaccine records through 
Texas ImmTrac vaccine registry and electronic clinical records verified HPV vac-
cination status. Demographic and clinical variables collected included DOB, gen-
der, race/ethnicity, cancer diagnosis, and cancer treatment.
Results: Of 210 records reviewed, 156 survivors were deemed vaccine-eligible. 
Of these, 21 (13.5%) received at least one vaccine, and only nine (5.9%) completed 
the three-dose series. Among females, 19% (16/84) initiated and 10.7% (9/84) 
Conclusion: We expect that AD will empower providers to make a strong recom-
mendation for the HPV vaccine and increase HPV vaccine initiation and completion 
rates in these rural clinic settings. Thus far, providers have been receptive to and 
interested in our findings, specifically showing interest in decreasing missed oppor-
tunities for vaccination, increasing the number of patients offered the vaccine, and 
developing strategies to remind patients to complete the vaccine series.
 Human Papillomavirus (HPV) Vaccination Rates 
Among Childhood Cancer Survivors in South Texas
A. Grimes, L. A. Shay, and L. Embry
Division of Pediatric Hematology/Oncology, UT Health San Antonio, San 
Antonio, TX, USA
Greehey Children’s Cancer Research Institute, San Antonio, TX, USA
Department of Health Promotion and Behavioral Sciences, UT Health School of 
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Background: The Advisory Committee on Immunization Practices (ACIP) recom-
mends routine human papillomavirus (HPV) vaccination for adolescents aged 
11–12 years. HPV vaccination is a series of two or three doses depending on the 
adolescents’ age. While vaccine initiation in Hispanics is higher compared to non- 
Hispanics both in the United States and Puerto Rico (PR), series completion remains 
an important concern. While many studies have explored series initiation, few stud-
ies have specifically examined barriers to series completion in minority populations, 
including Hispanics. To fill this knowledge gap, we conducted a qualitative study to 
explore barriers and facilitators to series completion among caregivers of Hispanic 
adolescents in Florida and PR.
Methods: Hispanic caregivers of adolescent boys and girls between the ages of 11 
and 17 years who received at least one dose of the HPV vaccine were recruited 
through community-based approaches at both sites, as well as local clinics in 
Tampa and the Puerto Rico Immunization Registry (PRIR). Eligible participants 
were consented and participated in either a telephone or in-person interview 
focused on understanding caregiver knowledge about HPV, exploring perceptions 
of HPV vaccination, and the barriers and facilitators of series completion. 
Quantitative data were analyzed using frequency distributions and qualitative data 
using deductive content analysis and coded using relevant constructs from the 
socio- ecological model.
 completing the vaccine series. Among males, only 6.9% (5/72) initiated the series 
and no males completed all three doses (0/72). Approximately 76% (119/156) of the 
sample was Hispanic/Latino. Among them, 14% (17/119) patients initiated the vac-
cine series and only 5.9% (7/119) completed. Furthermore, patients who received 
high-risk therapies (radiation, SCT) did not have increased uptake of the HPV vac-
cine compared to patients receiving only chemotherapy.
Conclusions: HPV vaccination rates among childhood cancer survivors in South 
Texas are lower than in the general population, both regionally and nationally. Given 
the increased susceptibility to secondary HPV-related malignancies, this study 
 demonstrates a clear need for enhanced efforts to increase HPV vaccination rates in 
this at-risk population.
 Barriers and Facilitators to HPV Vaccination Series 
Completion Among Adolescent Hispanics in Tampa and Ponce
S. T. Vadaparampil, L. Ruiz, L. Moreno, J. Garcia, M. L. Kasting, Ú. Martínez, 
P. Lake, P. Tiro, and G. P. Quinn
Moffitt Cancer Center, Tampa, FL, USA
Ponce Health Sciences University, Ponce, PR, USA
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Background: HPV vaccination is recommended for adolescents and young adults 
aged 11–26 years. Studies of adolescent HPV vaccination often rely on parental 
reporting of their children’s vaccination status when medical record review is not 
feasible. We evaluated the accuracy of parental reporting of daughters’ HPV vacci-
nation status among Hispanic parents who reported their daughters had not received 
any vaccine doses. We then examined parental correlates of correct classification of 
vaccination status.
Methods: To assess eligibility for an HPV educational intervention, interviewers asked 
parents of Hispanic girls, aged 11–17 years, about their daughters’ HPV vaccination 
history. We reviewed medical records to validate parental reports. We calculated the 
proportion of parents who accurately reported their daughters’ vaccination status 
and used hierarchical logistic regression modeling to determine socio-demographic 
characteristics associated with accurate vaccination reporting (AVR).
Results: Of 57 caregivers assessed for eligibility, 26 (46%) were consented, and 21 
(37%) completed the interview. All caregivers who were interviewed were female 
whose children had health insurance; one-third were between the ages of 30–40 years 
and most preferred communicating with their adolescents’ healthcare provider 
(HCP) in Spanish (~67%). Based on preliminary analysis of interviews, the most 
common intrapersonal-level (patient-related) barrier consisted of a lack of time to 
return for subsequent doses, while interpersonal-level (physician-related) barriers 
were lack of a strong recommendation, reminders for follow-ups, and confusion 
about how many doses were required and why. Organizational-level (system- 
related) barriers included patients having to go elsewhere for subsequent doses and 
clinics not having the vaccine in stock. Key facilitators of vaccination were aware-
ness of HPV prevalence and the vaccine efficacy, trusting the educational informa-
tion provided and having a personal experience with cancer.
Conclusions: Multiple factors contribute to low series completion rates among 
Hispanic adolescents. Results suggest that physicians and vaccination staff should 
emphasize the importance of series completion to patients and caregivers. This 
could in turn influence caregivers to prioritize returning for follow-up doses by 
sending reminders and reduce any potential confusion about how many doses are 
needed and why. Additionally, clinics should ensure that they have enough vaccine 
supply to meet the needs of age-eligible patients.
 Correlates of Accurate Parental Reporting of Hispanic 
Daughters’ HPV Vaccination Status
S. A. Rodriguez, L. S. Savas, P. Loomba, D. M. Lopez, S. W. Vernon,  
and M. E. Fernandez
Center for Health Promotion and Prevention Research, UT Health School of 
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Background: Groundbreaking milestones in regard to vaccine development are 
overshadowed by the low HPV vaccination rates nationwide. Data from the 2016 
National Immunization Survey Teen for youth aged 13–17 years indicates that only 
43.0% of females and 31.5% of males received all recommended doses. While the 
rates for Puerto Rico (PR) were similar to the rates observed at a national level, 
Results: We verified HPV vaccination status of 1109 daughters of participants. 
Overall, 70% of parents accurately reported their daughters’ vaccination statuses 
at  baseline, and 30% inaccurately reported their daughters’ vaccination statutes. 
Most daughters (56%) were between 13 and 17 years of age. Mean parental age was 
38.79 years and most parents (72%) had less than a 12th grade education. Most par-
ticipants (56%) lived in households earning more than $15,000 per year. Multivariable 
regression analysis revealed parents with younger daughters and households with 
higher income were significantly associated with accurate reporting of a daughter’s 
HPV status. Parents with daughters aged 11–12 years had higher odds of accurately 
reporting (OR = 1.68; 95% CI 1.19–2.38) that their daughters were unvaccinated at 
baseline compared to parents with daughters aged 13–17  years. Parents with a 
household income greater than $15,000 per year had higher odds of accurately 
reporting (OR = 1.44; 95% CI 1.02–2.04) that their daughters were unvaccinated 
compared to parents with household incomes less than $15,000 per year.
Conclusion: The results highlight the still prevalent problem of inaccuracies between 
actual HPV vaccination and self-report of vaccine receipt. Parental recall must be 
examined in studies that determine baseline vaccination rates to enable comparisons 
across groups. These findings have implications for future routine monitoring of 
vaccination coverage and may be particularly important for healthcare providers who 
need to ascertain the vaccination status of young adults.
 Association Between Family History of Cancer and HPV 
Vaccination in Puerto Rico
C. Jiménez-Lizardi, M. Soto-Salgado, C. Vélez-Álamo, A. Acevedo-Fontánez,  
and V. Colón-López
Interdisciplinary Program, Faculty of Natural Sciences, UPR Rio Piedras Campus, 
San Juan, Puerto Rico
UPR-MDACC Partnership for Excellence in Cancer Research, UPR Medical 
Sciences Campus, San Juan, Puerto Rico
Cancer Control and Population Sciences Program, UPR Comprehensive Cancer 
Center, San Juan, Puerto Rico
Graduate School of Public Health, UPR Medical Sciences Campus,  
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both are still lower than the Healthy People 2020 goal of reaching an 80% uptake. 
Compared to other cancers, less is known about the role of family history of cancer 
as an influence on HPV vaccination. This study aimed to determine the association 
between family history of cancer among parents/guardians and vaccinating their 
children against HPV.
Methods: An educational activity entitled “¡Habla de VPH!” for parents/guardians 
of newly admitted students from the University of Puerto Rico, Rio Piedras Campus 
(UPR-RP) held in the summer of 2014. This activity was a collaboration with the 
UPRRP Medical Services Department, the Puerto Rico Comprehensive Cancer 
Control Program, and the Puerto Rico Community Cancer Control Outreach 
Program (CCCOP) with the objective of disseminating general information to par-
ents/guardians regarding HPV and HPV vaccination, as well as provide information 
of the vaccination clinics available in PR.  For this study, eligible participants 
included parents/guardians and those who answered a survey that collected demo-
graphic information, HPV vaccination status of their children, HPV knowledge and 
family history of cancer. A multivariate logistic regression model was used to esti-
mate the prevalence odds ratio (POR) with their 95% confidence intervals (CI) for 
the association of family history of cancer among parents/guardians and vaccinating 
their children against HPV.
Results: Four hundred thirty-eight parents/guardians completed the survey. The 
mean age was 46.02 ± 2.26 years and the majority were females (84.5%). Age, sex, 
annual family income, and health insurance were significantly associated with hav-
ing their child vaccinated against HPV (p < 0.05). Multivariate logistic regression 
models showed that females (POR = 1.90, 95% CI: 0.99–3.64, p = 0.052) and par-
ents/guardians with the government health insurance (POR  =  2.84, 95% CI: 
1.41–5.72, p  =  0.003) were more likely to vaccinate their children against 
HPV. Although family history of cancer was not significantly associated with HPV 
vaccination, parents/guardians with family history of cancer were 11% (POR = 1.11, 
95% CI: 0.70–1.78, p = 0.648) more likely to vaccinate their children against HPV 
than parent/guardians without family history of cancer.
Conclusions: To our knowledge, this is the first study in PR to assess the association 
between family history of cancer and HPV vaccination. Gender and insurance are 
important predictors to consider when developing future HPV vaccination cam-
paigns. Although we did not observe a statistically significant association between 
HPV vaccination and parent’s family history of cancer, future studies should con-
sider if a specific cancer history (HPV-related cancers, genetic or behavioral related) 
or their own personal experience with HPV infection might drive the association 
with HPV vaccination of their children.
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Background/Purpose: Colorectal cancer (CRC) is the second most commonly 
diagnosed cancer and the third leading cause of cancer-related deaths among 
Hispanic men and women in the USA. While Hispanics in the USA show favorable 
outcomes for CRC compared to all other racial ethnic groups, Hispanics residing 
along the US–Mexico border exhibit disparities in both CRC incidence and mortal-
ity. Several risk factors may account for these late CRC stage diagnoses and mortal-
ity rates. The purpose of this study was to examine general (e.g., confidence to 
obtain screening) and cultural beliefs (e.g., fatalism) that may increase or reduce 
behavioral intentions to participate in CRC screening among Hispanics of Mexican 
descent.
Methods: Study participants included 153 Hispanic adults, who had never been 
screened/diagnosed for CRC, were at least 50 years old, and lived in the US–Mexico 
border region (e.g., Dona Ana, NM and El Paso, TX counties). Women composed 
73% of the sample. Factors assessed in this study included (1) perceived benefits of 
screening, (2) self-efficacy to obtain screening, (3) subjective (injunctive) norms for 
screening, (4) fear of screening, (5) cancer fatalism, (6) acculturation, (7) machismo, 
and (8) behavioral intentions to get screened. All measures were assessed via a self- 
report survey in the participants’ preferred language. Pearson correlations were 
calculated.
Results/Findings: Perceived benefits of screening, self-efficacy to obtain screen-
ing, and subjective (injunctive) norms for screening were all positively related 
(all r’s > 0.38, p < 0.05), and acculturation and machismo were negatively related 
(both r’s > 0.17, p < 0.05) to behavioral intentions to screen for CRC. Interestingly, 
cancer fatalism and fear demonstrated no significant relation to behavioral 
intentions.
Discussion: Hispanics of Mexican descent would benefit from interventions that 
target those belief systems that promote CRC screening. It is important to address 
culturally related beliefs acting as barriers to cancer screening and prevention.
 Factors Affecting Behavioral Intentions to Obtain Screening 
for CRC in Hispanics of Mexican Descent
K. Sondgeroth, R. Palacios, J. Padilla, and E. Bustos
Department of Public Health Sciences, New Mexico State University, Las Cruces, 
NM, USA
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Background: Colorectal cancer (CRC) is the fourth most commonly diagnosed can-
cer and the second leading cause of cancer-related death in men and women combined 
in the USA. If detected early, CRC is preventable and curable; however, low-income 
and minority groups carry the majority of the disease burden and have poorer survival 
once diagnosed compared to upper- and middle-income non- Hispanic whites. 
Minority groups in the USA also receive fewer colorectal cancer screening tests and 
are less likely to be up-to-date with screening than the population as a whole. In most 
states, less than 20% of minorities have been screened within the past year. In 2016, 
only 60% of Texans were up-to-date with screening. In Bexar County, San Antonio, 
the screening rate is even higher at 66%. However, several census tracts within Bexar 
County have CRC screenings rates below 50%. The purpose of this study was to 
increase CRC knowledge, attitudes, positive behavior change, intent for screening, 
and screening in South Texas through the implementation of Screen to Save: NCI 
Colorectal Cancer Outreach and Screening Initiative.
Methods: From March to December 2017, we partnered with CommuniCare Health 
Centers to recruit 139 patients and provide culturally tailored, evidence- based CRC 
education to increase knowledge, awareness, and CRC screening. CRC education 
was provided via Flip Chart, and pre/post surveys were administered to assess 
changes in CRC knowledge and intention to screen. A total of three surveys were 
offered in both English and Spanish, based on participants’ preference. The pre-
knowledge survey consisted of demographic information (education, ethnicity, and 
insurance status), screening history, family health history, and a total of 14 pre- 
knowledge test questions. The post-survey consisted of the same 14 knowledge ques-
tions as well as a section on intentions where patients were given five intention 
statements (such as “As a result of this initiative, I am more likely to talk to my doctor 
about screening”) and asked to rank on a scale of strongly agree to strongly disagree. 
A 3-month follow-up survey was conducted as a short phone interview and collected 
information on whether the individual completed screening, any barriers/challenges 
that prevented them from getting screened, and positive behavior change which eval-
uated whether the individual followed through with the intentions stated in their 
post-knowledge survey. All patients received CRC screening via FIT kit from 
CommuniCare Health Centers. All returned FIT kits were analyzed by CommuniCare 
in their lab. Patients who tested positive were linked to follow- up care.
Results: Of the 139 patients enrolled in the study, majority were female (74.1%), 
Hispanic (97.8%), and between the ages of 50 and 59 years. Eighty-two percent of 
 Implementation of Screen to Save: NCI Colorectal Cancer 
Outreach and Screening Initiative in South Texas
S. Prabhu, A. Flores, K. J. Gallion, E. Munoz, L. Tenner, and A. G. Ramirez
Institute for Health Promotion Research, UT Health San Antonio, San Antonio, 
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patients had an education level of high school or lower, and half (49.6%) of patients 
were uninsured. Over half of patients (57.6%) had never been screened for CRC in 
their life. Increase in CRC knowledge was observed for all 14 questions of the pre- 
and post-knowledge tests. Interestingly, only 8.3% of patients knew the risk factors 
for CRC. Majority of patients also did not know the age at which a colonoscopy and 
a stool test should be performed. At baseline, patients showed strong intention for 
positive behavior change and screening, with nearly all patients strongly agreeing or 
agreeing with all five intention statements. At 3-month follow-up, strong positive 
behavior change was observed with majority of patients (73.4%) talking to their 
doctor about CRC screening and half of patients (51.1%) completing CRC screen-
ing as a result of the initiative. About half (48.2%) of patients talked to friends or 
family about CRC screening.
Conclusion: Overall, Screen to Save was effective in improving CRC screening 
knowledge and intentions among CommuniCare patients using Flip Chart as an 
educational tool. At 3-month follow-up, strong positive behavior change was 
observed. However, patient-reported barriers and challenges show that stigma sur-
rounding CRC still remains.
 Implementation of a National Colorectal Cancer (CRC) 
Initiative Among Hispanics Across NCI-Designated Cancer 
Centers
A. Acevedo Fontanez, C. Barajas, K. J. Briant, J. Dang, J. Dejesus, M. Huerta, 
V. Landa, J. Lopez, C. Lopez De la Torre, M. Monge, S. Prabhu, A. Reyes, 
M. Serrano, K. Sondergoth, and S. L. San Miguel de Majors
University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
Yale Cancer Center, New Haven, CT, USA
City of Hope Comprehensive Cancer Center, Duarte, CA, USA
Baylor College of Medicine, Houston, TX, USA
Moffitt Cancer Center, Tampa, FL, USA
San Diego State University, San Diego, CA, USA
University of Illinois Chicago, Chicago, IL, USA
UT Health San Antonio, San Antonio, TX, USA
Columbia University Medical Center, New York, NY, USA
New Mexico State University, Las Cruces, NM, USA
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Introduction: Increasing CRC screening rates is one of the ten recommendations 
of the Blue Ribbon Panel for the Cancer MoonshotSM. To address these recom-
mendations, the National Cancer Institute’s (NCI) Center to Reduce Cancer 
Health Disparities (CRCHD) launched the national CRC Outreach and Screening 
Initiative, Screen to Save (S2S). S2S aims to increase CRC screening rates among 
men and women 50 years and older from racially and ethnically diverse commu-
nities and in rural areas across the USA. Among Hispanics in particular, CRC is 
the second most commonly diagnosed cancer and third leading cause of can-
cer death.
Methods: NCI-funded National Outreach Network (NON) and Partnerships to 
Advance Cancer Health Equity (PACHE) community health educators (CHEs) col-
laborated with community stakeholders to recruit participants and provide cultur-
ally tailored, evidence-based CRC education at various community, clinical and 
academic settings to increase knowledge, awareness, and CRC screening in their 
respective catchment areas. CHEs provided CRC education through an inflatable 
colon, an NCI PowerPoint presentation, and/or NCI flipcharts. CHEs administered 
NCI developed pre/post-surveys to participants during their S2S activities to assess 
any changes in CRC knowledge and intention to screen. This abstract focuses on 
Hispanic/Latino S2S participants 50 years and older. Statistical tests will be con-
ducted to evaluate the influence of S2S on participants’ CRC knowledge and screen-
ing intention scores.
Results: The S2S intervention was delivered to 3881 individuals, of which 1544 
self-reported as Hispanics/Latinos. Though data analysis is ongoing, we hypothe-
size that CRC knowledge and screening intention will increase significantly after 
implementation of S2S. We also predict that there will be no significant difference 
regionally but that differences may be seen by method and setting of intervention 
delivery.
Impact: The preliminary analysis will show the overall efficacy of S2S in increas-
ing CRC screening knowledge and intentions among Hispanic/Latino participants 
50 years and older through the use of culturally tailored, evidence-based methods. 
Differences seen by implementation type and setting may suggest that some meth-
ods or settings are more effective than others at improving CRC screening knowl-
edge and intentions.
Based on those findings CHEs will be able to target Hispanics/Latinos 50 years 
and over more effectively and perhaps improve lagging screening rates by using the 
most effective evidence-based implementation method.
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Background: Higher incidence and lower survival rates have been linked to racial/
ethnic and socioeconomic (SES) disparities in patients with pancreatic cancer. 
However, systematic evaluation of the interaction between race/ethnicity, SES, 
comorbidities, and type of surgical procedures to predict outcomes associated with 
pancreatic cancer are missing. Hence, we conducted this study to investigate these 
risk factors and outcomes of discharges associated with pancreatic cancer, with a 
specific focus on Hispanic population.
Methods: We surveyed Healthcare Cost and Utilization Project (HCUP) National 
Inpatient Sample (NIS) database for year 2014 to identify patients with pancreatic 
cancer (ICD9: 230.9, 157.1–157.4, 157.8, 157.9). To identify racial disparities, we 
examined age, median household income at zipcode level, various comorbidities 
(e.g., alcohol abuse, diabetes, obesity, liver disease, hypertension, and chronic 
 pulmonary disease), types of surgical treatments (surgical vs. nonsurgical options; 
Whipple vs. others) as a treatment choice, and death during hospitalization.
Results: From approximately seven million records, we identified 18,069 pancreatic 
cancer-related discharges. Majority of patients were non-Hispanic whites (NHW) 
(73%) followed by black (14%), Hispanic (8%), and others (5%) with a median age 
of 68 years (range: 0–90 years). Compared to NHW, Hispanics had a significantly 
higher prevalence of diabetes (40% vs. 30%, p < 0.001) and liver disease (8% vs. 5%, 
p < 0.001), whereas no significant differences were observed for obesity, hyperten-
sion, congestive heart failure, or alcohol abuse. Majority of Hispanic patients (39%) 
with pancreatic cancer belonged to lowest income quartile ($1–$39,999 per year) 
compared to NHW (20%), P-value <0.001. The only two factors associated with the 
difference in receiving Whipple procedure were having underlying liver disease and 
the income level, stratified by race/ethnicity. We did not identify any factors associated 
with differences in mortality rates during hospitalization.
Conclusions: We identified significant racial disparities such as higher prevalence 
of comorbidities, lower income levels, and different types of surgical procedures in 
Hispanic versus NHW patients hospitalized for pancreatic cancer. Future studies 
quantifying the impact of stage of illness at presentation, multiple comorbidities 
including smoking, rural/urban care setting, SES, insurance coverage on treatment 
choices, and outcomes associated with pancreatic cancer in different racial/ethnic 
groups are needed.
 Racial Disparities in Comorbidities, Income Levels, 
and Surgical Procedures Observed in Hispanic Patients 
with Pancreatic Cancer Compared to Non-Hispanic Patients: 
Results from the National Inpatient Sample Database
M. Peña, J. R. Kintada, S. Hegde, S. Rouhani, E. Muñoz, J. Michalek, A. Seifi, 
A. G. Ramirez, P. Kumar, and D. P. Shah
UT Health San Antonio, San Antonio, TX, USA
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Background: There is a need for describing and characterizing cancer treatments 
and outcomes in Latino populations. Osteosarcoma is the most common bone 
malignancy in children, adolescents, and young adults. Most study cohorts have 
10–15% Hispanic patients that encompass many different Hispanic backgrounds. 
The University of Texas Health Science Center at San Antonio (UTHSCSA) 
Sarcoma Team serves a Latino population that is predominantly Mexican American, 
thus providing a unique opportunity for the evaluation of this population. This study 
expands on previous data collected from January 2000 to December 2010 from the 
same institution, providing increased insights into outcomes of Mexican American 
children, adolescents, and young adults with osteosarcoma.
Methods: A retrospective analysis of demographics, tumor characteristics, response 
to treatment, and survival outcome of all localized osteosarcoma of the extremity 
patients below 30 years of age diagnosed and treated by the UTHSCSA Sarcoma 
Team between January 2000 and June 2017 was performed.
Results: In our original cohort from January 2000 to December 2010, we observed a 
significantly decreased 5-year event-free survival (EFS) in patients diagnosed before 
age 12  years (preadolescent) relative to patients diagnosed between ages 12 and 
29 years (11% vs. 57%, P < 0.001). Patients had a 5-year overall survival (OS) and 
event-free survival of 65% and 48%, respectively. In our expanded cohort from January 
2000 to June 2017, we evaluated 66 patients with a median age of 14 years (range, 
2–28 years) with localized high-grade osteosarcoma of the extremity. The expanded 
cohort was 68% Mexican American, with a median follow- up of 59 months (range, 
5–192 months). The analysis of our expanded cohort is ongoing, and we postulate that 
the findings will hold true, as we increase the cohort size and length of follow-up.
Conclusions: Analysis of our previous cohort, predominantly of Mexican American 
ethnicity, showed that preadolescent patients had an increased rate of relapse when 
compared with previous large studies. We also showed a trend toward decreased 
EFS for the entire cohort. We hypothesize that we will further validate these findings 
with this expanded cohort, and this will support further investigation into potential 
causes of poor outcome in this vulnerable Latino population.
 Characterization of Localized Osteosarcoma of the Extremity 
in Children, Adolescents, and Young Adults from South Texas: 
Increasing Insights into Hispanic Populations
K. Higgerson, R. Rajani, J. Heim-Hall, J. Y. Hung, A. M. Langevin,  
and A. J. Sugalski
School of Medicine, UT Health San Antonio, San Antonio, TX, USA
Department of Orthopedics, UT Health San Antonio, San Antonio, TX, USA
Department of Pathology, UT Health San Antonio, San Antonio, TX, USA
Division of Hematology and Oncology, Department of Pediatrics, UT Health  
San Antonio, San Antonio, TX, USA
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Introduction: Glucocorticoids have been a cornerstone of the treatment of childhood 
acute lymphoblastic leukemia (ALL) for decades. However, glucocorticoids are asso-
ciated with numerous adverse effects in children including avascular necrosis, growth 
impairment, and hyperglycemia. Among children with ALL who are exposed to high-
dose steroids throughout therapy, steroid-induced hyperglycemia (SIH) is a common 
problem, with an estimated incidence of 20.4% during induction alone (Lowas, 
Pediatric Blood Cancer 2009). SIH severity ranges from transient hyperglycemia to 
secondary diabetes with insulin dependence. In children with ALL, SIH is also associ-
ated with increased bacteremia, hospital readmission, and most importantly with 
diminished survival. Predisposing factors for SIH include a family history of diabetes, 
age > 10 years, and non-white ethnicity. Although it is known that Hispanic children 
have some increased genetic vulnerability to several drug-induced toxicities during 
ALL treatment, previous studies relied on self- reporting of ethnicity to describe these 
relationships. Therefore, we aimed to evaluate the association between SIH and 
Hispanic ethnicity in childhood ALL using Hispanic ancestral markers across a pre-
dominately Mexican-American patient population in South Texas.
Methods: We performed a retrospective chart review of 46 pediatric ALL patients 
treated at the South Texas Childhood Cancer and Blood Disorders Center at UT 
Health San Antonio between 2014 and 2017. Data collected included the  following: 
cancer diagnosis, date of diagnosis, age at time of diagnosis, gender, race/ethnicity, 
and two highest glucose values recorded. SIH was defined as serum glucose ≥ mg/
dL as fasting status was not available. Sixty-four Hispanic SNP ancestral markers, 
previously validated in the South Texas Hispanic population (Beuten, Annals of 
Human Genetics 2011), were analyzed using the Arizona Genomics Core: 
MASSArray. Three of the SNPs failed to capture. Allele frequencies for the remain-
ing 63 Hispanic SNPs were calculated using Qiagen’s Ingenuity Variant Analysis 
tool. Individual Hispanic SNP alleles were mapped to glucose values, and hypergly-
cemia association was evaluated by regression analysis, adjusting for age and gen-
der, using STATA software.
Results: Overall, 12/46 (26.1%) pediatric ALL patients met criteria for SIH.  Most 
patients (39/46, 84.8%) self-reported Hispanic ethnicity. Among Hispanic patients, 
SIH was seen in 25.6% (10/39). SIH incidence was similar in non-Hispanic patients, 
seen in 28.6% (2/7). Ancestral marker analysis and association studies are forthcoming.
Conclusion: Although limited by sample size, our data shows no association 
between self-reported Hispanic ethnicity and SIH.  However, Hispanic ancestral 
marker associations are still pending analysis. Although well-established that 
 Steroid-Induced Hyperglycemia and Hispanic Ancestry 
in Childhood ALL
R. Barrera and A. Grimes
Department of Pediatrics, UT Health San Antonio, San Antonio, TX, USA
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Introduction: Acute leukemia is an important cause of morbidity and mortality 
with differences in incidence and outcomes between patients of different racial/
ethnic backgrounds; however, most of the studies have focused on acute lympho-
blastic leukemia (ALL) in children. Hence, we conducted this study to examine the 
racial and ethnic disparities in incidence of ALL as well as other types of acute 
leukemia, specifically focusing on Latino population in South Texas.
Methods: Data were obtained from the US Surveillance, Epidemiology and End 
Results 18 (SEER) Program and the Texas Cancer Registry (TCR) under Limited- 
Use Data Agreements between sources and authors. Adult patients (15  years or 
older) were identified in both SEER and TCR databases from 2000 to 2014 and 
ICD-O-3 codes were used to select specific malignancies: ALL (9727–9729, 
9835–9837), acute promyelocytic leukemia (APL) (9866), and non-APL acute 
myeloid leukemia (AML) (9840, 9861, 9867, 9870–9874, 9891, 9895–9897, 9910, 
9920, 9930, 9931). Race/ethnicity was classified as Hispanic (H) and non-Hispanic 
white (NHW) per the North American Association of Central Cancer Registry 
(NAACR) Hispanic/Latino Identification Algorithm. For each malignancy, cases 
were obtained from SEER 18 and TCR, including both the State of Texas and the 38 
counties which comprise South Texas. Comparisons were made using SEER popu-
lation of NHW as point of reference. We used SEER∗Stat software v 8.3.4 
(SEER∗Stat, National Institutes of Health) to generate 2000–2014 average annual 
age-specific and age-adjusted acute leukemia incidence rates (per 1,000,000), rate 
ratios (RR), and 95% confidence interval (CI) for Hispanic and NHW populations 
in SEER, Texas, and South Texas regions.
Results: Hispanics in South Texas and specifically males had significantly higher 
RR for the development of ALL (p < 0.05) and lower for non-APL AML; there 
was no statistical difference for APL rates compared to NHW.  Within ALL, 
Hispanic children with ALL have poorer survival outcomes, it is unclear to what 
degree SIH may contribute, as SIH is known to be an independent risk factor for 
decreased survival in childhood ALL. Aggressive identification and management of 
SIH may improve survival outcomes among Hispanic children with ALL.
 Adult Hispanic Males Experience a Higher Incidence of Acute 
Lymphoblastic Leukemia Compared to Non-Hispanic Whites
M. R. Espinoza-Gutarra, E. Muñoz, D. P. Shah, A. Karnad, R. A. Mesa,  
and A. G. Ramirez
Department of Internal Medicine, UT Health San Antonio, San Antonio, TX, USA
Department of Population Health Sciences, Institute for Health Promotion 
Research, UT Health San Antonio, San Antonio, TX, USA
Mays Cancer Center at UT Health San Antonio, San Antonio, TX, USA
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Introduction: Over the course of 10 years, the Hispanic population in the United 
States has grown by 43% and is projected to make up 29% of the US population by 
2060. Since Texas is a minority-majority state, the demographic make-up foreshad-
ows the make-up of US population in the future where approximately 40% of the 
Texas population will be classified Hispanic. Hispanic is an umbrella classification 
for any person of Spanish descent and masks the complexity and heterogeneity 
within this group. Understanding the complexity of the Hispanic population requires 
going beyond this umbrella term. Mortality advantages exist in the Hispanic popu-
lation where both foreign-born and US-born Hispanic populations have better sur-
vival outcomes than native, non-Hispanic populations despite experiencing more 
disparities (i.e., lower SES, education, etc.). Unfortunately, little is understood 
among Hispanic subgroups in Texas regarding the Hispanic mortality paradox and 
how it pertains to cancer mortality. Since cancer is the second leading cause of death 
in United States and first among Hispanics, understanding the complexity and dif-
ferences within the Hispanic population will add to a growing body of literature 
regarding subgroup mortality advantages.
Methods: Using data from the Texas Cancer Registry, we will conduct a spatial 
exploratory data analysis to examine spatial patterns in cancer mortality among 
Hispanic subgroups in Texas from 2000 to 2014. We will use ARC GIS to map 
clusters for Texas counties to identify areas with higher and lower than average 
cancer mortality by Hispanic subgroup.
Results: We expect that cancer mortality outcomes will differ between Hispanic 
subgroups where mortality advantages will be seen among some groups but not 
others. Although, in general, a Hispanic paradox exists where mortality outcomes 
are more favorable among Hispanics despite existing disparities, more data is 
greater rates were seen in males and in the AYA (15–39 years) and 70–79 year 
groups (data not shown).
Conclusion: Latinos in South Texas experience a higher incidence of ALL and a 
lower incidence of most types of AML compared to NHW. Future studies are needed 
to identify specific risk factors associated with this higher burden in Hispanic 
population.
 Examining Spatial Differences in Cancer Mortality 
Among Hispanic Subgroups in Texas
D. R. Gordon and S. Schmidt
Department of Population Health Sciences, UT Health San Antonio,  
San Antonio, TX, USA
UT Health School of Public Health San Antonio, San Antonio, TX, USA
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Introduction: South Texas, defined as Public Health Region (PHR) 11, which 
includes Aransas, Bee, Brooks, Duval, Jim Hogg, Jim Wells, Kenedy, Kleberg, Live 
Oak, McMullen, Nueces, Refugio, San Patricio, Webb, and Zapata counties, as well 
as the Lower Rio Grande Valley (LRGV) counties of Hidalgo, Starr, Cameron and 
Willacy, is predominately Hispanic and currently experiencing rising cancer rates. 
Factors underlying specific increases in cancer incidence in this region are not 
currently well defined.
Methods: To investigate factors and cancer incidence rates in South Texas, we first 
conducted a systematic literature review focused on search terms related to diet and 
environmental factors, such as water contamination, air pollution, and pesticide 
exposure, in relation to cancer incidence in South Texas. We also analyzed data 
from the Texas Cancer Registry’s Web Query Tool for cancer incidence for Hispanics 
from 2005–2009 to 2010–2014 in PHR11 and LRGV counties.
Results: We identified elevated cancer incidence in comparison to the entire state, 
for leukemia, cervical, stomach, and liver cancers in PHR11, as well as targeted 
LRGV counties. Furthermore, based on our review, there is limited literature on the 
relationship between diet/environmental exposures and cancer incidence in the 
South Texas.
Conclusion: Little is known about the relationship between diet and environmental 
exposures and cancer incidence in South Texas. Our work is ongoing to investigate 
environmental factors and their association with specific cancer incidences 
mentioned above.
needed to understand and develop interventions among different subgroups specific 
to cancer mortality.
Significance: Understanding the cancer mortality differences among Hispanic sub-
groups will allow researchers and practitioners the ability to tailor health interven-
tions specific to mitigating the disparities and negative health issues among Hispanic 
subgroups in the United States.
 Examining Environmental Factors and Elevated Cancer 
Incidence in South Texas
S. Cantu, C. Umah, and N. Johnson
Department of Environmental and Occupational Health, Texas A&M School of 
Public Health, College Station, TX, USA
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This study examines racial and ethnic disparities in the trajectories of functional 
health limitations among older adults and explores how chronic conditions, such as 
cancer and health-related behaviors contribute, to the level and rate of change in 
functional limitations over time. Using data from the Health and Retirement Study 
(HRS) and a multiple-group latent growth model of functional limitations, findings 
reveal significant racial and ethnic disparities in functional status. These disparities 
are found to result primarily from differences in socio-demographic factors. 
Specifically, blacks and Hispanics are more likely to suffer functional limitations at 
the initial time period than non-Hispanic whites. However, net of years of educa-
tional attainment and wealth, a “disability crossover” is observed in the baseline 
odds of functional limitations from higher odds for blacks to higher odds for whites. 
In addition, non-Hispanic whites tend to have faster increases in the rate of change 
in functional limitations over time. Results also demonstrate that these observed 
racial and ethnic disparities in functional health derive from racial/ethnic group dif-
ferences in the presence of chronic conditions and health-related behavioral factors. 
Smoking and being overweight/obese is associated with the onset of functional 
limitations in older adults. Also, whites who are light drinkers had lower functional 
limitations at onset. None of the health-related behaviors influenced the rate of 
change in functional limitations over time across all three racial and ethnic groups.
These findings indicate that addressing racial and ethnic disparities in chronic 
conditions such as cancer and increasing healthful behavioral factors may minimize 
disparities in trajectories of functional health among older adults. Overall, func-
tional health of older adults can also be improved by implementing health interven-
tion programs such as early detection and screening and pursuing policies that 
support tobacco use cessation, weight reduction, and other health-related behaviors.
 Epidemiology and Surgical Management of Chondrosarcoma: 
A Case-Based Analysis
A. N. Saigal
 Disparities in Functional Health Trajectories  
Among Older Adults
R. B. Valdez and O. O. Akanni
Department of Family and Community Medicine and Economics, UNM, 
Albuquerque, NM, USA
Long School of Medicine, UT Health San Antonio, San Antonio, TX, USA
Patient Profile: KA is a 51-year-old Latina female with a chief complaint of left- 
sided shoulder pain for the last 2 years. Her past medical history includes right- sided 
pectoral melanoma and septic knee. Past surgical history includes right-sided mela-
noma excision, total knee arthroplasty, and rotator cuff repair. Her family history 
includes melanoma, breast cancer, prostate cancer, and colon cancer.
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Uveal melanoma (UM) is the most common primary malignancy of the eye and has 
a propensity for metastasis to the liver. There have been tremendous advancements 
in understanding the genomics of UM and the development of precision medicine 
for UM patients over the past decades, but the vast majority of this research has 
been performed in white populations of northern European ancestry. Hispanics/
Latinos represent the fastest growing racial/ethnic minority group in the USA, 
and they comprise a tremendous genetic heterogeneity due to different migratory 
patterns from Europe, Asia, Africa, and America, leading to genetically admixed 
Patient Workup: Her physical exam was notable for left shoulder pain with passive 
and active range of motion, positive Hawkins, Neer, and O’Brien tests, and tender-
ness to palpation throughout left shoulder. She previously received an MRI of the 
left shoulder showing a lesion in the proximal humerus. Biopsy of the lesion by 
interventional radiology showed cartilaginous proliferation with rare atypia. Based 
on workup, surgical excision and curettage with bone grafting was planned.
Surgical Procedures: A longitudinal incision in the deltopectoral interval of left 
shoulder was made and dissected down to proximal humerus. Using a 1/8th in. drill 
bit, multiple elliptical perforations were made throughout the proximal humeral 
cortex; the bony flap was removed in order to expose the bony lesion which was 
currettaged. A specimen was sent to pathology (report: cellular chondrocyte lesion 
with mild cellular atypia suspicious for chondrosarcoma) confirming pre-operative 
diagnosis by interventional radiology. Lesion was sprayed with 89% phenol, 
allowed to cure for 5 min and neutralized with isopropyl alcohol. The surgical site 
was then irrigated with normal saline and packed with 45 cc of cancellous bone 
chips and 2 cc of demineralized bone matrix putty. Finally the overlying periosteum 
was repaired and the wound closed.
Conclusion: Chondrosarcomas can present at any age and are more often axial than 
appendicular. Prognosis will vary considerably depending on the grade of the lesion. 
Clinicians should maintain a high index of suspicion for patients aged 50–70 years 
looking like they suffer from mass lesion-related bone pain—deep, dull, achy pain 
(especially at night), pathologic fractures, limited range of motion, or neuropathies. 
Advanced imaging is indicated in these cases. Surgical management can be of the 
intralesional or wide-excision varieties.
 Ancestral Analysis of Uveal Melanoma Patients
D. A. Rodriguez, M. I. Sanchez, C. L. Decatur, and J. W. Harbour
Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center, Miami, 
FL, USA
Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
Medicine, Miami, FL, USA
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Background: UV radiation is a major risk factor for skin cancer including mela-
noma, and incidence rates of melanoma have substantially increased over the past 
decades. Although Latinos have a lower incidence of melanoma compared to non- 
Latino whites, they tend to be diagnosed at younger ages, have a more advanced 
stage of the disease, and have lower survival rates. This project aimed at assessing 
the prevalence of sun protective behaviors and associated factors among Latinos in 
the USA.
Methods: This is a secondary data analysis of the 2005 Health Information National 
Trends Survey. Chi-square and Wilcoxon tests were used to detect differences 
between Latinos and other racial/ethnic groups. Logistic regression was performed 
to identify associations between sun protective behaviors with selected demographic 
variables including age, gender, education, income, health insurance status, and 
geographic location.
Results: Latinos do not regularly use sunscreen as recommended (78%), more than 
half (51%) do not seek shade, 62% do not wear a wide-brimmed hat, and 75% do 
not wear a long-sleeve shirt to protect themselves from the sun.
populations. Our ocular oncology center is in a unique position to elucidate the 
genetic ancestry of patients with UM, owing to our diverse catchment area. To 
determine genetic ancestry, we genotyped 48 UM patients, 20 self-reported 
Caucasian, 23 self- reported Hispanic, 2 self-reported Asian, and 3 self-reported 
black. European, African, East Asian, and Native American reference populations 
were obtained from the 1000 Genome project and the Human Genome Diversity 
Project (HGDP). A SNP overlap of over 300,000 SNPs was used to calculate global 
ancestral analysis. A PCA analysis of the genotyped data was performed and showed 
5% of self- reported Caucasians clustered outside of the European reference and 
showed a degree of admixture as seen in our Hispanic samples. The PCA analysis 
also showed that 30% of self-reported Hispanic patients clustered more closely to 
the European reference population while 70% showed admixture clustering closer 
to the African, East Asian, and Native American reference populations. These find-
ings confirm that genetic methods are required to accurately assess the contribution 
of ancestry to UM. This work lays the groundwork for future work in which we will 
use global and local genetic ancestry to assess the influence of ancestry on the risk, 
prognosis, and outcomes associated with UM.
 Sun Protective Behaviors Among Latinos in the US: 
A Secondary Data Analysis
S. Fragoso, E. Muñoz, and P. Chalela
UT Health School of Public Health San Antonio, San Antonio, TXUSA
Institute for Health Promotion Research, UT Health San Antonio, San Antonio, 
TX, USA
Appendix B: Cancer Epidemiology and Prevention
275
Background: Skin cancer is the most commonly diagnosed cancer in the USA, and 
melanoma incidence is increasing among the US Hispanic population. Even though 
the incidence of melanoma is lower for Hispanic than for non-Hispanic whites, 
when diagnosed Hispanics tend to be younger, have a more advanced stage of the 
disease and have lower survival rates. This is particularly important because 
Hispanics are the largest and fastest growing racial/ethnic group in the country and 
are heavily concentrated in the southern and western states which have among the 
highest ultraviolet indexes in the country. This study examines the prevalence and 
correlates of sun protective behaviors among low-income Latinas living along the 
US–Mexico border.
Methods: A survey was conducted with 200 adult women, living in the predomi-
nantly Latino region of South Texas. Participants completed an English or Spanish 
language phone survey in November 2012. Self-reported sunscreen use, shade seek-
ing, and use of sun protective clothing were the outcomes of interest. Correlates 
included selective demographic variables, knowledge of skin cancer risk, tanning 
bed use, past year sunburns, and acculturation.
Results: Multiple logistic regression revealed that sunscreen use was associated 
with age (OR 3.59, CI 1.08–11.98), education (OR 0.36, CI 0.18–0.73), sunburns 
last year (OR 2.19, CI 1.16–4.13) but not with cancer knowledge, tanning bed use, 
or acculturation.
Conclusion: Latinas in the border do not routinely practice sun protective behaviors 
and are in need of skin cancer prevention interventions. Further research is war-
ranted to design and evaluate intervention to increase sun protective behaviors and 
reduce the risk for skin cancer among this population group.
Conclusion: As the largest minority group in the country and given their low rate of 
sun protective behaviors, Latinos are a critical group to target for skin cancer pre-
vention. Tailored and culturally sensitive interventions are recommended to reduce 
skin cancer-related morbidity and mortality among Latinos. Public health education 
initiatives should be aimed primarily at younger, less educated, and lower income 
groups, and when possible, involve their families and healthcare providers.
 Sun Protective Behaviors Among Latinas Living  
in the US–Mexico Border
P. Chalela, E. Muñoz, and A. Ramirez
Department of Population Health Sciences, Institute for Health Promotion 
Research, UT Health San Antonio, San Antonio, TX, USA
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Background: Engaging Latinos in cancer prevention research is necessary to 
reduce the burden of tobacco-related cancers use among ethnic minorities, since 
many disparities continue to exist in tobacco use and exposure. Exacerbating this is 
that tobacco control actions and regulatory messages are not always conveyed in 
culturally specific ways or in the most linguistically appropriate manner, particu-
larly for ethnically diverse communities such as African-Americans, American 
Indians, Koreans, and Latinos. To obtain relevant information to support appropri-
ate approaches, Community Health Workers (CHWs) or Key Opinion Leaders 
(KOLs) may be helpful as sources. CHWs and KOLs are potentially central in 
addressing the effects of the tobacco retail environment as they are aware of their 
strengths, needs, and vulnerabilities.
Methods: This presentation discusses two studies within a project conducted in Los 
Angeles that use both CHWs and KOLs to inform regulatory practices. We present 
data from eight focus groups conducted with KOLs (N = 70) to explore the role that 
KOLs could play as potential channels for the FDA in delivering tobacco regulatory 
messages to retailers. We recruited KOLs who represented different industries and 
agencies to gain a broad understanding of the tobacco retail environment in different 
ethnic communities. We also present data and lessons learned from working with 
CHWs in a study conducted in tobacco retail outlets (N = 800). The data collection 
methods include store employee interviews and observations.
Results: Most of the KOLs felt that retailers were moderately to well-informed of 
tobacco laws. Less than half of the KOLs, however, believed that retailers were 
aware of FDA authority over tobacco products. When shown materials for a regula-
tory message, most of the KOLs expressed concern that the materials may not be 
effective given the language, colors, and content used. While most retailers, 70.8%, 
reported that they had no barriers to compliance, less than half, 43.5%, believed that 
the FDA had regulatory authority over tobacco products.
Conclusions: The findings from this project highlight how KOLs and CHWs each 
provide an independent window into their communities. The information gained 
from these different channels in turn creates a stronger foundation for future tobacco 
control messages and educational campaigns that are likely to be received well in 
ethnically and linguistically diverse populations.
 Addressing Tobacco Regulation in the Retail Environment 
with Community Voices
R. García, L. Baezconde-Garbanati, C. Soto, P. Escobedo, K. Blackman, J. Huh, 
and R. Bluthenthal
Department of Health Promotion and Community Health Sciences, Texas A&M 
University, College Station, TX, USA
Department of Preventive Medicine, University of Southern California,  
Los Angeles, CA, USA
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Background: Smoking among Latino young adults (18–29) in South Texas is high 
(23.2–25.7%), representing a serious public health problem. Yet few are reached by 
services to help them quit smoking. Young adults are heavy users of mobile devices 
for texting and access to mobile media. These have an extraordinary potential for 
assisting smoking cessation by providing peer modeling and eliciting social rein-
forcement for behavior change. We present preliminary results of Quitxt, a bilingual 
text messaging and mobile media service to help young adults quit smoking.
Methods: We constructed a bilingual texting and mobile media system that was pro-
moted in South Texas via social media advertising and other recruitment channels. 
The ads, which featured couples with different themes (disgust with cigarettes or con-
fidence in quitting success) and styles (cowboy, metro/urban, geek, punk, and graphic 
novel), asked potential participants who showed interest in quitting smoking to text a 
code to our system corresponding to the channel of recruitment. Text messages include 
links to web pages with additional content and YouTube videos with peer modeling of 
reasons and skills to quit smoking.
Results: Results showed that enrollments were achieved for 798 participants with a 
mean age of 29.3 years and 55% were below the age of 30 years. More men (57%) 
than women (43%) enrolled and 36% identified themselves as Hispanic or Latino. 
The mean number of cigarettes consumed per day was 11.5. Seven-month texted 
follow-up found that 21% (171) of the enrollees reported abstinence at that point. 
This is consistent with high rates of success found in studies of telephone counsel-
ing for young adults and confirms that text and mobile media service specifically 
designed for young adults provide a feasible and cost-effective approach to promot-
ing cessation.
Conclusion: Preliminary results provide evidence that young adult smokers in 
South Texas can be reached via mobile media service. The anticipated outcome is a 
scalable, culturally relevant, evidence-based, and cost-effective service with broad 
national reach to help young adult Latinos stop smoking, with the potential to 
reduce healthcare costs, reduce chronic disease burden, and improve quality of life 
among this young, fast-growing, at-risk population.
 Quitxt: A Text-Based Smoking Cessation Service for Young 
Adults in South Texas
P. Chalela, A. L. McAlister, K. J. Gallion, E. Muñoz, C. Despres, D. Akopian, 
S. Kaghyan, A. Fernandez, R. Diaz, and A. G. Ramirez
UT Health San Antonio, San Antonio, TX, USA
UT School of Public Health Austin, Austin, TX, USA
University of Texas San Antonio, San Antonio, TX, USA
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Background: Adjuvant endocrine hormonal therapy is highly effective and appro-
priate for nearly all women with hormone receptor-positive tumors, making such 
treatment the most widely prescribed therapy for patients with this type of breast 
cancer. Despite the proven benefits in reducing cancer recurrence and improving 
survival, hormone therapy adherence is suboptimal (less than 80%). About 33% of 
patients do not take their medication as prescribed and are at increased risk of dis-
ease recurrence and increased mortality.
Objective: We present the design and development process of a theory-based, cul-
turally tailored, interactive mobile app to improve adherence to endocrine hormone 
therapy among breast cancer patients as the initial phase of a two-group randomized 
clinical trial study.
Methods: Four focus groups (n = 21) were conducted with breast cancer patients 
and personal semi-structured interviews (n = 8) with oncologists, nurses, and patient 
navigators to assess barriers and facilitators to endocrine hormone therapy adher-
ence, key symptoms, app content, and features. Qualitative data informed the initial 
design and development of app mock-ups; these were assessed with two additional 
focus groups (n  =  10) and based on formative research a functional phone app 
prototype was developed for beta testing.
Results: Inputs from patients and healthcare team members helped to identify specific 
app content and features. Key themes included the importance of increasing patient 
education, enhancing self-efficacy, facilitating communication with the medical team, 
and helping patients to develop self-care skills to promote optimal adherence to hor-
mone therapy. Specific app features included notification pop-ups, reminders, motiva-
tional messages, symptom tracking and management tips, educational content, social 
networking among patients, communication with a patient navigator, local resources, 
including support groups, and technical support. In addition to colors, background, 
and icon preferences, patients emphasize the need for a user-friendly app that is easy 
to navigate with simple and clear educational content.
Conclusions: We followed an iterative and patient-centered design process to 
develop a bilingual, culturally tailored, and interactive mobile app prototype to be 
used in a randomized control trial. The anticipated outcome is a scalable, evidence- 
based, and easily disseminated intervention with potentially broad use to patients 
using oral anticancer agents.
 A Bilingual Mobile Application Prototype to Promote 
Endocrine Hormone Therapy Adherence in Breast  
Cancer Patients
P. Chalela, E. Muñoz, A. Fernandez, C. Despres, D. Inupakutika, D. Akopian,  
and A. G. Ramirez
UT Health San Antonio, San Antonio, TX, USA
University of Texas San Antonio, San Antonio, TX, USA
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Background: BRCA1/2 mutations are the most commonly identified Hereditary 
Breast and Ovarian Cancer (HBOC) mutations. Latinas have the second highest 
prevalence of BRCA1/2 mutations after Ashkenazi Jews. However, compared to 
non-Hispanic whites, Latinas have a lower use of HBOC cancer risk assessments 
(GCRA) (genetic counseling and testing if appropriate). While some studies have 
identified barriers for GCRA use in this population, few studies have focused on 
healthcare providers’ perspectives or provided insights into the counseling process 
for Latinas. The study aimed to examine provider’s perceptions on barriers and 
facilitators for at-risk Latina women use of GCRA services as well as their experi-
ences providing services to this population.
Methods: We conducted semi-structured interviews with 20 healthcare providers 
(e.g., genetic counselors, patient navigators) recruited nationally through snowball-
ing. Interviews were transcribed verbatim. Two coders independently coded each 
interview and then met to reconcile the codes using Consensual Qualitative Research 
guidelines.
Results: We identified 16 barriers and five facilitators to participate in GCRA. Barriers 
included financial (e.g., cost, lack of insurance), structural (suboptimal referrals), 
and psychosocial factors (e.g. limited awareness about GCRA, cancer stigma). The 
most frequently identified facilitators included the availability of low cost/no cost 
resources and motivation to inform the risk of relatives, especially given the impor-
tance of family in the Latino culture. The awareness about safety net programs and 
other resources to cover GCRA varied among providers. Genetic counselors 
described several challenges they faced during counseling with Latinas including 
language barriers, challenges obtaining accurate family histories, addressing mis-
conceptions, limited communication among relatives, addressing emotional con-
cerns, and barriers testing relatives outside the USA.
Conclusions: This project adds to the very small literature on providers’ perspec-
tives on GCRA participation in ethnic minorities. Increasing providers’ awareness 
about GCRA low cost/no cost resources and developing interventions to improve 
 Provider’s Perceptions of Genetic Cancer Risk Assessment 
for Latina Women at Risk of Hereditary Breast and Ovarian 
Cancer
A. Hurtado de Mendoza, K. D. Graves, L. Anderson, S. Gómez Trillos, Q. Zhu, 
S. Stearns, C. N. Evans, C. Campos, N. Gonzalez, and V. B. Sheppard
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, 
DC, USA
California State University, Long Beach, CA, USA
University of Pennsylvania, Philadelphia, PA, USA
Nueva Vida, Inc., Alexandria, DC, USA
Virginia Commonwealth University, Richmond, VA, USA
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Background/Introduction: Latinas at increased risk of hereditary breast and ovar-
ian cancer (HBOC) participate in genetic counseling and testing at strikingly lower 
rates than non-Hispanic whites and other minority groups. Increasing awareness of 
cancer risk and promoting uptake of appropriate risk reduction and management 
strategies, including use of genetic services, can help reduce cancer disparities. 
There is an urgent need for alternate models to facilitate risk appropriate referral to 
and navigation through genetic services that address socioeconomic, language, and 
cultural barriers.
Methods: We developed Programa de ÁRBOLES Familiares, an innovative training 
program to help bridge the gap between Latinas at risk for HBOC and genetic ser-
vices. Our program targets 250 bilingual English and Spanish community outreach 
and educational professionals (CORE-P). We aim to develop a trained network of 
CORE-P with referral-level competence to facilitate risk appropriate uptake of 
genetic services among Latinas at risk for HBOC.
Results: Programa de ÁRBOLES Familiares will consist of a 1.5  day in-person 
workshop followed by eight online modules. In-person training includes didactic 
and interactive activities related to family history, risk assessment, genetics and 
genetic testing, HBOC, risk management, HBOC in Latinas, communication, and 
ethical, legal, and social issues related to genetic testing. The eight online modules 
include topics related to identifying community members at risk for HBOC, educating 
the referral process will be important to enhance GCRA uptake among this popula-
tion. Exploring other genetic counseling modalities to overcome language barriers 
and targeting counseling to address cancer stigma and communication barriers 
among Latino families are warranted.
 Programa de ÁRBOLES Familiares: An Innovative  
Training Program for Community Outreach and Educational 
Professionals to Assess Risk of Hereditary Breast and Ovarian 
Cancer in Latinas
K. D. Graves, L. Jandorf, A. Hurtado-de-Mendoza, B. Peshkin, F. Lynce, 
M. Schwartz, G. P. Quinn, T. Pal, L. Moreno, K. Lopez, J. Garcia,  
and S. Vadaparampil
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, 
DC, USA
Icahn School of Medicine at Mount Sinai. New York, NY, USA
New York University School of Medicine, New York, NY, USA
Vanderbilt University, Nashville, TN, USA
Moffitt Cancer Center, Tampa, FL, USA
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Background: Breast cancer prognosis depends on stage at diagnosis and varies by 
intrinsic tumor subtype. In the USA, the distribution of tumor subtypes has been 
shown to differ between racial/ethnic groups with African American and Latina 
women more likely to be diagnosed with the more aggressive “triple negative” 
breast cancer (TNBC) compared to non-Latino white women. Latinos in the USA 
originate from different countries with different cultures and ancestral genetic back-
grounds, demonstrating the heterogeneity that exists. Information about the distri-
bution of tumor subtypes in Latin American regions is limited.
Methods: Data for these analyses come from The Peruvian National Cancer 
Institute (INEN), which include clinical information for 303 patients diagnosed 
with breast cancer between 2010 and 2015 and who are members of Indigenous 
American communities. We analyzed women from different groups: the Quechuas 
(Group 1; N = 223), Aimara (Group 2; N = 9), Ashankinka/Nomatsigenga/Yenesha 
(Group 3; N = 17), Awajun/Kichwa/Shawi/Shipibo-Konibo (Group 4; N = 29), and 
other communities (Group 5; N = 20). Some communities were combined based on 
previous literature describing their genealogical proximity. We compared tumor 
characteristics and survival between these groups using Fisher exact tests, T-tests, 
and a Cox Proportional Hazards model with predictors’ age at diagnosis, stage, 
about genetic risk, identifying genetics professionals, accessing resources, providing 
referrals to and navigating Latinas through genetic services.
Significance/Impact: We will assess the effectiveness and impact of our training 
program by evaluating changes in trainees’ knowledge, self-efficacy, and skills 
related to referral of high-risk Latina women to appropriate genetic services. We 
will assess community impact by trainee self-report regarding implementation of 
risk assessment procedures and education and referral of high-risk women to genet-
ics services. If successful, the ÁRBOLES Familiares training program can serve as 
a model for training CORE-P about other hereditary health conditions and provide 
a strong platform on which to expand trainees’ knowledge, self-efficacy, and skills 
related to genomic risk and technologies in the future.
 Breast Cancer Characteristics and Survival Among Different 
Indigenous American Communities in Peru
L. Tamayo, T. Vidaurre, J. Navarro Vásquez, S. Casavilca, 
J. I. Aramburú Palomino, M. Calderon, G. H. Rauscher, and L. Fejerman
Division of Epidemiology, University of Illinois at Chicago, Chicago, IL, USA
Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
Division of General Internal Medicine, Institute of Human Genetics and 
Comprehensive Cancer Center, University of California San Francisco, San 
Francisco, CA, USA
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tumor subtype, and treatment. Breast cancer subtype was defined as luminal A (ER/
PR+/HER2−), luminal B (ER+/HER2+), HER2 overexpressing (ER/PR− HER2+), 
and triple negative (ER/PR− HER2−) based on immunohistochemistry.
Results: Overall, tumors from the 303 Indigenous American women included in the 
present study were 37% luminal A, 20% luminal B, 23% HER2 overexpressing and 
19% triple negative. Our analyses showed that women from group 1 were diagnosed 
at an older age (55 vs. 48–50 years, p < 0.0001) and less frequently with TNBC 
compared to women from other groups (45% vs. 55–78%, p = 0.06). Compared to 
group 1, women from the other groups show a nonsignificant trend toward higher 
mortality (hazard ratio 1.5–1.9, p = 0.272). In the full model, including age, stage, 
tumor subtype, and treatment, the trend was no longer apparent. Whether the women 
had surgery had the strongest effect on survival (p  =  0.001) followed by stage 
(p = 0.0012) and TNBC (p = 0.0023).
Conclusion: Differences in survival between the women of different indigenous 
communities with breast cancer in Peru are most likely due to differences in access 
to care. There could be environmental factors or subtle sub-continental genetic dif-
ferences influencing the risk of TNBC.  However, the lower frequency of TNBC 
among the Quechuas could also be due to a reduced set of logistic barriers to reach 
INEN. The limited power of this study demonstrates the need for larger data sets for 
subgroup analysis in Latinas. The more we learn by analyzing diverse populations 
and subpopulations and revealing heterogeneity within Latin American women, the 
better equipped we will be to provide adequate care for all women.
 Increasing Uptake of Genetic Counseling Among Hispanics 
at Increased Risk for Inherited Breast Cancer
S. T. Vadaparampil, E. Castro, C. Ricker, L. Moreno, J. Garcia, R. Maldonado, 
M. Kasting, U. Martinez, H. Soliman, G. P. Quinn, and J. Dutil
Moffitt Cancer Center, Tampa, FL, USA
Ponce Health Sciences University, Ponce, PR, USA
USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
New York University School of Medicine, New York, NY, USA
Background: Despite the established role of BRCA and other high to moderate 
penetrance genes in increasing breast cancer (BC) risk in Hispanics, this group is 
less likely to participate in genetic counseling (GC) and testing compared to non- 
Hispanic whites. Guided by our prior work documenting barriers for utilization of 
genetic services among Hispanic women and the Behavioral Model of Health 
Services Utilization, we developed and pilot tested an educational intervention to 
increase the uptake of telephone GC.
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Background: During 2009–2013, 73,563 new breast cancer cases were reported in 
the State of Texas. During this 5-year period, the age-adjusted breast cancer inci-
dence rates averaged 113.3 per 100,000 population at risk for the disease. The State 
of Texas is one of the states with the lowest breast cancer incidence rates in the 
USA. However, when comparing these same rates between Texas counties, the values 
Methods: High-risk Hispanic female BC survivors without prior GC and/or test-
ing were recruited using community-based approaches in Tampa, Florida, and 
Ponce, Puerto Rico. Eligible participants were consented and completed a baseline 
survey. Participants were then randomized to receive (1) a brief fact sheet about 
BC survivorship and the option to receive a survivorship care plan (SCP) (control), 
or (2) an educational booklet about GC and testing (developed based on multiple 
rounds of cognitive debriefing and targeted to Hispanic women based on prefer-
ences) with the option to receive telephone GC and testing free of charge (inter-
vention). After randomization and mailing of educational materials, we followed 
up with participants 1 month after baseline to assess changes in knowledge and GC 
uptake. Quantitative data were analyzed using frequency distributions and inde-
pendent sample T-tests.
Results: From the 82 women assessed for eligibility, 66 met inclusion criteria, and 
51 (77.2%) consented and were randomized to the study conditions (n = 25 inter-
vention; n = 26 control). Most women at both sites were between the ages of 51 and 
60 years (52%), identified themselves as Hispanic white (68%), college  graduates 
(48%), and had health insurance (88%). One month after baseline participants com-
pleted the follow-up assessment, knowledge in the intervention group increased 
compared to control group (t(45) = −1.909; p = 0.045). The majority of women in 
both groups opted to receive the offered resources (76% of the participants in the 
intervention group opted to receive GC and 89% of the participants in the control 
group opted to receive an SCP). The most common reasons for declining GC 
included lack of time (n = 5) and anxiety (n = 1). Control group participants did not 
seek genetic counseling and/or testing during the study period.
Conclusions: Results from this pilot study show significant increases in GC knowl-
edge and utilization of genetic services, thus providing one approach to reducing 
disparities through the use of genetic and genomic services targeted to Hispanic 
populations.
 A Spatial Analysis of the Breast Cancer Incidence Rates 
in Texas Counties, 2009–2013
F. Ghirimoldi
Department of Demography, The University of Texas at San Antonio,  
San Antonio, TX, USA
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Background: In the United States (US), breast cancer disparities persist for 
Hispanics compared to other ethnic groups. Breast cancer is the leading cause of 
cancer-related death among Hispanic women, and Hispanic women receive mam-
mography screening at lower rates than other ethnic groups, which are associated 
with increased risk for possible late-stage diagnosis and lower survival rates.
show a great variability that cannot be fully understood by only considering the age 
structure of the population. To date the influence of specific behavioral and environ-
mental risk factors on the breast cancer incidence rates for Texas counties has not 
been accurately established. Thus, focusing on the effects of certain population and 
ecological characteristics distributed at these counties may help identify high-risk 
areas within the State of Texas. This study examines the ecological relationship 
between the breast cancer incidence rates and a series of known potential and proxy 
risk factors for the disease across Texas counties.
Data and Methods: The 2009–2013 Age-Adjusted Breast Cancer Incidence rates 
from the Texas Cancer Registry and data from the 2016 County Health Rankings 
were employed. A negative binomial model and an alternative regime linear model 
were fitted in order to measure the effect of potential and proxy cancer- related risk 
factors on breast cancer incidence rates in Texas counties and to identify high-
risk areas.
Results: The effects of the risk factors for the disease is not stationary and tend to 
vary in magnitude across Texas counties with different sociodemographic charac-
teristics. Counties located along the US–Mexico border showed lower breast cancer 
incidence rates, although these counties could be more vulnerable to the disease due 
to the high concentration of potential risk factors for the disease.
Significance: Promoting more health education programs and tailored interventions 
designed for reducing the impact of potential risks factors for the disease in high-
risk areas could help moderate disparities and reduce the burden of breast cancer for 
the Texas families.
 Systematic Review of Mammography Screening Educational 
Interventions for Hispanic Women in the United States
J. S. Luque, G. Soulen, A. Logan, K. E. Armeson, D. Garrett, C. B. Davila,  
and M. E. Ford
Institute of Public Health, Florida A&M University, Tallahassee, FL, USA
Department of Public Health Sciences, Medical University of South Carolina, 
Charleston, SC, USA
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
University of South Carolina, Columbia, SC, USA
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Methods: This systematic review aims to synthesize the current literature on educa-
tional interventions to increase mammography screening among Hispanic women. 
The review included studies with experimental and quasi-experimental designs pub-
lished between May 2003 and September 2017, which focused on diverse Hispanics 
in the US to increase the rates of mammography screening. Five studies met inclu-
sion criteria for the review.
Results: All studies used an interpersonal intervention strategy employing commu-
nity health workers, or promotoras, to deliver the intervention. For each study, odds 
ratios (OR) were calculated to estimate the intervention effectiveness based on simi-
lar follow-up time periods. The study ORs resulted in a narrow range between 1.02 
and 2.18, indicating a low to moderate intervention effect for these types of interper-
sonal cancer education interventions. The summary OR for the random effects 
model was 1.67 (CI 1.24–2.26).
Conclusion: Hispanics exhibit lower levels of adherence to screening mammogra-
phy. Interpersonal cancer education interventions such as the use of promotoras 
help to mediate the impact of major barriers to receiving a mammogram such as 
socioeconomic disadvantage, low health literacy, and lack of access to health care.
 Racial/Ethnic Disparities in Patient-Reported Quality of Care 
Measures Among Medicare Breast Cancer Patients: Analysis 
of the SEER-CAHPS Data Set
A. J. Farias, S. I. Bang, A. Hamilton, and X. L. Du
Department of Preventive Medicine, University of Southern California,  
Los Angeles, CA, USA
Gehr Family Center for Health System Science, University of Southern California, 
Los Angeles, CA, USA
Department of Pharmaceutical and Health Economics, Leonard Schaeffer Center 
for Health Policy and Economics, University of Southern California, Los Angeles, 
CA, USA
Department of Epidemiology, Human Genetics and Environmental Health, 
University of Texas Health Science Center at Houston, Houston, TX, USA
Background: Hispanics are less likely to receive appropriate adjuvant breast cancer 
treatment, which partially contributes to racial/ethnic disparities in cancer mortality. 
Excellent patient experiences with care, a measure of quality of care, is associated 
with receipt of recommended treatment for patients with chronic conditions; how-
ever, little is known about whether these measures are important for patients diag-
nosed with breast cancer. Therefore, the objective of this study was to identify 
racial/ethnic and socioeconomic differences in patient-reported experiences with 
care at the time of cancer diagnosis.
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Methods: We used the SEER cancer registry and patient surveys from the Consumer 
Assessment of Healthcare Providers and Systems (CAHPS)-linked dataset to iden-
tify Medicare breast cancer patients diagnosed between 1997 and 2011, over the age 
of 65 years, and who completed a CAHPS survey prior to the date of diagnosis. 
CAHPS survey responses were used to generate five composite measures of patient 
experiences with (1) getting needed care, (2) getting needed prescription drugs, (3) 
getting care quickly, (4) physician communication, and (5) customer service. We cre-
ated a binary measure for each composite score of 90–100 as excellent versus 80–100. 
In the multivariable logistic regression analyses examining racial/ethnic differences 
in the proportion of patients reporting excellent experiences with each composite 
measure, we included variables for age at survey, marital status, census tract-level 
poverty and education, SEER region, Medicare type (fee-for- services, Medicare 
advantage), survey mode (mail, telephone), comorbidities (0, 1, 2+), and survey year.
Results: Of the 10,144 patients, 80.7% were non-Hispanic white, 7.6% black, 7.1% 
Hispanic, and 4.6% Asian. The proportion of patients that reported excellent experi-
ences for each composite measure are: (1) 70.2% for getting medical care when 
needed, (2) 76.5% for getting prescription care when needed, (3) 58.9% for getting 
access to medical care quickly, (4) 65.4% for communicating with their physician, 
and (5) 62.4% for customer service. After controlling for potential confounders, 
Hispanics had lower odds of reporting excellent experiences with getting needed 
medical care (OR: 0.75, 95% CI: 0.63–0.91) and with getting prescription drugs 
(OR: 0.79, 95% CI: 0.65–0.97) compared to non-Hispanic whites. More impor-
tantly, this pattern persisted in the stratified analysis by cancer stage (0, I–III, IV) for 
Hispanics versus non-Hispanics whites diagnosed with stage I–III breast cancer.
Conclusion: Among Medicare breast cancer patients, Hispanics compared to non-
Hispanic whites reported poorer experiences with getting needed care and prescrip-
tion drugs prior to their diagnosis. Research is needed to determine whether these 
racial/ethnic differences in patient experiences with care are associated with receipt 
of appropriate cancer treatment.
 Racial/Ethnic Differences in Long-Term Adjuvant Endocrine 
Therapy Adherence and Mortality Among Medicaid-Insured 
Breast Cancer Patients in Texas: A TCR-Medicaid 
Retrospective Cohort Study
A. J. Farias, W. H. Wu, and X. L. Du
Department of Preventive Medicine, University of Southern California,  
Los Angeles, CA, USA
Gehr Family Center for Health System Science, University of Southern California, 
Los Angeles, CA, USA
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Background: Racial/ethnic disparities in breast cancer mortality may be attributed 
to differences in adherence to adjuvant cancer treatment. Our purpose was to deter-
mine whether the mortality disparities could be explained by racial/ethnic differ-
ences in long-term adherence to adjuvant endocrine therapy (AET).
Methods: We conducted a retrospective cohort study with the Texas Cancer Registry 
and Medicaid claims-linked dataset of women (20–64 years) diagnosed with local 
and regional breast cancer who filled a prescription for AET from 2000 to 2008. 
Adherence to AET was measured at three time points (1-, 3-, and 5-year adherence) 
using a value for the percentage of medication filled for each period divided by the 
total number of possible prescriptions prescribed (medication possession ratio, 
MPR). We created a binary variable of adherence (MPR ≥ 80%). We performed 
multivariable logistic regressions to assess racial/ethnic differences in the odds of 
AET adherence and Cox proportional hazard models to determine the risk of mor-
tality adjusting for AET adherence, potential confounding variables of area-level 
socioeconomic status, comorbidities, tumor prognostic factors, and other cancer 
treatment.
Results: Of the 1497 women with breast cancer who initiated AET, 56.9%, 42.3%, 
and 33.3% were adherent for 1, 3, and 5 years, respectively. The cohort was com-
prised of 37.8% non-Hispanic white, 18.6% black, 38.9% Hispanic, and 4.0% other 
race/ethnicity women with breast cancer. Hispanics compared to non- Hispanic 
whites did differ significantly in the proportion that were adherent to 5 years of AET 
(36.8% versus 35.3%). In the adjusted analysis for long-term adherence to AET, 
Hispanics did not have significantly increased risk of death compared to non- 
Hispanic white patients (HR: 1.13, 95% CI: 0.58–2.21). However, black compared 
to non-Hispanic white women had significantly lower odds of 3-year adherence 
(OR: 0.45, 95% CI: 0.28–0.73) and after controlling for 5-year adherence to AET in 
the fully adjusted model, the disparity in the risk of death between black versus non- 
Hispanic white women was reduced and no longer significant (HR: 1.86, 95% CI: 
0.94–3.66).
Conclusions: Long-term adherence to AET in the Medicaid population is subopti-
mal and racial/ethnic differences in AET adherence may partially explain disparities 
in mortality since Hispanics were not less likely than non-Hispanic whites to be 
adherent to AET. This study underscores the critical need to ensure long-term adher-
ence to AET for all racial/ethnic groups.
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Background: Annually, more than 230,000 women are diagnosed with breast cancer 
in the USA. Among Hispanic women, invasive breast cancer is the leading cause of 
cancer death in the United States. Further, Hispanic women are more likely to be 
diagnosed with regional and distant breast cancer than non-Hispanic white women. 
Timely diagnosis and treatment initiation are key in achieving best outcomes for 
these women; however, differences continue to exist in access to screening and 
diagnosis particularly among rural and minority populations. Despite lower overall 
mortality among Hispanic women who have breast cancer, having health insurance 
remains the most significant predictor of utilizing mammography services, with 
insurance rates being lowest for Hispanics. This research aims to examine the role 
that living in disadvantaged neighborhoods have on the likelihood of being diag-
nosed with late-stage breast cancer in Hispanic women in an attempt to understand 
disparities in accessing health care.
Methods: Using 2007–2014 data from the Surveillance, Epidemiology and End 
Results (SEER) Cancer Registry, the Texas Cancer Registry, and the Area Health 
Resource File, we construct a county-level deprivation index to examine disparities 
in late-stage breast cancer diagnoses among Hispanic and non-Hispanic women and 
net individual level characteristics. We use multilevel logistic regression models 
adjusting for spatial and temporal clustering.
Results: Preliminary results for women diagnosed with breast cancer between 2000 
and 2013  in the SEER registry data show that Hispanic women (OR  =  1.18; 
p < 0.01), women living in rural areas (OR = 1.12; p < 0.01), and women living in 
counties with higher levels of deprivation (OR = 1.06; p < 0.01) had higher odds of 
being diagnosed with late-stage breast cancer. Subgroup analysis for Hispanic 
women only showed that while rural/urban status did not impact their odds of late- 
stage diagnosis, the effect of the deprivation index remained unchanged.
Impact: Timely diagnosis of breast cancer is key in providing patients with 
chances for best outcomes, as late-stage diagnosis dramatically reduces 5-year sur-
vival rates. Identifying factors that limit timely diagnosis both on the individual 
and contextual level and how these factors differ among vulnerable patients 
(i.e., minority and rural women) can inform policy and program makers to design 
targeted interventions to improve access to care and treatment.
 County-Level Socioeconomic Deprivation and Late-Stage 
Breast Cancer Diagnoses Among Hispanic Women in the USA
S. Schmidt and D. R. Gordon
Department of Population Health Sciences, UT Health San Antonio,  
San Antonio, TX, USA
UT Health School of Public Health San Antonio, San Antonio, TX, USA
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Background: Germline testing for BRCA1/2 genes provides an opportunity to 
reduce mortality and morbidity by adopting appropriate risk reduction and screen-
ing options, in particular risk-reducing bilateral salpingo-oophorectomy (BSO). 
There is a paucity of data on Latinas and prophylactic measures among BRCA1/2 
carriers. Existing studies are limited either by the small number of Latinas or to a 
specific geographic location. Factors related to decision-making have also not been 
evaluated.
Methods: The UPTAKE study is an observational study of 100 Latinas with germ-
line BRCA1/2 mutations. Subjects were recruited nationally and, by telephone 
interviews, reported uptake of prophylactic surgeries (BSO, bilateral mastectomy in 
unaffected women, and contralateral mastectomy in carriers with breast cancer 
(BC)). Women with ovarian cancer were ineligible. All women had to have been 
informed that they carried a deleterious BRCA1/2 mutation at least 1 year prior to 
completing the interview. Objectives of this study were (1) to examine the rate of 
uptake of prophylactic surgeries; (2) to identify acculturation and attitudinal factors 
related to decisions made; (3) to examine relationships between primary language, 
receipt of genetic counseling (GC) and in which language it was provided and 
uptake of prophylactic surgeries.
Results: Our population was diverse in terms of country of origin: 57% were born 
in the USA, 23% in Mexico, 6% in Puerto Rico, 4% in El Salvador, 3% in Ecuador, 
and 7% in other countries of Latin America. Seventy-seven percent of patients 
received genetic counseling before undergoing genetic testing. The majority of the 
patients received their genetic test results from the genetic counselor (45%) or the 
medical oncologist (36%). Most patients did not undergo multigene panel testing 
(77%). Forty-three patients had a deleterious BRCA1 mutation; 45 had a deleterious 
 UPTAKE Study: Uptake of Preventive Surgeries 
Among Latinas with BRCA1/2 Mutations
F. Lynce, A. Serrano, S. Friedman, Z. Nahleh, J. Dutil, C. Campos, C. Ricker, 
P. Rodriguez, Y. Duron, C. Isaacs, and K. D. Graves
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, 
DC, USA
Force—Facing Our Risk of Cancer Empowered, Tampa, FL, USA
Texas Tech Physicians of El Paso, El Paso, TX, USA
Ponce School of Medicine and Health Sciences, Ponce, PR, USA
Nueva Vida, San Juan, Puerto Rico
University of Southern California Norris Comprehensive Cancer Center,  
Los Angeles, CA, USA
Virginia Cancer Specialists, Fairfax, VA, USA
Latino Cancer Institute, San Jose, CA, USA
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Background/Introduction: For Latina breast cancer survivors, breast cancer- 
related lymphedema (BCRL) is a treatment sequela with the potential to negatively 
impact physical and psychological function. Research has demonstrated that theory- 
based interventions can positively impact health behaviors that address BCRL 
development risk. Ethnic and cultural considerations can influence the outcome of 
such interventions, but may not be well understood in minority populations. With 
the increase in the Latino population in the United States, it is critical for the cancer 
care community to discover and address the factors which increase BCRL risk and 
may negatively impact long-term quality of life for this population. This literature 
review undertook to identify successful intervention strategies that address BCRL 
in the Latina population.
Methods: MEDLINE, Scopus, CINAHL, ONS website, and Google Scholar databases 
were searched. PRIMSA guidelines were used to assess and select articles for review. 
The review yielded 11 intervention studies from 2005 to 2017 addressing physical 
activity, diet, and quality of life concerns for the Latina breast cancer survivor.
Results: Most interventions using a theoretical framework were guided by social 
cognitive theory. For Latina breast cancer survivors, three strategies were found to 
be important for mediating healthful behavior change: overcoming language barriers, 
BRCA2 mutation and 12 had both. Sixty-eight percent of women opted to undergo 
BSO and 61% were satisfied with the decision. Non-US-born women were more 
likely to be dissatisfied with their decision to proceed with BSO (p = 0.03). In a 
logistic regression model, uptake of BSO was related to young age (p < 0.001), 
being US born (p = 0.03) and higher annual household income (p = 0.06).
Conclusions: To our knowledge, this is the largest study that evaluates uptake of 
prophylactic measures in Latinas known to be BRCA1/2 carriers. Our study included 
a heterogeneous group of participants in terms of country of origin, income, and 
level of education including English knowledge and was conducted across various 
academic and community centers in the country. The uptake of prophylactic surger-
ies among Latinas with germline BRCA1/2 mutations was slightly lower (68%) 
than what has been reported in non-Hispanic whites (71–74%) but higher than in 
African Americans (32–50%). Our findings suggest the need for targeted interven-
tions in this minority group to increase the uptake of measures with a reduction in 
mortality.
 Interventions Addressing Latinas with Breast Cancer-Related 
Lymphedema (BCRL): A Review
E. A. Anderson, M. Enriquez, and J. M. Armer
Sinclair School of Nursing, University of Missouri-Columbia, Columbia,  
MO, USA
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Background: It is imperative to identify lifestyle interventions to reduce the risk of 
recurrence in breast cancer survivors (BCS). Pro-inflammatory dietary patterns 
have been associated with elevated cancer risk. The Mediterranean diet (MD) is an 
anti-inflammatory (AI) dietary pattern consisting of high intake of fruits, vegeta-
bles, whole grains, nuts, legumes, fish, and monounsaturated fats such as olive oil; 
moderate intake of dairy and alcohol; and limited red and processed meat. 
Additionally, the variety of antioxidant containing spices and herbs (SH) used in the 
observing social modeling, and enhancing self-efficacy. This review suggests that 
family involvement, peer mentoring, culturally tailored educational materials, and 
time to practice self-care skills are important elements of a behavior intervention 
that can lead to successful adoption of BCRL-risk reducing behaviors.
Conclusion: The literature suggests that more theory-based, culturally tailored inter-
ventions addressing BCRL risk in the Latina community are needed. An increasing 
Latina population makes such research highly pertinent in today’s cancer care envi-
ronment. Future studies could identify additional population factors and clarify 
behavior themes to provide stronger guidance for researcher activities and health-
care professionals who care for these survivors. Understanding the unique factors 
that influence health behavior for Latina survivors at risk for or living with BCRL 
could improve long-term behavior maintenance. Implications for practice: 
Healthcare professionals may benefit from more education about BCRL risk factors 
in Latina breast cancer survivors. Survivorship care plans should be culturally tai-
lored and address interventions and assessment for long-term surveillance for 
BCRL. Culturally tailored assessment tools, education sources, and interventions 
should be developed and tested to address health behavior barriers. Family involve-
ment in BCRL risk reduction and management activities should be considered for 
this population.
 Dietary Intervention Among Breast Cancer Survivors 
Increased Adherence to an Anti-inflammatory Dietary 
Pattern: The Rx for Better Breast Health Randomized 
Controlled Trial
K. E. Zuniga, D. L. Parma, E. Muñoz, M. Wargovich, B. Brownell,  
and A. G. Ramirez
School of Family and Consumer Sciences, Nutrition and Foods, Texas State 
University, San Marcos, TX, USA
Department of Population Health Sciences, UT Health San Antonio,  
San Antonio, TX, USA
Department of Molecular Medicine, UT Health San Antonio, San Antonio, TX, USA
CanSurvive Cuisine, LLC, San Antonio, TX, USA
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MD may contribute to its AI activity and health protective role. The majority of 
dietary interventions among BCS have been conducted in non-Hispanic white 
(NHW) women; thus, there is a need to test the efficacy of interventions in more 
diverse BCS populations. The aim of this analysis was to determine if a 6-month, 
culinary-based, dietary intervention increased adherence to an AI dietary pattern in 
NHW and Latina BCS.
Methods: Overweight and obese, early stage (0–III), English-speaking BCS who 
had completed treatment at least 2 months prior to study enrollment were random-
ized to the intervention (I; n = 76) or control (C; n = 77). The sample was recruited 
from the San Antonio, Texas area; over 50% of the baseline sample was Latina. 
The I consisted of individualized, AI dietary guidelines and behavior-change cues 
delivered during six monthly in-person workshops, monthly motivational inter-
viewing telephone calls by trained patient navigators, and monthly newsletters tai-
lored to individual change readiness. Each workshop consisted of a didactic portion, 
a cooking demonstration with a chef skilled in AI food preparation, a tasting, and 
interactive discussion. C participants received monthly informational brochures and 
no navigational services. At baseline and 6 months, participants completed an MD 
adherence questionnaire, an assessment of SH use, and a 3-day food diary. MD and 
SH questionnaire scores and 3-day food record variables were analyzed with a 2 × 2 
repeated measures ANOVA.  McNemar’s test identified changes in adherence to 
individual MD guidelines and frequency of use of individual SH, between baseline 
and 6 months.
Results: MD scores in the I but not the C group significantly increased. The I group 
increased adherence to MD guidelines related to reduced red meat consumption 
(p = 0.008), increased fish and shellfish consumption (p = 0.001), and reduced con-
sumption of commercial sweets and baked goods (p = 0.007). No significant changes 
in MD guideline adherence occurred in the C group. SH scores significantly 
increased in the I but not the C group. The I group significantly increased the use of 
cinnamon, turmeric, garlic, ginger, black pepper, and rosemary (p’s < 0.05); only 
cinnamon use significantly increased in C group (p  =  0.039). Although calorie 
reduction was not a focus of the I, the I group significantly reduced caloric intake 
(p = 0.037).
Conclusion: An evidence- and theory-based dietary intervention in BCS success-
fully increased adherence to an AI dietary pattern. These results can inform the 
design of future AI dietary interventions in diverse BCS samples as well as other 
cancer populations.
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Background: Health communication strategies, increasingly including mobile 
health strategies, have been effective at improving cancer-related behaviors; how-
ever, conceptualizations of “culture” in health communications and research have 
generally meant African-American culture or Spanish language translations. Thus, 
how acculturation—the process of adapting to mainstream US culture—interacts 
with communication influence processes is unknown. US Latinos hold particular 
beliefs, values, and attitudes, and these may be related to the ways in which informa-
tion is processed. Explicating the dual processes of acculturation and media influ-
ence is critical to improving the efficacy of cancer communication strategies and 
eliminating Latino disparities. Diet behaviors provide an opportunity to examine 
how acculturation may complicate communication strategies, since epidemiological 
studies have demonstrated a “Dietary Acculturation Paradox”: as Latinos accultur-
ate, their risk for poor dietary behaviors increases. Specifically, acculturation to 
mainstream US culture is associated with increased consumption of high-fat foods 
including fast foods and decreased consumption of fruits and vegetables, making 
improved understanding of cultural influences on communication effects especially 
important for health communicators.
Purpose: This study—a work-in-progress at the time of abstract submission—aims 
to develop and test a set of culturally appropriate healthy diet text messages, extrap-
olating theoretical constructs that guide the integration of acculturation and cultural 
values and integrating these with the principles of message design and behavior 
change theories. The present study builds on findings from qualitative interviews 
with young adult Mexican-American women, which found that although feeling 
“Mexican” was a source of pride and that food was an important way to express 
one’s Mexicanness, that food was perceived as unhealthy. Stated in another way, 
participants felt that to be healthy, they felt they had to reject traditional ways of 
eating. Thus, while appeals to culture may be necessary to garner the attention of 
bicultural Latinos, messages that simply advise Latinos to eat their cultures’ “tradi-
tional” foods may backfire.
Methods: A team of bilingual, bicultural researchers developed original nutrition 
communication text messages using principles of cultural relevance and empow-
erment derived from the Decolonize Your Diet movement and cookbook. 
Development included a process of “transcreation” that has been previously 
employed. The messages will be tested with bicultural Mexican-American women 
aged 18–29 years and ultimately packaged as part of a mobile-enabled healthy 
diet intervention.
 Nutrition Communication for Cancer Prevention 
Among Latinas: Toward a Dynamic Conceptualization 
of Acculturation
A. S. Ramírez and K. Arellano-Carmona
Department of Public Health, University of California, Oakland, CA, USA
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Discussion: This project will advance understanding of the dynamic influence 
processes of acculturation and communication on diet behaviors to inform effec-
tive nutrition communication interventions for cancer prevention among bicul-
tural Latino/as.
 The LLEAD Study (Latinas Learning About Density): 
A Three-Arm RCT to Examine Psychological and Behavioral 
Effects of Density Inform Legislation in a US Federally 
Qualified Health Center
C. Radecki Breitkopf, C. Vachon, K. Ghosh, D. Rhodes, B. Borah, V. Pizzitola, 
V. Suman, J. Ridgeway, and S. Jenkins
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Department of Radiology, Mayo Clinic, Rochester, MN, USA
Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA
Background: Among Latinas, breast cancer is the most common cancer and the 
leading cause of cancer mortality. As more is known about the association between 
breast cancer risk and mammographic breast density, an increasing number of US 
states have adopted legislation that mandates written notification of breast density 
as part of the mammogram results letter. Examination of this notification has shown 
variability in content, understandability, and readability. The purpose of this study 
is to determine whether educational enhancement of mandated breast density noti-
fication results in increased knowledge of breast density as a breast cancer risk fac-
tor, decreased anxiety, and adherence to mammography among Latinas (primary 
cognitive, psychological, and behavioral outcomes).
Methods: LLEAD is an ongoing three-arm RCT comparing behavioral and psy-
chological outcomes in Latinas who receive mandated mailed notification per cur-
rent clinical practice (usual care) vs. two educationally enhanced approaches that 
are theory informed, culturally consistent, and novel in this context. Two thousand 
Latinas undergoing screening mammography in a federally qualified health center 
will be randomized 1:1:1 to mailed notification (usual care); mailed notification 
plus written breast density educational materials (enhanced); or mailed notifica-
tion, written breast density educational materials, plus verbal explanation by a pro-
motora (interpersonal). The study will examine the potential mechanisms through 
which written or verbal information influences motivation and continued screening 
behavior as well as potential moderating factors such as depression and breast can-
cer worry that have been linked to diagnostic delays among Latinas. The study 
includes multiple psychological measures (anxiety, depression, knowledge/under-
standing of breast density, perceived risk of breast cancer, breast cancer worry, 
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Introduction: Latinas continue to experience one of if not the highest rates of 
cervical cancer compared to other racial/ethnic groups in the United States. Latino 
parents seem to accept provider recommended HPV vaccines for their children, but 
continue to fall far below the Healthy People 2020 goal of 80% vaccination, espe-
cially for young boys. In 2016, up-to-date HPV vaccinations for Latino adolescents 
in the US was 49.9% (with 55.3% of females and 44.6% of males up-to-date). 
Furthermore, although national studies suggest higher vaccine rates among Latino 
children compared to other racial/ethnic groups, these national rates may be obscur-
ing rural Latino rates, especially in states or areas that have higher than national 
averages of foreign-born Latinos, and lower than average rates of educational attain-
ment and health insurance; all factors that can contribute to lower odds of vaccina-
tion status. For small rural towns, these factors may be exacerbated by economic, 
geographic, and social barriers to vaccine access. The Midwestern state in which the 
project was conducted does not have data available on Latino HPV vaccination rates. 
self-efficacy) and behavioral outcomes (continued adherence to mammography, 
discussion of breast density with a healthcare provider, uptake of supplemental 
screening). Measurement time points include baseline/enrollment, post-density 
notification, and 1 and 2 years post enrollment. Qualitative inquiry related to pro-
cess and outcomes of the interpersonal arm and cost analysis related to its imple-
mentation will be undertaken to understand the intervention’s delivery and 
transferability.
Results: This study is currently under way, thus trial results are unknown. Participant 
characteristics will be described for those presently enrolled; study measures 
(patient-reported, process, and outcome) and intervention materials will be pre-
sented along with challenges and “lessons learned” in implementing this trial and 
engaging Latinas in clinical research.
Significance/Impact: The effect of providing women with written notification of 
their breast density and its impact on breast cancer risk, absent other contextual 
information, may have unintended consequences, particularly among Latinas with 
lower health literacy and limited resources. Our study is intended to build the evi-
dence base in the area of cancer risk communication and offer empirically tested, 
generalizable educational strategies for delivering density information to Latinas in 
limited-resource settings.
 Applying a Community Engaged Model to Community-Clinic 
Linkages: Trial and Error in a Small Rural Town
J. Daniel-Ulloa, L. Seegmiller, A. Duarte, B. Baquero, and E. Moreno
University of Iowa Prevention Research Center, Iowa City, IA, USA
West Liberty Coalition, Washington, DC, USA
Appendix B: Cancer Epidemiology and Prevention
296
This project is a description of the process used by our research group to build 
partnerships, identify major barriers to access based on community input, and to 
implement a project to link community education and clinic resources to increase 
access to the HPV vaccine in a rural Latino population.
Methods: This project was guided by principles of community-based participatory 
research (CBPR). We describe the adaption of the step-by-step process to a small 
town setting. We framed the project into three phases: (1) community approach and 
entry, (2) assessment and development, (3) implementation and evaluation.
Results: In Phase 1, we contacted and began building relationships with several 
civic and social organizations in the town, most notably the local Catholic Church, 
but also several informal Latino community leaders. We conducted a Photovoice 
project, a community forum, and had dozens of informal conversations with Latino 
residents. Two main objectives were identified as next steps: (1) develop tailored 
education for the community and (2) provide access to the HPV vaccine in town. 
Phase 2 began with the development of a group-based health education intervention, 
that for a variety of important reasons failed to reach many community members 
and was determined an ineffective method to increase vaccination rates. Through 
conversation with community advisors and partners, it became apparent that educa-
tion did not have the necessary reach into the community and created confusion if 
we could not also provide access to the vaccine. This realization led to Phase 3 and 
the development and implementation of a community–clinic linkage to provide both 
HPV education and vaccination in a local setting.
Conclusion: The rural Latino population continues to grow around the country; how-
ever, the fastest growing Latino populations are often in rural or frontier areas and 
often in areas that have little experience serving Latinos. These emerging communi-
ties often lack access to health services and/or grassroot community organizations. 
Thus, it is important that we begin to examine, develop, and implement strategies that 
build on local resources and capital linked to resources in community settings. This 
project has been an attempt to develop such a process. Several important challenges 
were encountered and lessons learned that will provide important information for 
other similar communities across the Midwest and other rural areas.
 Building a Health Temple Primary Cancer Prevention 
Program Among Latinos
S. Wilmoth, E. Martinez, L. Carillo, M. Pan, E. Sosa, Z. Yin, D. Parra-Medina, 
L. M. Neira, A. Price, and M. He
The University of Texas at San Antonio, San Antonio, TX, USA
University of Austin, Austin, TX, USA
San Antonio Food Bank, San Antonio, TX, USA
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Introduction: The Building a Healthy Temple (BHT) Primary Cancer Prevention 
Program is a translational research program adapting and implementing “Body and 
Soul,” an evidence-based cancer prevention program created for African-American 
churches, into Latino churches. BHT aims to reduce cancer risks through the 
promotion of healthy lifestyles among Latinos.
Methods: BHT was a 4-month program adapting the four pillar model of B&S. BHT 
intervention components included Health Sermons, Health Bible Study, Nutrition 
Education and Cooking Demonstrations, Active Living Competition, Health 
Ministry Committee (HMC), church health-conducive environmental changes, and 
Peer Counseling by trained health lay leaders. The program was implemented in 17 
churches and reached approximately 3422 individuals in San Antonio’s low-income 
neighborhoods between 2014 and 2017. Using a one group pre/post-test design, 
BHT measures both congregational and individual level changes. Congregational 
level outcomes (i.e., nutrition and physical activity environment) were measured by 
the Congregational Health Index. Individual level eating and physical activity 
behavior were measured using the National Cancer Institute Dietary Screener 
Questionnaire and the International Physical Activity Questionnaire short form, 
respectively. Self-reported body mass index and waistline, as well as social demo-
graphics, were also assessed. Data were collected at baseline, endpoint, and 1-year 
follow-up.
Results: At the church level, BHT significantly improved churches’ nutrition envi-
ronmental/policy. Examples of nutrition environmental/policy improvements made 
by church HMCs include church provision of nutritious meals and refreshments; 
increase in healthy beverage availability; church provision of low-fat options; and 
church practice of food purchasing and preparation to reduce fat content of foods. 
BHT also improved church physical activity (PA) environmental and policy. 
Examples of PA environmental/policy improvements made by church HMCs 
include improved church-built environment to support PA; increased PA equipment 
availability at church; church promotion of PA; improvement in safety of church PA 
facilities. At an individual level, BHT was effective in reducing added sugars and 
added sugars from beverages, as well as increasing dairy and calcium consumption. 
BHT also increased the proportion of participants who met dietary guidelines for 
fruit and vegetables from 8.3% baseline to endpoint with 13.9% (n = 110, χ2 = 22.87, 
p < 0.05) of participants meeting USDA guidelines for fruit and vegetable consump-
tion. The percentage of participants meeting the Physical Activity Guideline 
(150 min of moderate or 75 munities of vigorous activity per week) significantly 
(n = 149, χ2 = 16.4, p ≤ 0.001) increased from 57% at baseline to 75% endpoint. In 
addition, BHT significantly decreased mean BMI and waist circumference among 
overweight and obese participants.
Conclusion: The BHT program targets three preventable cancer risk factors, i.e., 
poor nutrition, physical inactivity, and obesity, among Latinos. BHT has signifi-
cantly improved both church environment and individual lifestyle leading to reduced 
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cancer risks. BHT has the potential to be disseminated on a broad scale to meet 
community needs, impact practice and policy, and ultimately lead to the reduction 
in cancer risks among underserved Latinos.
 Culturally Relevant and Appropriate Cancer Risk Counseling 
and Education for Underserved Latinas
L. Mayorga, G. Juarez, and M. Perez
Department of Medicine, University of California Irvine, Irvine, CA, USA
Background: Research demonstrates that Latinas are highly likely to have cancer 
risk associated with genetic predisposition to breast cancer and ovarian cancer. In 
addition, underserved Latinas have a compelling need for access to genetic cancer 
risk assessment (GCRA) and cancer screening and prevention measures, along with 
culturally appropriate education.
Objectives: The primary purpose of this project was to evaluate the effectiveness of 
a culturally relevant GCRA educational intervention for Latinas.
Methods: Four focus groups were conducted consisting of Latinas that have under-
gone GCRA. Participants completed a demographic questionnaire that included 
items assessing perceived cancer risk and patient satisfaction. The focus groups 
entailed a facilitated discussion of the key study variables and other culturally rel-
evant issues that may impact the GCRA intervention. Descriptive statistics and 
thematic analysis were used and analyzed.
Results: Findings show that there is a perceived sense of lack of information, edu-
cation, and uncertainty about what to expect appeared to play a key role in distress. 
Most women initially had negative expectations (expecting the worse or bad out-
come), but ultimately felt hopeful that they could learn more about the GCRA 
process and what it meant for them. Information was cited as the primary contribu-
tor to positive psychosocial outcomes specifically increased locus of control and 
self-efficacy. Cultural themes identified were destiny, religious, and spiritual cop-
ing mechanisms, how cultural attitudes and beliefs influence lack of information, 
community awareness, and public health issues.
Conclusions: Findings indicate that the pre-GCRA window may be most distress-
ing for this population indicating that this may be the most appropriate time for 
psychological intervention.
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 Disseminating Cancer Education and Navigation Training 
to CHWs
K. Nimmons, B. Macareno, M. Sanchez, P. Saldana, C. Catanach, J. Helduser,  
and J. Bolin
Texas A&M University Health Science Center School of Public Health,  
College Station, TX, USA
Texas A&M University Health Science Center School of Rural Public Health, 
Health Policy and Management, College Station, TX, USA
Texas A&M Southwest Rural Health Research Center, Bryan, TX, USA
Background/Introduction: The Access to Cancer Training, Information, Outreach 
and Navigation (ACTION) project engages Community Health Workers (CHWs) 
and organizations to deliver culturally competent cancer education to vulnerable 
communities in Texas. By disseminating CHW training on Breast, Cervical, and 
Colorectal Cancer prevention, detection, treatment, survivorship, and cancer navi-
gation, the ACTION project aims to reduce disparities in cancer knowledge, screen-
ing, and outcomes.
Methods: With funding from the Cancer Prevention Research Institute of Texas, the 
team of CHWs and instructors prepared ten CHW training modules in-person and 
online, in English and Spanish. All modules are available at no charge to CHWs. In 
addition to training modules, the ACTION project provides print and online 
resources for cancer education and outreach for CHW use in their home communi-
ties. For organizations, the ACTION project provides packaged curricula, technical 
assistance, and supporting materials to assist with the implementation of new CHW 
cancer training and outreach programs across the state.
Results: Over 1000 CHWs received training and resources in the first 21 months of 
the 2-year project. Through partnerships with CHW organizations in Laredo, 
Harlingen, Rio Grande City, Corpus Christi, Tyler, Bryan, Austin, and Houston, 
ACTION CHW instructors trained 341 CHWs in person. An additional 746 CHWs 
received training through self-paced, online courses. As measured through pretests, 
baseline cancer knowledge for CHWs participating in-person was 80% and 84% for 
online. Posttest scores indicate an increase in 9.7% points for online participants 
and 10.9% points for in-person trainings.
Significance: Training and supporting CHWs is a promising strategy for improving 
cancer education and navigation knowledge. More informed CHWs and better- 
equipped CHW organizations can effectively promote behaviors to prevent, detect, 
and manage cancer diagnoses in their communities. Disseminating bilingual, 
community- based resources through in-person and online channels to CHWs and 
organizations has the potential to reduce disparities in accessing cancer information, 
screening, treatment, and survivorship services.
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 Improving Cancer Screening Outcomes in Latinos 
Through Culturally Appropriate Navigation Services
A. D. McCracken, L. Fornos, A. J. McCracken, L. Meraz, V. Mika, A. Taranova, 
and R. Villarreal
University Health System, Research and Information Management,  
San Antonio, TX, USA
Background/Introduction: For over a decade University Health System has pro-
moted healthy behaviors, such as early cancer detection and screening, in South 
Texas Latino communities using the A Su Salud model which combines aspects 
from Social Cognitive Theory, the Stages of Change, and the Health Belief model. 
We focused on screening for colorectal, breast, and cervical cancer because Latinos 
are more likely to be screened later and diagnosed with advanced stages of these 
cancers compared to non-Latino whites. Access to screening services is particularly 
difficult for uninsured and underinsured Latinos, who experience barriers to care 
such as transportation, financial limitations, fear, and cultural concerns. We aimed 
to motivate, initiate, and sustain health-seeking behavior changes by increasing 
patient knowledge about colorectal, breast, and cervical cancers and the benefits of 
preventive care, addressing cultural factors, and reinforcing a relationship of trust 
with the Health System.
Methods: Our patient navigation approach used a combination of culturally tai-
lored, social cognitive theory-based techniques to educate patients, dispel myths, 
provide social support and initiate system changes to remove organizational, 
 financial, and other major barriers associated with the completion of colonoscopies, 
mammograms, and Pap tests. The navigators served as liaisons between the com-
munity and patient care services to increase screening rates. Through face-to-face 
interactions, they created a link with patients which removed barriers to screening 
by providing support during the period between scheduling and completing the pro-
cedure, as well as on the scheduled screening date. Transportation to and from colo-
noscopy appointments and a companion for the ride home were provided for those 
who needed it, eliminating a common barrier for this population.
Results: A total of 11,292 patients were navigated to screening services, 2079 to 
colonoscopies, 4714 to mammograms, and 4499 to Pap tests. In addition to naviga-
tion services, our program funded a total of 38,403 screenings for colon, breast, and 
cervical cancers, reducing the financial burden on our community. Of those who 
completed cancer screenings, four patients were diagnosed with colon cancer, five 
women were diagnosed with breast cancer, 205 women received abnormal Pap 
results, and 21 women were diagnosed with cervical cancer. Program satisfaction 
was high, with 98% indicating the navigator worked with them to overcome chal-
lenges to receiving care, they were satisfied with the navigator program, and they 
would recommend this program to others.
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Conclusion/Significance/Impact: We successfully addressed financial, systemic, 
and cultural barriers to cancer screenings for Latino men and women. Results from 
a system change evaluation confirmed the program was cost-effective, integrated 
suitably into University Health System, improved the Health System’s ability to 
serve its patients, and earned high patient satisfaction. Use of the A Su Salud model 
to promote and sustain healthy behaviors in underserved Latino communities 
enabled the transformation of navigators into community champions who facilitated 
access to care where it may not have been possible previously.
 Outcome Evaluation of a Community Health 
Worker- Delivered Breast and Cervical Cancer Screening 
Intervention Targeting Low-Income Hispanics
L. S. Savas, N. I. Heredia, S. P. Coan, and M. E. Fernandez
Center for Health Promotion and Prevention Research, UT Health School of 
Public Health Houston, Houston, TX, USA
Background: Hispanic women are less likely to receive preventive breast and cervi-
cal cancer screenings, leading to later stage breast cancer diagnoses and lower sur-
vival rates, as well as higher cervical cancer incidence and mortality among 
Hispanics compared with non-Hispanic whites. We adapted an evidence-based 
community health worker (CHW)-delivered screening education and referral inter-
vention (Cultivando la Salud) developed for rural Hispanic migrant farmworkers, to 
deliver to medically underserved Hispanic women in urban settings. CHWs deliv-
ered the adapted intervention using new outreach and implementation strategies, 
including conducting group education rather than one-on-one education sessions. 
We examined the effect of the adapted intervention on increasing Pap and mam-
mography screenings.
Methods: We conducted a community-based randomized controlled trial to assess 
the effectiveness of the CHW-delivered screening education and referral program 
targeting low-income Hispanic women non-adherent to screening recommenda-
tions. Women were eligible if they were over-due for mammography and Pap 
screening based on age-specific American Cancer Society recommendations and 
had no history of cancer or hysterectomy (for the Pap screening group). Bilingual 
data collectors conducted baseline and follow-up surveys 6 months after baseline. 
Logistics regression was conducted using both intent-to-treat and per-protocol anal-
ysis to evaluate the effect of the intervention on mammogram and Pap screening, 
adjusting for covariates significant at the P < 0.20 in univariate analyses, as well as 
adjusting for time to follow-up in the per protocol analyses.
Results: We enrolled 1025 women in need of a breast and/or cervical screening. 
Women were randomized to mammography and Pap screening intervention and 
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control groups, according to screening needs. Among women followed up, 39.9% 
received a mammogram in the intervention group compared with 20.3% in the con-
trol group (P = 0.001) and 55.8% received a Pap screening in the intervention group 
compared with 27.4% in the control group (P = 0.001). Among the breast screening 
cohort, compared with the control group, women in the intervention group had 2.02 
increased odds of receiving a mammogram compared with women in the control 
group, based on the adjusted intent-to-treat analysis (adjusted OR = 2.02, 95% CI: 
1.42–2.87) and 2.17 times greater odds of screening in the adjusted per protocol 
analysis (adjusted OR = 2.17, 95% CI: 1.48–3.18). Among the cervical screening 
cohort, compared with the control group, women in the intervention group had 1.84 
increased odds of completing a Pap screening based on the adjusted intent-to-treat 
analysis (adjusted OR = 1.84, 95% CI: 1.21–2.78) and 3.09 increased odds based on 
the adjusted per protocol analysis (adjusted OR = 3.09, 95% CI: 1.88–5.08).
Conclusion: The adapted CHW-delivered intervention effectively increased breast 
and cervical cancer screenings among Hispanic women. Future research is needed 
to further strengthen the intervention effect among those who did not overcome 
personal and environmental barriers to complete needed screenings.
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 Challenges and Opportunities Using Mobile Technology 
for Data Collection in Biomedical Research: An Observational 
Discovery Science Investigation with Spanish-Speaking 
Latinas
A. Fernandez, M. Serrano, M. Garcia, K. Nerio, and K. Ashing
 Appendix C: Engaging Latinos in Research 
Across the Cancer Continuum
Health Equities Division, Center of Community Alliance for Research  
and Education (CCARE) City of Hope, Duarte, CA, USA
Background/Introduction: Mobile devices including phones offer significant con-
tributions to improve reach and convenience of research participation and data col-
lection. Technological advancements have enabled smartphone devices to track 
health behaviors such as physical activity and provide convenient feedback as well 
as survey data. High usage of mobile devices, i.e., smartphones among both US-born 
and immigrant Latinos may not similarly translate to mobile technology utility for 
research participation among Latinos and other ethnic minority populations. Among 
Latinos, smartphones are primarily used for communication as only 50% use the 
data application capabilities. The acceptability and application of mobile data har-
nessing tools can present both opportunities and challenges for engaging this popu-
lation in research. We report our observations of the challenges Latinas face using 
mobile technology for data collection.
Methods: Latina mothers were recruited from school to participate in a behavioral 
nutrition and physical activity study for cancer and chronic disease risk reduction. 
A total of 38 enrolled and 32 participated in the intervention.
Results: Sixty-three percent were Spanish speakers, 59% were foreign-born, 66% 
had ≤high school education, 91% reported income <$40,000. Participants used a 
mobile device to perform two tasks: (1) complete a REDCap online survey on a 
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tablet and (2) download and install a fitness tracker mobile application. Latinas 
rated their confidence in their ability to use mobile technology using a 4-point Likert 
scale. Participants with little/no confidence requested paper versions of the survey. 
Eighty-eight percent required individualized research staff assistance to complete 
the survey and set up their fitness tracker. Monolingual Spanish-speakers were more 
likely to report little/no confidence connecting to Wi-Fi (χ2 = 13.175, p < 0.01), 
downloading an app (χ2  =  11.277, p  =  0.01), creating an electronic account 
(χ2 = 7.882, p < 0.05).
Conclusion/Significance/Impact: Our findings suggest that lower-income, Spanish 
speakers require more assistance and ongoing guidance with technology applica-
tions and devices for research data collection. In fact, we found that about 20% 
shared the device (Fitbit) with family members, especially children to facilitate the 
participants’ use of the device. However, this threatened data accuracy. Therefore, 
studies using mobile technology should account for the added staffing and resources 
required to conduct studies with this population. Addressing this barrier may require 
a pre-study session to train research participants on the study’s technology applica-
tions. Further research is needed to evaluate and improve the applicability of mobile 
technology for increasing reach and participation, as well as validation of data accu-
racy for medically underserved and understudied populations.
 A Bigger Voice: Hispanics Increasing Diversity to Enhance 
Advocacy in Science (H-IDEAS)
B. Segarra-Vázquez, E. Pacheco-Acosta, and M. Martínez-Montemayor
University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
School of Medicine, Universidad Central del Caribe, Bayamón, Puerto Rico
Background and significance: Breast cancer is the most common cancer type and 
the number one cause of cancer death among women in Puerto Rico. Historically, 
breast cancer survivors have played an important role as advocates in advancing 
science. Moreover, there is a lack of representation of Hispanics in scientific review 
panels, and clinical studies increasing the need of representation in important 
forums to advocate for studies in Hispanics with breast cancer. The specific aim for 
the project is to create a scientific advocate group of trained Hispanic cancer sur-
vivors who will participate (1) in research proposal reviews, (2) as part of key 
personnel within research studies, (3) in patient recruitment from clinical studies, 
and (4) in cancer research information dissemination in Puerto Rico and abroad. 
By increasing minority populations trained to serve in review panels, engage in 
cancer research, and help in patient recruitment, this project ensures that everyone, 
including Hispanics, will have an equal opportunity to live long, healthy, and 
productive lives.
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Methods: This educational project will be conducted in a 1-year period. A group of 
15 breast cancer survivors were recruited. The inclusion criteria included: being a 
woman between the ages of 18 and 65 years, resident of Puerto Rico for at least 
10  years, being diagnosed with breast cancer, be bilingual (written and spoken, 
English and Spanish), and have an interest in the science of cancer and peer review 
research process. The participants were recruited through word of mouth, email, 
social media, and flyers. After the initial contact by the potential candidate, they had 
to complete an application, and a telephone interview was conducted. Once the 
participant was chosen, a written agreement was signed by each of them. The train-
ing began with an intensive 3-day curriculum with topics on cancer and breast can-
cer overview, introduction to genetics and immunology basics, experimental designs 
and evidence-based medicine, ethics, good clinical practices, and breast cancer 
clinical trials in Puerto Rico. Follow-up sessions are conducted every other month 
to increase and reinforce scientific advocacy knowledge as well as hand on activities 
such as poster development, oral presentations, and mock study sessions.
Results: Preliminary evaluation suggests that participants acknowledge the need of 
this projects to allow them to be proactive in their role as advocates. Also, they have 
demonstrated to be highly engaged and motivated to continue their journey as 
scientific advocates. Data in progress.
Conclusion: This innovative project is unique in addressing the needs for bigger 
voice of Hispanics as scientific advocates. To our knowledge, this is the first advo-
cacy training to Hispanics adapted to their culture and language.
 Éxito!: Increasing Latino Representation in Cancer Control 
Research
A. Perez, K. Gallion, R. J. Pasick, and A. G. Ramirez
UT Health San Antonio, San Antonio, TX, USA
Background: Cancer is now the top leading cause of death among Latinos, making 
it critical to develop the next generation of researchers who can tackle and solve 
Latino cancer issues. However, few Latinos seek doctoral degrees. Exito! Latino 
Cancer Research Leadership Training aims to increase ethnic diversity in the field 
of Latino cancer health disparities (CHD) by encouraging minority master’s-level 
students and master’s-trained health professionals to pursue a doctoral degree and a 
career in cancer health disparities.
Methods: Twenty-five participants attend a 5-day Summer Institute (SI). The SI is 
led by recognized Latino researchers, faculty, and role models. During the SI, partici-
pants are exposed to interactive activities, tips/tools for applying and completing a 
doctoral degree, information on funding, mentorship, and Latino CHD research. Ten, 
6-month internships in Latino CHD research are also awarded annually.
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Background: Cancer is the leading cause of death among Latinos in the 
USA. Louisiana has one of the highest cancer mortality rates and a Latinos’ growth 
rate higher than the national one. Although research has shown that Latinos have 
low health literacy and English skills, no study had focused on measuring or address-
ing cancer literacy in immigrant Latinos in Louisiana, where majority come from 
Centro America and have low education and English skills.
Objectives: To identify and address barriers to cancer screening, participation in 
cancer research, and donation of biospecimens among immigrant Latinos in 
Louisiana.
Methods: The Cancer Health Literacy Test (CHLT-30) was translated to Spanish, 
culturally adapted, pilot-tested, and validated among Latinos in Louisiana. Results of 
the assessment of cancer literacy were used to identify misconceptions and knowl-
edge gaps regarding cancer risks, screening, and research. Focus groups assessed the 
applicability of educational materials selected from the literature review and that 
addressed the gaps identified. The training “Cancer 101: A Cancer Education and 
Training Program” (Briant et al.), available in Spanish, was selected, adapted, and 
pilot-tested with ten Latinos from different age-ranges and educational backgrounds. 
The resulting training “Cancer 101 for Latinos” was developed using three different 
delivery options (print, video-based, and face-to-face). A field test of the feasibility 
and preliminary comparative effectiveness of the three interventions was conducted 
Results: From 2011 to 2017, 151 individuals have come through the SI and 37 
internships have been awarded. Results from the SI show a significant improvement 
in academic self-efficacy in attendees. Improvements in confidence toward applying 
to a doctoral program in the next 5 years are also seen. Results for internships show 
significant improvements in students’ research skills across all measured domains. 
Twenty-four percent (n  =  36) of our alumni are currently enrolled in a doctoral 
program.
Conclusion: Exito! results indicate an improvement in master’s-level students’ and 
master’s-level health professionals’ confidence and capacity to pursue and complete 
a doctoral degree leading to careers in cancer control research. The Éxito! program 
provides the necessary encouragement to build a new pipeline of Latino doctors and 
cancer researchers.
 Fostering Cancer Education and Participation in Research 
Among Immigrant Latinos
M. Echeverri, E. Yanez, and A. Napoles
Xavier University of Louisiana, New Orleans, LA, USA
National Institute on Minority Health and Health Disparities, Bethesda, MD, USA
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Introduction: Hispanics are the fastest growing population in North Carolina and 
have unique healthcare needs related to culture and language. To meet their needs 
and address the historically low participation in cancer clinical trials, we developed 
a bilingual Hispanic Clinical Trial Navigator (HCTN) position to support Hispanic 
adult and pediatric patients treated at Wake Forest Baptist Comprehensive Cancer 
with a stratified sample (by gender, age range, and education) of 54 Latinos, 
who were randomly assigned to the different arms (18 in each arm). All participants 
completed the same pre-post tests before and after the intervention and also com-
pleted evaluation of the training.
Results: A total of 500 Latinos (half women) completed the CHLT-Spanish version. 
In general, participants were young (42% 25–40 years old; 30% 41–55; 28% older 
than 55+) and had low educational levels (37% less than high school; 49% high 
school or some college; 14% advanced degrees). While 17% scored in the lower 
level of CHL (0–10), 49% scored in the medium level (11–20), and 34% in the 
higher one (21–30). Although majority of participants (>70%) were willing to 
participate in studies requiring to complete a survey, attend an educational interven-
tion, or give samples (saliva, cheek cells, urine, or blood), lower percentages (<45%) 
were willing to take an experimental natural supplement or drug, donate skin or 
tissue, or undergo a minor or major experimental procedure. For the field tests of the 
three interventions, 54 Latinos (24 males, 30 females) completed the study. There 
were no significant pre-post test differences by education, gender, or intervention 
type; but there was a slight difference (p = 0.06) in the interaction between differ-
ence scores and age. Ultimately, the difference scores proved that overall partici-
pants learned more about cancer after receiving an intervention, regardless of type. 
In the learning process, there was a significant difference (p < 0.05) with education 
in the posttest scores.
Conclusion: Addressing cancer literacy in immigrant Latinos is becoming critical 
for increasing their participation in cancer screening and research. Results show that 
educational interventions may be the best approach to address lack of knowledge 
and trust about cancer research. However, considering that no intervention method 
(print, video-based or face-to-face) produced higher knowledge changes, we recom-
mend the use of hybrid educational methods to address the learning needs of immi-
grant Latinos.
 Hispanic Patient Navigation: Improving Cancer Care 
and Clinical Trial Participation
C. Strom, M. A. Combs, K. Weaver, J. Ruiz, and K. Winkfield
Office of Cancer Health Equity, Wake Forest Baptist Comprehensive Cancer Center, 
Winston-Salem, NC, USA
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Center (WFBCCC). The HCTN is a novel approach to integrate culturally and lin-
guistically competent navigation with support around clinical trial decision-making. 
The purpose of this analysis was to evaluate the services provided during the pro-
gram’s first year and its impact on clinical trial participation.
Methods: Retrospective data from November 1, 2015 to October 31, 2016 was 
obtained from a navigation database, WFBCCC cancer registry, and clinical trial 
system. Data were reported in the aggregate, and clinical trial participation rates 
were compared to data prior to the hiring of the HCTN (November 1, 2014 to 
October 31, 2015).
Results: There were 108 pediatric and adult patients navigated during the first year; 
55 breast screening/diagnostic, and 53 cancer treatment. The majority of patients 
were female (87%) with a mean age of 45  years. The most common diagnoses 
among treatment patients were breast (47%), hematologic (34%), and gastrointesti-
nal (6%) malignancies. Major patient barriers identified by include treatment logis-
tics/transportation (87%), financial/insurance (70%) information/education (55%), 
and continuity of care (53%). In addition to education and referrals, the HCTN was 
able to remove potential barriers to trial participation through transportation assis-
tance (31%), meal vouchers (21%), and parking validation (40%). In the year prior 
to the HCTN, there were 88 newly diagnosed Hispanic patients with a clinical trial 
participation rate of 20% in treatment/non-treatment intervention studies. With 
HCTN navigation, clinical trial participation among Hispanic patients navigated 
was 34%.
Conclusions: Navigation is now available in a majority of community cancer cen-
ters and is an opportunity to provide culturally and linguistically appropriate 
patient support around cancer and clinical trials. Our initial data indicates a success 
in increasing Hispanic participation in cancer clinical trials utilizing a HCTN. Future 
data analysis is planned after completion of the second year of the program. Placing 
HCTNs in cancer treatment settings could be a cost-effective and efficient method 
of providing navigation, while also facilitating state-of-the-art care through clini-
cal trials. Opportunities exist for additional studies of navigation to increase clini-
cal trial participation in underserved populations. Increased and equitable 
participation in clinical trials is necessary in ensuring that the future of cancer care 
is applicable to all.
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 Localized Translation and Real-Time Interpretation 
of Informed Consent Forms in Pediatric Oncology Clinical 
Trial Participation
M. P. Lopez, A. M. Langevin, V. Diaz, and F. Maldonado
Department of Pediatric Hematology/Oncology, UT Health San Antonio,  
San Antonio, TX, USA
Background: Pediatric oncology patients and Limited English Proficiency (LEP) 
parents commonly experience language, social, and cultural barriers throughout the 
course of treatment, particularly at the time of diagnosis. Hispanic linguistic and 
cultural studies combined are essential to positively impact health services and trial 
participation for LEP families.
Methods: The cohort consisted of 42 LEP families. We (1) collected recurrent ques-
tions and clarifications during initial consenting with a Mexican Spanish (es- MX) 
language variant under the Spanish Language Family text corpus and (2) catego-
rized the patients’ and LEP parents’ lexical variations at follow-up visits by clarifying 
geographical origin.
Results: We observed that (1) 93% of Spanish LEP parents and patients responded 
positively to the es-MX translation of consent forms, (2) 61% favored lexical varia-
tions of northern Mexico, (3) 29% favored lexical variations of central Mexico, 
(4) 7% favored lexical variations of Central and South America, (5) 3% of patients 
opted to not enroll in a clinical trial based on other sociolinguistic challenges.
Conclusion: Our data indicated that (1) localization of the consent form translation 
and (2) vocabulary with a high regional affinity in interpretation interactions allevi-
ated difficulties and engaged the parent as an active member of the child’s clinical 
trial participation.
Impact: This retrospective analysis was conducted to validate the applicability of 
knowledge of patient linguistic preferences as essential for interpretation and trans-
lation of clinical trials to ensure full participation. We hope to add sociocultural, 
sociolinguistic, and treatment compliance measurements to future analysis and see 
this work as a first step toward cognitive debriefing analysis.
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 Development and Feasibility Testing of the My Guide 
Intervention for Hispanic Breast Cancer Survivors
B. Yanez, D. Buitrago, J. Buscemi, A. Perez-Tamayo, J. Guitelman,  
and F. Penedo
Department of Medical Social Sciences, Northwestern University Feinberg School 
of Medicine, Chicago, IL, USA
Department of Psychology, DePaul University, Chicago, IL, USA
Department of Surgery, University of Illinois at Chicago, Chicago, IL, USA
ALAS-WINGS, The Latina Breast Cancer Association, Chicago, IL, USA
Background: Breast cancer (BC) is the most commonly diagnosed type of cancer 
among Hispanic women living in the USA, and relative to non-Hispanic white 
women, Hispanic women report poorer quality of life (QOL) after treatment. 
Smartphone interventions are a viable approach for addressing healthcare accessi-
bility issues and improving QOL outcomes among cancer survivors, especially 
among Hispanics with documented increased levels of Internet use for accessing 
health information. This study describes the development and iterative testing pro-
cess of My Guide, a culturally tailored smartphone-based intervention for Hispanic 
breast cancer survivors.
Methods: To develop the My Guide content, we conducted semi-structured field 
interviews with English- or Spanish-speaking Hispanic breast cancer survivors 
(n = 9). Transcribed interviews were coded for prevalent themes using NVivo soft-
ware. Next, our study team conducted preliminary usability testing on participants 
and community stakeholders (n  =  9). Finally, Hispanic breast cancer survivors 
(n = 25) were enrolled in a 4-week feasibility study to assess the initial satisfaction 
and demand for My Guide.
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Results: The most prevalent themes in the semi-field interviews were fear of recur-
rence (mentioned in 89% of interviews), patient–provider communication and 
social support (mentioned in 100% of interviews), and side effects of cancer treat-
ment, psychological well-being, and breast cancer knowledge (mentioned in 78% of 
interviews). Eighty-five percent of eligible participants enrolled in the My Guide 
feasibility trial, and the retention was 90%. The mean number of hours spent using 
the application across the 4 weeks was 8.54 h (SD = 4.44). The mean score on the 
satisfaction survey was 4.59/5 (SD  =  0.76), in which higher scores reflect more 
favorable reviews of the application. Results from feasibility trial revealed addi-
tional content and features that women wanted in future versions of the My Guide 
application. These data were used to improve the My Guide application, which is 
currently being testing in a randomized clinical trial.
Conclusions: Study findings underscore the relevant needs and concerns for 
Hispanic breast cancer survivors and suggest that the My Guide Smartphone appli-
cation may be a feasible application. Considerations for developing a culturally and 
linguistically adapted smartphone application will be discussed.
 Disparities in Financial Hardship Among Hispanic 
and Non- Hispanic White Colorectal Cancer Survivors
M. P. Banegas, W. Wiggins, A. Rajput, V. K. Chiu, A. Y. Kinney,  
and J. A. McDougall
Kaiser Permanente Northwest, Center for Health Research, Portland, OR, USA
University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA
Department of Internal Medicine, University of New Mexico School of Medicine, 
Albuquerque, NM, USA
Department of Surgery, University of New Mexico School of Medicine, 
Albuquerque, NM, USA
Introduction: With rising cancer care costs and a growing burden of out-of-pocket 
cost-sharing requirements, patients diagnosed with cancer have become increas-
ingly financially vulnerable. Yet racial/ethnic variation in the financial experiences 
of individuals with cancer remains largely understudied. The objective of this study 
was to assess financial hardship among Hispanic and non-Hispanic whites in a 
population- based sample of colorectal cancer survivors.
Methods: Individuals diagnosed with localized or regional colorectal cancer from 
2004 to 2012 were identified from the population-based New Mexico Tumor 
Registry, a member of the National Cancer Institute’s Surveillance, Epidemiology, 
and End Results Program. Potential participants were asked to complete a survey (in 
English or Spanish), by mail (paper) or telephone, to assess the experiences of 
colorectal cancer survivors in New Mexico. Hispanic and rural cancer survivors 
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were oversampled. Information on ethnicity and primary language spoken was used 
to form three exposure groups: (1) primarily English-speaking Hispanics, (2) 
Spanish-speaking Hispanics, and (3) non-Hispanic whites. Financial hardship was 
measured by four items asking participants if they ever (1) had to borrow money or 
go into debt, (2) had to file for bankruptcy, (3) were unable to cover their share of 
medical care costs, or (4) made other financial sacrifices because of cancer, its treat-
ment, or lasting effects of treatment. We created a dichotomous measure of any 
financial hardship based on responses to these four measures. Multivariable logistic 
regression was used to estimate adjusted odds ratios (ORs), adjusting for participant 
sociodemographic, geographic, and health literacy characteristics.
Results: Among 277 colorectal cancer survivors, 40% (n = 111) identified as Latino 
or Hispanic (n = 67 English-speaking and n = 44 Spanish-speaking). Financial hard-
ship was reported by 68% of Spanish-speaking Hispanics, 42% of English-speaking 
Hispanics, and 38% of non- Hispanic whites. In multivariable analyses, Spanish-
speaking Hispanics were significantly more likely to report treatment- related finan-
cial hardship (OR 3.09, 95% CI 1.39–6.87), compared to non-Hispanic whites; 
although, no significant difference was observed between English-speaking 
Hispanics and non-Hispanic whites (OR 0.83, 95% CI 0.42–1.64). Rural county 
residence, health literacy and marital status were also found to be significantly asso-
ciated with financial hardship, in multivariable adjusted analyses.
Conclusions: Our findings highlight important disparities in the financial hardship 
from cancer between Spanish-speaking Hispanic and non-Hispanic white colorectal 
cancer survivors. Given that prior evidence suggests cancer survivors who experi-
ence financial hardship are more likely to delay or forgo care and may have poorer 
health outcomes, future research is needed to assess the unique financial experi-
ences among Spanish-speaking Hispanic cancer survivors. Such efforts may inform 
the development of interventions to reduce financial hardship from cancer in this 
at-risk population and potentially prevent widening disparities in cancer outcomes.
 Going Through Cancer Together as a Family: 
The Experiences of Hispanic Mothers Diagnosed with Cancer
R. L. Palacios, F. M. Lewis, K. Sondgeroth, C. Reyes, and E. T. Loggers
Department of Public Health Sciences, New Mexico State University,  
Las Cruces, NM, USA
School of Nursing, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
WA, USA
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 
Seattle, WA, USA
Division of Hematology and Oncology, University of Washington, Seattle, WA, USA
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Background: Approximately 1.5 million cancer survivors are parents of minor chil-
dren, with approximately 80% of these survivors being women under the age of 
50 years. Approximately one third of these mothers are in the early phases of cancer 
treatment and recovery. Most of what is known about the challenges of parenting 
dependent children following a cancer diagnosis is based on studies with NHW 
mothers. However, relatively little is known about the experiences of Hispanic 
mothers diagnosed with cancer and their families, particularly those residing along 
the US–Mexican border. This is unfortunate given that Hispanics demonstrate sig-
nificant disparities in cancer care, outcomes, and overall disparities compared to 
NHWs. The purpose of this study was to describe, in their own words, the lived 
experiences of Hispanic mothers who were in the early phases of cancer treatment 
and recovery while concurrently rearing dependent children.
Methods: Nine cancer-diagnosed Hispanic mothers of Mexican descent partici-
pated in focus groups or individual interviews, responding in their preferred lan-
guage. Study questions assessed parent–child communication surrounding cancer, 
parenting experiences while managing the cancer, family support, and the impact of 
cancer on the family. Study data were transcribed verbatim, translated to English, 
and coded using inductive content analysis within a framework of grounded theory. 
Trustworthiness of study results was protected by coding to consensus, systematic 
peer debriefing, and maintaining an audit trail.
Results: The core construct that organized the data was “Going through Cancer 
Together as a Family” which consisted of 48 categories organized across 15 
domains. The data were organized into four key areas: (1) the advantages of being 
open and honest about the cancer with the children; (2) what and how much to share 
with her children about the cancer; (3) mom’s evaluation of her maternal role and 
the impact of her cancer on her children; and (4) the children’s choice to take care 
of the mother even as they retained her identity as mom.
Conclusion/Significance: Mothers and children mutually assisted and protected 
each other from the negative impact of cancer. This study highlights the importance 
of research examining the dimensions of relational coping among Hispanic women 
diagnosed with cancer and their families.
 Health Behavior Engagement, Obesity, and Symptom 
Management in Latina Breast Cancer Survivors: 
A Qualitative Study
G. Juarez, D. H. Sorkin, M. Sharif, D. B. Mukamel, Y. Chen, A. Kobsa, A. Police, 
S. Al-Majid, and K. Biegler
Department of Medicine, University of California Irvine, Irvine, CA, USA
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Background: Breast cancer survivors are at risk for weight gain, obesity, and dia-
betes. Relative to other ethnic groups, Latinas are at even greater risk of diabetes 
and obesity and are more likely to experience other breast cancer-related symptoms, 
including fatigue and negative mood. Symptom burden is further compounded in 
this population by lower socioeconomic status and limited access to resources (e.g., 
car transportation, specialty medical care). Importantly, engaging in health behavior 
change to achieve weight loss can significantly reduce the number symptoms and 
their severity among breast cancer survivors. Thus, understanding the complex 
interplay of obesity, health-behavior engagement, and symptom experience among 
a group of high-risk, under-resourced Latina breast cancer survivors is a critical 
next step for addressing this disparity.
Purpose: To obtain an in-depth understanding of Latina breast cancer survivors’ 
perception of factors that contribute to their own health, and the potential connec-
tion between their engagement in particular health behaviors and whether these 
behaviors alleviated symptoms.
Methods: We conducted 17 focus groups in both English and Spanish with 70 
Latina women who had undergone treatment for breast cancer to further understand 
the role of Hispanic culture in the breast cancer survivor experience, cultural- 
specific motivators and barriers, as well as symptom burden, to engaging in a healthy 
lifestyle during survivorship.
Results: A common theme that emerged from the focus groups was that a healthy 
lifestyle helped alleviate some of their symptoms. Some quotes to provide direct 
examples include: “For me, the more that I exercise the more active I feel. I also 
want to be healthier and to feel better. When I do not exercise I feel more fatigued, 
more tired. The body is not the same after you have been through a lot.” In response 
to asking what made her start walking another patient said: “Well, because I was 
feeling like I was not feeling good with myself. I was feeling bloated and the doctor 
said that it would probably help. So I did and I just felt better, you know. I know, so 
I started walking a lot and like 30–40 minutes a day.”
Conclusions: Findings suggest under-resourced, high-risk Latina breast cancer sur-
vivors recognize a potentially important link between healthy behavior and symp-
tom management. This awareness has the potential to be leveraged to create 
meaningful lifestyle modification programs.
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 Latino Adolescent and Young Adult Childhood Cancer 
Survivorship
J. A. Contreras and T. S. Page
School of Nursing, UT Health San Antonio, San Antonio, TX, USA
Background: Survivorship concerns of Latino adolescents and young adults may 
be different from those of the general population due to varied understandings of 
the disease and illness, age, language barriers, cultural beliefs, and values; there-
fore, engaging this population in research is vital to successful care delivery and 
survivorship. About 5000 adolescents are diagnosed with cancer each year in the 
USA. Adolescents and young adults with cancer are usually treated by pediatric 
cancer specialists if they have a type of cancer more common in children, and by 
adult cancer specialists if they have a type more common in adults. Either way, they 
are unlikely to run into other patients like themselves and often feel out of place. 
This research is essential because of the need to address cancer care needs and 
concerns post treatment of diverse ethnic populations in the state of Texas to create 
an optimal Survivorship Care Plan (SCP). This research will explore the experi-
ences and concerns of adolescents and young adults (AYA), and their parents, post 
childhood cancer treatment, in order to determine their understanding of follow-up 
care and then to determine the optimal format and content of a survivorship care 
plan. Results of this inquiry will reveal common themes experienced by the partici-
pants and provide information about the impact of childhood cancer after comple-
tion of treatment. Findings may be used to improve the transition of care from the 
tertiary cancer care setting to the community, after treatment, for this specific 
patient population.
Methods: A qualitative descriptive analysis approach will explore participants’ 
experiences and concerns as a childhood cancer survivor. This inquiry will employ 
focus group semi-structured interviews as well as one-to-one interviews as tools of 
data collection as per the qualitative approach. Purposive sampling of participants 
will be employed to recruit participants aged between 15 and 39  years, male or 
female, and have lived more than 5 years post active treatment from the UHS South 
Texas Pediatric Blood and Cancer Center in San Antonio, Texas. Verbal informed 
consent will be obtained from all adults and assent will be obtained from children. 
Semi-structured interviews will be audio recorded and later transcribed, cross-
checked for accuracy, and analyzed to identify common themes that emerge.
Significance: Unique factors are associated with a cancer diagnosis in the Latino 
AYA population. In addition to cultural, physical, and biological differences, ado-
lescents and young adults face a unique range of psychosocial issues that may affect 
their care and transition into survivorship. Data gathered during these interviews 
will provide valuable information that may be used to develop survivorship care 
plans and help improve follow up care for this population. The Institute of Medicine 
reports the needs for SCP to “summarize the potential late effects, their prevention, 
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symptoms and treatment, recommendations for cancer screening, psychosocial 
effects, financial issues, recommendations for a healthy lifestyle, genetic counsel-
ing, referrals for follow-up care and a list of support resources (2017).” However, 
gaps in existing knowledge related to SCP, particularly in the Latino population, 
interfere with the provision of quality health services. This research will fill the gaps 
in Latino adolescent and young adult survivorship care plan development.
 Latino/a Adolescents Coping with Parental Cancer 
Within a Cultural Context
Amanda Marín-Chollom
Department of Epidemiology, Mailman School of Public Health, Columbia 
University, New York, NY, USA
Background: Parental cancer has a strong influence on the psychological well- 
being of children at all ages. Children and adolescents whose parents have more 
distress and advanced disease tend to have lower rates of healthy psychological 
adjustment. Children from the US Latino/a population may face additional chal-
lenges, such as racism and acculturative stress that compound the stress of having a 
parent with cancer. At the same time, facets of the Latino/a culture may play a cru-
cial role in how Latino/a adolescents adapt to parental cancer, specifically the 
Latino/a cultural values of familismo (familism), espíritu (spirit), and respeto 
(respect). This cross-sectional study examined the relation of Latino/a cultural val-
ues to coping and psychological adjustment among adolescents and young adults 
(AYAs). Specific aims were to examine (1) the associations between AYA’s stress 
and coping responses and psychological adjustment to their mother’s cancer; (2) the 
direct and moderation effect of three Latino/a cultural values—familismo, espíritu, 
and respeto—on the coping-adjustment association; (3) the effects of age and gen-
der on coping responses, cultural values, and psychological adjustment outcomes; 
and (4) the associations between severity of the parent’s cancer and the parent’s 
level of distress with AYA’s psychological adjustment.
Methods: The sample included 38 Latino/a AYAs who were coping with their 
mother’s breast cancer (n = 24). AYAs and mothers completed questionnaires in 
English or Spanish in-person or by mail. A subsample of seven AYAs completed an 
optional interview. Psychological adjustment was measured by symptoms of depres-
sion (Center for Epidemiological Studies Depression Scale (CES-D); Eaton et al. 
2004; Faulstich et  al. 1986) and anxiety (adults: Generalized Anxiety Disorder 
scale; Spitzer et  al. 2006; AYAs: Spence Children’s Generalized Anxiety Scale, 
Spence 1998). Stress appraisals and coping responses were measured with six sub-
scales from the Response to Stress Questionnaire (RSQ; Connor-Smith et al. 2000) 
and the religious subscale from the Brief COPE (Carver 1997); Latino/a cultural 
values of familismo and respeto were measured with the Mexican-American 
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Cultural Values Scale (MACVS; Knight et al. 2009); the espíritu value was mea-
sured with the Systems of Belief Inventory (SBI-15; Holland et al. 1998).
Results: Results demonstrated that stress appraisals and the coping responses of 
secondary control, disengagement, involuntary disengagement, and involuntary 
engagement coping were positively correlated with symptoms of depression and 
anxiety. The Latino/a cultural values of familismo and espíritu were associated, 
both directly and indirectly, with fewer symptoms of depression and anxiety. Higher 
endorsement of these values was associated with lower symptoms of depression and 
anxiety and greater primary control and religious coping use. Protective patterns of 
familismo and espíritu were evident in their interactions with coping responses. 
At higher levels of familismo, secondary control coping was negatively associated 
with symptoms of depression, but at lower levels of familismo, secondary control 
coping was positively associated with symptoms of depression. A similar pattern 
was also found for the espíritu value with both primary and secondary control cop-
ing. However, this buffering effect was less evident for involuntary modes of coping 
(disengagement and involuntary disengagement coping). AYAs whose mother was 
in active treatment had greater anxiety. Age, gender, severity of mother’s cancer, 
and mother’s distress were unrelated to coping or adjustment outcomes.
Conclusion: The findings suggest that Latino/a AYAs experience significant dis-
tress, but those with higher levels of familismo and espíritu may fare better than 
those with lower levels of these values. The creation of psychosocial interventions 
for Latino/a AYAs should incorporate or strengthen Latino/a values; however, these 
culturally tailored interventions need to be based on needs assessments of Latino/a 
AYAs and their families, and their communities.
 Preliminary Insights into the Impact of the Affordable Care 
Act on Breast Cancer Care and Outcomes Among Patients 
Receiving Care at an Urban Safety-Net Hospital: Work 
in Progress
A. Guzman, A. Silva, C. Picard, M. S. B. Hunt, and N. Saiyed
Loyola Public Health Sciences Department, Sinai Urban Health Institute, Chicago, 
IL, USA
Introduction: Non-Latina (nL) black and Latina women are diagnosed with 
breast cancer at a younger age and at later stages than nL-white women. 
Furthermore, compared to nL white women, the breast cancer mortality rate is 
higher in nL-black women, and quality of life is lower for Latina breast cancer 
patients. The etiology of these breast cancer disparities is multifactorial. However, 
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poor access to health care and lack of adequate insurance coverage are often 
implicated. Through its various provisions, the Patient Protection and Affordable 
Care Act (ACA) has the potential to (1) increase access to cancer care, particu-
larly among the most vulnerable and (2) reduce racial/ethnic disparities in cancer 
care and outcomes. It is critical to understand the degree to which healthcare 
policy can help improve these two  factors. The current project will carry out a 
preliminary assessment by using medical record and cancer registry data to quan-
tify the impact of ACA provisions on cancer care access and outcomes among 
minority breast cancer patients.
Methods: The study population will include women diagnosed (2010–2016) with 
breast cancer at Mount Sinai Hospital, a safety-net institution in Chicago. The fol-
lowing information is being abstracted from medical records and the hospital can-
cer registry: demographics (race, ethnicity, age), insurance status (Medicaid, 
private, uninsured), mode of detection (screen detected vs. symptomatic), tumor 
characteristics, and treatment information. Descriptive statistics will be calculated 
to compare patient, tumor, care, and treatment characteristics between the pre- and 
post-ACA periods overall and by racial/ethnic group. Logistic regression models 
will be used to report proportions and estimate differences with bias-corrected 
bootstrapped 95% confidence intervals.
Results: At present, data from 2012 to 2015 has been abstracted (n = 167). The 
study population consists of 41% Latina, 46% nL-black, and 5% nL-white breast 
cancer patients. The pre- and post-ACA periods were defined as 2012–2013 and 
2014–2015, respectively. Among nL-black and Latina women, the proportion of 
Medicaid-enrolled patients increased, while the proportion of uninsured decreased 
post-ACA, with Latina women experiencing a greater shift (p = 0.076). In addition, 
the proportion of screen-detected breast cancers increased while symptomatically 
presented cancers decreased post-ACA (p = 0.216). At completion of data collec-
tion, we will examine changes in insurance status, mode of detection, timeliness to 
breast cancer care, and cancer stage pre- and post-ACA, appropriately adjusting for 
disease characteristics (i.e., stage, grade, hormone receptor status).
Discussion: The provisions of the ACA aim to decrease the number of uninsured, 
particularly targeting minorities, and increase access to appropriate cancer care. 
It remains unclear the extent to which such provisions will impact breast cancer- 
related care and outcomes in underserved black and Latina populations. Furthermore, 
little is known of the differences in improvements of the breast cancer care contin-
uum between Latina and black women as a result of the ACA. Efforts aimed at 
evaluating the impact of the ACA on cancer outcomes and disparities should be 
supported, as they will help inform future policy recommendations.
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 Utilization of Palliative Therapies Among Hispanics 
with Stage IV Non-small Cell Lung Cancer
N. Duma, U. Durani, J. R. Molina, and T. J. Moynihan
Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Background: Racial disparities in the treatment of lung cancer are well docu-
mented. However, research in disparities in palliative care is limited. Early integra-
tion of palliative care in advanced non-small-cell lung cancer (NSCLC) has been 
proven to improve quality of life and overall survival in this subset of patients. We 
proposed to study the use of palliative treatments for stage IV NSCLC among 
Hispanic patients.
Methods: Using the National Cancer Database (NCDB), we identified all Hispanic 
patients (self-reported) diagnosed with stage IV NSCLC from 2005 to 2013. Cases 
with incomplete data, unknown life/death status or classified as Hispanic by sur-
name only were excluded. Hispanics were grouped based on place of origin. Pearson 
chi-square tests were used to estimate differences in categorical data; predictors of 
palliative care referral/use were determined by logistic regression analysis.
Results: Ten thousand four hundred forty-one patients were included. The median 
age was 66 years. Regarding place of origin: 15.5% of patients were from Mexico, 
8% from South/Central America, 7% from Cuba, 6% from Puerto Rico, 2.4% from 
the Dominican Republic, and 57.6% were no-otherwise specified. When all Hispanic 
patients were included, 3.5% received surgery, 45% radiation, and 52.9% chemo-
therapy. Overall, 2.2% of patients received a referral for palliative pain management 
± other palliative therapies. When divided by place of origin, Dominican patients 
had the highest percentage of pain management referrals at 5.5% (p < 0.01) fol-
lowed by Puerto Rican patients (2.4%). On the other hand, only 1.3% of patients 
from South/Central America were referred to pain management. In multivariate 
analysis, Dominican Republic origin (OR: 3.30, 95%CI: 1.69–6.44, p < 0.01), bone 
metastasis (OR: 1.98, 95%CI: 1.17–3.3, p  <  0.01), and a Charlson comorbidity 
index ≥2 (OR: 2.07, 95%CI: 1.11–3.85, p < 0.02) were significant predictors of 
receiving a pain management referral. We observed an increased number of pain 
management referrals over time with 1.4% of Hispanic patients getting a referral in 
2004 vs. 2.9% in 2013 (p < 0.02).
Conclusions: We observed that only a small percentage of Hispanic patients with 
metastatic NSCLC cancer are receiving referral for palliative care/pain manage-
ment. Several cultural beliefs and barriers may play a role in these findings. 
Providers should offer early referrals to pain management/palliative care to all 
patients with metastatic NSCLC independent of their race or ethnicity.
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